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Abstract 
 
Menstruation is the leading cause of iron deficiency anaemia in pre-menopausal women. 
When combined with regular exercise, iron deficiency (ID) risk in menstruating women is 
increased. This may be exacerbated in those with heavy menstrual bleeding (HMB), which 
despite no validated diagnosis, is thought common in the general population but is under-
investigated in exercisers. Accordingly, the potential relationship between menstruation, 
ID and performance remains unknown. The aims of this research were to: a) identify HMB 
prevalence (utilising a diagnostic series) and association with fatigue and perceived 
disruption to exercise training/performance in exercising women; b) evaluate the impact 
and existing diagnosis of ID.  
A ‘Female Health Questionnaire’ was developed to identify HMB amongst other factors in 
an exercising population (n=789), elite athletes (n=90) and London Marathon runners 
(n=1073). The relationships between iron status, HMB and fatigue or the perception that 
the menstrual cycle disrupts exercise training/performance was then investigated in 
exercising women (n=271). Finally, a clinical trial assessed the impact of intravenous iron 
repletion (single dose of 20 mg·kg-1) on exercise and aerobic capacity, haematological 
markers, fatigue and mood disturbance in non-elite, iron deficient (serum ferritin ≤30µg·L-
1), exercising women (n=32).  
HMB was identified to be common (37% elite athletes, 36% marathon runners), and 
associated with perceived disruption to exercise training/performance and fatigue, but 
these relationships were independent of iron status. Iron repletion improved exercise and 
aerobic capacity, but only in those more severely iron deficient (serum ferritin <15µg·L-1), 
with wide individual variation, unrelated to baseline serum ferritin. 
In conclusion, HMB is a risk factor for ID, physiological and psychological function 
decrements in exercising women. Intravenous iron repletion effectively restores iron status 
and improves functional exercise capacity when true ID exists. Serum ferritin as a 
biomarker for ID and its associated normative data should be re-evaluated to avoid false 
positive ID diagnosis.  
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Impact statement 
 
UCL research has highlighted a lack of awareness and understanding of common issues 
experienced by exercising women that can affect both their exercise performance and 
general health. These findings should inform future practice amongst sports physicians 
and sports scientists, and a forthcoming research focus should be placed on identifying 
treatment options.  
 
The menstrual cycle has the potential to affect exercise performance. However, the causes 
for this and optimal treatment options are largely unknown. Prior research assessing 
menstrual dysfunction in athletes has primarily focussed on amenorrhea and 
oligomenorrhea. However, here, heavy menstrual bleeding (HMB) was shown to be a 
prevalent issue in both recreational and elite level athletes, with more than 1 in 3 reporting 
a history of this condition. Menstruation is the leading cause of iron deficiency in developed 
countries, likelihood is inevitably exacerbated in those with HMB. HMB was found to have 
a detrimental effect on physiological and psychological function.  
 
Those who exercise have an increased risk of iron deficiency, and supplementation 
amongst this populous is common. Accordingly, nearly 80% of elite athletes reported use 
of iron supplementation. However, many were found to supplement without prior 
knowledge of iron status. Unnecessary iron supplementation is not beneficial to exercise 
or aerobic capacity, it can cause several unwanted side effects and is a primary risk factor 
in those with genetic abnormalities that predispose them to iron overload.  
 
There has been a previous lack of clarity surrounding the diagnosis of iron deficiency, 
particularly amongst those who exercise. Serum ferritin is the primary marker used for 
diagnosis, and cut-offs typically range from 12 - 40 µg·L-1. However, applying the principle 
that a positive response to iron repletion indicates iron deficiency, the results from a recent 
clinical trial suggest that existing diagnostic guidelines and markers need to be re-
evaluated. Diagnosing iron deficiency using a serum ferritin cut-off of 30 µg·L-1, an overall 
improvement in physiological and psychological function was seen when exercising 
women had their iron stores repleted. However, when broken down into groups based on 
severity of iron deficiency, as defined using serum ferritin, endurance and aerobic capacity 
only increased in those with more severe iron deficiency (serum ferritin < 15 µg·L-1). 
However, amongst this group there was a range of individual variation in response, not 
predicted by baseline serum ferritin. This trial firstly highlighted that existing serum ferritin 
diagnostic cut-offs may be too lenient, and secondly suggests that while serum ferritin can 
be used to identify those with an increased iron deficiency risk, measurement of other iron 
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status markers alongside this is necessary to enhance diagnostic ability. For best practice, 
iron status should be monitored longitudinally, with intervention only when a significant 
decline is observed. 
 
Sports physicians should assess for HMB on presentation in athletes and need to be aware 
of the potential impacts it can have. Other markers in addition to serum ferritin should be 
used for iron deficiency diagnosis, and both athletes and athlete support personnel need 
to ensure that appropriate advice is sought prior to supplementation.  
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Figure 7.7 The relationship between change in total haemoglobin mass and change 
in total V̇O2max in response to the intravenous iron injection. 
Figure 7.8 Relationship between change in total haemoglobin mass and a. 5 km 
personal best time; b. weekly exercise volume; c. baseline V̇O2max; d. 
CHCM, and haematocrit in response to intravenous iron, p < 0.05; f. 
Relationship between change in haemoglobin concentration ([Hb]) and 
change in V̇O2max in response to intravenous iron. 
Figure 7.9 Relationship between change in total haemoglobin mass and baseline 
platelet biomarkers. a. association between change in haemoglobin mass 
and baseline mean platelet component; b. association between change in 
haemoglobin mass and platelet distribution width. 
Figure 7.10 Effects of intravenous iron on fatigue (MFI). A comparison between 
subscale Multidimensional Fatigue Inventory scores (MFI; median ± IQR) 
at baseline and post-injection. 
Figure 7.11 Effects of intravenous iron on fatigue (Piper fatigue score). A comparison 
between subscale Piper fatigue scores (PFS; median ± IQR) at baseline 
and post-injection. 
Figure 7.12 Effect of intravenous iron on mood disturbance using the BRUMS mood 
scale. A comparison between mood disturbance at baseline and post-
injection. 
Figure 8.1 An overview of the conclusions. i. There is an association between HMB 
and IDA and IDNA; ii. The association between HMB and perceived 
reported effects of the menstrual cycle on exercise training and 
performance is independent of IDA and IDNA; iii. The relationship between 
HMB and fatigue is not mediated by IDA and IDNA; and iv. There was an 
overall increase in exercise and aerobic capacity in response to 
intravenous iron in iron deficient (serum ferritin < 15), non-elite exercising 
women, however this response was not universal and independent of 
serum ferritin. However, a reduction in fatigue was observed in all. There 
is potential for IDA and possibly IDNA to actually be responsible for HMB. 
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1 Chapter 1 
1.1 General introduction 
In the words of Nelson Mandela “Education is the most powerful weapon which you can 
use to change the world..” 
 
Athletes are always striving for the best. Pushing their bodies to their physiological limit. 
But while the positive health effects of regular exercise are clearly established (5), it is also 
important to ‘first do no harm’ (6). Research shows that athletes respond differently to the 
general population (7). Sports medicine and sports science researchers are constantly 
trying to address how we can help athletes to perform better; run faster, recover better, 
reduce risk of injury and illness. However, in the past, the vast majority of research has 
been conducted in male athletes (8).   
 
Historical context 
Historically, medical trials were solely conducted in men. This gender bias in research 
dates back to before World War II where women were labelled as ‘protected subjects’ due 
to fear that any clinical testing could potentially cause harm to unborn foetuses (9). The 
fluctuations in hormones through the menstrual cycle also caused concern, increasing the 
complexity of studies resulting in a need for greater sample sizes, adding to the expense. 
Despite observations that women and men are physiologically different, men were deemed 
to be adequate proxies for women (10,11).  
 
In 1990, the National Institutes of Health, a part of the United States health agency, formed 
the Office of Research on Women’s Health in an attempt to overcome this research gender 
gap and to ensure adequate research into women’s health was conducted (10). Despite 
clear advances in research through the publication of resources (12), development of 
centres of excellence and the formation of multiple independent bodies (10), in 2010 a 
report by the Institute of Medicine concluded that research findings were not being 
effectively translated into general practice (13). A recent review looking at female 
representation in 1,382 sport and exercise research studies involving over six million 
participants between 2011 - 2013 found the representation of women to be only 39% (8). 
Further, within studies, where both genders were included in research, the relative 
representation of females across three key sports science journals was found to be 33 - 
37%. There were even fewer female only studies (14). Evidently, this is a significant cause 
for concern, and must be addressed.  
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Research has increasingly attempted to assess how athletic performance may be affected 
by the changes in levels of ovarian hormones (15,16). For example, Sung et al. (2014) 
found resistance training in the follicular phase to be more effective in the development of 
muscular strength when compared to training in the luteal phase, suggesting that for 
maximal benefit strength training could be based on time in the menstrual cycle (17). There 
is a need to investigate this further in the future as it could have significant implications for 
optimal performance.  
 
Female physiology and the menstrual cycle 
The ovarian hormones fluctuate in a cyclical pattern over an average of 28-days (15). As 
previously highlighted, this hormonal cycle can be a confounding factor to research in 
women, therefore where studies are conducted in women, the impact of the menstrual 
cycle is often ignored altogether, alternatively, women are only tested in the follicular 
phase, where hormone levels are at their lowest, or only women using a contraceptive 
device to stabilise hormone levels are included (16). Evidently, this has resulted in distinct 
knowledge gaps.  
 
A number of elite athletes have recently attributed sub-optimal sports performance to their 
menstrual cycle (18-20), but scientific knowledge surrounding female physiology is yet to 
elucidate conclusive reasons for this (15). Dependent on sport type, training volume and 
performance level, 6 - 79% of exercising women experience reproductive system 
irregularities (21). The principal menstrual cycle dysfunctions studied in exercising women 
are primary and secondary amenorrhea, anovulation, luteal phase deficiency and 
oligomenorrhea (22-24). Accordingly, pre-pubertal participation in intensive exercise is 
associated with a three-fold increase in susceptibility to amenorrhea (25). Yet, other 
menstrual cycle dysfunctions are seldom researched (24). 
 
Heavy menstrual bleeding  
Heavy menstrual bleeding (HMB) is defined by the National Institute for Care Excellence 
(NICE) in the United Kingdom, as “excessive menstrual blood loss which interferes with a 
woman’s physical, social, emotional and/or material quality of life” (26), while historically 
defined as 80 mL blood loss or more (27). However, as will be explained further in this 
thesis, neither of these are universally used or recognised, and are clearly difficult to 
evaluate. Therefore, other surrogates for diagnosis have been applied. But there is yet to 
be a recognised and validated means for HMB diagnosis. This is likely in part due to a lack 
of clarity regarding the desired outcome or impact of HMB, be it psychological or 
physiological impact. Is it the sheer psychological impact of perceived large amounts of 
blood loss or is it the repercussions or the associated factors that occur from excessive 
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blood loss, such as iron deficiency. Where there is an increase in menstrual blood loss, 
risk of iron deficiency is clearly enhanced, which can ultimately progress to iron deficiency 
anaemia (IDA). Despite being very common, IDA is slow to manifest and often goes 
unnoticed. It can significantly impact both quality of life and exercise performance. 
Identification of HMB could both highlight IDA risk and also enable earlier detection of a 
potentially debilitating issue (28,29).  
 
Despite this, there is a lack of research evaluating whether excessive blood loss is indeed 
an issue amongst those who exercise. Consequently, the potential for HMB to affect 
exercise performance is unknown, in addition to the reasons for this. This will be addressed 
in Chapter 4, where, using a combination of a number of existing definitions, the prevalence 
of HMB in both marathon runners and elite athletes will be evaluated (15). 
 
Historically, the primary treatment option for menstrual cycle dysfunctions has been 
through hormonal intervention, for example use of the oral contraceptive pill (OCP) or 
intrauterine devices (15,30,31). The use of hormonal intervention will provide a more stable 
hormonal milieu and is often used as a treatment option for HMB (15,31). However, recent 
research has identified negative outcomes of the use of hormonal contraceptives, such as 
the OCP, for example, OCP use has been associated with increased inflammation, 
decreased aerobic ability and a reduction in maximal power, while significantly, also 
potentially masking an underlying energy deficiency (31-34). The effects on performance 
of other possible forms of hormonal contraception such as intrauterine systems, the depot 
injection, the vaginal ring and the hormonal implant need further research.  
 
In summary, there is an evident need to assess prevalence of other menstrual cycle 
dysfunctions that could be an issue in athletes to try and elucidate reasons for reported 
effects on performance. Identification of HMB could highlight potential iron deficiency risk. 
Given the highlighted repercussions associated with use of hormonal contraception 
methods, alternative treatment options are also necessary.  
 
Menstruation and iron status 
Iron is an essential element, required by all cells, and vital for physiological function and 
physical performance (35,36). As a result of menstrual blood loss, women are particularly 
susceptible to iron deficiency and IDA (37). Due to the increased menstrual blood loss 
associated with HMB, it is recognised as an important risk factor for iron deficiency 
(28,29,38). However, as a result of the highlighted lack of research surrounding HMB in 
exercising women, it is unknown how this may affect performance and whether iron is 
causative. This will be addressed in chapter 5, where the mediating effect of iron status in 
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the association between identified HMB, and a reported disruption of the menstrual cycle 
to exercise training/performance will be evaluated. HMB and iron deficiency are both 
associated with increased fatigue (28,38), however to my knowledge, the role of iron in the 
causal pathway between HMB and fatigue has not been assessed. Excess fatigue will 
clearly impact exercise performance, and needs consideration if indeed HMB is found to 
be prevalent amongst those who exercise, therefore this will be addressed in chapter 6.  
 
Iron status and exercise capacity 
The impacts of IDA on exercise performance are well established (36), however, the 
consequences of iron deficiency without anaemia are less clear (39). The World Health 
Organisation (WHO) define IDA in non-pregnant woman as a haemoglobin concentration 
([Hb]) < 12.0 g·dL-1 and a serum ferritin < 15 µg·L-1 (40). But, there is much ambiguity 
surrounding the diagnosis of iron deficiency without anaemia, particularly amongst the 
exercising population. The WHO indicate that iron depletion occurs in both men and 
women when serum ferritin < 15 µg·L-1 (41), however a lack of iron in bone marrow has 
been observed when serum ferritin is 30 µg·L-1 (42). As a result of the haemoconcentration 
that can ensue post exercise and its acute phase reactant property, serum ferritin is subject 
to transient increases post exercise, potentially masking an underlying deficiency (43,44). 
Accordingly, it is estimated that day-to-day variation in serum ferritin in endurance athletes 
is 13 - 75% (45). Therefore, especially in elite athletes, cut-off values for serum ferritin used 
by sports medicine doctors to indicate iron deficiency in women, and therefore the point at 
which to intervene with either oral or intravenous iron supplementation are typically high, 
and may be as high as 40 µg·L-1 (46).  
 
Applying the principal that that a positive response to iron therapy indicates iron deficiency 
(47), studies evaluating the impact of iron repletion in iron deficient but not anaemic 
athletes when using a an inclusion criteria for serum ferritin ranging from 12 - 40 µg·L-1 
have produced conflicting results (48-54). This is likely due to inconsistencies in study 
protocols, the varying serum ferritin cut-off values, small sample sizes, and differing 
administration routes (48-54). Further, previous studies, using intravenous iron repletion 
have only been conducted in elite and well-trained populations (51,52), who, as previously 
highlighted, may respond differently to non-elite athletes (7). Since intravenous injections 
bypass gut absorption (55), they offer a much faster and more efficient way for repleting 
iron stores and assessing the effect. This will be addressed in chapter 7, where the impact 
of iron repletion will be evaluated in non-elite exercising women, with a serum ferritin ≤ 30 
µg·L-1.  
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It has been suggested that iron repletion may afford some other non-haematological 
effects in those who are iron deficient. In a non-athletic population, reductions in fatigue 
and improved cognition and quality of life have been observed in response to iron repletion 
(56,57). In fact, a recent study hypothesises that cognitive function is impaired prior to 
physical function when iron stores are sub-optimal (58). However, previous studies in iron 
deficient, exercising women have only evaluated the effect of iron repletion on 
physiological and haematological outcomes in isolation, subjective markers of fatigue and 
mood have not previously been considered in conjunction. Therefore, chapter 7 will also 
incorporate measures of fatigue and mood disturbance alongside markers of aerobic and 
exercise capacity.  
 
There are numerous side effects to oral supplementation including gastrointestinal distress 
and nausea (59), while supplementation when iron levels are sufficient is not associated 
with an improved performance (60). In fact, excessive supplementation can increase 
oxidative stress and inflammation (61). Further, in light of the transient increases in 
hepcidin, the peptide hormone responsible for control of iron absorption (62), that occur in 
response to iron, unnecessary supplementation has the potential to worsen iron status, 
due to windows of limited potential for absorption (51). Therefore, there is an evident need 
for better clarification about when intervention is necessary. 
 
This thesis will first assess whether HMB, when identified using a diagnostic series, is 
indeed a problem in those who exercise. It will then identify the prevalence and establish 
whether it is associated with reported disruption to exercise training/performance caused 
by the menstrual cycle. This will then be considered in relation to iron status. Finally, when 
using serum ferritin for diagnosis, the impact of iron deficiency on aerobic and exercise 
capacity in conjunction with fatigue and mood disturbance will be evaluated. Existing 
criteria and markers used for iron deficiency diagnosis will be questioned, alongside 
highlighting the impact that a deficiency has. This will also enable the assessment of 
whether iron deficiency, possibly caused by HMB, could be a cause for some of the 
reported detrimental effects on performance attributed to the menstrual cycle in women.   
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2 Review of the literature 
 
Exercising women are prone to a number of health issues, some caused or exacerbated 
by their participation in sport (7). These have the potential to impact on their exercise 
performance and general state of health and well-being. Results from a number of different 
studies have found risk of iron deficiency to be increased in those who exercise, with 
evidence suggesting 24 – 47% of exercising women to be iron deficient (59). In fact, the 
IOC recommends regular screening for iron deficiency (6). This section firstly explains what 
iron is and its role in the body. The diagnosis, causes of, and susceptibility to iron deficiency 
will then be discussed in addition to the possible effects it may have, particularly in those 
who exercise. Treatment options and optimal dietary sources will then be highlighted. The 
second half of this review will provide an overview of cellular and systemic iron 
homeostasis, describing the impact of exercise on iron metabolism. 
 
2.1 What is iron? 
2.1.1 Chemistry of iron 
Iron the most abundant element in the earth’s core, and the fourth most abundant in the 
earth’s crust (63). It has an atomic number of 26 and is a d-block element in the periodic 
table with an electron configuration of 1s22s22p63s23p63d64s2. As a transition metal, it can 
exist in many oxidation states from -2 to +6, however it is most commonly found in either 
its ferrous (Fe(II); Fe2+) or ferric (Fe(III); Fe3+) ionic form. Since the electrons in the 3s and 
4d outer subshells are close in energy, iron is very reactive, being able to change oxidation 
states and exchange electrons readily, therefore having good redox potential.  
 
The physical state of iron is dependent on the surrounding environment (64). It reacts 
readily with oxygen, and is influenced by the temperature and pH of its surroundings (64). 
The reactive nature of iron ions, with unoccupied d orbitals, means that it does not tend to 
exist alone in the environment, coordinating reversibly with various organic and inorganic 
ligands alongside a concomitant transfer of electrons (35). The primary ligands to which 
iron binds are oxygen, sulphur and nitrogen, for example, it is commonly found bound to 
oxygen as haematite (Fe2O3) or magnetite (Fe3O4) (35). It’s ability to adjust redox potential 
and electronic spin state (1000mV to -550mV) means that it is highly useful in human 
physiology and has evolved to become an invaluable element for biochemical reactions 
(35,65). It is therefore evident that a lack of iron is likely to have a significant impact on 
physiological function.   
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Despite iron being an essential micronutrient for all living organisms (66,67), excess free 
iron within tissues under aerobic conditions can be very harmful. With very good redox 
potential, iron is highly toxic, readily reacting with oxygen, to produce reactive oxygen 
species (ROS) based on Fenton and Harber-Weiss reactions (68). Therefore, regulatory 
protection mechanisms have evolved, as will be discussed further in this thesis, 
significantly, in part as a means for protection against the harmful effects of free iron, in 
aerobic conditions, and at a neutral pH, iron is most commonly found in its ferric form (69). 
The insoluble nature of ferric (Fe3+) ions reduces iron availability in this environment. This 
means that despite the physical abundance of iron, acquisition at a neutral pH, in aerobic 
conditions, is problematic (69).  
 
2.2 Distribution of iron in the body 
Typically, the human body contains 3 - 4 g of iron (70). Very specific transport processes 
and mechanisms have evolved to enable the controlled uptake of the insoluble ferric iron 
into the bloodstream (69). The majority of body iron is intracellular, and approximately two 
thirds (~2 – 3 g) is incorporated into haemoglobin within erythrocytes, and around a tenth 
is stored as myoglobin within muscle (71). The rest is located to macrophages (in the liver, 
spleen and bone marrow), iron containing proteins and enzymes (such as transferrin), with 
any excess iron being stored as either ferritin or haemosiderin (typically 0 - 1g) (71). Ferritin 
and haemosiderin are iron storage proteins and are primarily found in the liver and spleen, 
but can also be found in the duodenum, bone marrow, skeletal muscle and other 
anatomical areas (72). Since iron containing proteins are essential for ATP production, iron 
is present in all cells to some extent. Despite the toxic nature of iron, there is no specific 
iron excretion mechanism, therefore regulation of iron metabolism, transport and storage 
occurs in a tightly controlled process, and control of total body iron is maintained through 
the regulation of iron absorption which will be discussed in the second part of this section 
(73).  
 
On a daily basis, very little iron is lost, amounting to approximately 1 - 2 mg each day, and 
this is primarily from epithelial shedding, particularly from skin and the gastrointestinal and 
genitourinary tracts, in addition to sweat (74,75). Menstruating women inevitably 
experience increased blood loss, and, on average this amounts to another 1 – 2 mg each 
day when bleeding (74).  
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2.3 Functions of iron 
Iron is required for many biological functions, including; oxygen transport and storage, 
cellular and mitochondrial respiration, electron transfer reactions, cell growth and 
differentiation, while also vital for immune function (35). The majority of iron exists in 
complexes bound to proteins, either coordinated to amino acid side chains or forming part 
of a prosthetic group (73). Being necessary for their synthesis and function, iron-containing 
proteins can either be haem compounds, such as haemoglobin and myoglobin, haem 
enzymes, such as haem oxidase, or non-haem compounds, such as metalloflavoproteins 
(67). A summary of the different types of iron-containing proteins and examples of their 
key roles of iron are described below:  
 
2.3.1 Iron-containing haem compounds 
2.3.1.1 Oxygen transport in blood 
Oxygen is transported in the blood in two forms, approximately 98% is reversibly bound to 
haemoglobin in erythrocytes, and the remaining 2% is dissolved in the plasma. Within each 
erythrocyte there are approximately 270 million haemoglobin molecules. On a daily basis, 
erythropoiesis typically requires 20 - 30 mg of iron as more than two million erythrocytes 
are produced and cleared each second (76). Therefore, the majority of plasma iron is 
directed to the bone marrow for this process (76).   
 
Haemoglobin is a tetrameric protein made up of two pairs of interconnecting polypeptide 
globulin chains. One pair of chains is alpha-like and the other is beta-like. Each chain has 
a haem prosthetic group comprised of a protoporphyrin IX tetrapyrrole ring and a central 
iron atom, which is typically in its ferrous (Fe2+) form (35). Dioxygen can reversibly bind to 
the haem prosthetic groups, facilitating oxygen transport in the circulation (35,77). Since 
each haemoglobin molecule has four haem groups, there are four oxygen binding sites, 
and therefore it can bind to and transport four oxygen molecules. Haem synthesis is a 
complex process involving eight different reactions and enzymes. Half of the reactions take 
place in the cytoplasm and half in the mitochondrion. Iron is essential for functioning of the 
enzyme 5-aminolevulinic acid synthase, which controls the first step in haem synthesis, in 
the mitochondrion (78). Therefore, iron availability in part dictates the initial rate-limiting 
step in haem synthesis (35). The following four steps in the haem synthesis pathway occur 
in the cytoplasm. Then the final three reactions take place in the mitochondrion, with the 
process ultimately involving the insertion of ferrous iron into the protoporphyrin ring (78). 
This final step is catalysed by ferrochelatase, an enzyme that also contains iron as part of 
an iron-sulphur cluster (79,80). Iron regulatory proteins and iron regulatory elements are 
involved in iron sensing to ensure enough iron is present to enable synthesis of erythroid 
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haem. Therefore, iron is both a vital part of haem and the erythropoiesis process (81). Iron 
is essential for the process by which oxygen is transported from the lungs to tissues for 
oxidative phosphorylation. 
 
Maximal oxygen uptake, which can also be termed V̇O2max is determined by both the 
amount of oxygen in the blood and the oxygen consumption of skeletal muscle (1). As the 
transport of oxygen in blood is dependent on haemoglobin, this is clearly dependent on 
sufficient iron availability. The unloading of oxygen at target tissues from haemoglobin is 
dictated by the surrounding environment. The affinity of haemoglobin for oxygen varies 
dependent on pH, pCO2, the presence of phosphates and the temperature. Changes in 
these conditions alter the haemoglobin-iron interaction, which in turns reduces or increases 
oxygen affinity (35). 
2.3.1.2 Oxygen transport in muscle  
Iron is also a component of myoglobin, a protein that functions to transport oxygen from 
erythrocytes to muscle myocytes. Myoglobin consists of a single polypeptide chain, 
containing eight alpha helices (82). Similarly to haemoglobin, it has a porphyrin ring 
containing a central ferrous (Fe2+) ion. The ferrous ion interacts with six ligands in a 
myoglobin molecule, one of which is the binding site for oxygen, to which it can bind 
reversibly (82). Myoglobin will reduce in states of iron deficiency, decreasing oxygen 
availability for myocyte function (83).  
2.3.1.3 Electron transfer reactions and iron containing enzymes 
There are a number of iron-containing proteins that are involved in oxidative 
phosphorylation in the inner mitochondrial membrane, where a series of redox reactions 
occur as proteins donate and accept electrons in the electron transfer respiratory chain 
(84). This action creates a pH electrochemical gradient across the membrane, which is 
then used by protons as they enter the mitochondrion through ATP synthase, driving ATP 
synthesis from ADP. A total of 40 different proteins are involved in the respiratory chain 
including both haem-containing proteins and non-haem iron-sulphur proteins (35).  
 
ATP functions to store and transport chemical energy within cells for metabolism. ATP is 
required by all cells, and when the body is placed under increased physiological strain, for 
example, during exercise, demand for ATP is increased. Hence, there are large numbers 
of mitochondria in muscle tissue to meet the increased ATP requirements that typically 
occur in this tissue. Energy is released from ATP as it is broken down into ADP.  
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2.3.2 Iron containing haem enzymes 
Iron-containing haem enzymes are a group of enzymes which have a haem prosthetic 
group typically complexed to another enzyme (84). Cytochoromes are a type of haem-
containing enzymes, and are involved in oxidative phosphorylation. Haem is located at the 
active site, and electrons are simultaneously accepted or donated by the iron ion, as it 
changes oxidation state, transferring between its reduced ferrous (Fe2+) state and its ferric 
(Fe3+) oxidised state (35). Specific examples include cytochromes b, bc1 and c, 
cytochrome c oxidase and succinate dehydrogenase (85). Cytochrome bc1 also has an 
iron-sulphur protein with a 2Fe-2S centre, which is called a Rieske Centre (86). 
 
2.3.3 Iron containing non-haem enzymes 
Iron-sulphur proteins form a group of non-haem enzymes, where iron is bound to either 
two or four sulphur atoms (86). Iron-sulphur cluster biogenesis takes place in mitochondria 
(84). The iron-sulphur groups are typically ligated to cysteine residues on proteins (86). 
Ferredoxins (e.g. NADH dehydrogenase) are an example of iron-sulphur proteins which 
are involved in electron transfer reactions in mitochondria. Again, here an iron ion 
simultaneously loses or gains an electron transferring between its reduced ferrous (Fe2+) 
state and its ferric (Fe3+) oxidised state, without a significant change in structure. Unlike 
cytochromes, iron-sulphur proteins are non-haem, and they specifically accept or donate 
a single electron. They are also involved in regulatory iron sensing and the ligation of 
certain substrate ligands (87). Many cytosolic and mitochondrial types of iron-sulphur 
proteins have been identified and more are likely to be discovered as technology advances 
(88).  
 
2.3.4 Immune function 
Iron is required for the immune response, however invading pathogens also require iron, 
so internal iron sequestering is necessary to prevent pathogenic availability and therefore 
survival (35,89). Inevitably, pathogens have evolved, finding ways to leach iron for survival. 
However, protection mechanisms are in place to reduce iron availability; firstly, the majority 
of iron is intracellular, located to haemoglobin and myoglobin reducing availability; and 
secondly any free iron in the circulation is primarily sequestered by high affinity proteins, 
namely haptoglobin and haemopexin (35,89).  
 
The iron-regulatory peptide hormone hepcidin is also involved when an infection is present, 
in a process that will be described further subsequently, its expression is upregulated, 
increasing release from the liver, and limiting iron release into the circulation, promoting 
cellular storage (90), and potentially preventing uptake into enterocytes through control of 
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divalent metal transporter 1 expression (91). As part of the immune response, extra 
hepcidin is also released from some immune cells, including macrophages and neutrophils 
(92). There are a number of further mechanisms which restrict iron availability, limiting 
intracellular iron availability, sequestering iron (89).  
 
2.3.5 Other functions 
In addition to the above, iron is necessary for many other physiological processes, for 
example iron-sulphur clusters as cofactors for many processes (93). Indeed, it is thought 
that more necessary functions of iron will be discovered in time (93). DNA synthesis for 
example is iron dependent, with iron being an essential cofactor for the production of the 
rate limiting enzyme, ribonucleotide reductase (71). It is also required for DNA replication, 
steroid synthesis, gene regulation and cell proliferation and differentiation (71).  
 
2.4 A lack of iron: iron deficiency and iron deficiency anaemia 
Iron deficiency can be defined as a reduction in total body iron, typically occurring when 
iron losses exceed iron absorption over extended periods of time. Iron deficiency is the 
most common nutritional deficiency globally (94). Given the many essential roles of iron, a 
lack of iron has the potential to fundamentally impact upon physical, physiological and 
psychological function. Accordingly, there is much scope for impairments to exercise 
capacity and functional performance as will be discussed in more detail subsequently. 
 
Iron deficiency can occur in isolation or in conjunction with anaemia. Anaemia can be 
defined as a reduction in erythrocytes or a reduction in haemoglobin (95). Accordingly, iron 
deficiency anaemia (IDA) occurs when the cause for the reduction in erythrocytes and 
haemoglobin is a lack of iron. Where iron deficiency occurs in isolation, and therefore body 
iron stores are either reduced or depleted, typically defined by a decrease in serum ferritin, 
but haemoglobin ([Hb]) is still within the clinical reference range used for the diagnosis of 
IDA ([Hb] 12.0 – 16.0 g·dL-1 in women), iron deficiency non-anaemia (IDNA) is diagnosed. 
In IDNA it is assumed that iron supply for erythropoiesis is suffice, however if left untreated, 
IDNA can progress to IDA.  
 
Both iron deficiency and IDA can manifest in many ways including fatigue, muscle 
weakness, dizziness, pallor, often with non-specific signs and symptoms that are slow to 
develop so can often go unnoticed with the establishment of a new sense of ‘normal’. As 
a result, the impacts are often not appreciated until iron levels are repleted (96). There are 
also some neurological sequelae that can occur as a result of IDA including pica (a 
compulsive need for non-food materials including ice, paper and dirt), restless leg 
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syndrome, reduced neurotransmitter synthesis, hypomyelination and neurocognitive 
effects (97).  
 
2.5 Diagnosis of IDA and iron deficiency 
The World Health Organisation (WHO) define anaemia as a [Hb] < 13.0 g·dL-1 in men, [Hb] 
< 12.0 g·dL-1 in non-pregnant women, and [Hb] < 11.0 g·dL-1 in pregnant women (95). The 
most accurate means for diagnosing iron deficiency is through bone marrow aspiration, 
however due to the invasive nature of this technique, it is seldom used (98). Since a good 
correlation has been found between serum ferritin and total body iron stores under steady 
state conditions, this is typically used as the primary marker of iron status, and therefore 
for the diagnosis of iron deficiency (99). The WHO define iron depletion as serum ferritin < 
15 µg·L-1 (41). Iron deficiency anaemia (IDA) is therefore defined as [Hb] < 13.0 g·dL-1 
alongside a serum ferritin < 15 µg·L-1 in men, and as [Hb] < 12.0 g·dL-1 alongside a serum 
ferritin < 15 µg·L-1 in non-pregnant women (100). 
 
However, the efficacy and reliability of both [Hb] and serum ferritin have been questioned, 
particularly in certain populations, including in those who exercise (45). Accordingly, the 
clinical ranges may be of limited significance in this group.  
 
2.5.1 Serum ferritin for diagnosis of IDA in regular exercisers  
It is widely acknowledged that serum ferritin is the primary means for assessing iron stores 
in healthy individuals (101). However, the suitability and reliability of serum ferritin as a 
means for indicating iron levels in those who exercise has been questioned. In endurance 
athletes specifically it is estimated that day-to-day variation is 13 - 75% (45). Levels have 
been shown to increase directly after exercise (102). One study found a 22% increase in 
serum ferritin in response to a maximal rowing ergometer test (102). The cause is not fully 
understood, but several factors have been suggested including: a.) a haemoconcentration, 
as a result of exercise-induced plasma volume shifts; b.) the effect of an inflammatory 
response, where since ferritin is an acute phase protein, dependent on intensity, exercise 
may trigger a transient increase in inflammatory cytokines, acutely increasing levels of 
serum ferritin; and c.) an exercise-induced red blood cell lysis (43,44). Accordingly, there 
is evident potential for underlying iron deficiency to be masked, and for there to be a 
disconnect between serum ferritin levels and iron stores in bone marrow. It is therefore 
important to appreciate that serum ferritin only reflects body iron stores in the absence of 
inflammation. 
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The specific serum ferritin cut-off for iron deficiency diagnosis is also unclear. When 
compared to a bone marrow aspiration, a diagnosis of iron deficiency using serum ferritin 
< 16 µg·L-1 has a specificity of 98% and a sensitivity of 75% (98). Further, the absence of 
bone marrow iron stores have been demonstrated when ferritin ≤ 12 µg·L-1 (103). However, 
there has been much debate over the point at which low serum ferritin levels may have a 
detrimental impact on physiological function, and therefore athletic performance. The 
typical reference range in women is extremely broad, from 10 – 200 µg·L-1 (104,105). Yet, 
in 1993, Hallberg et al. suggested a lack of iron stores and signs of iron deficient 
erythropoiesis when serum ferritin was 25 - 40 µg·L-1 (98). Others also question the lower 
end of the reference range, feeling that despite being the point at which the WHO specify 
iron depletion, an iron deficient state will have already been reached by this point, likely 
affecting physiological function (98,106). Another study showed that when using a serum 
ferritin cut-off of 30 µg·L-1, the sensitivity and specificity for iron deficiency diagnosis 
improved to 92% and 96% (42). While Heinrich et al. (1970) identified that a cut-off of 30 
µg·L-1, through the assessment of the absorption rate of 59Fe, could conclusively be used 
to identify iron deficiency, while the possibility of pre-latent iron deficiency needs to be 
considered in those with a serum ferritin in the range of 30 – 99 µg·L-1 (107). As a result, 
there is a lack of consensus over the required serum ferritin level to prevent a negative 
impact on performance in sports medicine, where the pursuit for optimal performance is 
paramount (46). As will be discussed further in Section 2.13, diagnostic criteria used in 
studies assessing the impact of iron deficiency have used a range of cut-offs for iron 
deficiency diagnosis, and this will be addressed further in this thesis.  
 
2.5.2 Haemoglobin concentration ([Hb]) for diagnosis in those who exercise 
[Hb] is dependent on the total circulating mass of haemoglobin and plasma volume. 
Therefore, [Hb] is susceptible to distinct variation through intravascular fluid shifts, so 
exercise, posture and hydration status can all impact on the result, potentially causing an 
inaccurate representation (108,109). For example, an acute haemoconcentration can 
occur post exercise, while a haemodilution, a pseudoanaemia, can also result in response 
to an expansion in plasma volume in response to chronic training (44,110). In a 
measurement which will be discussed subsequently, the use of total haemoglobin mass 
provides a more reliable alternative (Section 2.5.3). Since the total amount of oxygen 
transported in plasma is minimal, this provides a much more accurate means for assessing 
oxygen carrying capacity (1). 
 
The typical female [Hb] reference range is broad, (12.0 - 16.0 g·dL-1), therefore there is 
potential for significant decreases in [Hb] to occur before IDA is diagnosed, effectively 
creating a relative state of IDA. This was again highlighted as an issue by Hallberg et al. 
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in 1993, he proposed that the relative decrease in [Hb] from the individual’s habitual optimal 
value should be interpreted as opposed to the individual value itself (98). This suggests 
that [Hb] should be longitudinally monitored, however determination of a baseline ‘normal’ 
value may be problematic. 
 
Clinically, both [Hb] and serum ferritin measurements are required for the diagnosis of IDA. 
Transferrin saturation and serum iron may also be considered. However, despite the 
evident questions of the suitability of serum ferritin and [Hb], and ambiguity over cut-off 
values for diagnosis, the use of serum ferritin and [Hb] are currently acknowledged to be 
the most efficient and cost effective means for diagnosing IDA and iron deficiency, so these 
are frequently measured in isolation (111,112).  
 
2.5.3 Other candidate markers for the determination of iron status 
In addition to transferrin saturation and serum iron, other biomarkers that may be more 
effective for analysis of iron status and warrant future investigation include transferrin and 
soluble transferrin receptor. Soluble transferrin receptor is less biologically variable than 
serum ferritin, and is not an acute phase reactant (113). It is also a marker of increased 
erythropoiesis (114). Interestingly, the serum transferrin receptor/log ferritin index has also 
shown significant potential for the indication of IDA and iron deficiency, with indication 
improving when combined with the individual readings of serum ferritin and serum 
transferrin receptor (115). However, particularly in a sports medicine context, serum ferritin 
is currently the primary measure used (111,112). 
 
Red cell indices including mean corpuscular haemoglobin concentration (MCHC), mean 
corpuscular haemoglobin (MCH) and mean corpuscular volume (MCV) can also be used 
for the diagnosis of pre-latent anaemia and anaemia. These are often measured as part of 
the full blood count alongside [Hb], and can particularly be used to aid diagnosis of the 
specific type of anaemia as will be explained further in Section 2.7.  
 
2.6 Total haemoglobin mass 
Total haemoglobin mass offers a different means for indirectly assessing iron status. Total 
haemoglobin mass represents the total circulating mass of haemoglobin in the body. By 
definition, anaemia indicates a deficiency in [Hb], which will cause a reduction in maximal 
oxygen uptake (1). Maximal oxygen uptake, also termed V̇O2max, is determined by both the 
amount of oxygen in the blood and the oxygen consumption of skeletal muscle, with iron 
being essential for both. Clinically, [Hb] is typically used to determine the amount of oxygen 
in that can be carried in the blood, hence this is used for IDA diagnosis. Therefore, in states 
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of IDA, V̇O2max will be compromised. However as demonstrated in Figure 2.1, the 
correlation between V̇O2max and [Hb] is small, reflecting the confounding influence of blood 
volume on [Hb], again questioning the suitability of [Hb] for IDA diagnosis (1). There is a 
much stronger relationship between total haemoglobin mass and V̇O2max (Figure 2.2), 
suggesting this to be a more reliable means for indication of a reduction in maximal oxygen 
transport uptake than [Hb], and for the indication of when IDA is present (1). 
 
Figure 2.1 – The association between haemoglobin concentration and maximal oxygen 
uptake (V̇O2max). Figure adapted from (1). 
 
Figure 2.2 – The association between total haemoglobin mass and maximal oxygen 
uptake (V̇O2max). Figure adapted from (1). 
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2.7 Prevalence of IDA, anaemia and iron deficiency 
In 2011 the World Health Organisation (WHO) estimated that globally, anaemia is present 
in 2 billion individuals, equating to 29.0% of non-pregnant women of a reproductive age 
(aged 15 - 49), increasing to 38.0% of pregnant women (aged 15 - 49), with the greatest 
prevalence being in infants aged 5 - 59 months, where 42.6% were found to be anaemic 
(273.2 million) (116). This research did not include men or the elderly, however earlier 
research conducted from 1993 - 2005 found prevalence in men to be 12.7%, equating to 
260 million, while prevalence in the elderly was 23.9% (164 million) (37). Therefore, 
pregnant women and young infants are at the greatest risk of anaemia, while risk is lowest 
in adult males. The increased prevalence in the elderly is likely due to a greater likelihood 
of inflammatory conditions or illnesses which compromise iron absorption.  
 
The most common cause of anaemia across the world is iron deficiency, being the cause 
for approximately half of all cases of anaemia (117). While more common in less developed 
countries, IDA, anaemia and iron deficiency are prevalent conditions across the total 
population (116).  
 
Despite relatively cheap and effective treatment options, iron deficiency is the most 
common nutritional deficiency globally, thought to affect approximately 50% of the total 
population (94,111). According to the National Diet and Nutrition Survey in the general 
population in the United Kingdom, the prevalence of iron deficiency (serum ferritin < 15 
µg·L-1) in adult men aged 19 - 49 is 0 - 2.5 %, whereas in non-pregnant women this is 
ranges from 8.2 – 16.0 % (118). As will be described subsequently, there are certain 
groups with an increased susceptibility to iron deficiency, and this thesis will specifically 
focus on those who exercise (59). This risk is clearly greater in menstruating women, and 
exacerbated further as volume of menstrual blood loss increases. There is however 
significant variation in statistics defining the prevalence of both iron deficiency alone and 
IDA in exercising women in the literature. In exercising women specifically, prevalence of 
IDNA varies from 24 – 47% (59), while IDA prevalence in exercising women varies from 8 
– 14% (119-121). Part of this ambiguity is likely to be caused by the effects of different 
sport, intensity and volume of training in addition to other factors which will be explained 
further in this thesis. 
2.8 Types and causes of anaemia 
There are different types of anaemia, with a variety of different associated aetiologies and 
characteristics. These are identified by assessing the characteristics of red blood cells, 
including their size and [Hb]. Historically, this classification system, as outline outlined by 
Maxwell Wintrobe in the 1930s, used MCV and MCHC for anaemia-type identification 
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(122,123). More recently red cell distribution width (RDW) was added to improve diagnostic 
ability (124), however due to variation in the technology used for assessment and therefore 
reference intervals there is a need for a variety of algorithms and calculation to aid 
diagnosis (125,126). With the advance of technology, new techniques and tools are 
emerging designed to increase the reliability and accuracy of the diagnosis of anaemia, 
producing specific percentages of cells that are hypochromic, macrocytic and microcytic 
(126). The different types of anaemia and possible aetiology and characteristics associated 
with them are explained below:  
2.8.1 Macrocytic anaemia 
In macrocytic anaemia, erythrocytes are larger than normal, this is typically diagnosed by 
an increased mean corpuscular volume (MCV) or a greater percentage of macrocytic cells 
(126). There are two types of macrocytic anaemia; megaloblastic or non-megaloblastic, 
which are caused by a number of different factors including; a nutritional deficiency 
(primarily vitamin B12 or folate), drug use, the presence of a chronic illness (e.g. 
hypothyroidism, reticulocytosis) or a disordered bone marrow (127,128). These will either 
result in a defect in DNA synthesis, or a defect to the erythrocyte membrane (127,128). 
Typically, where there is a DNA defect, erythrocytes are oval in shape, whereas where the 
membrane is defected, cells are round (125,128). The most likely cause of megaloblastic 
macrocytic anaemia in exercising women is a vitamin B12 or folate deficiency, and a lack 
of either of these nutrients causes a defect in DNA synthesis, resulting in oval shaped 
erythrocytes (127,128). Under these circumstances, RNA synthesis continues regardless, 
and dyspoietic cells are produced which are larger than normal in size, with a bigger 
nucleus (127). The most common cause of non-megaloblastic macrocytic anaemia is 
excessive alcohol intake (129). 
2.8.2 Microcytic anaemia 
In microcytic anaemia, haemoglobin synthesis is affected, and as a result erythrocytes are 
smaller with a lower haemoglobin content than normal and therefore mean corpuscular 
volume (MCV) is low and there are an increased number of hypochromic cells (126). There 
are four different causes of microcytic anaemia including thalassaemia, iron deficiency, 
anaemia of inflammation and sideroblastic anaemia (130).  
 
Thalassaemia  
This is a hereditary condition where there is a mutation to either the ∝- or )- globin gene, 
resulting in either a reduction in or a lack of synthesis of the respective haemoglobin chain 
(130). As a result, a reticulocytosis occurs. 
 
Iron deficiency anaemia  
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This is the most common type of anaemia and occurs because there is insufficient iron for 
the erythropoietic process, causing cells to be microcytic and hypochromic. Senescent 
erythrocytes will therefore have less iron impacting upon the essential functions for which 
iron is required. IDA can be multifactorial and the causes will be explained in further detail 
in Section 2.9.  
 
Anaemia of inflammation  
An increased production of inflammatory cytokines causes renal erythropoietin release to 
be supressed, while also resulting in increased hepcidin release, reducing iron uptake and 
entry into the circulation (130,131). As a result, erythropoiesis is reduced. 
 
Sideroblastic anaemia  
This can be either acquired or hereditary. Iron accumulates in the mitochondria of atypical 
developing erythroblasts. Iron is not available for haem synthesis, resulting in the 
development of ringed sideroblasts as opposed to erythrocytes (130). One relatively rare 
cause of sideroblastic anaemia is a vitamin B6 deficiency (132). Pyridoxal phosphate, 
which is a catabolically active form of vitamin B6, acts as a cofactor for 5–aminolevulinate 
synthase, which catalyses the initial step in haem synthesis, where coenzyme A, 5-
aminolevulinic acid and carbon dioxide and produced from the reaction between succinyl-
CoA and glycine (133). Therefore, a lack of vitamin B6 will inevitably affect haem synthesis.  
  
There are a number of techniques used for identification of the aetiology of microcytic 
anaemia, including determining the proportion of hypochromic cells. In states of IDA, more 
red blood cells are hypochromic than microcytic when compared to those with a )-
thalassaemia trait (134).  
2.8.3 Normocytic anaemia 
In some cases during early state anaemia, after acute blood loss or if there are multiple 
underlying anaemia causes present, countering one another (e.g. iron and vitamin B12 
deficiencies), values for MCV can be within the normal range (128). This is a common form 
of anaemia, highlighting the need for the newer means for diagnosis (126).  
 
2.9 Causes of iron deficiency 
Iron deficiency is frequently multifactorial, and there are four primary causes including:  
1. Increased loss 
2. Decreased intake 
3. Increased demand 
4. Decreased absorption 
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1. Increased loss 
This is most commonly caused by a large amount of blood loss. There are several ways 
that this can occur, examples include: a haemorrhage, major surgery, illness, childbirth, 
significant menstrual blood loss, blood donation, excess use of non-steroidal anti-
inflammatories, bleeding defects, and athletic-related losses (135). Particularly in less 
developed countries, malaria is a major cause of increased blood loss through 
intravascular haemolysis, with a resulting haematuria. The immune response to malaria 
also supresses erythropoietin release.   
 
2. Decreased intake 
Women typically eat less iron rich food than men, and unsurprisingly risk of a lack of intake 
is increased in vegetarians and vegans (36). However, poverty and malnutrition resulting 
in a lack of dietary iron intake are the most common causes of iron deficiency particularly 
in less developed countries (135). 
 
3. Increased demand 
Infants and adolescents have an increased requirement for iron as they grow, and pregnant 
women, particularly in their second and third trimesters also have an increased need as 
foetal and maternal erythroid mass increases. Demand is also increased post-partum; 
however, this is likely offset by the absence of menstruation (136). Increased erythropoietic 
stimuli will also require increased iron, this could be as a result of a hypoxic stimulus, 
increased exercise training, or administration of erythropoiesis stimulating agents (135). 
 
4. Decreased absorption 
Conditions resulting in inflammation, increasing hepcidin production will reduce iron 
absorption, such as irritable bowel disease and chronic heart failure. A reduction in iron 
absorption can also occur as a result of various types of infection which may trigger an 
immune response such as malaria, or other conditions specifically inhibiting absorption 
such as Helicobacter pylori infections, coeliac disease and bariatric surgery (135-138). 
Alternatively, the consumption of certain foods (as will be discussed further below) can 
also have an impact. 
 
Notably, there are genetic conditions that can result in loss of function or mutations to 
genes involved in iron metabolism which can increase susceptibility to iron deficiency.   
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2.10 Iron bioavailability, types of dietary iron, and essential trace 
elements 
2.10.1 Iron bioavailability and types of dietary iron 
The typical western non-vegetarian diet contains approximately 7 mg per 1000 kCal of iron, 
however of this, it is estimated that only 5 – 35 % is absorbed (67). On a daily basis, this 
equates to in the region of 1 - 2 mg. Recommended daily intake for non-pregnant 
premenopausal women is 18 mg, which is significantly more than the 8 mg advised for 
men (139). However, absorption of iron is dependent on a number of factors including the 
type of iron (i.e. haem or non-haem) (140). Haem iron primarily comes from the 
haemoglobin found in animal sources; meat and fish. Whereas non-haem iron typically 
comes from plant-based sources, including vegetables, fruits, legumes, fortified cereals, 
nuts and pulses. 
 
The bioavailability of haem iron is superior to that of non-haem, therefore absorption of 
haem iron is better. Approximately 15 – 35 % of haem iron is absorbed, compared to 2 – 
20 % of non-haem iron. However, typically, intake of non-haem iron is much greater than 
haem iron, so its relative contribution to total iron is often larger (140,141). 
 
As will be explained further, despite being easier, research is inconclusive as to the 
mechanism by which haem iron is transported into enterocytes. The haem iron transporter 
- HCP1 has been suggested, but clarity as to the specific process is lacking (142). As will 
be described in further detail below, absorption of non-haem iron is more complex, hence 
explaining the difference in bioavailability. There is also potential for various other dietary 
elements to affect absorption of iron, non-haem iron in particular (140,143).  
 
2.10.1.1 Essential trace elements for iron absorption 
Alongside ensuring iron intake and uptake is suffice, it is also important to appreciate the 
influence of other elements which are also necessary for iron acquisition and metabolism. 
One such example is copper. This is an essential trace element for iron absorption, and a 
deficiency can also be a cause for anaemia with or without iron deficiency (144). Despite 
definitive research in animal models, the exact mechanism by which this manifests in 
humans is not conclusive (144).There are a number of copper-dependent proteins that are 
involved in iron uptake and utilisation, and a lack of copper has been found to result in a 
drop in [Hb] (145,146). It has previously been suggested that the mechanism involves a 
reduction in copper-dependent ferroxidases, in a process that will be described further 
subsequently, the copper-dependent ferroxidases ceruloplasmin (in hepatocytes and 
macrophages) and hephaestin (in enterocytes), are necessary for the oxidation of ferrous 
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iron to ferric iron for transferrin binding and transport in the circulation, in addition to 
preventing harmful ferrous iron from entering the circulation (144,145). However, 
increasing evidence suggests that this may not be the primary mechanism by which a 
copper deficiency impacts, and that there are other copper-dependent processes which 
are also involved in iron uptake and utilisation that cause erythropoiesis to be restricted 
when there is a lack of copper (144). Evidently, while copper uptake needs to be suffice 
for the maintenance of optimal iron status, further research is required to this avail.  
 
2.10.2 Dietary factors that can impact iron absorption 
There are several dietary elements that are thought to play a role in the cellular uptake of 
dietary iron. As previously explained, with no iron excretion mechanism, there is a tightly 
regulated uptake process. This is primarily controlled by an internal feedback mechanism 
involving iron sensing and hepcidin, however dietary factors can also have a significant 
influence.  
 
Research demonstrating the inhibiting and enhancing effects of dietary elements is often 
inconclusive, primarily because the effects are problematic to measure. The effect of an 
element that enhances dietary iron uptake may be offset by an inhibitor, for example eating 
a kale and broccoli salad with wholegrain bread. Kale and broccoli are good sources of 
ascorbic acid, aiding iron uptake, while the wholegrain bread is rich in fibre and phytates, 
potentially countering this (147).   
 
While there is a known association between iron absorption and iron stores (ferritin) (98), 
there is a dearth of conclusive research assessing the combined effect of dietary iron intake 
and menstruation on risk of iron deficiency. Very few have found a correlation between 
total dietary iron intake and iron status (148-151). Specific haem intake however has been 
found to correlate more effectively by most (147,149,152,153). Accordingly, some have 
found vegetarianism to be associated with an increased risk of low serum ferritin (154,155), 
including a recent meta-analysis (156). Yet interestingly, in 2005, a study was conducted 
in the United Kingdom comparing iron status in those following a lacto-ovo-vegetarian diet 
(no meat or fish for at least a year), a poultry/fish diet and a red meat diet (157). Serum 
ferritin in the poultry/fish diet was found to be significantly greater than the other two 
groups, which were very comparable (157). However, this study also established that 
menstrual blood loss was a much more significant predictor of serum ferritin levels than 
iron intake (157). With blood loss being inversely proportional to serum ferritin levels (157). 
In fact, dietary iron intake was not associated with serum ferritin, despite the superiority of 
the poultry/fish diet. While iron status in those following a lacto-oco-vegetarian diet did not 
appear to differ to those following a red meat diet, total iron intake was actually greater in 
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those in the lacto-ovo-vegetarian group, potentially explaining this finding (157). Evidently 
further research is required to specifically evaluate the impact of diet on iron status, 
including assessing the effect of other nutritional elements that could alter absorption.  
2.10.2.1 Enhanced iron uptake 
Ascorbic and citric acid 
Ascorbic and citric acids found in foods such as fruits, vegetables and juices are the only 
factors that can enhance iron uptake in a vegetarian diet (158). Ascorbic acid can act in 
two ways to optimise iron uptake. The primary mechanism is through its ability to reduce 
ferric iron to ferrous iron prior to entry into enterocyte, facilitating iron absorption (159). It 
is also thought to be able to chelate iron, further enhancing iron uptake (159). However, 
the positive impact of ascorbic and citric acids on iron uptake can be reduced by cooking 
and processing, therefore careful handling should be applied (160). Studies assessing the 
effect of ascorbic acid on iron status have been equivocal, with some concluding no impact, 
however there are a number of possible confounding factors that should be considered, 
including the absence of a control group, other potentially confounding deficiencies, 
insufficient time for an effect to manifest, and small sample sizes (147). Further, the criteria 
used for iron deficiency diagnosis varied and not all participants were deficient. Conversely, 
a randomised controlled trial where 122 iron deficient women ([Hb] ≥ 11.0g·L-1 and serum 
ferritin ≤ 40µ·L-1) were given fruit juice daily, some fortified with iron and some not, found 
that iron status only improved in those consuming the fortified juice (161). This suggests 
that iron intake may need to be increased alongside ascorbic acid. 
 
Animal and fish products 
Intake of meat, poultry and fish has also been shown to enhance non-haem iron uptake. 
Yet, despite the efficacy being well evidenced, the specific mechanism by which animal 
tissue may aid iron uptake is unsure. It has been suggested that the peptides within the 
animal tissue act in a similar way to ascorbic acid, reducing and chelating iron (162,163). 
Others have suggested a specific involvement of glycosaminoglycan’s and L-a-
glycerophosphocholine (164,165). Evidently further research is warranted as these factors 
could have a significant impact on iron status. 
2.10.2.2 Inhibition of iron uptake 
Factors that can specifically inhibit iron absorption include phytates (phytic acid), calcium, 
tannates, phosphates, carbonates, oxalates, polyphenols and peptides from partially 
digested proteins (140).  
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Phytates and polyphenols 
Phytates from foods such as grains (e.g. oats and bran), vegetables, seeds, nuts and fruits, 
are thought to be the primary and most potent inhibitor, and phytate intake should be 
considered alongside meals when determining iron absorption (140,143). Phytic acid 
chelates iron, resulting in the formation of an insoluble complex which cannot be digested 
or absorbed due to a lack of phytase enzymes in the intestine (166-168). Intake of ascorbic 
acid can however counteract these effects (169). The processing and cooking of phytates 
can also reduce their inhibitory effects (143). Polyphenols, typically occurring in 
vegetables, fruits, cereals, tea, coffee, legumes and wine also have an inhibitory effect 
(170,171).  
 
Dairy products and calcium 
Calcium has been found to have a negative impact on both haem and non-haem iron 
absorption (172,173). This inhibition is suggested to occur at the point of initial uptake into 
the enterocyte (174). The extent to which calcium can have an impact, particularly when 
eaten in conjunction with other foods, is unsure, and again further research is required to 
decipher this. Inhibitory effects of other animal proteins such as egg, milk and albumin in 
addition to soy protein have also been demonstrated (175,176). 
 
Future research should address the potential for iron fortified products and further evaluate 
the interrelation of and effect of consumption of dietary elements on the absorption of iron.  
 
2.11 Susceptibility to iron deficiency in exercising women 
There are a range of populations with an increased susceptibility to iron deficiency; for the 
purposes of this review, two groups will be focused on: 
• Exercising population 
• Menstruating women 
2.11.1 Iron deficiency in the exercising population 
Those who exercise have been found to have an increased susceptibility to iron deficiency, 
likely experiencing increased losses and a reduction in absorption as explained further 
below. As a result, demand is increased, and dietary intake or absorption rate is often not 
sufficient to meet increased requirements.  
2.11.1.1 Increased loss 
There are four mechanisms by which increased iron losses occur through exercise 
including sweating, gastrointestinal bleeding, haematuria (presence of blood in urine), and 
exercise-induced haemolysis. 
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Sweating 
Iron is a physiological constituent of sweat, and it is therefore inevitable that exercise is 
associated with increased iron losses through increased sweat (177). Exercising in the 
heat, for longer durations and at a higher intensity can therefore potentially increase iron 
loss. Interestingly, iron loss through sweat during exercise appears to be greater in the first 
hour than in the second (178), so training more than once a day may cause greater iron 
loss than completing one longer session.  
 
Gastrointestinal bleeding 
Gastrointestinal complaints are common amongst those who exercise, with 30 – 70% 
reporting this (179). Iron losses can also occur as a result of gastrointestinal bleeding (180). 
Due to the exercise-induced vascular shunts where blood flow to the skin and muscles is 
increased, blood flow to the gastrointestinal tract will decrease (181,182). The reduction in 
blood flow can cause the cells of the gastrointestinal tract to become starved of oxygen 
and other essential substrates, resulting in necrosis and mucosal bleeding, and therefore 
iron loss (182). Gastrointestinal damage, resulting in blood loss can also be caused by use 
of non-steroidal anti-inflammatories and other painkillers, use of which is thought 
widespread by athletes (182).  
 
Haematuria 
Likely to be dependent on intensity, exercise can cause haematuria (blood in urine). The 
effects of the mechanical trauma that can ensue with exercise can cause microscopic 
legions in the glomerulus and bladder resulting in blood loss (183,184). Furthermore, the 
repetitive impact from exercising can also cause haemolysis in the glomerulus, further 
increasing blood loss (184,185).  
 
Exercise induced haemolysis 
Exercise-induced red blood cell lysis is also postulated to result in increased iron losses 
(186). The exact mechanism for this is not yet fully understood (187,188). But the extent 
to which this occurs is likely to be dependent on the type of exercise, increasing in high 
impact sports, however haemolysis has been reported in non-impact sports such as 
swimming where high intensity muscle contractions may compress blood vessels, resulting 
in red cell lysis (180,189). The extent of haemolysis in weight baring sports, for example 
running, or sports with a large amount of contact such as rugby is likely to be significantly 
greater, while also thought dependent on exercise intensity, biomechanics and the ground 
surface (180,186). Interestingly, research suggests running speed and exercise intensity 
are more of a determinant of haemolysis rate than ground surface (188). As red blood cells 
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are destroyed, haptoglobin will sequester the haemoglobin, in a process that will be 
described in the second part of this chapter. The magnitude of haemolysis can be identified 
by post-exercise free plasma haptoglobin measurements (180,190). Haptoglobin binds to 
the haemoglobin that is released when red cell lysis occurs, sequestering the iron 
(191,192). In response to a significant amount of haemolysis, haptoglobin levels will 
decrease (193).  
2.11.1.2 Decreased intake  
Typically consuming less dietary iron, women have been found to be at an increased risk 
of insufficient intake than male counterparts (194-196). With risk also inevitably 
exacerbated in vegetarians and vegans (36). 
2.11.1.3 Increased demand 
Exercise creates an increased erythropoietic stimulus and causes various iron-dependent 
pathways to be upregulated to meet increased physiological demand. Accordingly, 
required daily intake is suggested to be elevated by 30-70% in those who exercise, since 
iron is essential for erythropoiesis (194,195,197). A practice often used by elite athletes, 
training at altitude also accelerates erythropoiesis, further increasing demand for iron 
(198).  
2.11.1.4 Reduced absorption 
The exercising population are also at increased risk of iron deficiency through reduced 
absorption. As will be explained further in the second part of this review, hepcidin is the 
key regulator of systemic iron metabolism, and as an acute phase protein, it is also 
upregulated in response to particular pro-inflammatory cytokines (199). Depending on the 
intensity, exercise can cause an inflammatory response. For example, research has shown 
increases in interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor (TNF) in 
response to exercise (200,201). These cytokines have been shown to increase in 
individuals both immediately and 2 hours after a marathon (202). As a result, transient 
hepcidin increases can occur post exercise, which may impact upon iron absorption into 
the gut and subsequently, the bloodstream. Research suggests that hepcidin levels 
typically peak 3 – 6 hours after the exercise-induced peak in the pro-inflammatory 
cytokines (203). In light of this, dietary iron consumption or oral iron administration during 
this time is likely to be ineffective (204). Therefore athletes who are in hard training have 
an increased susceptibility to iron deficiency, and this is exacerbated by those who train 
more than once a day, reducing the window of possibility for iron absorption (204). A recent 
study found that even after 12 hours of rest, when comparing athletes and non-athletes, 
hepcidin levels were significantly greater in athletes, highlighting the significant potential 
for reduced absorption (205). Recent research has however found that iron status 
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supersedes inflammation in control of hepcidin regulation therefore in states of iron 
deficiency the magnitude of the hepcidin response may be attenuated (51,203). 
Regardless, this effect has the potential to worsen iron status, and previous studies have 
found both iron deficiency and IDA to be more common in exercising women when 
compared to sedentary controls (120,121,206). Significantly, it is well-known that athletes 
frequently supplement with iron, with some supplementing without prior knowledge of iron 
status (39). Supplementation can incur unwanted side effects, increase oxidative stress 
and inflammation (61), while also causing transient increases in hepcidin, reducing iron 
absorption and potentially worsening iron status (51). The use of non-steroidal anti-
inflammatory drugs has also been shown to reduce absorption.  
 
2.11.2 Iron deficiency specifically in exercising women 
Most research suggests that the prevalence of IDA and iron deficiency is higher in athletes 
than in non-athletes, with risk specifically increasing in exercising and menstruating 
women. There are a multitude of factors that increase susceptibility, which are shown in 
Figure 2.1. Significantly, menstrual blood loss has been estimated to equate to iron loss of 
1 – 2 mg per day during menstruation (74), and when compared to men, women typically 
consume less iron (194-196). Numerous studies have attempted to assess the prevalence 
of iron deficiency in exercising women, however, given that this is likely confounded by 
different serum ferritin cut-off values to indicate iron deficiency (ranging from 12 - 40 µg·L-
1), specific prevalence has not been defined, with results suggesting that 18 – 57% of 
exercising women are iron deficient (106). The ambiguity may also be in part due to the 
level of the athlete, the type of sport they compete in, the training volume, training surface, 
diet, and intensity, in addition to volume of menstrual blood loss and dietary iron intake 
amongst other possible factors. It is also important to consider that particularly in the case 
of elite athletes, some sports and/or federations may undertake regular screening for the 
assessment of iron status, which could confound prevalence data. The prevalence of IDA 
in a group of elite level soccer players was found to be 29% (207). While in a mixed group 
of athletes from a range of different sports, both those primarily aerobic-based and 
anaerobic-based, iron deficiency was found in 47.4% (208). Another study in elite 
basketball players found IDA in 14% of female athletes, with 35% being iron deficient (119). 
While prevalence of IDA in a group of US recreational athletes was found to be 9.7%, and 
iron deficiency 39% (120). Evidently, there is significant variation in reported IDA and iron 
deficiency prevalence. A significant confounder to the prevalence data is the ambiguity 
surrounding the definition of these conditions when using [Hb] and serum ferritin as 
diagnostic tools.  
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Figure 2.3 – Factors that contribute to increasing the susceptibility to iron deficiency in 
exercising women. 
 
2.11.3 Iron deficiency in menstruating women 
As previously highlighted, prevalence of iron deficiency in women of a reproductive age is 
greater than male counterparts and post-menopausal women. The primary cause of both 
iron deficiency and IDA in high-income countries is menstrual blood loss (74,209). It is 
inevitable that those with increased menstrual blood loss have a greater likelihood of being 
iron deficient or having IDA. Average volume of blood loss each menstrual period is 
estimated to be 30 - 50 mL, but this can vary significantly, but is difficult to measure (210). 
In 1964, Hallberg and Nilsson used an alkaline haematin method to quantify menstrual 
blood loss (27). In this process, haem is extracted from collected sanitary products using 
5% sodium hydroxide (27). However, this process is expensive, labour intensive and 
deemed unhygienic by some, and so is infrequently used. It has however been refined 
(211), but the introduction of ‘ultra-slim’ sanitary products interferes with haem absorption, 
affecting reliability, and increasing potential for [Hb] to be underestimated (212). 
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Once menstrual blood loss and [Hb] are obtained, using the following formula, menstrual 
iron loss can be evaluated (157): 
 *+,-./012	3/4,	24-- = 	*+,-./012	62447	24--	 × 	[:6] × 	0.00334$@A2+	2+,B.ℎ  
 
While found to substantially vary between individuals (213), the volume of blood loss by 
an individual does not tend to vary much between cycles (214). Research evaluating 
determinants in control of blood loss assessed non-identical and identical twins, concluding 
a significant genetic component, with identical twins showing much less variation in blood 
loss (215). Suggesting that volume of blood loss is primarily genetically controlled. It is 
thought that for every 1 mg of iron lost, there is a concomitant decrease of 6.9 µg·L-1 in 
serum ferritin (157). Therefore the enhanced risk of iron deficiency in this group is evident 
(74,157).  
2.11.3.1 Heavy menstrual bleeding (HMB) 
Iron losses in those with heavy menstrual bleeding (HMB) are on average 5 - 6 times 
greater than those without each cycle (216). The National Institute for Care Excellence 
(NICE) of the United Kingdom define HMB as “excessive menstrual blood loss which 
interferes with a woman’s physical, social, emotional and/or material quality of life” (26). 
Earlier research applied a more quantitative approach for the definition, classifying HMB 
to be present when there is at least 80 mL of blood loss each cycle (217). However, the 
subjectivity of the NICE definition is hard to evaluate, there are no means to quantify what 
equates to “interferences” with the different aspects of quality of life. While there are 
numerous issues associated with measuring total volume of blood loss, including those 
associated with hygiene, in addition to the potential for an appreciable amount of blood to 
be lost extraneously and therefore not collected by sanitary products (212). Also, given 
that total blood volume can significantly vary from person to person, a loss of 80 mL blood 
will be far more significant in some individuals than others. The existing means for 
diagnosis as specified by the NICE is through the opinion of the woman herself (26), which 
is inevitably problematic particularly given that this is a personal topic which is not 
commonly discussed, meaning that awareness is likely to be poor. It is therefore clear that 
there is a need for an improved means for HMB diagnosis. The American College of 
Obstetrics and Gynaecology go some way to providing a more objective diagnosis, 
recognising the presence of any of the following symptoms to equate to HMB:  
1. bleeding that lasts more than 7 days;  
2. bleeding that soaks through one or more tampons or pads every hour for several 
hours in a row;  
3. needing to change pads or tampons during the night; or  
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4. menstrual flow with blood clots that are as big as a quarter or larger (218).  
 
Similarly, Fraser et al. (2015) have recently identified a four-part diagnostic series which 
has been used effectively to facilitate diagnosis (28). If two or more of the symptoms are 
reported, a diagnosis of HMB is made (28). The criteria include;  
 
1. Passing of large blood clots;  
2. Need for double sanitary protection (both towels and tampons);  
3. Need for frequent changes of tampons and towels (meaning changes every 2 
hours or less, or 12 sanitary items per period); and  
4. Flooding through to clothes or bedding (28). 
 
Clearly, both of these guidelines rely on self-report and are perceptual in nature. However, 
they are clearly more objective than the diagnosis by the NICE, and a combination of these 
was applied in this thesis.  
 
Depending on the criteria utilised, in the general population, approximately 20 - 30% of 
menstruating women have HMB (219,220). This may be in conjunction with, or occur as a 
result of other conditions, for example, endometriosis, polycystic ovary syndrome or a 
bleeding disorder such as von Willebrand disease (219). However, a study in university 
students found only 20.7% of those identified with HMB (n = 82) to have an underlying 
menstrual cycle-related pathology or a bleeding disorder (Gursel et al. 2014). Suggesting 
HMB to be a condition in its own entirety.  
 
Using the four-part diagnostic criteria outlined above, Fraser et al. (2015) conducted an 
internet-based survey across five European countries, including France, Spain, Germany, 
Netherlands and Switzerland. A total of 4506 were surveyed, and overall HMB prevalence 
was found to be 27.2% (28), and therefore in accordance with previous indications of 
prevalence (219,220). More specifically the prevalence per country was: France - 30.3%, 
Spain - 32.9%, Germany – 32.9%, Netherlands – 22.2% and Switzerland – 25.0% (28). 
The results from this survey also showed that approximately half of those with HMB had 
not sought medical help (28). However, worryingly, half of those who reported seeking 
medical help did not have HMB diagnosed (28). Further, of those with HMB, 81.8% 
indicated that their symptoms were not under control, and the majority indicated that HMB 
affected their quality of life (28). 
 
A number of studies have examined the prevalence of IDA and iron deficiency in those 
with HMB, finding approximately 3 in 5 to be iron deficient, and 1 in 4 to have IDA (19,20). 
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While highlighting the potential impact that increased menstrual blood loss can have on 
iron status, the relevance to this amongst those who exercise is uncertain, as no research 
into HMB has been conducted within this population. This will be addressed in this thesis. 
 
Despite HMB having a significant impact on quality of life, mood, energy levels and 
productivity, due to the sensitivity of the condition, particularly amongst certain cultures, it 
frequently goes unnoticed. Significantly, the symptoms of HMB are similar to those seen 
in iron deficiency and IDA, so notwithstanding the likely relation between the two, there is 
potential for one to be missed in diagnosis (28). However as previously highlighted, the 
prevalence of HMB in the athletic population is unknown.  
 
2.12 The menstrual cycle in female athletes 
Athletes are more likely to have an irregular menstrual cycle than non-athletes, and 
inevitably dependent on sport type, training volume and performance level, 6 - 79% of 
exercising women experience reproductive system irregularities (21). Pre-pubertal 
participation in intense exercise typically delays onset of menarche by around a year, and 
also increases likelihood of future menstrual disorders (24). In exercising women, the most 
researched and commonly discussed dysfunctions include primary and secondary 
amenorrhea, anovulation, luteal phase deficiency and oligomenorrhea (22-24,31). The 
prevalence of oligomenorrhea (infrequent menstruation) and amenorrhea (absent 
menstruation) is increased in athletes when compared to the general population, and in 
particular in those competing in certain sports and events where a low body mass is 
desirable for performance, training volumes are large and/or where there is substantial 
focus on aesthetics, such as ballet and endurance running (15,31). In fact, it has been 
suggested that up to 69% of those who exercise have secondary amenorrhea (where 
individuals have had at least one menstrual cycle previously, but then absent menstrual 
cycle for at least 6 months), compared to 2 - 5% of the general population (31). 
Susceptibility to secondary amenorrhea is also increased in those with a delayed circadian 
rhythm due to alterations in melatonin release, e.g. in flight attendants (221). This is 
hypothesised to be caused by the impact of melatonin on luteinising hormone, and could 
have implications for athletes undergoing long haul travel, however further research is 
required to investigate this (222).  
 
Amenorrhea can be caused by a number of factors, as discussed widely in the literature; 
one factor particularly relevant in those who exercise is energy deficiency. The female 
athlete triad is a term used, specifically relating to menstrual dysfunction in exercising 
women, describing the interrelationship between low bone density, low energy availability 
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and menstrual dysfunction (223). In 2014 however, the IOC created a new term – Relative 
Energy Deficiency in Sport (RED-S) (224). This more broadly demonstrates the impact that 
an energy deficiency in sport can have. The potential role of iron in the female athlete triad 
will be discussed further in Section 2.11 (2). 
 
There have been a number of cases where athletes have cited their menstrual cycle to be 
a cause for poor athletic performance in the press (18-20). However, research defining the 
effects of the menstrual cycle on exercise, and suitable strategies to mitigate these is 
absent. With the primary research focus being on dysfunctions associated with 
amenorrhea (24,31), there is an evident need to consider other menstrual dysfunctions. It 
is outside of the scope of this thesis to look at all types of dysfunction, however the primary 
issue that is likely to be associated with iron deficiency; heavy menstrual bleeding, will be 
addressed.  
 
It is possible that risk of IDA and iron deficiency is further increased in those who exercise 
and have HMB, however despite some research in the general population, there is a lack 
of research in the exercising population. In light of the interferences with a women’s 
physical, social, emotional and/or material quality of life, as per the NICE definition for HMB 
(26), notwithstanding the known negative impacts of IDA and the potential impacts of iron 
deficiency it is important to address whether this may be a problem in this population, 
where the potential to impact exercise performance is evident. This thesis will identify the 
effect of HMB and iron deficiency with or without anaemia on markers of exercise 
performance. If indeed HMB is found to be prevalent amongst exercisers, awareness 
needs to be raised as it is currently not a dysfunction that is commonly considered amongst 
the athlete populous (31).  
 
2.13 Effect, diagnosis and treatment of iron deficiency 
IDA has a distinct impact on exercise performance, however the impact of iron deficiency 
without anaemia (IDNA) is less certain. Much previous research evaluating the effects of 
IDNA and the efficacy of treatment has focused on clinically unwell populations, where 
other medical issues, such as heart failure or kidney disease, are likely to confound results 
(225,226). These results are therefore not applicable to exercising, healthy populations in 
whom there exists substantial ambiguity as to the impact on performance, the clinical 
diagnosis and optimal treatment options. The primary reasons for this are: 
 
• There is a lack of a universally agreed consensus on serum ferritin cut-off values 
for the diagnosis of iron deficiency – optimal levels of serum ferritin for those who 
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exercise are unknown and research addressing the possible impacts of iron 
deficiency have typically used cut-off values ranging from 12 - 40 µg·L-1 (48-54).  
• Differing administration routes, which are likely to have varying efficacy – studies 
have used intravenous injections, oral tablets or intramuscular injections. 
• Differing study protocols – studies have used different dosing strategies, i.e. a 
single high intravenous dose compared to smaller doses spread across a length of 
time, and different time courses for follow up testing, typically ranging from 24 
hours – 12 weeks post iron treatment. 
• Small sample sizes – the absence of a power calculation in some studies has 
further made the drawing of conclusions problematic.  
• Differing populations – some studies use elite and well-trained athletes, whereas 
some use non-elite, recreational exercisers. Elite and highly trained athletes are 
likely to undergo increased physiological stress compared to the more general 
exercising population, resulting in differing responses to interventions such as iron 
administration, and possibly having differing optimal levels of iron stores (48-54). 
Further, potential for significant increases in exercise and aerobic capacity is much 
smaller, as these are likely to already be very high. So, despite increases being 
meaningful on an individual level, these may not be reflected statistically. 
 
2.13.1 Effects of iron deficiency in animal models 
The effect of IDNA in animals has been shown. Several murine studies have been 
conducted comparing IDA, IDNA and iron sufficient rats (227-229). IDNA was found to 
cause suboptimal mitochondrial function and capacity, likely through modifications to iron-
containing proteins. Specifically, Finch et al. (1976) attributed the reduced function to the 
non-haem containing enzyme ∝-glycerophosphate (227), while Willis et al. (1987) 
observed a reduction in cytochrome c alongside other iron-containing enzymes (228). 
Evidently, IDNA has the potential to have non-haematological effects, altering oxidative 
enzymes and mitochondrial function and future human studies are required to assess this 
further specifically at a cellular level. 
 
2.13.2 Effects of iron deficiency on exercise performance 
This thesis will primarily focus on how iron deficiency may impact upon components of 
exercise performance in humans. Where [Hb] is reduced in states of IDA, maximal oxygen 
uptake, V̇O2max, as determined by the amount of oxygen in the blood and the oxygen 
consumption of skeletal muscle, is reduced (1). On the other hand, V̇O2max can increase 
through an increase in cardiac output and [Hb]. Cardiac output is most likely to increase 
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through an enhanced blood volume, which can occur as a result of an increase in 
erythrocyte mass, again necessitating iron (1).  
As explained in section 2.6, IDA is typically measured using [Hb], however as 
demonstrated in Figures 2.1 and 2.2, there is a minimal relationship between V̇O2max and 
haemoglobin concentration, likely reflecting the influence of blood volume on this reading. 
Figure 2.2 demonstrates that total haemoglobin mass correlates much more closely with V̇O2max, suggesting that this may provide a more accurate means for indication (1). As 
previously highlighted, being an essential part of myoglobin, iron deficiency will also impact 
oxygen transport to muscle myocytes. Further, a lack of iron will impair the function of iron-
containing oxidative enzymes, including those involved in the electron transfer process in 
mitochondria, affecting the production of ATP.  
 
The reduction in oxygen carrying capacity associated with IDA evidently explains how this 
condition affects exercise performance. However, where absolute haemoglobin mass and 
therefore oxygen-carrying capacity is not affected in states of IDNA, the impact on exercise 
performance is less certain (46,110). Given the many other essential roles of iron, there is 
evidently still significant potential for a negative impact on physiological function. While 
non-haematological effects have been shown in animals (227-229), some have 
demonstrated other factors that could impact either directly or indirectly on exercise 
performance. For example, iron deficiency has recently been associated with an increased 
risk of osteoporosis (230), while, in non-athletes, research suggests cognitive performance 
may be affected, which could impact upon exercise performance through a lack of 
motivation and concentration (57). This will be discussed further below. Low iron stores 
have also been associated with increased levels of oxidative stress (231).  
 
Yet studies assessing the impact of iron repletion in IDNA athletes have led to inconclusive 
results, questioning not only the mechanism of impact of IDNA but the accuracy of the 
diagnosis itself. Research is hampered by a lack of human studies, in addition to studies 
purely looking at IDA and not IDNA and a number of other factors which will be discussed 
further below. Since iron deficiency can be indicated by a positive response to iron therapy 
(47), it could be suggested that where no improvements in functional outcome are seen, 
iron deficiency is either not present or did not impact on the measured outcomes. The 
following section will focus on previous key studies that have assessed the impact of iron 
repletion on functional performance.  
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2.13.3 Previous research evaluating the impact of iron therapy in iron deficient, 
exercising participants 
It has been widely demonstrated that where serum ferritin is < 40 µg·L-1, iron therapy will 
result in significant elevations in serum ferritin, regardless of the supplementation route 
(46,232). However, research pertaining to whether this is associated with a concomitant 
improvement in performance is equivocal. A number of studies have been conducted in an 
attempt to evaluate this, and summary of the findings from these, categorised by the 
different routes of administration, are described below and summarised in Table 2.1. Some 
have shown increases in iron status to be transient, returning to initial pre-supplementation 
levels with no associated impact on performance (51,233). Inevitably, where the gut is 
bypassed, i.e. using intravenous injections, increases in serum ferritin will occur regardless 
of baseline values. 
2.13.3.1 Oral supplementation 
The majority of previous research evaluating the impact of iron deficiency on 
haematological markers and performance measures have used oral iron repletion. This 
means for iron therapy is cheap and easy to administrate. However, conclusive findings 
from these studies are lacking, with distinct variation in study protocol, participant type, 
markers of assessment, and inclusion criteria. Firstly, excluding the study Powell and 
Tucker, (234) oral iron supplementation has been shown to increase serum ferritin when 
measured at a pre-determined follow-up point (49,50,52,54,235-241). The lack of increase 
in serum ferritin in the study by Powell and Tucker may have been due to follow-up blood 
tests being only 14 days after iron supplementation was initiated (234). Normal practice is 
to allow a period of at least three months for repletion of iron stores using oral iron (242), 
and while the other studies here demonstrated a significant increase in serum ferritin 
levels, at the end of the predetermined trial period some participants still had low serum 
ferritin levels. For example, in the eight week supplementation period applied by LaManca 
and Haymes (1993), five participants still had a serum ferritin < 20 µg·L-1 at the end of the 
trial (236). 
 
Improvements in V̇O2max were only evident in the studies conducted by La Manca and 
Haymes (1993) (236), Friedmann et al. (2001), (237) and in the severely iron deficient 
group in the study by Wachsmuth et al. (2015) (241). However, while an increase in in V̇O2max was not seen, an improvements in endurance times or energy efficiency, and a 
reduction in energy expenditure were evident in a number of studies (50,238,239,243). 
Significantly, participants in the studies conducted by Wachsmuth et al. (2015) (241) and 
Friedmann et al. (2001) (237) undertook the period of supplementation for amongst the 
longest time across all studies here, being 70 and 84 days respectively, and the baseline 
serum ferritin levels for inclusion were low (serum ferritin < 12 µg·L-1 and < 20 µg·L-1 
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respectively). While other studies applied the similar inclusion criteria, these studies were 
longer, therefore, it is possible that the individuals in the other studies had been taking oral 
supplementation for an insufficient time period for an impact to be significant. The only 
other study that was comparable in length was that by Matter et al. (1987) (235) lasting for 
77 days. However, this study applied a more lenient criteria for inclusion (serum ferritin < 
40 µg·L-1), potentially explaining the differing findings here. Conversely, while none of the 
participants in the study by LaManca and Haymes (1993) were diagnosed with anaemia, 
a significant increase in [Hb] was seen post treatment, suggesting that a relative state of 
anaemia was present, therefore improvements in maximal exercise capacity are likely to 
be due to increased oxygen transport (236).  
 
Evidently, there is significant variation in the inclusion criteria used for iron deficiency 
across these studies, ranging from a serum ferritin of < 12 µg·L-1 used by Radjen et al. 
(2011) (240) and in the trial completed by Wachsmuth et al. (2015) (241) to a serum ferritin 
of sFer < 40 µg·L-1 used by Matter et al. (1987) (235). This could be another factor 
explaining some of the variation in findings, and could be enhanced further by the variation 
in study duration. For example, despite using an inclusion criteria of a serum ferritin of < 
12 µg·L-1, the duration of the study conducted by Radjen et al. (2011) was only 56 days, 
so the absence of a change in exercise measures could be attributed to insufficient 
supplementation duration (240). Another significant factor that needs consideration is the 
compliance of supplementation. This is particularly significant given the negative side 
effects associated with oral iron supplementation, which could discourage use. 
Accordingly, a compliance of only 30% was reported in one study (239). While some 
studies did monitor compliance, this can be difficult to accurately measure. 
 
As highlighted in a recent review, it is likely that some of these oral supplementation studies 
have not conducted a power or an effect size calculation, amounting to another factor 
pertaining to the ambiguity of results (244). While, significantly, the performance level of 
the participants in these studies also varied. Further, a number of studies assessed 
participants at the onset of a training block, therefore there was an inevitable increase in 
exercise performance markers, despite this being controlled for (50,239), there is still 
potential for this to distort findings.  
 
Considering the known increase in hepcidin after iron administration, taking oral iron too 
frequently, and taking a dose that is too high for requirement has the potential to worsen 
iron status. Hepcidin levels have been found to increase for three hours post 
supplementation, therefore whenever iron is taken, iron absorption may not be possible for 
the subsequent three hour period, this is particularly significant if this falls at a meal time 
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(180,203). Further, if iron is taken in the period after exercise, the acute inflammatory 
response may drive hepcidin levels up, again preventing iron absorption (180,203). 
Therefore, despite evident increases in serum ferritin, absorption may have been limited 
and could have confounded study results.  
2.13.3.2 Intramuscular iron therapy 
Likely due to the pain associated with injection, there is a sparsity of studies assessing the 
impact of iron repletion using intramuscular iron therapy. Both studies that did apply this 
method followed very similar protocols (48,53). Trained women were administered 2 mL of 
iron every other day for 10 days (5 x 2 mL) into the gluteus maximus (48,53). A comparable 
increase in serum ferritin was seen when participants were tested 5- and 10-days after 
study initiation, and 20- and 24-days after study initiation respectively (48,245). To evaluate 
performance, Blee et al. (1999) assessed a variety of measures intending to indirectly test 
anaerobic power and endurance capacity, finding the iron administration to have no impact 
(48). Peeling et al. (2007) also concluded similar findings, seeing no improvement in 
submaximal or maximal exercise capacity (53). Therefore, despite effectively restoring 
serum ferritin, from the two studies assessing intramuscular iron therapy, it can be 
concluded that there was no impact on performance. Despite this, there is potential that 
the small sample sizes in these studies could have limited the applicability of the results, 
while the criteria used for diagnosis of iron deficiency was also very lenient (Table 2.1).  
2.13.3.3 Intravenous iron therapy 
Similar to research assessing intramuscular iron therapy, likely due to the only relatively 
recent development of safer formulations (55), few studies have evaluated the effect of 
intravenous iron therapy in exercising women. Using highly trained distance runners, both 
Garvican et al. (2014) (52), and Burden et al. (2015) (51) found intravenous iron injections 
to significantly increase serum ferritin. Garvican et al. (2014) (52) also found an increase 
in V̇O2max and total haemoglobin mass in response to intravenous iron therapy. However, 
this finding was not mirrored in the study by Burden et al. (2015) (51) where no changes 
were seen in any markers of performance. The reasons for this are unsure and could be 
attributable to several factors. Firstly, despite the total dose of iron administered being 
similar (500 mg and 550 ± 171 mg, the latter calculated using the Ganzoni formula (246)), 
Burden et al. (2015) (51) administered this in a single high bolus, while Garvican et al. 
(2104) (52) spread administration out over 6 weeks (2 – 4 injections). Secondly, the criteria 
used for diagnosis differed, Burden et al. (2015) (51) used a serum ferritin < 40 µg·L-1 for 
men, and a serum ferritin < 30 µg·L-1 for women, while Garvican et al. (2014) (52) used a 
serum ferritin ≤ 35 µg·L-1 in addition to a transferrin saturation < 20%, or a serum ferritin ≤ 
15 µg·L-1 alone. Therefore, the inclusion criteria used in the study by Garvican et al. (2014) 
(52) was stricter than that used Burden et al. (2015) (51) suggesting that the participants 
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in this trial may not have been deficient. Finally, the follow up tests were performed at 
different times, with Garvican et al. (2014) (52) testing participants around one week after 
study completion and Burden et al. (2015) 24 hours post injection and 4 weeks post 
injection. Therefore, it is possible that despite the significant increase in serum ferritin, the 
impact of iron repletion on exercise performance in the case of the latter may not have had 
time to manifest within 24 hours, and the positive effects of this may have been lost after 
four weeks. However, the fact that serum ferritin levels were still supraoptimal at this point 
counters this later hypothesis. Evidently, the performance level of the participants in both 
trials was very comparable, with the desired effect of restoring iron status being obtained. 
With only 7 athletes in each study receiving iron, it is possible that more participants may 
be required to evaluate this further. 
 
Clearly further clarification is required here, a topic that will be addressed in this thesis. 
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Table 2.1 – A summary of the effects of iron repletion on physical performance in iron deficient but not anaemic exercising participants. 
Study Inclusion criteria 
Subjects 
(treatment 
and 
placebo) 
Administration 
route 
Dosing 
protocol and 
duration 
Effect 
Matter et al. 1987 (235) sFer < 40 µg·L-1 n = 29 F Oral 
 50 mg 
elemental iron, 1 
x day, 77 days 
No improvement in V̇O2max 
Rowland et al. (1988) 
(243) 
sFer < 20 µg·L-1 n = 14 F Oral 
325 mg, 1 x day, 
28 days 
No improvement in V̇O2max but 
improved 
endurance 
performance 
Powell and Tucker (1991) 
(234) 
sFer < 35 µg·L-1 n = 10 F Oral  
Ferrous 
sulphate, 130 
mg 1 x day, 14 
days 
No change in blood 
iron indices or 
metabolic 
parameters 
Klingshirn et al. (1992) 
(54) 
sFer < 20 µg·L-1, 
[Hb] > 12.0 g·dL-1 
n = 18 F Oral 
50 mg, 2 x day, 
56 days 
No improvement in V̇O2max 
Fogelholm et al. (1992) 
(49) 
sFer ≤ 25 µg·L-1, 
[Hb] > 12.0 g·dL-1 
n = 31 F Oral 
100 mg, 1 x day, 
56 days 
No change in blood 
lactate or V̇O2max 
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LaManca and Haymes 
(1993) (236) 
sFer < 20 µg·L-1 n = 20 F Oral 
50 mg, 2 x day, 
56 days 
Improved V̇O2max 
and decreased 
blood lactate 
Hinton et al. (2000) (50) 
sFer < 16 µg·L-1, 
[Hb] > 12.0 g·dL-1 
n = 42 F Oral 
10 mg, 2 x day, 
42 days 
Improvement in V̇O2max 
Friedmann et al. 2001 
(237) 
sFer < 20 µg·L-1 
n = 23 F, 
17 M 
Oral 
100 mg 2 x day, 
84 days 
Improvement in V̇O2max, no change 
in blood volume 
Hinton and Sinclair (2005) 
(238) 
sFer < 16 µg·L-1 
IDNA 
n = 20 
M+F 
Oral 
30 mg, 1 x day, 
42 days 
No improvement in V̇O2max, improved 
energetic efficiency 
Della Vale and Haas 2011 
(239) 
[Hb] > 12.0 g/dL, 
sFer < 20 µg/l 
n = 40 F Oral 
50 mg, 2 x day, 
42 days 
No improvement in V̇O2max 
Radjen et al. 2011 (240) 
[Hb] > 12.0 g/dL, 
sFer < 12 µg/l, 
TSAT > 16% 
n = 17 F Oral 
50 mg, 1 x day, 
56 days 
No improvement in V̇O2max 
Wachsmuth et al. (2015) 
(241) 
sFer < 12 µg·L-1, or 
sFer < 25 µg·L-1 > 
12 µg·L-1, [Hb] > 
12.0 g·dL-1 
n = 22 F Oral 
100 mg, 1 x day, 
70 days 
Improvement in V̇O2max in severe, 
not in moderate. 
Improved 
haemoglobin mass 
in both groups 
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Garvican et al. (2014) (52) 
sFer ≤ 35 µg·L-1 + 
TSAT < 20% or sFer 
≤15 µg·L-1, [Hb] > 
12.0 g·dL-1 
n = 13 F, 
14 M 
Oral and IV 
Oral – 105 mg, 2 
x day, 42 days; 
IV - 550 mg 
(ferric 
carboymaltose 
2-4 injections), 
42 days 
Improvement in V̇O2max and 
haemoglobin mass 
only in IV group 
Burden et al. (2015) (51) 
sFer < 40 µg·L-1 for 
men, sFer < 30 
µg·L-1 for women, 
[Hb] > 12.0 g·dL-1 
n = 9 F, 6 
M 
IV 
500 mg, single 
dose 
No change in 
performance 
markers or total 
haemoglobin mass 
Blee et al. (1999) (48) 
sFer < 40 µg·L-1, 
[Hb] > 11.5 g·dL-1 
n = 15 F IM 5 x 2 ml, 8 days 
No change in 
performance 
markers 
Peeling et al. (2007) (245) 
sFer < 35 µg·L-1, 
[Hb] > 11.5 g·dL-1 
n = 16 F IM 5 x 2 ml, 10 days 
No improvement in V̇O2max 
 
 
Oral – oral iron, IV – intravenous iron, IM – intramuscular iron, F = female participants, M = male participants, sFer – serum ferritin,  [Hb] – 
haemoglobin concentration, TSAT – transferrin saturation
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2.13.3.4 Overall assessment of iron therapy in iron deficient individuals 
It is evident that providing sufficient time is allowed, where individuals have a suboptimal 
baseline serum ferritin (< 40 µg·L-1), oral, intramuscular or intravenous iron therapy will 
cause this to increase. Therefore, despite evident increases in serum ferritin, in the case 
of the oral supplementation studies, the time course for supplementation may have been 
insufficient for the restoration of iron status to affect markers of exercise performance. 
Accordingly, it is significant to note that in the studies where oral iron supplementation was 
taken for a longer time period, improvements in exercise performance markers were seen 
(236,237,241). However, the observed effect of iron repletion in both the intramuscular 
studies (48,53), and the results from the intravenous study conducted by Burden et al. 
(2015) (51) conflict this, since despite the follow up serum ferritin levels being significantly 
greater than those seen in the oral repletion studies, no increases in markers of exercise 
performance were seen. Conversely, the intravenous iron therapy study by Garvican et al. 
(2014) (52) did show increases in both maximal exercise capacity and total haemoglobin 
mass. Significantly, the criteria for inclusion in the latter study by Garvican et al. (2014) 
(52) was much stricter than that of the other injection studies, suggesting that existing 
diagnoses for iron deficiency may need to be re-evaluated. Given the highlighted adverse 
effects of excess iron, there is an evident need to address the point at which 
supplementation should be applied, and this will be addressed in this thesis. 
 
Additionally, given the wide reference range for [Hb] and the discussed potential for 
intravascular fluid shifts, despite the inclusion of IDNA participants only, it is possible that 
improvements in aerobic capacity in some studies could actually be due to increases in 
[Hb] (52). A state of IDA could have been masked. Significantly, a moderate effect of iron 
therapy on [Hb] was shown in a recent meta-analysis (46).  
 
There was also a wide variation in performance level of the participants in these studies. 
The participants in both studies using intravenous iron for repletion and both studies using 
intramuscular iron for repletion were highly trained and elite (48,51-53). Whereas the 
participants in the oral supplementation studies were of a wide range of ability from the 
more elite to recreational level. In fact, despite the fast development of the female fitness 
industry, no injection studies have been conducted in recreational level athletes. This is 
likely to be because negative performance impacts are more likely to be appreciated and 
highlighted in the elite populous, with a rapid need for restoration, where both athletes and 
coaches are carefully monitoring performance (48,51,52,180). Additionally, due to cost 
implications and accessibility, the use of intravenous iron therapy for the treatment of iron 
deficiency is clearly more likely in this population, and accordingly, to date, repletion by 
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this means has only been evaluated in elite and well-trained athletes (51,52). Given that 
highly trained athletes may respond differently to recreational exercisers, there is clearly a 
need to evaluate this further. This could have a substantial impact, and will be addressed 
in this thesis.  
 
Considering the conflicting results from previous research outlined here, and in light of the 
significant variation in measurements seen in those who exercise (45), it could be 
suggested that the use of serum ferritin and the criteria for diagnosis when using serum 
ferritin for iron status evaluation should be questioned. This is something of particular 
interest in this thesis, and will be evaluated further.  
 
Additionally, the differing evidence highlighted here suggests that a more overarching 
review in this area is warranted. The substantial variation in study design may make a 
meta-analysis problematic to conduct, so a review that is more systematic in nature would 
be more appropriate. This should enable a better evaluation of the required need for further 
study. Sub-group analysis could then be conducted based on trial protocol and participant 
status, and could lead to more tangible outcomes.  
 
2.13.4 Other relevant effects of iron deficiency 
IDA and anaemia are leading causes of fatigue, however the association between IDNA 
and fatigue has been less conclusive. Similar to the assessment of exercise performance 
in response to iron therapy, when assessing the impact of iron repletion on fatigue there 
have also been conflicting results, with some finding fatigue to decrease (56,226,247,248), 
while others not (249). Psychology plays a significant part in sports performance, however, 
none of these studies were conducted in an exercising population, something that will be 
addressed further in this thesis. 
 
2.13.5 The impact of iron therapy on fatigue and mood disturbance  
To my knowledge, one study has assessed the effect of iron supplementation on mood 
disturbance and fatigue in an exercising population alongside measuring exercise 
performance and haemoglobin mass (58). The aim of this study was to determine whether 
in fact serum ferritin cut-offs for both exercise related and cognitive impacts of iron 
deficiency need to be higher. An inclusion criteria for serum ferritin between 30 – 100 µg·L-
1 was applied (58). Evidently, this is outside of the typical criteria used by many for the 
diagnosis of iron deficiency. In response to oral supplementation, the results showed that 
despite not finding any significant increase in haemoglobin mass or any measureable 
improvements in exercise performance, there was a reduction fatigue and mood 
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disturbance (58). This could have been due to a placebo effect, or alternatively it could 
suggest that for optimal cognitive performance serum ferritin should be higher than often 
thought, with effects on aerobic capacity occurring secondary to cognitive impacts (58). In 
support of this, a study specifically looking at unexplained fatigue in women, concluded 
that to prevent fatigue, a ferritin cut-off of < 50 µg·L-1 should be applied (247). This will be 
addressed further in this thesis since it has the potential to impact upon sports performance 
in addition to everyday health. 
 
Clearly, there is reason to suggest that iron deficiency could impact upon both exercise 
performance (physical and psychological) and fatigue (50,238,239,250), however there is 
also compelling evidence countering this (51). Given the known negative impacts of iron 
overload and toxicity further investigation is important in this thesis, particularly as 
supplementation is believed common amongst the exercising population (39).  
2.14 Iron deficiency and the female athlete triad 
A review article has recently been published suggesting a role for iron deficiency in the 
female athlete triad (2). As previously described, the female athlete triad is a syndrome 
that has three primary causes, including a poor energy status, impaired bone health and a 
compromised reproductive function (31). All three factors are frequently seen in female 
athletes, be it together, or in isolation, and are particularly common in those competing in 
endurance sports, or in events with an increased drive for thinness (31). The effects of 
these can be severe and detrimental to a woman’s exercise performance, and significantly, 
to their health (31). Typically, low energy availability drives the impaired bone health and 
compromised reproductive system while also impacting upon numerous other non-vital 
biological processes, many of which are also seen in iron deficiency (2). For example, both 
iron deficiency and energy deficiency are associated with an increased risk of 
hypothyroidism, and in an energy deficient state, the presence of iron deficiency is likely to 
exacerbate risk of hypothyroidism (251,252).  
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Figure 2.4 – Potential relationship between iron deficiency and the female athlete triad in 
exercising women as outlined in a recent review. Figure adapted from (2).  
 
As highlighted previously, iron deficiency and IDA have been suggested to have a role in 
cognitive function, with research suggesting that it also decreases serotonin and 
noradrenaline function (253). Since the development of eating disorders is believed to be 
significantly driven by anxiety, the reduction in these hormones could be, in part, 
responsible for restrictive eating behaviours (253). Undereating inevitably increases risk of 
iron deficiency, and those who exercise are more susceptible to this, not least because 
exercise can cause appetite suppression (254). Iron deficiency itself has also been found 
to reduce appetite, exacerbating the issue (2).  
 
Increases in oestrogen have been found to decrease hepatic hepcidin expression, 
therefore in energy deficient states, the lower levels of oestrogen may cause increased 
hepcidin expression, resulting in an increased susceptibility to iron deficiency (255). 
However, those with lower levels of oestrogen are also more likely to be amenorrhoeic so 
wouldn’t be experiencing monthly blood loss, hence studies suggest that iron status may 
be balanced (2). Further research should address this relationship. 
 
There is increasing evidence to suggest an association between iron deficiency with or 
without anaemia and an impairment in bone health (230), a factor that is compromised in 
those with endocrine suppression and a reduced energy availability. To conclude, evidently 
there are some significant overlaps between the biological repercussions of a lack of iron 
and the female athlete triad, often with one accentuating the effects of the other (2). More 
research is required particularly in human models, since most research to date has been 
conducted in rodents. Significantly the causative effects of one on the other should also be 
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considered i.e. does iron deficiency have an impact on oestrogen suppression, since this 
could help inform treatment options.  
 
2.15 Management and treatment of iron deficiency 
There are a number of treatment options that can be applied when iron deficiency is 
diagnosed. These are outlined below: 
2.15.1 Dietary intervention 
Dietary modifications should be the first method that should be considered when iron stores 
are deemed suboptimal (111). Appreciably however, this may not be sufficient to meet 
demand, meaning that other options are necessary (250). Dietary iron can either be haem 
(from animal sources) or non-haem (all other types of iron) as will be explained further 
below. Absorption of haem iron is far more efficient than non-haem, and there are several 
factors that can influence absorption, which will be outlined.  
2.15.2 Oral supplementation 
Oral iron is a common and cost-effective method used for repleting iron stores. While 
considered safe, the long-term effects of supplementation are unknown. As oral iron is 
typically poorly absorbed, complete repletion of iron stores can take three to six months 
(256). There are a number of common side effects associated with oral iron 
supplementation including abdominal discomfort, constipation, heartburn, vomiting and 
nausea (256). Up to 70% of patients administered oral iron are suggested to experience 
gastrointestinal side effects, with ferrous sulphate particularly problematic (257). In order 
to reduce side effects, a reduction in frequency and dosage of supplementation has been 
suggested, and that iron should be taken alongside food (inevitably this may impact 
absorption), while liquid formulations instead of oral formulations may also help (256). 
Several other side effects have been associated with unnecessary or excessive 
supplementation; excessive supplementation has been associated with increases in 
oxidative stress and inflammation in young and healthy individuals (61). while also 
increasing risk of haemochromatosis, particularly in those with the haemochromatosis HFE 
gene (258).  
 
Increased intake of dietary and oral iron is also primary risk factor in those with genetic 
abnormalities that predispose them to iron overload, for example in those with 
haemochromatosis (7). Haemochromatosis is a hereditary condition, occurring where 
there is a mutation in the HFE gene located in the short arm of chromosome 6 (259). Most 
cases of haemochromatosis are caused by a HFE mutant genotype. HFE is involved in 
iron sensing, and is therefore involved in regulation of hepcidin, where there is a mutation 
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therefore, hepcidin expression may be limited, increasing iron bioavailability (259). In those 
who have homozygous or heterozygous mutations of the C282Y or H63D alleles, or 
alternatively with a compound mutation of C282Y/H63D, risk of clinically significant iron 
overload is increased, therefore caution should be applied with supplementation (259). 
Approximately 0.4% Caucasians carry a homozygous C282Y mutation, and 6% a 
heterozygous C282Y mutation (260). Interestingly, prevalence of HFE gene mutations 
seems to be particularly high in elite endurance athletes (259). 
 
The timing of dosing is imperative since a large intake of iron will cause a transient increase 
in hepcidin, therefore reducing subsequent iron absorption (203). Therefore, if oral iron is 
taken just prior to a meal, absorption of dietary iron from the meal could be substantially 
reduced. Significantly, a recent study concluded lower and less frequent doses to be more 
effective at repleting iron stores (261). Suggesting that for optimal absorption it may be 
best to supplement with smaller doses of oral iron every other day (261). Caution should 
also be applied to ensure oral supplementation is not taken when inflammation is likely, 
e.g. post intense exercise, as the increased hepcidin levels will prevent absorption. 
Research has recently found hepcidin levels to remain elevated for 3 - 6 hours post the 
inflammation that ensues with exercise (203).  
 
Oral iron usage has been found to be common in the sporting context, particularly given 
the known association between exercise and iron loss (39). This has been demonstrated 
in cycling, where a third of elite French cyclists were found to supplement excessively, 
greater than advised, resulting in hyperferritaemia (39). Coaches often encourage athletes 
to supplement in phases of hard training, particularly when fatigue is reported or observed 
regardless of prior knowledge of iron status. Burden et al. (2015) has suggested that this 
may be counterproductive because where iron status is sufficient, an increase in iron will 
elevate hepcidin, resulting in a decrease in iron absorption, possibly having a detrimental 
effect on performance (51).  
2.15.3 Intravenous injections 
There are some instances where oral iron is not an appropriate means for iron repletion. 
Therefore, other administration routes such as intravenous or intramuscular injections are 
necessary. Intravenous iron injections are particularly used when oral iron will not meet 
demand, for example after significant blood loss, or in circumstances where absorption is 
ineffective, for example in inflammatory conditions such as irritable bowel disease. 
Historically, there have been a number of severe risks associated with intravenous iron 
injections, including anaphylaxis caused by allergic reactions (262). However, new 
formulations of parenteral iron are much safer (263). Here, iron is delivered in a 
carbohydrate complex, enabling it to be released slowly (262,264). As a result, large doses 
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can be administered over a relatively short period (typically 30-60 minutes). Intravenous 
iron injections have the ability to fully restore iron levels in a one-off dose through direct 
injection into the bloodstream meaning that controlled absorption is bypassed. The main 
negative associated with intravenous iron is the expense. 
2.15.4 Intramuscular injections 
Although effective, use of intramuscular injections for the restoration of iron levels is not 
common, and accordingly little research has been conducted using this means for iron 
repletion (74). Injections are painful and are associated with gluteal sarcomas and skin 
discolouration (265).  
 
2.16 Effects of iron supplementation in iron sufficient athletes 
Notably, previous research has shown no performance benefit of iron supplementation in 
non-iron deficient or anaemic athletes, identified by the lack of response of iron status 
markers to oral iron therapy (60). Given the associated risks and side effects, unnecessary 
supplementation is not recommended and can result in severe health repercussions 
(59,61,187).   
 
 
The second part of this literature review will firstly focus on the transport, delivery and 
storage of iron. It will then outline the control and maintenance of iron metabolism. Given 
the fundamental roles of iron described in the first section of this review, a biochemical 
understanding of these processes is essential when assessing iron status in the female 
athlete. 
 
2.17 Transport, delivery and storage of iron 
2.17.1 Iron transport within blood 
On entry into the circulation, ferric iron is picked up and scavenged by transferrin for tissue 
delivery. Transferrin is a 75 - 80 k-Da glycosylated protein plasma iron carrier, primarily 
secreted by the liver with a half-life of eight days (71). In addition to binding to plasma iron, 
it also binds to iron in extracellular fluids such as cerebrospinal and lymph fluids, and is 
distributed equally between the extracellular fluid and plasma (71). Each transferrin protein 
can transport up to two ferric ions to target tissues, undergoing a conformational change 
in the process (71,73). The binding of iron is pH-dependent, and iron is not bound in acidic 
conditions (71). The process of iron scavenging followed by tissue delivery is very dynamic, 
and is regulated by the expression of transferrin receptors 1 and 2, which are located on 
target tissues (266). Despite this being a vital process, only a very small amount of iron is 
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bound to transferrin, amounting to approximately 3 mg, and equating to less than 0.1% of 
total body iron (67). However, in order to meet erythropoietic demands, transferrin is turned 
over more than ten times each day (67). The majority of iron making up this dynamic pool 
comes from recycled senescent erythrocytes, taken up by reticuloendothelial 
macrophages in a process which will be described in further detail below (67).  
 
Under normal physiological conditions only approximately 30% of transferrin is saturated 
with iron (71). Where iron is present in plasma but is not bound to transferrin, it is termed 
non-transferrin-bound iron (NTBI). Transferrin has a high affinity for iron, so NTBI is 
typically only present where there is either a lack of transferrin (atransferrinemia) or if all 
transferrin is saturated. In these instances, other transporters such as albumin, citrate or 
acetate will bind to the NTBI (73). Ferritin within plasma also transports iron to tissues, 
however the mechanism for this is yet to be fully elucidated.  
 
2.17.2 Iron tissue uptake 
Since the primary means for iron delivery to cells is via transferrin, target cells express 
transferrin receptors. The primary transferrin receptors are transferrin receptors 1 and 2, 
and levels of these typically correlate with iron requirements of the cell. The iron-containing 
transferrin binds to the cell surface transferrin receptors, forming a holo-transferrin-
transferrin receptor 1 complex (85). This will enter cells via receptor-mediated endocytosis, 
forming clathrin coated pits (267). The low pH environment in the formed endosome which 
is created by proton pumps, causes the complex to breakdown (85). Ferric iron is then 
reduced to ferrous iron, a reaction catalysed by the ferriductase six-transmembrane 
epithelial antigen of phosphate 3 (STEAP3) (85). Ferrous iron crosses the endosomal 
membrane via DMT1, entering the labile iron pool in the cytolsol (85). From here there are 
a number of different destinations for ferrous iron dependant on need, as explained below. 
Apotransferrin is then recycled and released. The effectiveness of iron uptake is dictated 
by the iron content of transferrin. 
2.17.2.1 Ferrous iron in cells 
There are three primary destinations for intracellular ferrous iron, as explained below: 
 
Cellular iron utilisation 
The majority of iron is transported to the mitochondria either for incorporation into haem or 
for incorporation into iron dependent proteins. The process by which iron transverses cells 
and enters mitochondria is yet to be decisively elucidated, in part confounded by a variation 
in different cell types (268,269). It is also likely that iron is transported to cells via several 
different processes. Firstly, a direct mechanism by which iron is delivered to the outer 
  
69 
 
mitochondrial membrane directly from the endosome has been demonstrated in 
reticulocytes (268,269). Secondly, iron in the cytosolic labile iron pool has been found to 
form low and high molecular weight intracellular complexes (270,271). While further 
research is required to gain a better understanding of these, chaperone proteins such as 
glutathione (GSH) (272), poly C binding proteins (e.g. poly (rC) binding protein 1 - PCRP1) 
(273), and monothiol glutaredoxins (e.g. glutaredoxin 3 - Grx3-type) (274), have been 
implicated in assisting with iron transport throughout the cell, including to mitochondria 
(85). Finally, it has also been postulated, and demonstrated in murine and yeast cells that 
the mitochondrial membrane potential can drive direct entry of iron into mitochondria 
(275,276). Further research is evidently required to more specifically identify the 
mechanisms involved in human cells, and to establish the specific intracellular organelles 
to which chaperones are responsible for transport.  
 
There is also a degree of ambiguity surrounding the mechanism by which iron transverses 
the outer and inner mitochondrial membranes (277). Voltage dependent anion channels, 
which are the primary means for transport of metabolites into and out of mitochondria, exist 
in high abundance in the outer mitochondrial membrane, so it has been suggested that 
iron may enter via these (277). However, DMT1 isoforms have also been identified which 
present another option for iron import (278,279). 
 
Mitoferrin 1 and 2 (MFRN1 and 2) are responsible for iron import across the intracellular 
mitochondrial membrane (280). A study in mouse erythroid cells found that iron was 
transported from transferrin receptor 1 containing endosomes through binding to the 
MFRN 1 importer. This is stabilised through interaction with an ATP-binding cassette 
transporter – Abcb10, facilitating iron entry (281).   
 
Once in mitochondrion, iron will either be stored, used for the biosynthesis of iron-sulphur 
clusters or used for haem synthesis. 
 
Cellular iron storage 
In a cell, when the demand is low, and iron is in excess, it can be stored as ferritin within 
the cytosol. Some cell types also have iron stored as ferritin in mitochondria (MTFT) (267). 
When required, nuclear receptor coactivator 4 targets ferritin for iron release back into the 
cytosolic labile iron pool (282).   
 
Cellular iron export 
Excess iron can also be exported out of the cell via ferroportin (Section 2.18), with the aid 
of ceruloplasmin or hephaestin. 
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2.17.3 Iron storage 
As previously explained, the majority of body iron is located to haemoglobin. Due to the 
toxicity of unbound iron, the storage of excess iron is crucial for optimal physiological 
functioning. Ferritin and haemosiderin are the iron-storage complexes which are 
responsible for this.  
 
Ferritin is a spherical heteropolymeric, intracellular, cytosolic iron-storage protein 
consisting of 24 heavy (H) or light (L) type subunits that form a hollow sphere which can 
contain up to 4500 iron atoms (3,73). Cytoplasmic chaperones such as poly (rC)-binding 
protein 1 (PCBP1) transport iron in its ferrous form to ferritin (273). Here, it is oxidised back 
to ferric iron, a process which is catalysed by the heavy type subunits which act as 
ferroxidases (73).  
 
While the majority of ferritin is intracellular, there is also some found within serum. 
Research suggests that a small amount of iron may be delivered to tissues by plasma 
ferritin (73). Serum ferritin is primarily comprised of light-type (L) subunits, and is thought 
to be secreted by macrophages, hepatocytes and Kupffer cells (283,284). This ferritin is 
less iron rich than that found within tissues (285). As previously highlighted, since serum 
ferritin correlates with iron stores in most physiological situations, in the clinical setting it is 
typically used as a means for measuring iron status (286,287). However, this is not always 
the case, as it is particularly susceptible to transient variation in certain situations, in states 
of inflammation, or post exercise, as previously highlighted (73,288). However, due to its 
role as an acute phase reactant, it is often used as a marker of both acute and chronic 
inflammation, and can be used as a non-specific marker of illness (288). Accordingly, the 
use of serum ferritin to evaluate iron status needs to be treated with caution.  
 
Iron is also stored as haemosiderin. Iron from the labile pool is taken up by ferritin and is 
then transformed into haemosiderin for storage; haemosiderin is a complex of ferritin (289). 
The reverse of this happens for iron mobilisation back into the labile pool from 
haemosiderin via ferritin (289).  
 
2.17.4 Toxicity of iron 
As previously highlighted, there is no physiological mechanism for excreting surplus iron. 
Excess free iron within tissues under aerobic conditions can be very harmful, causing 
excessive production of reactive oxygen species (ROS) (68). Through evolution, 
organisms have developed proteins which can bind to iron to prevent harmful damage, 
while keeping it stable and accessible for physiological requirements. Based on the Fenton 
and Harber-Weiss reactions, iron in excess will catalyse the production of hydroxyl radicals 
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from hydrogen peroxide and superoxide (68,290). While production of ROS within cells is 
normal, excess production is harmful, and iron overload can cause cellular damage, for 
example, it will result in the peroxidation of lipid membranes (291,292). At physiological pH 
and under aerobic conditions however, extracellular iron is bound to transferrin keeping 
iron in its soluble state, making it available, while also preventing toxicity. In homeostatic 
conditions, approximately 30% of transferrin is bound to iron, however once transferrin 
saturation exceeds 80%, it becomes saturated resulting in an increase of NTBI (266,293). 
This NTBI is potentially harmful, having the ability to catalyse ROS-producing reactions. It 
can form chelates, which are subsequently internalised into cells in an unregulated 
manner, causing damage (68). The insolubility of iron at neutral pH and under aerobic 
conditions is therefore vital in serving as a protection mechanism (294).  
 
2.17.5 Release of free iron and haemoglobin into the circulation 
Under normal physiological conditions 10 - 20% of total erythrocytes are haemolysed early, 
before the end of the typical red blood cell lifespan and prior to senescence and 
macrophage identification for phagocytosis (295). During haemolysis, the erythrocytes 
release haemoglobin freely into plasma. Similarly to iron, free haemoglobin is toxic, 
causing an increased production of ROS (296). However, the two glycoproteins 
haptoglobin (Hp) and haemopexin (HPX) act as scavengers for the released haemoglobin 
and haem, primarily functioning to prevent their pro-inflammatory and pro-oxidant effects 
(297). 
 
Both Hp and HPX are acute phase proteins, therefore their expression can be induced by 
inflammatory mediators. Hp, is secreted by hepatocytes, and specifically binds to the 
released haemoglobin, sequestering the iron (191,192). The Hp-Hb complex will then bind 
to the cluster of differentiation receptor 163 (CD163) on the surface of macrophages and 
will be endocytosed, resulting in Hb breakdown and iron release (295,298). Where there 
is a significant amount of haemolysis, Hp will be unable to sequester all the free 
haemoglobin. As a result, the haemoglobin will readily be oxidised to ferrihaemoglobin, 
releasing free haem (299). Ferrihaem will then be transported to HPX by albumin (297). 
HPX has the highest haem binding affinity of any known haem-binding protein, and 
typically binds haem that is released from early haemolytic erythrocyte breakdown (299). 
On binding, the haem-HPX complex undergoes receptor-mediated endocytosis via the 
LDL receptor-related protein (LRP1) (299,300). These receptors are particularly located to 
hepatocytes, macrophages and in splenic tissue, therefore the haem will enter these 
tissues, and will be broken down, freeing the iron (299). Essentially, Hp and HPX facilitate 
the recycling of haemolysed erythrocytes, while also protecting against the harmful effects 
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of free haemoglobin and haem. Hp and HPX biomarker levels can be used as a means for 
assessing haemolysis.  
 
2.18 Maintenance of iron homeostasis 
Maintenance of iron homeostasis is a very refined and important process which is 
controlled at both a systemic and cellular level.  
 
2.18.1 Iron entry into the circulation 
There are three cell types from which iron can enter the circulation, all of which are involved 
in the maintenance of iron homeostasis;  
• Intestinal enterocytes – these are primarily located to the upper jejunum and 
duodenum. They are responsible for absorption of dietary iron.  
• Macrophages - these are typically located to the spleen, liver or bone marrow. They 
are responsible for the recycling of iron from senescent erythrocytes. 
• Hepatocytes – these store iron, releasing it when needed.  
2.18.1.1 Iron entry into the circulation via intestinal enterocytes 
Iron absorption into the circulation via intestinal enterocytes takes the form of 3 phases as 
shown in Figure 2.3: 
1. Iron transport into enterocytes. 
2. Iron transport across enterocytes. 
3. Iron release from the basolateral enterocyte membrane. 
 
1. Iron transport into enterocytes 
The mechanism by which iron it taken up into enterocytes is dictated by the type of iron. 
As previously highlighted, there are two types of dietary iron, namely haem iron (typically 
animal sources) and non-haem iron (typically non-animal, plant sources), the bioavailability 
of which varies. Uptake of haem iron across the apical enterocyte membrane is much more 
efficient than uptake of non-haem iron, however the exact mechanism of haem uptake has 
historically been unsure. Recent research suggests a role for haem carrier protein 1 
(HCP1), a hydrophobic protein consisting of nine transmembrane domains (301). 
Expression of HCP1 can be controlled both pre- and post- translationally (142,302). 
However some have found this protein to have a role in folate transport as opposed to 
haem transport, so further research is required (303).   
 
The process by which non-haem iron is absorbed is much more complex (Figure 2.5). At 
the typical physiological pH (approximately 7.4), ferrous iron (Fe2+) is oxidised to ferric iron 
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(Fe3+), which is insoluble, and therefore direct entry into cells is not possible. However, the 
gastric acid and ferric reductase enzymes (such as duodenal cytochrome B) in the proximal 
duodenum lower the pH, enabling the reduction of ferric iron back to ferrous iron, which 
can then be transported across the apical membrane of enterocytes by a ferrous iron 
transporter such as divalent metal transporter 1 (DMT1) (67).  
 
 
Figure 2.5 – The mechanism by which iron enters enterocytes, and is then either stored 
within the cell or is exported from the basolateral membrane into the circulation. The 
mechanism for haem iron entry into the cell is not yet understood, however it is 
hypothesised to involve the haem carrier protein 1 (HCP1). Non-haem iron enters the cell 
via divalent metal transporter 1 (DMT1), an iron transport protein, after being reduced by 
duodenal cytochrome B (Dcytb), a ferriductase. It is then either stored as ferritin or 
transported through the cell for export via ferroportin. Figure adapted from (3). 
 
The reduction of ferric iron to ferrous iron in the presence of oxygen is catalysed by a 
ferrireductase such as duodenal cytochrome B (Dcytb), located on the apical enterocyte 
membrane (304,305). Dyctb is a di-haem transmembrane oxidoreductase which reduces 
ferric iron, and requires endogenous or secreted reductants to act as an electron donor in 
the process (304,306,307). Ascorbate is thought to be the primary reducing agent, 
however some research also suggests that this process could be facilitated by other 
reductants (308). While much research has focused on the role of ascorbate in the control 
of iron uptake (304), other roles for this ester have been suggested in addition to increasing 
the reductase activity of Dyctb (304,306).  
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Once reduced, ferrous iron (Fe2+) enters enterocytes via a divalent mental transporter 
(DMT1), this is a protein that transverses the apical cell membrane. DMT1 is located on 
the brush border of the apical enterocyte membrane and in addition to ferrous iron, it can 
also transport other metals providing they have a valency of two. DMT1 is coded by the 
SLC11A2 gene, and has 12 transmembrane domains, terminating in the enterocyte 
cytoplasm (309,310). The primary function of DMT1 is to co-transport protons alongside 
ferrous iron into cells (310,311). The required proton gradient is thought to be driven by a 
sodium/hydrogen exchanger on the apical brush border membrane (3). The efflux of 
positive ions also assists with iron absorption by lowering the surrounding pH aiding partial 
release of ferric iron from its protein carriers, prior to its reduction by Dyctb to ferrous iron 
(304).  
 
2. Iron transport across enterocytes 
 
Within enterocytes, haem iron is thought to be mobilised by haem oxygenase 1 (HO-1), 
this frees ferrous iron ions into the labile iron pool (312). The specific transport process of 
both haem and non-haem derived ferrous iron within enterocytes is unsure, however it is 
thought that it is either chelated by small molecular weight organic acids, intracellular 
proteins or by amino acids (3). Poly-r(C)-binding iron-trafficking proteins have been 
suggested in this role (313). Depending on cellular iron status, iron will either be 
transported straight across the enterocyte to the basolateral membrane for entry into the 
blood, or will be stored. When iron is in excess, or suffice, it is stored as ferritin. In humans, 
enterocytes are typically sloughed every 2-5 days, so stored iron that has not been 
transported into the circulation will be lost (314).  
 
3. Iron transport across the basolateral membrane 
Iron is exported from enterocytes into the bloodstream via ferroportin, the only mammalian 
ferrous iron export protein discovered to date (315). It is coded by the SLC40A1 gene and 
has a 12-transmembrane domain terminating in the cytoplasm (316-318). It has been 
specifically localised to enterocytes, hepatocytes, macrophages and on the placental 
syncytiotrophoblast, clearly suggesting these as key sites for the regulation of iron 
homeostasis (319). 
 
Transport of iron via ferroportin is coupled to the re-oxidation of its ferrous form to its 
insoluble ferric form. The process is catalysed by the multicopper ferroxidase, hephaestin, 
which is located on the basolateral membrane (320,321). Once in the bloodstream, ferric 
iron will be picked up by transferrin, the glycosylated protein plasma iron carrier. Transferrin 
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transports iron throughout the circulation while also removing it from ferroportin to maintain 
the gradient to drive cellular iron export (73).  
2.18.1.2 Iron entry into the circulation via macrophages 
The average lifespan of an erythrocyte is 120 days, and when the cells reach senescence 
macrophages remove them from the circulation by erythrophagocytosis, in a process that 
usually takes place in the spleen, liver or bone marrow (322). On a daily basis, it is 
estimated that 0.8% of iron in erythrocytes is recycled, amounting to approximately 40 - 60 
mg (70,73). Within macrophages, the erythrophagocytosis occurs in the hydrolytic 
environment of phagolysosomes. This results in the breakdown of first the erythrocyte and 
then haemoglobin, freeing haem (73). The specific mechanism by which haem is broken 
down and iron is released has not yet been elucidated. However, the enzyme haem 
oxygenase-1 (HO-1) has been found to break down haem, releasing the iron (73).  
 
Depending on current iron status, the released iron is either stored within the macrophage 
cytoplasm or is transported into the bloodstream. The export of iron from macrophages 
into the bloodstream again occurs via ferroportin, and is controlled by hepcidin, in a 
process described in more detail subsequently (71). However iron is oxidised by the 
multicopper ferroxidase protein ceruloplasmin as opposed to hephaestin as in enterocytes 
(320). Four of the six copper atoms in each ceruloplasmin protein are involved in this 
oxidation process.(323)  
 
Significantly, on a daily basis, the iron that arises from the breakdown of senescent 
erythrocytes in macrophages forms the vast majority of iron that enters the plasma 
(approximately 20 mg per day) (324). Intestinal uptake only typically amounts to 1 - 2 mg 
(70).  
2.18.1.3 Iron entry into the circulation via hepatocytes 
Iron can also enter the circulation from hepatocytes. Again, it is released via ferroportin, 
and is controlled by hepcidin expression. In a similar process to iron export from 
macrophages and enterocytes, a copper ferroxidase is responsible for the oxidation of 
ferrous iron prior to transferrin binding. Formed through alternative splicing, a different form 
of ceruloplasmin containing a glycosylphosphatidylinositol anchor catalyses this reaction 
(325). Hepatocytes provide a long-term store of iron, and release is thought to be slower 
than from macrophages (135).  
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2.19 Regulation of iron homeostasis 
In order to maintain homeostasis and control iron absorption and release, a number of 
specific proteins and hormones are involved at both a systemic and cellular level. At a 
systemic level this control is primarily transcriptional, while at a cellular level this is post-
transcriptional.  
2.19.1 Systemic control of iron homeostasis 
2.19.1.1 Hepcidin 
Hepcidin is a 2.7 kDa peptide hormone consisting of 25 amino acids and containing four 
disulphide bonds (76). Coded by the HAMP gene, it is primarily produced by hepatocytes 
and is responsible for the regulation of iron entry into the plasma through controlling both 
absorption across the basolateral membrane of enterocytes and the entry of recycled iron 
from macrophages and stored iron from hepatocytes (62). Other cell types have also been 
found to express hepcidin mRNA at a much lower level, including adipocytes, 
cardiomyocytes, parietal cells and cells of the immune system (76). It typically exists in the 
circulation as a free protein, however a small fraction is weakly bound to albumin and !2-
macroglobulin (326).  
 
Hepcidin controls iron plasma entry post-translationally through its effect on ferroportin 
(199). On binding with ferroportin, it causes it to be internalised, and ubiquitinated (327). It 
is then endocytosed into endosomes and degraded (76,327). As a result, plasma delivery 
of iron into the bloodstream is prevented, and iron accumulates in the cell (328). Therefore, 
when levels of hepcidin are high, iron absorption from enterocytes and release from 
macrophages and hepatocytes is reduced, decreasing plasma iron. When iron levels are 
low, and therefore hepcidin levels are low, iron uptake from enterocytes and macrophage 
and hepatocyte release into the circulation is increased, elevating plasma iron (329). If 
hepcidin levels remain high, the iron stored in enterocytes will be lost as these cells are 
sloughed (330). Hepcidin has also been found to alter expression of DMT1, therefore 
influencing iron uptake into enterocytes (91).  
 
Being the site of hepcidin production, the liver appears to be the primary controller of HAMP 
expression. Interestingly, circadian rhythm also has an effect on hepcidin release, as 
release is thought to increase through the day (136).  
 
HAMP gene expression is homeostatically controlled by a number of factors, including iron 
status, erythropoiesis, hypoxia and inflammatory mediators, and will now be discussed in 
further detail (331,332).  
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2.19.1.2 Increased hepcidin expression 
There are two primary factors that result in an increase in hepcidin expression including 
iron overload and inflammation and infection. 
 
Iron overload 
HAMP expression increases in response to elevated iron both in the liver and in plasma 
through independent pathways. Firstly, elevated levels of iron in the liver cause expression 
of the growth factor and cytokine bone morphogenetic protein 6 (BMP6) to increase (333). 
As a member of the transforming growth factor beta superfamily (TGF-ß) (334), once 
activated, this binds to haemojuvelin, a co-receptor ligand required for activation of the 
BMP signalling pathway. The BMP6/haemojuvelin complex then binds to the activated 
BMP receptor (333,334), initiating an intracellular signalling cascade starting with the 
phosphorylation of SMAD (contraction of Sma and Mad) (76). This results in an increase 
in signalling to the proximal and distal ends of the HAMP promoter, causing HAMP 
expression to be upregulated, increasing hepcidin production, therefore reducing iron 
absorption into the bloodstream (335-337).  
 
The mechanism by which plasma iron dictates hepcidin release is not yet fully understood, 
however it has been elucidated that both iron in the liver and plasma transferrin saturation 
are sensed by transferrin receptors 1 and 2 and the hepatic haemochromatosis protein 
HFE (338). When iron levels are high, HFE and transferrin receptor 2 are thought to bind 
together to form a signalling complex which then results in hepcidin activation and an 
associated reduction in iron absorption (338). 
 
Inflammation and infection 
HAMP is a type II acute phase protein (199), therefore expression increases as a result of 
release of particular cytokine inflammatory mediators through the Janus kinase/signal 
transducers and activators of transcription 3 (JAK/STAT-3) pathway (333,339). For 
example, interleukins such as IL-6 and IL-22 have been shown to increase HAMP gene 
transcription (199,340). A separate additional independent mechanism for increase in 
hepcidin release not involving the STAT-3 pathway has recently been suggested, which is 
activated in response to other TGF-ß superfamily cytokines (341). This is particularly 
significant for those who exercise, since these cytokines are likely to be upregulated post-
exercise, and recent research has specifically focused on the association between 
exercise and hepcidin release. Peeling et al. (2017) found a 7.5 fold increase in serum 
hepcidin three hours post exercise (342). It was concluded that a number of factors dictate 
this including the release of IL-6, baseline serum ferritin and serum iron, in addition to 
exercise duration (342). Despite previous research showing that iron status supersedes 
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inflammation in control of hepcidin expression (51), it is evident that those who exercise 
are likely to experience transient increases in hepcidin, and attention should be applied to 
the timing of dietary iron intake for maximal iron absorption.   
 
As previously highlighted, given that iron is essential for the survival of most micro-
organisms, this inflammation-induced hepcidin release acts as a defence mechanism, 
restricting iron uptake and therefore protecting against the invasion of these foreign bodies 
(333). Interestingly however, cytokines involved in the type I pathways (e.g. IL-1 and TNF-!) do not have the same impact on HAMP expression (199). 
2.19.1.3 Suppression of hepcidin expression 
There are three primary causes for a suppression of hepcidin expression, including iron 
deficiency, hypoxia and an increased erythropoietic stimulus. 
 
Iron deficiency 
In iron deficient states, there are a couple of pathways by which hepcidin expression is 
thought to be supressed. Firstly, evidence suggests that the serine protease matriptase-2 
is induced in the liver, and cleaves haemojuvelin, disrupting the BMP6/haemojuvelin 
complex, resulting in the cessation of HAMP expression (343). Secondly, plasma iron can 
also specifically block hepcidin signalling through the action of transferrin receptor 1 on 
HFE (344). It sequesters HFE, preventing binding to and interaction with transferrin 
receptor 2, and therefore stopping the resulting activation of hepcidin (344). 
 
As a result of menstruation, resting levels of hepcidin in premenopausal women are likely 
to be lower than those of postmenopausal women (330). 
 
Hypoxia 
Historically, it was believed that hypoxia directly supresses hepcidin. The mechanism was 
thought to involve the hypoxia inducible factors (HIFs), which are stabilised under hypoxic 
conditions (345). Up until recently, research has suggested that these could either directly 
supress hepcidin expression through the HAMP promoter or indirectly through a reduction 
in BMP6 signalling (346). However, further more recent research suggests that an 
increased erythropoietic drive, and therefore increased erythropoietin (EPO) release was 
required alongside this to supress hepcidin (347). Under hypoxic conditions this would 
most likely be seen, as oxygen demand is increased. 
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Increased erythropoietic drive 
Despite much previous uncertainty, research is increasingly suggesting that erythropoiesis 
alone can directly supress hepcidin expression. However, there has been much ambiguity 
as to the direct mechanism of action. When erythropoietic demand is elevated, EPO 
production is increased, inevitably enhancing iron requirements. Recently, using mouse 
models, Kautz et al. (2014) have discovered erythroferrone, a hormone which has been 
postulated as an erythroid regulator of hepcidin (347). This is encoded by the Fam132b 
gene, and is a member of the Clq/tumour necrosis factor family (348). It is hypothesised to 
be released by erythrocytes in response to increased erythropoietin (EPO), and has been 
found to supress hepcidin via the JAK/STAT pathway (347). However, to date only very 
limited and inconclusive human research has been conducted, the vast majority has been 
conducted in mice (81). Erythroblasts have been found to express the erythroferrone gene 
(81), however function and mechanism of action is yet to be elucidated.  
 
Both hypoxia and increases in EPO are also thought to induce matriptase-2 production in 
a similar mechanism to that in iron deficiency (76). 
 
2.19.2 Cellular control of iron homeostasis 
Since all cells require iron, yet an excess of iron is toxic and harmful, tight regulation and 
control at a both a cellular level and a systemic level is necessary. Cellular iron 
homeostasis is controlled by iron regulatory proteins (IRPs) and iron response elements 
(IREs). With regard to iron uptake, they function to control the regulation and expression 
of DMT1 and Dcytb, and therefore can dictate non-haem iron uptake. In states of iron 
deficiency, DMT1 and Dcytb expression is increased, when iron levels are optimal, 
expression is decreased.  
2.19.2.1 Iron regulatory proteins (IRPs) and Iron response elements (IREs) 
The function of iron regulatory proteins 1 and 2 (IRP 1 and IRP 2) is to sense cytosolic iron 
levels and then to either influence mRNA stability or alter translation of key proteins 
involved in the regulation of intracellular iron homeostasis (349). IRPs also regulate many 
other genes, demonstrating the wide range of tissues and proteins that are iron dependent, 
while also essential for mitochondrial function (349). IRPs post-transcriptionally regulate 
the expression of IREs. IREs are conserved stem-loop structures. In the case of the control 
of iron uptake into enterocytes and therefore the control of DMT1 expression, IREs are 
found on the DMT1 mRNA. They are also found on the mRNA of transferrin receptor 1, 
ferroportin, HIF-2! and ferritin, as will be discussed subsequently (349).  
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There is tissue specific variation in the response to IRP-IRE binding, largely dependent on 
the location of mRNA binding (93). For example, in conditions of iron overload IRPs bind 
to the 5’UTR of specific target mRNAs such as L- and H- ferritin, ferroportin and HIF-2! to 
reduce translation, preventing iron uptake and storage (71). While in iron deficient states, 
IRPs can bind to the 3’UTR of DMT1 and transferrin receptor 1 mRNA to increase iron 
absorption (349). Significantly, much of these processes have been conducted in murine 
models, therefore further mammalian human research is required to ascertain the exact 
roles of IRPs in iron homeostasis.  
2.19.2.2 Ferroportin 
As previously highlighted, ferroportin is the only known iron export protein. Its expression 
can be regulated at different levels, including transcriptionally, translationally and post-
translationally.  
 
1. Transcriptional control of ferroportin 
 
Research evaluating the control of ferroportin at a transcriptional level is not as conclusive 
as translational and posttranslational control. Two primary mechanisms have been 
hypothesised. 
 
Within macrophages specifically, it is thought that both haem and iron are key in regulation 
of ferroportin transcription. This regulation is believed to be via the transcriptional repressor 
Btb And Cnc Homology 1 (Bach1) (350), which is suggested to be able to sense cellular 
levels of both haem and iron (351). On activation, it will have a number of downstream 
effects resulting in increased haem-oxygenase 1, ferritin and ferroportin transcription, while 
also triggering iron release from haem (350). Haem activation of haem-oxygenase 1 alone 
further stimulates iron release (352). The released iron will then bind to IRPs, preventing 
IRP binding to 5’UTR ferroportin and ferritin IREs, and as a result transcription is increased 
(353).  
 
Expression of ferroportin is also thought to be regulated at a transcriptional level by hypoxia 
inducible factor 2 alpha (HIF-2!) (354). Since HIF-2! requires oxygen for breakdown and 
prolyl hydroxylase 2 requires iron for function, in hypoxic conditions or iron deficiency, HIF-
2! is not broken down by prolyl hydroxylase 2, and it instead binds to HIF-1ß. Increased 
expression of HIF-2! results in increased transcription of genes which specifically result in 
increased iron uptake, including ferroportin, Dcytb and DMT1 (354,355). Therefore, in 
hypoxia or iron deficiency, iron uptake and entry into the bloodstream is increased.  
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2. Translational control of ferroportin  
Translation of ferroportin is controlled by IRP 1 and IRP 2. To inhibit translation, these bind 
to the 5’UTR of IRE’s in ferroportin mRNA (356). 
 
3. Posttranslational control of ferroportin  
Posttranslational ferroportin expression is controlled by the peptide hormone hepcidin, as 
previously explained (327). This is believed to be the primary and most important 
mechanism for controlling plasma iron entry and maintaining homeostasis (357). 
 
Non-hepcidin internalisation of ferroportin 
While hepcidin is the only ligand that can cause ferroportin internalisation and degradation, 
ceruloplasmin is also essential for iron export (358). In the absence of ceruloplasmin, 
ferroportin is internalised and degraded (358).   
 
Cellular iron is primarily homeostatically controlled by iron status and hypoxia.  
 
2.19.2.3 Adequate iron or iron overload impact on cellular activity 
When cellular iron stores are optimal or too high, activity of IRP 1 and IRP 2 is reduced. 
IRP 1 binds to an iron-sulphur cluster, where it functions as a cytosolic aconitase, stopping 
activity, and IRP 2 is degraded by ubiquitin ligase (312). A lack of IRP activity causes 
transferrin receptor mRNA to be degraded, therefore preventing extra cellular iron entry 
(312). This also allows translation of ferritin and ferroportin mRNA to enable storage and 
export of iron.  
 
2.19.2.4 Iron deficiency and hypoxia impact on cellular activity 
When there is a cellular iron deficiency, IRP 1 is released from the iron-sulphur cluster, 
and IRP 2 is stabilised. Both IRPs will then bind to IREs located in the UTRs in the mRNA 
of key iron uptake, storage and export proteins to influence expression. As a result, iron 
uptake is increased, and storage and export are decreased (71).  
 
In addition to the previously discussed impact of hypoxia on hepcidin expression, it has 
been suggested that the hypoxic stimulus also drives hepcidin-independent responses at 
a cellular level, increasing iron absorption by increasing expression of iron transporters 
(81). In murine models, in addition to increasing expression of DMT1 and DcytB (359), HIF-
2! has been shown to upregulate ferroportin expression by binding to the promoter on 
ferroportin response elements in states of both hypoxia and iron deficiency (81,354,360-
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362). However, since these conclusions were drawn from murine studies, and future 
mammalian research is required. 
 
2.20 Summary 
Exercise clearly has the potential to increase susceptibility to iron losses, and therefore 
menstruating women who exercise are inevitably at increased risk of deficiency. Given the 
likely impact on iron status, research is required first examining the prevalence of HMB in 
those who exercise. The effects that this has on outcomes which have the potential to 
affect performance then need to be considered. The importance of iron is evident, and 
while the repercussions of IDA are clear, an increased understanding surrounding the 
impact and diagnosis of IDNA is evidently required. This will enable a more accurate 
assessment of prevalence and when intervention is required. Existing ambiguity may in 
part be due to the suitability of markers used for its diagnosis. Iron homeostasis is a very 
tightly controlled process, and exercise can cause necessary modification in homeostatic 
mechanisms, which are essential given the adverse impacts of excess free iron. 
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2.21 Overall aims and hypotheses of this thesis  
2.21.1 Thesis aims 
i. To establish the prevalence of HMB amongst exercising women of different 
performance levels when HMB was identified using a self-created, non-
validated criteria. Then to identify whether this was associated with the 
perception that the menstrual cycle disrupts exercise training/performance in 
this population and with a history of self-reported anaemia. 
ii. Using the same criteria for HMB, firstly to identify whether identified HMB 
presence increased likelihood of iron deficiency and IDA and secondly to 
evaluate whether iron status is involved in any relationship between identified 
HMB and the perception that the menstrual cycle disrupts exercise 
training/performance in an exercising population. 
iii.  Again, applying the same criteria for HMB identification, to first identify any 
association between HMB, iron status and fatigue in an exercising population, 
and second to evaluate whether an association between identified HMB and 
fatigue is mediated by IDA.  
iv. Finally, to evaluate the impact of iron repletion, using a single intravenous iron 
injection, on exercise and aerobic capacity, haematological markers and 
subjective measures of fatigue and mood disturbance in iron deficient (serum 
ferritin ≤ 30 µg·L-1), non-elite, exercising women. 
 
As outlined in Figure 1.1, the primary hypotheses for this thesis are: 
 
i. When identified using a four-part series (outlined in chapter 3), HMB is 
common in exercising women, being more common in those who are 
recreational. and associated with both the perception that the menstrual cycle 
disrupts exercise training/performance and a history of self-reported anaemia. 
ii. Identified HMB increases risk of iron deficiency and IDA, and iron deficiency is 
on the pathway between identified HMB and the perception that the menstrual 
cycle disrupts exercise training/performance in exercising women. 
iii. The presence of identified HMB and iron deficiency, IDA or anaemia all 
increase fatigue in exercising women. The relationship between identified HMB 
and fatigue is mediated by IDA. 
iv. Iron repletion in non-elite, iron deficient (serum ferritin ≤ 30 µg·L-1) exercising 
women improves exercising and aerobic capacity and reduces fatigue and 
mood disturbance. 
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Figure 1.1 - An overview of the hypotheses. i. There is an association between HMB (when 
identified using a self-report, four-part series) and IDA and ID; ii. IDA and IDNA are on the 
causal pathway between identified HMB and perceived disruption to exercise 
training/performance caused by the menstrual cycle. iii. The relationship between HMB 
and fatigue is mediated by IDA and ID; and iv. ID causes a reduction in aerobic and 
exercise capacity, while also being associated with increased fatigue. 
 
 
3 General methodology 
 
Chapter 3 outlines the methods that have been used in more than one study in this thesis. 
Where methodologies have been applied uniquely to a chapter, these will be expanded 
upon within the relevant individual chapter. Therefore, here the development of the 
‘Female Health Questionnaire’ will be detailed, including how and why the specific 
questions were included, in addition to the university ethics approval process. 
 
3.1 Female Health Questionnaire 
 
The ‘Female Health Questionnaire’ was developed with the primary aim of identifying the 
presence of heavy menstrual bleeding (HMB) when using the outlined means for diagnosis 
  
85 
 
in this thesis. Other questions were then asked alongside it so that these findings could be 
put into context through the consideration of typical exercise training, association of HMB 
with iron status, awareness of both HMB and iron status and the potential impacts that 
HMB may have on ability in exercise. The questionnaire was developed by the author of 
this thesis, and was evaluated by the primary supervisors involved in this PhD. Excluding 
the criteria used for the diagnosis of HMB, all questions were novel, and included for the 
reasons outlined in this chapter. 
 
3.1.1 Diagnosis of Heavy Menstrual Bleeding (HMB) 
 
As previously highlighted, the identification of HMB both in research and when patients 
present in the clinical setting is challenging with no validated criteria. Both the criteria 
applied by the National Institute for Health and Care Excellence in the UK (NICE) of 
‘excessive menstrual blood loss which interferes with a woman’s physical, social, 
emotional and/or material quality of life’ (26,363), and the objective definition of a loss of 
80 mL of blood or more each period (213), are very difficult to assess. There is no validated 
guidance for the measure and interpretation of impacts on physical, social, emotional 
and/or material quality of life. The use of quality of life questionnaires have been proposed, 
however the subjective nature of these can be challenging. While the assessment of blood 
loss is inevitably difficult, with significant issues surrounding hygiene. Further, blood 
volumes can vary significantly between individuals, and it could be argued that a specific 
value can equate to a considerably different proportion of total blood volume in different 
individuals, affecting the severity of the increased loss. Further, not all menstrual loss is 
blood, enhancing the potential for measurement inaccuracies (212). Clearly there is a lack 
of clarity as to whether it is the physical blood loss that should be reflected in the definition 
or whether it is more perceptual, relating to the impact that it has on the individual. It is also 
significant to note that the aetiology of HMB is often unknown. Using the pictorial blood 
assessment chart, an assessment of cause for HMB in university students found only 
20.7% of those with HMB (n = 82) had an underlying bleeding disorder or menstrual cycle-
related pathology such as polycystic ovary syndrome (Gursel et al. 2014). Suggesting HMB 
to be a condition in its own entirety.  
 
As a result, more recently, a number of different methods have been suggested to try and 
provide a more robust means for HMB diagnosis, as recently explained in a Special Report 
published by Women’s Health (364). Yet there is still a lack of agreement. Therefore, it is 
important to acknowledge that throughout this thesis the criteria applied for identified HMB 
is not validated. 
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In this thesis the following criteria was applied for HMB diagnosis, where HMB was 
identified if a history of two or more symptoms was reported: 
1. Flooding through to clothes or bedding 
2. Need of frequent changes of sanitary towels or tampons (meaning changes 
every 2 hours or less, or 12 sanitary items per period 
3. Need of double sanitary protection (tampons and towels) 
4. Pass large blood clots 
 
This criteria applied a combination of the diagnostic series created by Fraser et al. (2015) 
(28), and the criteria applied by the American College of Obstetrics and Gynaecology 
(218). Both provide a novel option and are based on the symptoms commonly experienced 
by individuals reporting HMB in primary care. The criteria created by Fraser et al. (2015) 
includes the following symptoms, and individuals are told to indicate a history of any of the 
symptoms in the previous year. If two or more are indicated, HMB is diagnosed: (28)  
 
1. Flooding through to clothes or bedding 
2. Need of frequent changes of sanitary towels or tampons (meaning 
changes every 2 hours or less, or 12 sanitary items per period 
3. Need of double sanitary protection (tampons and towels) 
4. Pass large blood clots 
 
While the criteria utilised by the American College of Obstetrics and Gynaecology (218) 
includes the following symptoms. The identification of a history of any one of these at any 
time indicates HMB (218):  
 
1. Bleeding that lasts more than 7 days. 
2. Bleeding that soaks through one or more tampons or pads every hour for 
several hours in a row. 
3. Needing to wear more than one pad at a time to control menstrual flow. 
4. Needing to change pads or tampons during the night. 
5. Menstrual flow with blood clots that are as big as a quarter or larger. 
 
While these symptoms are inevitably subject to individual perception, they go some way to 
providing a more objective means for the diagnosis of HMB, while also capturing the 
perceptual elements highlighted by the NICE.  
 
Previous research has found a correlation between the number of sanitary towels and 
tampons used with total blood loss (365). However, not all research is in agreement with 
this as the changing of tampons and towels may also be reflective of a women’s state of 
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hygiene, as previously been found (366). Further, this does not capture the size or type of 
tampon or towel used. Despite being less likely to have an effect in developed countries, 
the socio-economic status of an individual may also impact upon this and still needs to be 
considered. The passing of large blood clots, need for double sanitary protection and 
flooding through to clothes or bedding, while still subjective in nature, are more objective 
than the number of tampon and towel changes. The need for double protection and 
flooding through to clothes and bedding indicates excess flow alone.  
 
Limitations with the HMB diagnosis applied in this thesis 
Evidently the diagnosis of HMB throughout this thesis and globally has to be interpreted 
with caution. Essentially, the end goal of HMB identification needs to be established – be 
it purely the need for further gynaecological assessments, the effects on quality of life or 
alternatively the potential increased susceptibility to other potential medical conditions or 
issues such as iron deficiency. For the purposes of this thesis, the key aims are to establish 
whether symptoms associated with HMB are something experienced by those who 
exercise, while also considering both the potential impact on iron status in this population 
and an association between this and the perception that the menstrual cycle disrupts 
training/performance. These have not previously been considered. If indeed deemed to be 
an issue amongst this population, and found to be associated with a compromised iron 
status and self-reported menstrual cycle disruption to exercise training/performance, this 
tool could be utilised by sports physicians to provide an indication of risk, suggesting when 
gynaecological and/or haematological input should be advised.  
 
Evidently, it must be acknowledged that the fact that this criteria is novel, means that 
comparison between prevalence here and previous research is subject to inaccuracy. 
 
Notable other methods for the quantification of blood loss have been tested including the 
Pictorial Blood Assessment Chart (367), however again this has a subjective element, 
making effectiveness questionable.  
 
3.1.2 Accompanying questions in the Female Health Questionnaire 
 
Questions 1 and 11 - Age 
Firstly, to ensure participants were 18 years or older, there was a requirement to ask for 
both age and date of birth. On analysis, both were checked for inconsistencies. Age was 
also asked to enable identification of any associations between this and HMB presence.  
 
Questions 2 and 3 - Performance level and exercise volume of the participants 
  
88 
 
The total exercise time and personal best times (in the last year) were requested to 
determine whether there was an association between the performance level of the athlete, 
in addition to determining whether those who exercised more were less likely to suffer 
HMB. As highlighted previously, typically amenorrhea and oligomenorrhea are the principle 
menstrual cycle dysfunctions experienced in those who exercise, other menstrual 
dysfunctions are often ignored, and perceived to be less prevalent. 
 
Question 4 - Frequency of periods 
Participants were asked to report the number of periods they have had in the past year to 
enable assessment of whether this was associated with HMB presence, in addition to 
gaining an indication of menstrual cycle patterns within athletes. Again, questioning the 
existing perceptions of amenorrhea and oligomenorrhea.  
 
Question 5 – Advice for heavy periods 
Previous research suggests that HMB awareness is poor, while also often prone to 
misdiagnosis. Given the association between HMB and negative impacts on quality of life, 
in addition to the financial burden that is associated with HMB, it is important to assess 
this. While not directly asking whether an individual is aware about whether they have 
heavy periods, this question enabled identification of willingness to seek help if perception 
is that an individual has heavy periods. Significantly this information could be used to help 
inform future practice, including highlighting the need to put in place interventions to 
improve education and discussion. 
 
Question 6 - Awareness of anaemia 
HMB is associated with an increased risk of anaemia, therefore the capturing of this 
information will provide an assessment of whether appropriate tests are being performed 
in clinical care, in addition to explanation of outcome. Further, this will also enable 
assessment of iron status awareness amongst athletes, in addition to gaining an indication 
of whether supplementation use is informed.  
 
Question 7 – Use of iron supplementation 
Given the increased risk of iron deficiency both in those with HMB and in those who 
exercise, use of iron supplementation was relevant here. Further, since supplementation 
in athletes is thought common, this will also provide an indication of usage. 
 
Question 9 - Use of the oral contraceptive pill (OCP) 
The oral contraceptive pill (OCP) is used by exercising women for a number of different 
reasons other than birth control. It is often used as a means to regulate their menstrual 
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cycle, or to treat amenorrhea, dysmenorrhea, HMB or to relieve other symptoms (226). 
However, there is little research looking at any other physiological effects of the OCP in 
this population that could potentially be detrimental to performance. A number of studies 
have recently been published suggesting that it could result in increased inflammation 
(368,369), oxidative stress (370), and a reduction in aerobic capacity (371). For the 
purposes of this research we wanted to capture general prevalence of OCP usage, while 
also determining if this seems to be a common treatment option used by those with HMB. 
 
Question 10 – perception of whether an individual feels that their menstrual cycle disrupts 
their exercise training/performance 
Given the hypothesised effects that the menstrual cycle can have on performance, it was 
important to establish whether individuals perceived their menstrual cycle to be disruptive. 
Any relationship between the indication of this and identified HMB (when identified using 
the criteria in this thesis) with or without an associated compromised iron status, can then 
be investigated.  
 
 
3.1.3 Limitations with the existing ‘Female Health Questionnaire’. 
There are a number of limitations to the Female Health Questionnaire used in this thesis 
that will now be explained.  
 
Time frames - there is a disparity in time frames used in this questionnaire. Both question 
3 (performance times) and question 4 (number of periods) ask in context of the previous 
year, where as question 9 asks for current use, whereas the rest of the questions (2, 5, 6, 
7, 8 and 10) ask or imply experiences ‘ever’. Inevitably this will confound results, making 
conclusive evaluation problematic, therefore results must be interpreted with caution.  
 
Question 5 – this only asks whether any ‘help/advice’ was sought, it does not specifically 
ask from whom this was sought. To gain a better indication of medical understanding and 
awareness it would be advisable to have directly asked whether medical help/advice had 
been sought. 
 
Question 6 – this asked whether participants had ever ‘had’ anaemia, to their knowledge. 
This is perceptual and does not suggest diagnosis. Therefore, to evaluate this more 
accurately it would have been better to specifically ask whether they had ever been 
‘diagnosed’ with anaemia. 
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Question 7 – this question asked whether an individual has supplemented with iron. It does 
not capture whether supplementation was prescribed. While it is significant to note 
supplementation use without knowledge of anaemia, and in chapters 5 and 6, 
supplementation use without a current iron deficiency, it is difficult to evaluate medical 
practice because it is based on adherence to treatment and perception around need for 
supplementation (which as previously highlighted is deemed common in the athletic 
population). 
   
Question 9 – this only captures OCP use, and does not factor in other forms of 
contraception. It is also important to appreciate that use of hormonal contraception can 
cause altered bleeding, which could for example induce episodes of heavy bleeding. These 
are actually withdrawal bleeds and not specific episodes of menstruation, thus confounding 
study results.   
 
Subjectivity – clearly the subjective nature of these questions must be appreciated and is 
acknowledged in each chapter.  
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Female Health Questionnaire 
 
The research group at St Mary’s University, London in collaboration with University College 
London are investigating iron status in endurance athletes. One of the key factors 
considered to impact upon iron status in female athletes is blood loss during the menstrual 
cycle. This is further exacerbated in those who experience larger blood losses (heavy 
menstrual bleeders). Currently little research has been conducted in this area, therefore 
we are conducting a survey-based study firstly to look at the prevalence of menstrual 
issues amongst female athletes and secondly to investigate how the menstrual cycle 
affects training and performance. Could all women who read this please answer the survey 
– not just those who feel they might have an issue with their menstrual cycle. 
 
In order to participate in this study you must be: 
• Female 
• 18 years or older 
• Pre-menopausal 
 
By completing this survey you are giving consent for the information you provide to be 
included in this study. Your participation is voluntary and is specific to this study, and shall 
not be taken to imply consent to participate in any subsequent experiment or deviation 
from that detailed. All information will remain confidential as to your identity, and you may 
withdraw from the study at any time without reason. 
 
 
If there is anything you do not understand or wish to ask questions about, please feel free 
to ask. 
 
 
Thank you for participating 
 
 
Do you agree to these terms?  
 
YES  NO    
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1. Age  
 
2. How much time do you spend exercising each week? 
 
 
 
 
 
 
 
 
 
3. Please specify your personal best times for all/any of the below in the last year: 
 
 
 
 
 
  
 
 
 
 
 
4. Approximately how many periods have you had in the last year?   
 
5. Have you ever sought advice/help for heavy periods? 
 
 
 
6. To your knowledge, have you ever had anaemia? 
 
 
  
 
7. Have you ever supplemented with iron? 
 
 
 
  Time (minutes) 
Running     
Cycling     
Swimming     
Other     
  Time (minutes) 
5km run (inc Parkrun)   
10km run   
Half marathon   
10M TT cycle   
25M TT cycle   
2km row   
YES   
 
NO   
YES   
 
NO   
 
DON’T KNOW   
YES   
 
NO   
 
DON’T KNOW   
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8. Have you ever experienced any of the following? (tick all that apply) 
 
 
 
 
 
 
 
 
9. Do you currently use the oral contraceptive pill? 
 
 
 
10. Do you feel that your menstrual cycle disrupts your training/performance? 
 
 
 
11. Date of birth: (dd/mm/yyyy) 
 
 
12. We will be conducting more research in this area. If you are happy to be contacted 
further please provide your email address: 
 
 
 
 
 
 
 
 
 
 
  
Flooding through to clothes or bedding   
Need of frequent changes of sanitary towels or tampons    
(meaning changes every 2 hours or less, or 12 sanitary items per period) 
 
Need of double sanitary protection (tampons and towels)   
Pass large blood clots   
YES   
 
NO   
YES   
 
NO   
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3.2 University ethics approval process 
Since the IRONWOMAN trial was to be conducted in the performance laboratory at St 
Mary’s University, Twickenham, all university ethical approval sought in this PhD was 
through this committee. 
 
St Mary’s University have a three-tiered Ethical Application System, as follows: 
 
Level 1 – Low risk research, can be signed off by supervisor and is logged by the ethics 
rep. and reported to the ethics sub-committee. 
Level 2 – Medium risk research, where there is greater potential for harm to participants. 
This is signed-off by supervisor and sent to the school ethics representative for review. 
This will then either be approved or will be deemed high risk and will undergo a Level 3 
review. 
Level 3 – This involves research that is associated with physical or psychological risk. This 
will be reviewed by the University Ethics Sub-Committee, and the student and supervisor 
will be invited to attend a review meeting. Research will either be approved, rejected or 
amendments will be advised. In instances where further ethics approval is required (e.g. 
NHS ethics approval), this will need to be presented in addition to the application. 
 
The ‘Female Health Questionnaire’ was approved for use in the studies in this thesis via 
Level 3 approval. In Chapter 7, the IRONWOMAN Trial was firstly approved via the NHS 
Ethics Committee (approval number: 15/LO/1570), and it was then approved via the Level 
3 route. The clinical trials registration number for this trial was ISRCTN14032359. 
 
In Chapters 5 and 6, while the ‘Female Health Questionnaire’ was approved via the St 
Mary’s University ethics committee, the blood tests were conducted as part of routine 'well-
woman' health appointments. Despite all participants providing written informed consent, 
the analysis of this data was not initially meant to be for a research study, it was meant to 
form a retrospective audit, therefore IRB ethical approval was not sought. However more 
laterally it was decided to analyse this due to the impact that these findings could have. 
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3.3 Female Health Questionnaire v2 
This questionnaire was specifically derived for chapters 5 and 6, and with an opportunity 
to ask a few more questions, this was slightly longer than version 1. The alterations from 
version 1 and reasons for asking these are outlined below: 
 
Questions 2 and 3 - height and weight 
Information about height and weight were added firstly in order to determine whether 
these were risk factors for HMB or a compromised iron status, and secondly to determine 
whether these were confounders. This data was already due to be collected. 
 
Question 4 - Presence of co-morbidities 
The presence of co-morbidities have the potential to confound the results increasing risk 
of HMB and/or iron deficiency so it is important to capture and control for this information 
if necessary.  
 
Question 5 - premenopausal  
Given the association between age and fatigue, participants were required to be 
premenopausal. Further, in order to investigate the association between HMB and current 
iron status, it was important to only include premenopausal women.  
 
Addition of question 7 (competition level of participants) and removal of question 3 
(exercise performance times) from v.1 
In the first version of the questionnaire this question was hard to quantify. The primary aim 
of question 3 was to gain a better indication of the performance level of the participants, 
however, with the possibility of there being a language barrier, and given the potential for 
different sports involvement, and focusing on the end goal of identifying competition level, 
this question was simplified.  
 
Question 11 – knowledge of iron deficiency 
Due to the limitations on total question number in version 1, a history of iron deficiency was 
not requested. To gain a better understanding of knowledge of iron status, this question 
was included. 
 
Questions 11, 12 and 13 – knowledge of anaemia and iron deficiency and iron 
supplementation in the previous 3 months 
As current iron status was being measured it was important to gain an understanding of 
awareness of this through asking this question. Additionally, by capturing current 
supplementation use it enabled evaluation of unwarranted iron use (particularly if no 
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knowledge of iron deficiency or anaemia is indicated), in addition to factoring this into 
analysis as a potential confounder.  
 
Removal of question asking about OCP use  
Since this was not factored into analysis in version 1, this was removed.  
 
Question 14 - Do you feel that your menstrual cycle disrupts your everyday 
lifestyle/exercise performance? 
This was slightly altered from the question used in the first version of the questionnaire. 
The main reason for this was that the group we collaborated with in Singapore wanted to 
gain a better generic understanding of potential menstrual cycle impact and the initial 
cohort did not just comprise exercisers. Therefore it is difficult to compare this question to 
that in the previous version, however, regardless this can still be used to ascertain whether 
iron status is involved in any association identified.   
 
3.3.1 Limitations with the Female Health Questionnaire v2 
A number of the limitations of version 1 of this questionnaire still apply for version 2. 
Similarly to version 1, the time scales in this questionnaire are inconsistent making causal 
inferences problematic. The majority of the questions here however are ‘ever’.  
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Female Health Questionnaire 
 
The research group at St Mary’s University, London in collaboration with University College 
London and Vifor Pharma are investigating iron status in endurance athletes. One of the 
key factors considered to impact upon iron status in female athletes is blood loss during 
the menstrual cycle. This is further exacerbated in those who experience larger blood 
losses (heavy menstrual bleeders). Currently little research has been conducted in this 
area, therefore we are conducting a survey-based study firstly to look at the prevalence of 
menstrual issues amongst female athletes and secondly to investigate how the menstrual 
cycle affects training and performance. Could all women who read this please answer the 
survey – not just those who feel they might have an issue with their menstrual cycle. 
 
In order to participate in this study you must be: 
• Female 
• 18 years or older 
• Pre-menopausal 
 
By completing this survey you are giving consent for the information you provide to be 
included in this study. Your participation is voluntary and is specific to this study, and shall 
not be taken to imply consent to participate in any subsequent experiment or deviation 
from that detailed. All information will remain confidential as to your identity, and you may 
withdraw from the study at anytime without reason. 
 
If there is anything you do not understand or wish to ask questions about, please feel free 
to ask. 
 
 
Thank you for participating 
 
 
 
Do you agree to these terms?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES  NO  
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1. Age 
 
2. Height _________metres 
 
3. Weight ______kg 
 
4. Please state any co-morbidities (e.g. diabetes, heart failure, kidney disease) 
_________________________________________________________________ 
  
5. Are you premenopausal? 
 
 
 
 
6. How much time do you spend exercising each week? 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Competition level (if more than one form of exercise is performed please select the 
answer to reflect the highest level): 
 
 
 
 
 
 
 
 
 
 
8. Approximately how many periods have you had in the last year?   
 
9. Have you ever sought advice/help for heavy periods? 
 
 
 
10. To your knowledge, have you ever had anaemia? 
 
 
  
 
If YES, have you experienced this in the last 3 months? 
 
 
 
11. To your knowledge, have you ever been deficient in iron? 
 
YES    NO   
  Time (minutes) 
Running     
Cycling     
Swimming     
Other  (please 
detail exercise type 
and time) 
  
 
 
 
   
Do not exercise   
Recreational, just for fun   
Take part in races, in a relatively non-competitive manner 
 
Regional level   
National level   
International level  
YES    NO   
YES    NO    DON’T KNOW   
YES    NO    DON’T KNOW   
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If YES, have you been deficient in the last 3 months? 
 
 
 
 
12. Have you ever supplemented with iron? 
 
 
 
 
If YES, have you supplemented in the last 3 months? 
 
 
 
 
13. Have you ever experienced any of the following? (tick all that apply) 
 
 
 
 
 
 
 
 
 
14. Do you feel that your menstrual cycle disrupts your everyday lifestyle/exercise 
performance? 
 
 
 
15. Date of birth: (dd/mm/yyy) 
 
 
16. We will be conducting more research in this area. If you are happy to be contacted 
further please provide your email address: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
YES    NO    DON’T KNOW   
YES    NO    DON’T KNOW   
YES    NO    DON’T KNOW   
YES    NO    DON’T KNOW   
Flooding through to clothes or bedding   
Need of frequent changes of sanitary towels or tampons    
(meaning changes every 2 hours or less, or 12 sanitary items per period)  
Need of double sanitary protection (tampons and towels)   
Pass large blood clots   
YES    NO   
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4 The identified prevalence of heavy menstrual bleeding 
(HMB) and its association with reported menstrual cycle 
driven disruption to exercise training/performance in elite 
and non-elite athletes 
 
4.1 Abstract 
Background: Despite the use of a number of different means for diagnosis, HMB has 
been found to be common in the general population, yet the prevalence of heavy menstrual 
bleeding (HMB) in exercising women is unknown. HMB is associated with an increased 
incidence of iron deficiency and iron deficiency anaemia, both of which may have a 
significant effect on exercise training and performance. 
Methods: A ‘Female Health Questionnaire’ was designed incorporating a diagnostic HMB 
series, demographics, exercise ability data, training status, knowledge of anaemia, iron 
supplementation and perception of whether the menstrual cycle disrupts exercise 
training/performance. The survey was conducted in two stages; initially online, advertised 
via social media, and then repeated via face-to-face interviews with runners registered for 
the 2015 London Marathon.  
Results: 789 participants responded to the online survey (median age: 30 years (24 – 37 
years), and 1073 completed the survey at the marathon (median age: 33 years (27 – 40 
years). Utilising a diagnostic series, HMB was identified in half of those online (54%), and 
by more than a third of the marathon runners (36%). Surprisingly, HMB was also identified 
to be prevalent amongst elite athletes (37%). Overall, 32% of exercising women reported 
a history of anaemia, and 50% had previously supplemented with iron. Only a minority 
(22%) had sought help/advice for heavy periods.  
Conclusions: When using this diagnostic series, HMB was found to be highly prevalent in 
exercising women, associated with self-reported anaemia, increased use of iron 
supplementation and a perceived disruption to exercise training/performance caused by 
the menstrual cycle. Further research is needed to investigate the impact of HMB, iron 
deficiency and anaemia in exercising women.   
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4.2 Introduction 
Heavy menstrual bleeding (HMB) is thought common, affecting approximately a quarter of 
the general female population (28). By definition, HMB can negatively impact physical, 
emotional and social quality of life and reduce work capacity (26,372), but individuals are 
reluctant to seek help, with only a small minority (6%) of women seeking medical advice 
annually (373). It was estimated in 2010 that HMB cost the National Health Service of the 
UK more than £50 million (374). Yet, as highlighted in both chapters 2 and 3, the absence 
of a unified and validated identification criteria has made historical diagnosis and 
comparison between different populations problematic. The recent advent of more 
objective criteria, such as the four-part diagnostic criteria by Fraser et al. (28), and the 
criteria outlined by the American College of Obstetrics and Gynaecology (218), makes 
evaluation significantly easier. 
 
With the primary research focus on menstrual dysfunction in exercising women being on 
amenorrhoea and oligomenorrhea, other dysfunctions are seldom considered (49,54). The 
prevalence of HMB, and the impact it may have on performance in those who exercise is 
unknown. This group already have an increased susceptibility to iron deficiency through a 
greater erythropoietic drive, increased iron losses, the post-exercise inflammatory 
response and often a limited dietary iron intake (178,180,186,375-379). Considering that 
menstrual blood loss in those with HMB is typically five to six times greater than those 
without (216), it would seem prudent to suggest that iron deficiency risk may be 
exacerbated in those who both exercise and have HMB. This clearly has potential to inhibit 
exercise performance.  
 
Despite increasing anecdotal reports (18-20), the causes for the impact of the menstrual 
cycle on exercise performance are unknown. HMB could provide one explanation.  
 
4.2.1 Study aims 
1. The primary aim was to identify the prevalence of HMB amongst exercising women 
when adopting a self-created criteria (outlined in chapter 3), and to establish 
whether it differs according to exercise performance level (i.e. between elite 
athletes and recreational exercisers); 
2. The secondary aim was to determine whether HMB was related to a perceived 
disruption to exercise training/performance caused by the menstrual cycle.  
4.2.2 Study hypotheses 
1. HMB, when identified using the outlined criteria (chapter 3) is common in those 
who exercise. 
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2. Identified HMB is more common in recreational than elite athletes. 
3. Identified HMB is associated with the reporting that the menstrual cycle disrupts 
exercise training/performance 
 
4.3 Materials and Methods 
4.3.1 Ethics and participant consent 
This research was approved by the St Mary's University Ethics Committee. The 
participants were informed that by indicating that they agree to the terms and completing 
the survey they have provided written informed consent for their information to be used in 
this study. 
4.3.2 Inclusion criteria 
The inclusion criteria were:  
• Female;  
• Aged ≥ 18 years;  
• Pre-menopausal;  
• Undertake regular exercise (≥ 90 minutes/week).  
4.3.3 Participants 
Stage 1 - Participants were exercising women either recruited online, and through social 
media, including Twitter, Facebook, online blogs and forums, university newsletters, 
websites, or recruited by word of mouth. 
Stage 2 – Participants were women attending the 2015 Virgin Money London Marathon 
Exhibition prior to competing in the marathon. 
 
4.3.4 Study design 
The 12-item ‘Female Health Questionnaire’ as described in Chapter 3, including free-text 
and yes-no polar questions was used and designed to take 2-3 minutes to complete. The 
four-part criteria was used to identify those with a self-reported history of the identified HMB 
symptoms and information was collected on age, recent ‘personal best’ sports 
performance times (running, cycling, swimming and rowing), training volume, previous self-
reported knowledge of a history of anaemia and iron supplementation, the menstrual cycle 
and disruptions caused by it, and current oral contraceptive pill (OCP) use. 
4.3.4.1 Stage 1 - online questionnaire 
Stage 1 aimed to identify whether HMB, when using this series for diagnosis, was a 
problem in exercising women, and therefore whether to continue further investigation. The 
questionnaire was administered online between 22 January 2015 and 19 May 2015. A link 
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was provided to the internet-based survey in addition to some brief information about the 
research.  
4.3.4.2 Stage 2 - marathon exhibition questionnaire 
Stage 2 aimed to establish unbiased prevalence of HMB. Women registering for the 2015 
London Marathon at the pre-event exhibition were surveyed using paper versions of the 
‘Female Health Questionnaire’ as used in stage 1. No bias was applied when selecting 
women to question and to avoid a response bias a scripted standardised introduction was 
made providing no specific information about the context of the survey. To ensure 
maximum response yield, surveys were completed at the time of asking. The questions 
and format of the paper copies used at the Exhibition were identical to the online survey to 
maintain equivalency and reliability of this mixed mode strategy (380). 
 
4.3.5 Data Analysis 
All stage 1 data were downloaded into an excel spreadsheet. stage 2 data were inputted 
anonymously into an excel spreadsheet. The statistical analysis was completed using a 
predictive analytic software statistics computer package (IBM SPSS Statistics for 
Macintosh, Version 21.0, Armonk, NY: IBM Corp.). Statistical significance was set at p < 
0.05.  
 
All data were tested for normality using a Shapiro-Wilk test. Data were analysed 
descriptively to summarise the prevalence of HMB (identified using the outlined criteria), 
known anaemia, iron supplementation, the seeking of advice/help for heavy periods, age, 
average total weekly exercise time, 5 km personal best time in the last year (where 
provided), current OCP usage, number of periods in the last 12 months and the perceived 
disruption of the menstrual cycle on exercise training/performance in both stages 1 and 2. 
Chi-squared tests were used to determine whether there was an association between HMB 
and self-reported menstrual cycle disruptions to training/performance, previous seeking of 
advice/help for heavy periods, a reported history of anaemia and iron supplementation, 
and OCP use in each of stages 1 and 2 and amongst elite athletes. Mann-Whitney U tests 
were used to determine whether age, average total weekly training volume, 5 km personal 
best time (where given), and the reported number of periods per year were related to 
identified HMB presence.  
 
After combining both groups, a sub-analysis was conducted to separate out elite athletes 
using the following criteria: 5 km ≤ 18 minutes, 10 km ≤ 36 minutes, half marathon ≤ 80 
minutes, 2 km row ≤ 7 minutes: 45 seconds (elite running criteria defined using the 2015 
‘Great Run’ series definitions of ‘elite’, rowing criteria defined by GB Rowing physiologist).  
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Chi-squared tests were used to determine whether there was a difference in identified 
HMB, self-reported menstrual cycle disruptions to training/performance, a reported history 
of anaemia and iron supplementation, previous seeking of advice/help for heavy periods, 
a reported history of anaemia and iron deficiency, and current OCP use.  
 
Both linear regression and a Kruskal-Wallis H test with a post hoc analysis and Bonferroni 
correction were used to determine whether 5 km personal best time was linked to the 
number of HMB symptoms reported, and Mann-Whitney U tests were used to determine 
whether participant performance level (based on 5 km personal best) was related to 
identified HMB incidence.  
 
A multivariable binomial logistic regression was then used to assess the relationship 
between identified HMB, the reporting that the menstrual cycle disrupts 
training/performance and a reported knowledge of anaemia.  
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4.4 Results 
4.4.1 Participant characteristics - stage 1 
A total of 789 surveys were completed online. Participant characteristics are shown in 
Table 4.1. More than half (54.1%) of the participants were identified to have a history of 
HMB (identified using the outlined criteria - reporting experiencing two or more of the 
diagnostic HMB series at some point; Table 4.1). While 55.4% stated that their menstrual 
cycle disrupts their training/performance (Table 4.1).  
 
Table 4.1 – Participant characteristics, including identified prevalence of heavy menstrual 
bleeding (HMB). 
 
Stage 1 
(n=789) 
Stage 2 
(n=1073) 
Elite athletes 
(n=90) 
Age (years) 30 (24 - 37) 33 (27 – 40) 27 (24 – 33) 
Weekly exercise volume 
(min) 
360 (212.5 – 
530) 
300 (240 – 450) 580 (420 – 820) 
5 km PB (min:s) – 
previous 12 months 
23:55 (20:00 – 
27:32) 
25:53 (23:00 – 
28:00) 
17:26 (16:31 – 
17:50) 
Identified HMB 54.1% (427) 35.5% (381) 36.7% (33) 
Reported menstrual cycle 
disruption to 
training/performance 
55.4% (437) 31.7% (340) 51.1% (46) 
Seeking of advice/help for 
heavy periods 
24.1% (190) 21.1% (226) 23.3% (21) 
Knowledge of a history of 
anaemia 
38.4% (303) 28.0% (300) 52.2% (47) 
History of iron 
supplementation 
57.2% (451) 45.3% (486) 78.9% (71) 
Periods/year 12 (8 – 12) 12 (4 – 12) 11 (4 – 12) 
Current OCP use 31.9% (252) 36.4% (391) 36.7% (33) 
PB – personal best, HMB – heavy menstrual bleeding, OCP – oral contraceptive pill  
Values are median (IQR). 
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4.4.2 Participant characteristics - stage 2 
One thousand and ninety-one (1091) face-to-face surveys were collected and inputted into 
the Bristol Online Survey platform manually by the lead investigator and an assistant. 
Those with missing data or those completed by women who did not meet the inclusion 
criteria were excluded, resulting in a final sample size of 1073 for further analysis. Eight 
individuals declined to complete the survey once they had read the study information, and 
61 declined answering the survey prior to being informed about the content typically citing 
a lack of time. Therefore, in stage 2, the survey was fully completed by 94% of randomly 
approached female marathon runners. Participant characteristics are shown in Table 4.1, 
which highlights the prevalence of HMB (when identified using the outlined criteria) in 
women undertaking the 2015 London Marathon to be 35.5% (Table 4.1). Overall nearly 
one third (31.7%) reported that their menstrual cycle disrupts their exercise 
training/performance (Table 4.1). 
 
4.4.3 Results from stages 1 and 2 
Across both stages, those identified with a history of HMB were more than three times 
more likely to cite that their menstrual cycle disrupts their exercise training/performance 
(stage 1: OR: 3.54; 95% CI: 2.64, 4.76; p<0.0005; stage 2: 3.21; 95% CI: 2.45 – 4.20; 
p<0.0005; Table 4.2). In both stages, those with a history of HMB were found to be older 
(stage 1: 31 (24 – 35) years vs. 29 years (24 – 39); U = 87030; p<0.0005; stage 2: 36 (29 
– 40) years vs. 31 (27 – 38) years; U = 152120; p<0.0005; Table 4.2), but there was no 
difference in total weekly exercise volume (stage 1: 360 (240 – 540); U = 75160; p=0.51, 
stage 2: (300 (240 – 480) minutes vs 345 (240 – 420) minutes; U = 128639; p=0.51; Table 
4.2) between those who did and did not report HMB. However, those reporting HMB had 
slower 5 km personal best times in both stages 1 (24 min: 05s (20:40 – 28:00) vs 22 min 
:59s (19:10 – 26:09); U = 36714; p=0.002) and 2 (26min :00s (23:25 – 28:04) vs 25 min: 
00s (22:18 – 28:00); U = 57633; p=0.008; Table 4.2).  
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Table 4.2 - The perception that the menstrual cycle disrupts training/performance, seeking of help/advice for heavy periods, knowledge of a history of 
anaemia and iron supplementation in those who have and have not met the heavy menstrual bleeding HMB criteria, when identified using the outlined 
criteria. 
 Stage 1 Stage 2 Elite athletes 
 
HMB 
n = 427 
No HMB 
n = 362 
OR (95% 
CI) 
p-value 
HMB 
n = 381 
No HMB 
n = 692 
OR (95% 
CI) 
p-value 
HMB 
n = 33 
No HMB 
n = 57 
OR (95% 
CI) 
p-value 
Reported 
menstrual cycle 
disruption to 
training/ 
performance 
69.3%*** 
(296) 
39.0% 
(141) 
3.54 (2.64 
– 4.76) 
<0.0005 
48.3%*** 
(184) 
22.5% 
(156) 
3.21 (2.45 
– 4.20) 
<0.0005 66.7% (22)* 
42.1% 
(24) 
2.75 (1.12 – 
6.73) 
0.03 
Seeking of 
advice/help for 
heavy periods 
37.2%*** 
(159)* 
8.6% 
(31) 
6.34 (4.17 
– 9.61) 
<0.0005 
44.6%*** 
(170) 
8.1% (58) 
9.15 (6.51 
– 12.85) 
<0.0005 42.4% (14)*** 
12.3% 
(7) 
5.26 (1.84 – 
15.04) 
0.001 
Knowledge of a 
history of 
anaemia 
43.1%** 
(184) 
32.9% 
(119) 
1.55 (1.16 
– 2.07) 
0.003 
38.1%*** 
(145) 
22.4% 
(155) 
2.13 (1.62 
– 2.80) 
<0.0005 57.6% (19) 
49.1% 
(28) 
1.41 (0.59 – 
3.33) 
0.44 
History of iron 
supplementation 
61.4%* 
(262) 
41.9% 
(189) 
1.45 (1.09 
– 1.93) 
0.01 
55.1%*** 
(210)* 
39.9% 
(276) 
1.85 (1.44 
– 2.38) 
<0.0005 81.8% (27) 
77.2% 
(44) 
1.33 (0.44 – 
3.91) 
0.60 
Current OCP use 
24.6%*** 
(105) 
40.6% 
(147) 
2.10 (1.55 
- 2.84) 
<0.0005 25.5%*** (97) 
42.5% 
(294) 
2.16 (1.64 
– 2.85) 
<0.0005 30.3% (10) 
42.1% 
(24) 
1.62 (0.65 - 
4.03) 
0.29 
 Stage 1 Stage 2 Elite athletes 
 
HMB 
n = 427 
No HMB 
n = 362 
U p-value 
HMB 
n = 381 
No HMB 
n = 692 
U p-value 
HMB 
n = 33 
No HMB 
n = 57 
U p-value 
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Age (years) 
31 (24 – 
35)*** 
29 (24 – 
39) 
87030 0.002 
36 (29 – 
40)*** 
31 (27 – 
38) 
152120 <0.0005 
25.5 (22 – 
34.5) 
26 (24 – 
30.5) 
1003 0.71 
Weekly exercise 
volume (mins) 
360 (240 – 
540) 
360 (240 
– 525) 
75160 0.51 
300 (240 – 
480) 
345 (240 
– 420) 
128639 0.51 
590 (465 – 
720) 
530 (420 
– 850) 
913 0.96 
5 km PB (min:s) – 
previous 12 
months 
24:05*** 
(20:40 – 
28:00) 
22:59 
(19:10 – 
26:09) 
36714 0.002 
26:00 (23:25 
- 28:04)*** 
25:00 
(22:18 – 
28:00) 
57633 0.008 
17:21 (16:34 
– 17:55) 
17:28 
(16:31 – 
17:46) 
665 0.29 
Periods/year 
12 (9 – 
12)*** 
12 (6.25 
– 12) 
84643 <0.0005 12 (6 – 12) 
12 (4 – 
12) 
125151 0.23 11 (8 – 12)* 
9 (2 – 
12) 
1091 0.04 
HMB – heavy menstrual bleeding, OR – odds ratio, CI – 95% confidence interval for the odds, U – Mann Whitney U test statistic, PB – personal best. 
Values are median (IQR). Where percentages are given, the number in the brackets is n. 
Significant difference between those reporting and not reporting HMB within each group are shown as follows ***p < 0.005, **p < 0.01, *p < 0.05. 
 
The elite athletes are represented twice in this table – both within the stage data and as a separate group.  
  
109 
 
 
Across both stages, a known history of anaemia was reported by 603 participants (32.4%), 
while 1049 (56.3%) specified that they either did not have this or were unsure whether they 
have had this condition. Those meeting the HMB criteria were more likely to report a 
historical knowledge of anaemia (stage 1: 43.1% vs 32.9%; OR: 1.55; 95% CI: 1.16 – 2.07; 
p<0.0005; stage 2: 55.1% vs 39.9%; OR: 2.13; 95% CI: 1.62 – 2.80; p<0.0005; Table 4.2). 
Use of iron supplementation was also more common in those identified with HMB (stage 
1: 61.4% vs 41.9%; OR: 1.45 (1.09 – 1.93); p=0.01; stage 2: 55.1% vs 39.9%; OR: 1.85; 
95% CI: 1.44 – 2.38; p<0.0005; Table 4.2). Less than a quarter of all surveyed reported 
having sought advice/help for heavy periods (22.3%), with this increasing in those who met 
the HMB criteria (stage 1: 37.2% vs 8.6%; OR: 6.34 (4.17 – 9.61); p<0.0005; stage 2: 
44.6% vs 8.1%; OR: 9.15, 95% CI: 6.51 – 12.85; p<0.0005; Table 4.2). In stage 1, those 
identified with HMB cited more periods over the last year than those without (12 (9 - 12) vs 
12 (6.25 – 12); U = 84643; p<0.0005; Table 4.2), however there was no difference in 
number of periods in the last year reported by participants with and without HMB in stage 
2 (12 (6-12) vs 12 (4-12); U = 125151; p=0.23; Table 4.2). In both stages 1 and 2, those 
identified to not have a history of HMB were approximately twice as likely to use the OCP 
(40.6% vs 24.6%;  OR: 2.10, 95% CI: 1.55 - 2.84; p<0.0005, stage 2: 42.5% vs 25.5%; 
OR: 2.16; 95% CI: 1.64 – 2.85; p<0.0005; Table 4.2) than those with HMB.  
 
4.4.4 Elite Athletes 
When a sub-analysis of the elite athletes identified in both groups was conducted, 36.7% 
met the HMB criteria, with more than half (51.1%) indicating that their menstrual cycle 
disrupts their training/performance. The presence of HMB increased the odds of reporting 
this by 2.75 times (95% CI: 1.12 – 6.73 p=0.03; Table 4.2).  
 
4.4.5 Elite vs non- elite athletes 
The prevalence of HMB was as common in elite athletes as the rest of the participants 
(p=0.19; Table 4.3). Elite athletes were also as likely to report that their menstrual cycle 
disrupts their training/performance, to have sought help for heavy periods (p=0.83) and to 
currently use the OCP (p=0.67). However, elite athletes were more likely to report 
knowledge of a history of anaemia (p<0.0005), and to have supplemented with iron than 
those who were not elite (p<0.0005; Table 4.3). 
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Table 4.3 – A comparison between elite and non-elite characteristics. 
 
Elite 
n = 90 
Non-elite 
n = 1772 
Chi-squared p-value 
HMB  36.7% (n=33) 
43.7% 
(n=775) 
X2 = 1.73 0.19 
Reported disruption 
to training/ 
performance 
51.1% (n=46) 
41.2% 
(n=731) 
X2 = 3.44 0.06 
Knowledge of a 
history of anaemia 
52.2% (n=47) 
31.4% 
(n=557) 
X2 = 16.92 <0.0005*** 
History of iron 
supplementation 
78.9% (n=71) 
48.9% 
(n=867) 
X2 = 30.81 <0.0005*** 
Current OCP use 36.7% (n=33) 
34.5% 
(n=611) 
X2 = 0.18 0.67 
Seeking of 
advice/help for heavy 
periods 
23.3% (n=21) 
22.3% 
(n=173) 
X2 = 0.049 0.83 
HMB – heavy menstrual bleeding, OCP – oral contraceptive pill 
Values are percentage (n). 
Significant difference between elite and non-elite athletes are shown as follows ***p < 
0.005, **p < 0.01, *p < 0.05. 
 
Association between HMB and performance outcomes  
There was a relationship between 5 km personal best time in the last year and the number 
of HMB symptoms reported to have been experienced, each additional symptom reported 
was associated with a 16.9 second increase in reported personal best time (B = 16.93; 
95% CI: 4.88 – 28.98; p=0.006).  
 
When simply comparing those meeting and not meeting the criteria for identification of 
HMB, median 5 km times were significantly different (25 min: 0 s vs. 24 min: 24 s; U = 
184312; p=0.002). When 5 km personal best times were divided into quartiles (Q1 being 
the fastest athletes), a significant difference was seen in the number of HMB symptoms 
reported by participants in the groups (χ2(3) = 13.981, p=0.003). A post-hoc analysis 
demonstrated that there was a significant difference between Q1 and Q4 (p=0.001; Figure 
4.1).  
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Figure 4.1 – Reported number of symptoms of in the outlined heavy menstrual bleeding 
(HMB) diagnostic series across participants when ranked based on 5 km personal best 
times. Q1 represent those with the fastest times, Q4 the slowest.  
Values are median ± IQR.   
Significant differences between groups are shown as follows: * p = 0.001.  
Q – quartile, PB – personal best.  
 
4.4.6 Association between HMB, a reported knowledge of a history of 
anaemia and disruptions to exercise training/performance caused by 
the menstrual cycle 
In an unadjusted logistic regression model, those identified with HMB were 3.74 times more 
likely to report that their menstrual cycle disrupts their exercise training/performance (95% 
CI: 3.08 – 4.54; p<0.0005; Table 4.4) compared to those not identified with HMB. This 
relationship was slightly attenuated when adjusting for a historical knowledge of anaemia 
(OR: 3.53, CI: 2.90 – 4.29; p<0.0005; Table 4.4). Accordingly, there is evidence to suggest 
that those reporting historical anaemia knowledge are also more likely to report exercise 
training/performance disruption caused by their menstrual cycle (OR: 1.64; CI: 1.33 – 2.02; 
p<0.0005; Table 4.4). After controlling for covariates, (age, 5 km personal best (PB), typical 
weekly exercise volume and a history of iron supplementation), there was still a significant 
relationship between identified presence of HMB and reported disruptions to 
training/performance caused by the menstrual cycle, this was however minimally reduced 
(OR: 3.16; CI: 2.46 – 4.05; p<0.0005). However, the relationship between menstrual cycle 
driven disruption to exercise training/performance and knowledge of a history of anaemia 
was abolished (OR:1.08, CI: 0.79 – 1.48; p=0.62; Table 4.4). 
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Table 4.4 - The unadjusted and adjusted results from the logistic regression of the 
perception that the menstrual cycle disrupts exercise training/performance. 
 Unadjusted model 
Adjusted for anaemia 
history only 
Adjusted for multiple 
covariates 
 OR 
95% 
CI 
p-value OR 
95% 
CI 
p-value OR 
95% 
CI 
p-value 
HMB 3.74 
3.08 
– 
4.54 
<0.0005*** 3.53 
2.90 
– 
4.29 
<0.0005*** 3.16 
2.46 – 
4.05 
<0.0005*** 
Knowledge of a 
history of 
anaemia 
   1.64 
1.33 
– 
2.02 
<0.0005*** 1.08 
0. 79 
– 1.48 
0.62 
Age       1.00 
0.98 – 
1.01 
0.57 
5 km PB (last 12 
months) 
      1.00 
1.00 – 
1.00 
0.59 
Typical weekly 
exercise volume 
      1.00 
1.00 – 
1.00 
0.65 
History of iron 
supplementation 
      1.59 
1.17-
2.15 
0.003*** 
HMB – heavy menstrual bleeding, PB – personal best time, OR – odds ratio, CI – 95% 
confidence interval for the odds  
Significant interaction of the variable in the model are shown as follows: ***p < 0.005, **p 
< 0.01, *p < 0.05. 
 
Anaemia and iron supplementation 
Across the total population, 50.3% (937 participants) reported having previously 
supplemented with iron, while 32.4% (603 participants) reported knowledge of having had 
anaemia. A total of 20.6% (384 participants) reported supplementing with iron without 
knowledge of a history of anaemia. This increased in elite athletes to 26.7% (24 
participants). Further, of those who said they were unaware of whether they had ever had 
anaemia (210 participants), 50.5% (106 participants) reported that they have taken iron 
supplementation. 
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4.5 Discussion 
This is the first study to identify that HMB when defined using self-reported responses to 
the outlined criteria, is a common problem amongst exercising women. Stage 1 of this 
research was used to ascertain whether HMB, when identified using this means, was a 
prevalent issue experienced by exercising women. It is acknowledged that this online 
survey was likely to be biased because women with menstrual cycle issues were more 
likely to complete the questionnaire, however with 54.1% meeting the HMB criteria this 
demonstrated that this is a significant problem within this populace when diagnosed by this 
means. To obtain unbiased prevalence data a large study, (stage 2) incorporating a 
number of controls to prevent bias, was conducted at the 2015 London Marathon 
Exhibition. This found that 35.5% of marathon runners met the outlined criteria for a history 
of HMB, therefore confirming the outcome in stage 1 that this is a common problem 
amongst exercising women when identified using this means. Utilising a different rule for 
diagnosis, HMB has previously been shown to affect more than a quarter of the general 
female population (28), but this is the first study to investigate prevalence amongst 
exercising women, regardless of diagnostic tool. 
 
Only 43.1% and 38.1% of those with HMB from stages 1 and 2 had sought help/advice for 
heavy periods. HMB and discussion around the menstrual cycle is deemed a sensitive 
subject by some, and women may not feel comfortable discussing it with medical 
professionals or amongst peers, meaning that they may not know that their situation is 
abnormal. In the case of von Willebrand disease for example, a condition characterised by 
heavy bleeding, women typically report normal blood flow (381,382). Being a genetic 
condition, family members are also likely to have von Willebrand disease, and therefore a 
similar excess of blood loss, so it is thought normal. Alternatively, others may have just 
adjusted to living with it, feel that there is no solution, or that they don’t have time to seek 
advice. Some also feel it is a normal cleansing process (383). This highlights the need for 
increased HMB awareness, but also highlights the need for a universally recognised 
means for diagnosis. However, this does support previous research which has 
demonstrated that almost half of those with HMB who have sought help did not have HMB 
confirmed (28), and the results of an audit conducted by the Royal College of Obstetricians 
showed that once diagnosed one third were not given treatment in primary care (384). This 
suggests that an increased awareness of HMB prevalence, associated symptoms and 
treatment options is required amongst medical professionals. Further, a review of 
treatment methods has shown there to be considerable variation in the treatment 
procedures and medications used, highlighting the need for further research and again, 
improved awareness (385). This is particularly significant given the large economic burden 
associated with HMB, identified both in the UK and the USA (386). Significantly, an earlier 
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study only found 20.7% of the participants identified with HMB to have an underlying 
bleeding disorder or menstrual cycle related pathologies (Gursel et al. 2014). In light of 
this, an increased awareness and future research into treatment options and underlying 
aetiology could result in significant beneficial financial implications.  
 
The finding in this study that those meeting the HMB criteria were more likely to report 
knowledge of a previous diagnosis of anaemia than those who did not meet the HMB 
criteria is consistent with previous research, highlighting the increased iron deficiency and 
anaemia risk associated with HMB (19,20). There is potential for this to be greater as more 
than half of all respondents said that they were unaware of whether they have been 
anaemic. In the general population IDA has been shown to affect two thirds of women with 
HMB (26). Considering the increased iron losses (178,186,387,388), and the potential for 
reduced iron absorption (199) in those who exercise, the prevalence of iron deficiency and 
IDA in those identified with HMB in this group may be even greater.  
 
Approximately one in three participants in stage 2, and more than half of those in both 
stage 1 and within those defined as ‘elite’ reported that their menstrual cycle disrupts their 
exercise training/performance. While this result in stage 1 is inevitably subject to bias, the 
results in stage 2 highlight that this is a common perception amongst exercisers. The 
identified presence of HMB increased the likelihood of reporting this, and those identified 
with HMB in stage 2 were more than three times more likely to cite this than those not 
identified with HMB. It could be hypothesised that an underlying iron deficiency with or 
without anaemia could be driving this perceived effect. When assessing the total 
population, and looking at both identified HMB and knowledge of a history of anaemia 
together, those who identified anaemia knowledge were also more likely to report that their 
menstrual cycle disrupts their training/performance, supporting this hypothesis. However, 
the addition of this to the relationship between HMB and menstrual cycle-related 
disruptions to training/performance marginally attenuated this association, potentially 
countering this. Further, when additional confounders were added, the relationship 
between knowledge of a history of anaemia and citations that the menstrual cycle disrupts 
training/performance became insignificant (p=0.62). However, in light of the potential for 
confusion regarding anaemia and iron deficiency, the lack of historical awareness of iron 
status, and the absence of haematological measures, this clearly warrants further 
research. It is also important to gain a better understanding of how iron deficiency without 
anaemia can have an impact on performance, as research is currently conflicting as will 
be addressed later in this thesis. 
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Interestingly, more than half of the population reported supplementing with iron, with this 
being substantially higher amongst those who were defined as elite (p<0.0005). Many elite 
athletes routinely supplement with iron, and this was shown here with 78.9% reporting 
supplementation. Further, more than half of those who reported they were unaware of 
whether they have ever had anaemia, indicated that they have supplemented with iron. 
Coaches often encourage supplementation without prior knowledge of iron status due to 
the unfounded but common belief that iron deficiency is rife and supplementation may 
benefit performance. Indeed, one in five of the total population and one in four of the elite 
population who took iron supplementation did not report a historical knowledge of anaemia. 
While it must be appreciated that they could have had iron deficiency alone, meaning that 
it is difficult to draw definitive conclusions from this observation, typically many have a 
limited understanding of the difference between anaemia and iron deficiency causing them 
to be grouped together. Significantly here, less than half of those identified with HMB have 
sought help/advice for heavy periods, therefore it is necessary to raise awareness as while 
the effects of iron deficiency are yet to be conclusively elucidated, the impacts of IDA on 
both general wellness and exercise performance are well established as previously 
highlighted (386).  
 
The sub-analysis from the elite athlete sample identified more than one third to have a 
history of HMB, with prevalence being no different to the non-elite population here and 
actually being greater than or similar to that identified in the general population – diagnosed 
using a different diagnostic series (28). This is somewhat surprising given the historical 
research focus on the female athlete triad and the new term ‘Relative Energy Deficiency 
in Sport’ – RED-S, particularly in elite athletes (224,389). However, it must be appreciated 
that some of this group were from stage 1, potentially overstating prevalence, and that 
different criteria were used to identify prevalence in the general population. It is well 
documented that elite female athletes, particularly endurance athletes are susceptible to 
amenorrhea and oligomenorrhea often as a result of a relative energy deficiency 
associated with a high training volume (9,31,390). It could therefore be hypothesised that 
increases in training volume would equate to increased risk of amenorrhea or 
oligomenorrhea, potentially decreasing HMB incidence, but this was not the case in this 
study with no identified relationship between total number of minutes exercised per week 
and identified HMB presence. However, the lack of a timescale for the presence of HMB 
symptoms makes conclusions to this avail problematic. Those with faster 5 km personal 
best times were however less likely to have a HMB history. The slower times seen in Q4 
where HMB prevalence was higher when compared to Q1 could be caused by an 
increased incidence of IDA in Q4, which is impacting upon performance, alternatively 
increased rates of amenorrhea in Q1 could reflect the lower HMB incidence seen here. 
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However, these differences were only marginal, and further research is required before 
forming a definitive conclusion. This study suggests that other menstrual cycle issues in 
athletes across all levels may be commonplace, highlighting the need for further and more 
general research across other menstrual cycle dysfunctions in exercising women as they 
clearly have potential to negatively impact performance.  
 
4.5.1 Limitations 
There are a number of limitations of this study. Firstly, the self-reported nature of this 
questionnaire could have resulted in inaccurate data, however the HMB diagnostic criteria 
does not lean itself to comparison bias, but it must be appreciated that there is no 
universally recognised diagnosis for HMB. Secondly, stage 2 data was only collected in 
marathon runners, which may not be representative of other running events and sports. It 
has been shown that exercise increases susceptibility to iron deficiency (36), however 
blood parameters including markers of iron status have not been measured therefore 
associations between HMB identification and awareness of anaemia are subject to 
inaccuracy. There are a number of limitations associated with the Female Health 
Questionnaire as outlined in chapter 3 that need to be considered. Essentially, there are 
inconsistencies in the time periods used for assessment, performance times are within the 
last year, OCP use is current, where as the majority of other questions are based on any 
time in history. Additionally, any underlying causes for HMB presence were not captured, 
and the presence of illnesses (e.g. endometriosis) or the use of medication was not 
recorded, these could increase the likelihood of participants meeting the criteria for HMB 
diagnosis. Further, only OCP use was asked, use of other types of hormonal 
contraceptives were not requested. To obtain standardised performance comparisons a 
means for knowing finishing time in the marathon would strengthen ability to determine 
any relationships between participant performance level and HMB presence. Relationship 
between BMI and HMB presence could also be explored. Further studies are required to 
address these limitations.  
 
4.6 Conclusions 
This study has demonstrated that utilising the pre-defined diagnostic series, HMB, when 
identified by the self-report of symptoms, is common in the exercising population. 
Surprisingly, when utilising this diagnostic means it was as common amongst elite athletes 
as recreational level exercisers. HMB was associated with a known history of anaemia, 
iron supplementation, disruptions of the menstrual cycle to exercise training/performance 
and slower performance times. Further research is however needed to explore the 
association between HMB, iron deficiency and exercise performance, firstly to confirm this 
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association with haematological markers, and secondly to determine whether the 
disruption to exercise training/performance could be due to a deficiency of iron. The lack 
of advice/help for heavy periods sought by the participants in this study suggests that 
women may not feel or appreciate that this is a problem, have learnt to cope with it or do 
not want to discuss it, suggesting that more research, education and awareness is needed. 
Iron supplementation amongst athletes is very common, particularly amongst those 
categorised as elite, often despite prior knowledge of iron status.  
 
To conclude, regarding the outlined hypotheses for this chapter, when identified using the 
outlined criteria, HMB was found to be prevalent in those who exercise, therefore the first 
hypothesis can be accepted. However, the second hypothesis that identified HMB is more 
common in recreational athletes was not found. Finally, the third hypothesis can also be 
accepted as those identified with HMB were more likely to report that their menstrual cycle 
disrupts their training/performance. 
 
4.7 Future Perspectives 
This study clearly highlights that when identified using this means, HMB is a common 
problem in exercising women. Due to the potentially significant poor awareness of this 
menstrual cycle dysfunction, and the evident potential it has to affect performance, 
education needs to be improved. Medical professionals need to be made aware of its 
perhaps somewhat surprising prevalence in this population, and athletes should be alerted 
to the typical symptoms. Treatment options also need careful consideration. Since the 
analysis of elite athletes was from both study groups, future research must find an elite 
population in its own entity to gain another indication of prevalence. 
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5 The association between identified heavy menstrual 
bleeding and iron status, and the association of these with 
the perception that the menstrual cycle disrupts exercise 
training/performance in exercising women.   
 
5.1 Abstract 
Background: In chapter 4, when utilising an outlined diagnostic series for diagnosis 
(chapter 3), HMB was identified to be common in exercisers in the United Kingdom, while 
also associated with the perception that the menstrual cycle disrupts exercise 
training/performance and a historical knowledge of anaemia. The mechanism by which 
HMB may disrupt exercise is unknown, but could be caused by a compromised iron status. 
Iron status, alongside HMB presence has not previously been established in exercising 
women, where the menstrual cycle is frequently deemed to disrupt exercise 
training/performance. With the previous chapter significantly also highlighted a poor 
awareness of iron status, with few identified with HMB reporting to have sought help/advice 
for heavy periods.  
Methods: Healthy, exercising and regularly menstruating women in Singapore (n=271; 
median age: 38 years (29 – 43 years), weight: 57.0 kg (50.2 - 63.0 kg), height: 1.60 m 
(1.56 - 1.64 m), BMI: 22.1 kg·m-2 (20.0 - 24.3 kg·m-2)) completed a ‘Female Health 
Questionnaire’ and had blood sampling at routine healthcare appointments. 
Results: Overall, HMB was identified in 60 women (22.1%) and 40 (14.8%) were 
diagnosed with IDA (haemoglobin < 12 g·dL-1 and serum ferritin < 15 µg·L-1), while 82 
(30.3%) had ‘severe’ iron deficiency (serum ferritin < 15 µg·L-1), and 130 (48.0%) 
‘moderate’ iron deficiency (serum ferritin < 30 µg·L-1). Women identified with HMB were 
three times more likely to suffer IDA (28.3% vs 10.9%; OR: 3.23, CI: 1.59 – 6.57; p<0.0005) 
and more than twice as likely to suffer severe (48.3% vs 25.1%; OR: 2.79, CI : 1.54 - 5.05; 
p=0.001; Table 4.2) or moderate (65.0% vs 43.1%; OR: 2.45, CI: 1.35 - 4.45; p=0.003) iron 
deficiency. Among those identified as having HMB, few reported seeking advice/help for 
heavy periods, while awareness of IDA and ID was poor. Both HMB and IDA were 
associated with reporting that the menstrual cycle disrupts everyday lifestyle/exercise 
performance, but iron deficiency alone was not. Those with HMB were more than four 
times more likely to report this disruption (OR: 4.15, CI: 0.13,0.44; p<0.0005), and this 
relationship is likely to be independent of IDA.  
Conclusions: When identified using the outlined criteria, HMB, iron deficiency and 
associated IDA are common in this population with a similar prevalence to the general 
population. HMB increased risk of a compromised iron status. HMB and IDA were 
independently associated with the perception that the menstrual cycle disrupts disrupts 
everyday lifestyle/exercise performance, however the effect did not appear to be 
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cumulative. However, awareness of iron status spears to be poor and needs to be 
heightened, while many identified with HMB had not sought advice/help for heavy periods.  
 
5.2 Introduction 
In chapter 4, when identified using a diagnostic series (outlined in chapter 3), HMB was 
identified in approximately one in three exercising women of all ability in the United 
Kingdom (391,392). A similar percentage also cited that their menstrual cycle disrupts their 
exercise training/performance, increasing to nearly half of all those identified with HMB. 
However, if indeed HMB does cause a disruption to exercise training/performance, the 
mechanism by which this manifests is not known. There was a profound association 
between HMB and a self-reported knowledge of a history of anaemia and iron 
supplementation, however this has not previously been shown in this population using 
haematological measures. As explained in chapter 2, given that those who exercise are 
likely to already have an increased susceptibility to iron deficiency (178,186,376,387), the 
presence of HMB could exacerbate this further.  
 
If indeed those with HMB who exercise regularly have iron deficiency, with or without 
anaemia, it could be hypothesised that this could in part be the cause for women to cite 
detrimental effects of their menstrual cycle on their exercise training and performance. 
Considering the known impact of IDA on oxidative metabolism, and the potential impact 
that iron deficiency alone may have on other iron-dependent pathways this is plausible. 
Further, given the previously established lack of awareness of HMB and iron status (28), 
it could be further be hypothesised that the identified presence of HMB, resulting in a 
deficiency in iron is unknown. 
 
Significantly, since the study conducted in chapter 4 was the first time HMB was considered 
in those who exercise, there was an additional need to determine whether HMB presence 
in a similar population subset was comparable in other countries. 
  
5.2.1 Study aims 
The aims of the present study were to:  
1. The primary aim was to assess the incidence of HMB (when using an outlined 
criteria (chapter 3), in the absence of a universally applied verified diagnostic 
means), and its association with iron deficiency and IDA using haematological 
measures in women who undertake regular exercise.  
2. The secondary aims were then to gain an indication of the level of awareness of 
HMB and iron status; and to identify whether there is an association between 
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identified HMB, iron deficiency and IDA and perceived disruption to everyday 
lifestyle/exercise performance caused by the menstrual cycle. If an association 
between HMB and a reported disruption of the menstrual cycle to exercise 
training/performance is identified, the role of iron status in this relationship will be 
evaluated. 
5.2.2 Study hypotheses 
HMB, when identified using the outlined criteria, is common in this population., and 
the identified presence of HMB is associated with an increased likelihood of iron 
deficiency and IDA. 
1. Awareness of iron status in those with a compromised iron status and the seeking 
of help/advice for heavy periods in those with HMB is limited. 
2. Iron status is involved in the relationship between identified HMB and individuals 
reporting that their menstrual cycle disrupts their everyday lifestyle/exercise 
performance.  
5.3 Materials and methods 
5.3.1 Ethics and participant consent 
The ‘Female Health Questionnaire’ was approved by the St Mary’s University Ethics 
Committee. Participants provided written consent at the time of clinic attendance allowing 
for the anonymous use of their data for research.  
5.3.2 Inclusion criteria 
The inclusion criteria were: 
• Female; 
• Aged ≥18 years;  
• Pre-menopausal;  
• Undertake regular exercise (≥ 60 minutes/week or indicated taking part in races).  
5.3.3 Exclusion criteria 
The exclusion criteria were: 
• Not menstruated in the past 12 months; 
• Incompletion of questionnaires. 
5.3.4 Participants 
As a result of a collaboration between a research group in Singapore, exercising women 
attending routine healthcare assessments run by The Singapore Anti-Tuberculosis 
Association (SATA) in Singapore were used in this research. Due to limited funds, this 
sample provided an opportune group to study, but as a result, this population must be 
defined as a ‘convenience’ sample.  
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5.3.5 Study design 
A retrospective analysis of this convenience sample was performed to assess exercise 
and menstrual cycle characteristics, iron status and HMB, as identified using the pre-
identified criteria, in all women attending clinics for routine healthcare assessments run by 
The Singapore Anti-Tuberculosis Association (SATA) Healthcare, Singapore (insurance 
screening and drop-in clinics). SATA CommHealth are a non-profit organisation and were 
also selected to run the health checks for the Singapore ‘National Population Health Survey 
2016/17’ (110,393). 
 
As part of the routine ‘well woman’ assessment, patients had a routine blood test and were 
asked to complete a short ‘Female Health Questionnaire’ (v2 – as outlined in chapter 3 
and is abbreviated version of that used in chapter 4), to audit aspects of their health, 
menstrual cycle, and exercise activity (typical weekly exercise volume broken down into 
discipline). Since the population of Singapore is considered homogenous, with relatively 
little variety in types of industry and a small total area, it is assumed that this sample was 
largely representative of the average population, while also appreciating that this 
population all exercise regularly so may experience slight physiological variance as would 
be expected in regular exercisers. The median BMI in this study was 22.1 kg·m-2, which is 
in accordance with data from the 2007 National Health Surveillance Survey which found 
mean BMI in women between the age of 18 and 49 to range from 20.9 – 23.0 kg·m-2 (394). 
It is also notable that SATA CommHealth describe themselves as having a focus on 
community health, providing ‘basic health screening packages at affordable mass-market 
prices for everyone’. While also frequently used by local companies, providing annual 
check-ups (395). SATA CommHealth are a non-profit organisation and were also selected 
to run the health checks for the Singapore ‘National Population Health Survey 2016/17’ 
(396). 
 
From July 2015 to November 2015 a total of 777 women attended the healthcare 
assessments, 84 were excluded due to non-completion of the questionnaires, a further 206 
were excluded as they had not menstruated in the previous year, a final 216 were excluded 
due to not meeting the specified exercise level criteria (Figure 5.1). Therefore, data from 
271 regularly exercising and menstruating women were included in the study. 
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Figure 5.1 – Derivation of study sample. 
 
 
 
 
Excluded (n=84) 
• Incomplete questionnaires 
Women with completed questionnaires 
(n=693) 
 
Menstruating women, with completed 
questionnaires (n=486) 
 
Excluded (n=206) 
• Not menstruated in the last 
year 
Women assessed for eligibility (n=777) 
 
Excluded (n=216) 
• Does ≤ 60 minutes 
exercise/week or does not 
compete in races. 
 
Menstruating women who regularly 
exercise (n=271) 
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5.3.6 Measurements and definitions 
Female Health Questionnaire 
All participants completed the ‘Female Health Questionnaire’, comprising the structured 
series of questions taking 2-3 minutes for completion including a four-part criteria for the 
identification of HMB (392). The questionnaire was an abbreviation of that used previously 
in chapter 4, and described in chapter 3 (28). This also captured additional demographics 
including height and weight (measured by the practitioner at the time of venepuncture).  
 
The questionnaire also asked the participants to report their exercise competition level (If 
participants did more than one form of exercise they were requested to report the response 
that reflects the highest level), the options included: 
1. Do not exercise 
2. Recreational, just for fun 
3. Take part in races, in a relatively non-competitive manner 
4. Regional level 
5. National level 
6. International level. 
 
Blood measures 
As part of the SATA ‘well woman’ routine assessments, blood is taken to check the 
patient’s full blood count, urea and electrolytes, and serum ferritin. Following the guidelines 
from the World Health Organisation (WHO), for the purpose of this study, IDA was defined 
as [Hb] < 12.0 g·dL-1 and serum ferritin < 15 g·dL-1. Also in accordance with the WHO 
guidelines, ‘severe’ iron deficiency was diagnosed using a serum ferritin cut-off value of < 
15 µg·L-1 (40). This is in accordance with the WHO criteria for when iron stores are depleted 
(40). Since, a lack of iron in bone marrow has been observed when serum ferritin is 30 
µg·L-1, and using this cut-off value, sensitivity and specificity for iron deficiency diagnosis 
has been found to be 92% and 96% respectively (42). Therefore, for the purposes of this 
study, ‘moderate’ iron deficiency will be defined implementing a cut-off for serum ferritin of 
< 30 g·dL-1. 
 
5.3.7 Data analysis 
Paper questionnaires were completed at the time of clinic attendance and inputted 
anonymously alongside blood results to a secured database.  
 
Statistical analysis was performed using a statistics computer package (IBM SPSS 
Statistics for Macintosh, Version 21.0, Armonk, NK: IBM Corp.). Statistical significance was 
set at p<0.05.  
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All data were tested for normality using the Shapiro-Wilk test, and data were analysed 
descriptively to evaluate all questionnaire variables and iron status. Chi-squared tests were 
used to assess whether there was an association between HMB, when identified using the 
outline criteria (chapter 3), and both presence and historical knowledge of iron deficiency, 
IDA, anaemia, the use of iron supplementation and reporting whether the individual 
perceives that their menstrual cycle disrupts their everyday lifestyle/exercise performance. 
Mann Whitney U tests were used to determine whether haemoglobin concentration, serum 
ferritin, age, weight, height, BMI, typical exercise volume and participant competition level 
varied between groups. Chi-squared tests were also used to determine whether, in those 
identified with HMB, prevalence of IDA or iron deficiency was different based on whether 
or not participants reported seeking advice/help for heavy periods. Chi-squared tests were 
also used to determine if there was a difference in reporting disruptions of the menstrual 
cycle to everyday lifestyle/exercise performance between those with and without IDA or 
iron deficiency. Mann Whitney U tests were used to assess whether there was a difference 
in [Hb] and serum ferritin when comparing those who did and did not report these 
disruptions.  
 
Cross-sectional predictive factors for reported disruptions to everyday lifestyle/exercise 
performance caused by the menstrual cycle and identified HMB were determined using 
binary logistic analyses. The independent variables assessed were the identified presence 
of HMB, anaemia, and then other relevant covariates including age, BMI, exercise volume 
and competition level.  
5.4 Results 
5.4.1 Participant Characteristics 
From July 2015 – Nov 2015 a total of 271 women were included (Figure 5.1). The median 
age was 38 years (29 – 43 years), weight: 57.0 kg (50.3 – 63.0 kg), height: 1.60 m (1.56 – 
1.63 m) (Table 5.1). Most undertook exercise recreationally (43.2%), or indicated regularly 
taking part in races (40.2%), while 2.6% reported being at a regional level and 1.5% at a 
national or international level, 12.2% did not complete this question. Overall, 41.7% 
reported £ 120 minutes of exercise each week, 32.5% reported ³ 120 but < 210 minutes, 
18.8% reported ³210 but < 420 minutes, while 7.0% reported ³ 420 minutes of exercise 
each week.  
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Table 5.1 - Clinical characteristics of participants.  
 
Total Sample Range (min-max) 
[Hb] (g·dL-1) 13.0 (12.2-13.6) 6.9 – 16.3 
Serum ferritin (µg·L-1) 31.0 (12.0-56.0) 0.5 – 276 
IDA 14.8% (n=40)  
Severe ID 30.3% (n=82)  
Moderate ID 48.0% (n=130)  
HMB 22.1% (n=60)  
Age (years) 38 (29-43) 17 – 60 
Weight (kg) 57.0 (50.3-63.0) 40.3 – 120.0 
Height (m) 1.60 (1.56-1.63) 1.40 – 1.79 
Body Mass Index (kg·m-2) 22.1 (20.0-24.3) 16.2 – 53.3 
Weekly exercise volume 
(minutes) 
120 (60-210)  
Competition level 2 (2-3)  
Seeking of advice/help for 
heavy periods 
11.4% (n=31)  
Knowledge of a history of 
anaemia 
17.7% (n=48)  
Knowledge of a history of 
anaemia in last 3M 
1.8% (n=5)  
Knowledge of a history of 
iron deficiency  
22.5% (n=61)  
Knowledge of a history of 
iron deficiency in last 3M 
3.0% (n=8)  
History of iron 
supplementation 
31.4% (n=85)  
Reported disruption of 
the MC to everyday 
lifestyle/exercise 
performance  
26.2% (n=71)  
[Hb] – haemoglobin concentration, IDA – iron deficiency anaemia, ID – iron deficiency, MC 
– menstrual cycle 
Values are median (IQR). Where percentages are given, the number in the brackets is n. 
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5.4.2 Identified prevalence of HMB, iron deficiency and IDA 
Of the 271 women, the median [Hb] was 13.0 g·dL-1, and 14.8% had IDA ([Hb] < 12.0 g·dL-
1, serum ferritin < 15 µg·L-1; Table 5.1). The median serum ferritin was 31.0 µg·L-1 (Table 
5.1). Iron deficiency was common; nearly one third (30.3%) had severe iron deficiency 
(serum ferritin < 15 µg·L-1; Table 5.1), and nearly half (48.0%) moderate iron deficiency 
(serum ferritin < 30 µg·L-1; Table 5.1).  
 
Table 5.2 – A comparison of characteristics between those with and without heavy 
menstrual bleeding (HMB), when identified using the outlined criteria. 
n 
HMB Not HMB Test statistic p-value 
60 211   
% 22.1% 77.9%   
[Hb] (g·dL-1) 12.9 (11.7-13.6) 13.0 (12.3-13.6) U = 5579 0.16 
Serum ferritin 
(µg·L-1) 
18.5*** (7.8-35.0) 34.0 (15.5-62.0) U = 4087 <0.0005*** 
IDA 28.3%* (n=17) 10.9% (n=23) X2 = 11.284 0.001*** 
Severe ID 48.3%** (n=29) 25.1% (n=53) X2 = 11.931 0.001*** 
Moderate ID 65.0%** (n=39) 43.1% (n=91) X2 = 8.954 0.003*** 
Age (years) 39 (27-43) 37 (29-44) U = 6160 0.75 
Weight (kg) 57.0 (51.3-64.0) 56.7 (50.0-62.0) U = 4087 0.19 
Height (m) 1.60 (1.57-1.63) 1.60 (1.55-1.64) U = 6294 0.63 
Body Mass Index 
(kg·m-2) 
22.5 (20.3-25.4) 22.1 (19.9-24.1) U = 6752 0.09 
Weekly exercise 
volume (minutes) 
120 (60-180) 120 (60-210) U = 6328 >0.99 
Competition level 2.5 2.5 X2 = 3.44 0.63 
Seeking of 
advice/help for 
heavy periods 
33.3%*** (n=20) 5.2% (n=11) X2 = 36.464 <0.0005*** 
Knowledge of a 
history of anaemia 
30.0%* (n=18) 14.2% (n=30) X2 = 8.87 0.01* 
Knowledge of a 
history of anaemia 
in last 3M 
1.7% (n=1) 1.9% (n=4) X2 = 0.10 0.95 
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Knowledge of a 
history of iron 
deficiency 
30.0% (n=18) 20.4% (n=43) X2 = 4.08 0.13 
Knowledge of a 
history of iron 
deficiency in last 
3M 
1.7% (n=1) 3.3% (n=7) X2 1.07 0.59 
History of iron 
supplementation 
43.3% (n=26) 28.0% (n=59) X2 = 5.13 0.08 
Reported 
disruption of the 
MC to everyday 
lifestyle/exercise 
performance  
50.0%*** (n=30) 19.4% (n=41) X2 = 22.58 <0.0005*** 
[Hb] – haemoglobin concentration, IDA – iron deficiency anaemia (([Hb < 12.0g·dL-1, serum 
ferritin < 15µg·L-1), severe ID – severe iron deficiency (serum ferritin < 15µg·L-1), moderate 
ID - moderate iron deficiency (serum ferritin < 30 µg·L-1), HMB – heavy menstrual bleeding, 
MC – menstrual cycle.  
Values are median (IQR). Where percentages are given, the number in the brackets is n. 
Significant difference between those reporting and not reporting HMB are shown as follows  
***p < 0.005, **p < 0.01, *p < 0.05. 
 
Of the 271 women, a total of 22.1% met the outlined criteria for HMB (two or more 
symptoms of the outlined diagnostic series in chapter 3). Those identified with HMB were 
more than three times more likely to suffer IDA (28.3% vs 10.9%; OR: 3.23, CI: 1.59 – 
6.57; p<0.0005); Table 5.2) and twice as likely to suffer severe (48.3% vs 25.1%; OR: 2.79, 
CI: 1.54 - 5.05; p=0.001; Table 5.2) or moderate (65.0% vs 43.1%; OR: 2.45, CI: 1.35 - 
4.45; p=0.003; Table 5.2) iron deficiency compared to those without HMB. On average, 
women identified with HMB had a lower serum ferritin (18.5 µg·L-1 (7.8 – 35.0 µg·L-1)  vs. 
34.0 µg·L-1 (15.5 – 62.0 µg·L-1); p<0.0005; Table 5.2). However, median haemoglobin 
concentration did not vary between groups (p=0.16; Table 5.2). There was no difference 
in demographics or training and competition status between those identified with and 
without HMB (all p>0.05; Table 5.2). 
 
5.4.3 Level of awareness of HMB and iron status 
Overall, amongst those with IDA, severe iron deficiency and moderate iron deficiency 
awareness of iron status appeared poor (Table 5.3). Less than half of those with IDA 
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reported prior knowledge of anaemia (40.0%), with one in 10 (10.0%) reporting recent 
awareness (in the previous three months). Similar statistics were seen in those with iron 
deficiency, with only 40.2% of those with severe iron deficiency reporting prior knowledge, 
and 6.1% reporting knowledge in the previous three months (Table 5.3). Across all 
individuals, supplementation was reported by 31.4% at any one point in time (Table 5.1). 
Five percent of those with IDA and less than five percent of those with iron deficiency 
reported use of supplementation (Table 5.3).  
 
Table 5.3 – Reported historical knowledge of anaemia, iron deficiency and use of 
supplementation in those with iron deficiency anaemia and severe (serum ferritin < 15 µg·L-
1) and moderate (serum ferritin < 30 µg·L-1) iron deficiency. 
 n 
Anaemia 
history 
Anaemia 
history – 
3 months 
ID 
history 
ID history 
– 3 
months 
Iron sup 
– 3 
months 
IDA 40 
40.0% 
(n=16) 
10.0% 
(n=4) 
52.5% 
(n=21) 
12.5% 
(n=5) 
5.0% 
(n=2) 
Severe ID 82 
28.0% 
(n=23) 
3.7% (n=3) 
40.2% 
(n=33) 
6.1% 
(n=5) 
4.9% 
(n=4) 
Moderate 
ID 
130 
23.8% 
(n=31) 
3.1% (n=4) 
33.8% 
(n=44) 
4.6% 
(n=6) 
3.8% 
(n=5) 
IDA – iron deficiency anaemia, ID – iron deficiency, ID sup – reported supplementation 
with iron in the previous 3 months 
Values are percentage (n). 
 
Advice/help for heavy periods had rarely been sought, with only a third of those identified 
with HMB reporting having sought this (Table 5.2). More than a third of those (35.0%) who 
were both identified to have HMB and to have sought advice/help for heavy periods had 
IDA (Table 5.4). But there was no difference in the prevalence of IDA or iron deficiency 
amongst those identified with HMB and who have and have sought advice/help for heavy 
periods (Table 5.4; all p>0.05).  
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Table 5.4 – The likelihood of having IDA, or severe (serum ferritin < 15 µg·L-1) or moderate 
(serum ferritin < 30 µg·L-1) iron deficiency based on whether those identified with HMB 
have or have not sought advice/help for heavy periods.  
 
HMB + 
advice/help 
HMB no 
advice/help 
X2 p-value 
IDA 35.0% (n=7) 25.0% (n=10) 0.657 0.42 
Severe ID 55.0% (n=11) 45.0% (n=18) 0.534 0.47 
Moderate ID 75.0% (n=15) 60.0% (n=24) 1.319 0.25 
HMB – heavy menstrual bleeding, IDA – iron deficiency anaemia, ID – iron deficiency, X2 
– Chi-squared test statistic 
Values are percentage (n). 
 
5.4.4 Association between identified HMB, iron deficiency and IDA with 
reported menstrual cycle disruptions to everyday lifestyle/exercise 
performance 
The identified presence of HMB meant that individuals were more than four times more 
likely to report that their menstrual cycle disrupts their everyday lifestyle/exercise 
performance (50.0% vs 19.4%; p<0.0005; Table 5.5). Similarly, women with IDA were also 
more likely to report a disruption of their menstrual cycle to their everyday lifestyle/exercise 
performance compared to those without IDA (45.0% vs 22.9%, p=0.003; Table 5.5). This 
finding was not however mirrored in those with either severe or moderate iron deficiency 
(p=0.17 and p=0.42 respectively; Table 5.5). While there was also no difference in [Hb] or 
serum ferritin in those who did, and did not report this (p=0.14 and p=0.07 respectively; 
Table 5.6)  
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Table 5.5 – Likelihood of reporting that the menstrual cycle disrupts everyday 
lifestyle/exercise performance in those identified with heavy menstrual bleeding (HMB), 
iron deficiency anaemia (IDA) and severe and moderate iron deficiency (ID). 
 Yes No X2 OR CI p-value 
HMB 
(n=60) 
50.0%* 
(n=30) 
19.4% 
(n=41) 
22.58 4.15 
2.52 - 
7.63 
<0.0005*** 
IDA 
(n=40) 
45.0%* 
(n=18) 
22.9% 
(n=53) 
8.56 2.75 
1.37 – 
5.50 
0.003 
Severe 
ID (n=82) 
31.7% 
(n=26) 
23.8% 
(n=45) 
1.84 1.49 
0.84 - 
2.64 
0.17 
Moderate 
ID 
(n=130) 
28.5% 
(n=37) 
24.1% 
(n=34) 
0.66 1.25 
0.73 - 
2.15 
0.42 
HMB – heavy menstrual bleeding, IDA – iron deficiency anaemia, ID – iron deficiency, X2 
– Chi-squared test statistic, OR – odds ratio, CI – confidence interval for 95% confidence 
of the odds 
A significant difference between those reporting that their menstrual does or does not affect 
training and performance is shown as follows: ***p<0.005. 
 
Table 5.6 – The effect of iron status on the perception of whether the menstrual cycle 
disrupts everyday lifestyle/exercise performance. 
 
Disruption to lifestyle/performance  
 Yes No U p-value 
Haemoglobin 
(g·dL-1) 
12.7 (11.9-13.6) 13.1 (12.3-13.6) 6268 0.14 
Serum ferritin 
(µg·L-1) 
29.0 (8.5-44.5) 32.5 (13.0-57.5) 6065 0.07 
U – Mann Whitney U test statistic 
Values are median (IQR). 
 
In an unadjusted logistic regression model, those identified with HMB were 4.15 times more 
likely to report that their menstrual cycle  disrupts everyday lifestyle/exercise performance 
(95% CI: 2.25 – 7.63, p<0.0005; Table 5.7) compared to those without HMB. Adjusting for 
IDA reduced the odds ratio between HMB and the reporting of this, however there was still 
a very strong association (p<0.0005). There was little evidence to suggest that an 
interaction between identified HMB and IDA was related to disruptions to everyday 
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lifestyle/exercise performance caused by the menstrual cycle, since the relationship 
between HMB and the citing of disruptions was marginally reduced by the addition of IDA 
to this model. This suggests that IDA does not have an impact on this relationship (p=0.47; 
95% CI: 1.01 – 4.41; Table 5.7).  
 
After controlling for other covariates (age, BMI, competition level and weekly exercise 
volume), the relationship between identified HMB and reported disruptions to everyday 
lifestyle/exercise performance caused by the menstrual cycle was only slightly attenuated 
(OR 3.66, 95% CI: 1.89 – 7.09; p<0.0005; Table 5.7).  
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Table 5.7 – The unadjusted and adjusted results from the logistic regression of the 
perception of disruptions of the menstrual cycle to everyday lifestyle/exercise performance. 
 Unadjusted model Adjusted for IDA only 
Adjusted for IDA and 
other covariates 
 OR 
95% 
CI 
p-value OR 
95% 
CI 
p-value OR 
95% 
CI 
p-value 
HMB 4.15 
2.25 
– 
7.63 
<0.0005*** 3.71 
1.99 
– 
6.92 
<0.0005*** 3.66 
1.89 – 
7.09 
<0.0005*** 
IDA    2.11 
1.01 
– 
4.41 
0.047* 1.80 
0.25 – 
1.25 
0.16 
Age       0.98 
0.95 – 
1.01 
0.27 
BMI       0.98 
0.91 – 
1.05 
0.50 
Competition 
level 
      1.02 
0.65 – 
1.59 
0.93 
Weekly 
exercise 
volume 
      1.00 
1.00-
1.00 
0.34 
HMB – heavy menstrual bleeding, IDA – iron deficiency anaemia, BMI – body mass index, 
OR – odds ratio, CI – confidence interval for 95% confidence of the odds 
Significant interaction of the variable in the model are shown as follows: ***p < 0.005, **p 
< 0.01, *p < 0.05. 
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5.5 Discussion 
In marathon runners in the United Kingdom in chapter 4, approximately one in three met 
the identified criteria for HMB (as outlined in chapter 3), with the presence of HMB being 
associated with both a reported historical knowledge of anaemia and a perceived 
disruption of the menstrual cycle to everyday lifestyle/exercise performance (392). In the 
present study, we firstly aimed to assess HMB prevalence, when identified using the same 
criteria as in chapter 4, in this ‘convenience’ sample – also appreciating this group likely 
forms a different ethnic population, and then to confirm the association between identified 
HMB and haematological measures of iron deficiency and IDA. We then wanted to 
determine whether the perception that the menstrual cycle disrupts everyday 
lifestyle/exercise performance, a similar factor previously found to be associated with HMB 
could be as a result of iron deficiency with or without anaemia be it known or unknown. 
Finally, we wanted to gauge the level of awareness of both HMB and iron status. We firstly 
identified that, when using this means for identification, HMB was common in this 
population, with prevalence similar to that reported in both the general population 
previously (28) and in the marathon runners in chapter 4 (28,392). Risk of iron deficiency 
and IDA was found to significantly increase in those identified with HMB. Both HMB and 
IDA independently increased the likelihood of individuals reporting that their menstrual 
cycle disrupts their everyday lifestyle/exercise performance. However, the combination of 
HMB and IDA did not increase this association, suggesting no cumulative effect. Further, 
neither iron deficiency alone, nor individual [Hb] or serum ferritin levels were associated 
with this. Significantly, similarly to in chapter 4 awareness of iron status appeared to be 
poor and a relative few identified with HMB reported the seeking of advice/help for heavy 
periods.  
 
Prevalence of IDA in exercising women is thought to be between 8 – 14% (119-121), and 
the findings from this study are similar to this, as 14.8% were found to have IDA. The 
ambiguity surrounding the diagnosis of iron deficiency has meant that the prevalence of 
iron deficiency amongst those who exercise is unsure, as described extensively in chapter 
2, but using a variety of serum ferritin cut-off values, most conclude it to be around one 
third (46,51,244). In the present study, using a serum ferritin cut-off of < 15 µg·L-1, in 
accordance with the WHO’s criteria, nearly one third (30.3%) were iron deficient. This 
increased to nearly half (48.0%) when using a more lenient serum ferritin cut off-of < 30 
µg·L-1. This is significantly greater than that observed in the general United Kingdom 
population (using a serum ferritin < 15 µg·L-1 women: 8.2 – 16.0 %; men: 0 – 2.5 %) (118). 
This is likely due to the effect of exercise-induced iron losses (178,186,376,387), often 
reduced dietary intakes in exercising women (194,195,397), and the effect of a post 
exercise inflammatory response, reducing absorption (377).  
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Similarly to in chapter 4, awareness of iron status in this cohort appeared poor. Of those 
with IDA, 90.0% reported no knowledge of having this within the last three months. These 
findings were mirrored in those with iron deficiency, and this clearly needs to be addressed. 
Similarly, only one third of those identified with HMB indicated that they have sought 
advice/help for heavy periods suggesting that awareness of HMB may also be limited. 
Previous studies in the general population support this, highlighting that women with HMB 
scarcely seek help, with estimates of only 6% consulting medical professionals about their 
symptoms (398). As highlighted in chapter 4, this is likely to be confounded by the sensitive 
nature of HMB and the menstrual cycle, meaning that it is not a subject matter typically 
discussed, and significantly, with some cultures in particular believing it to be a normal 
cleansing process (383). Significantly in this study, in those identified with HMB, the 
prevalence of IDA or iron deficiency was no different between those who have or have not 
sought advice/help for heavy periods. While the source of this help was not identified, if 
this means of help was from medical professionals, it could be suggested that they may 
not be carrying out appropriate tests when conducting an assessment. Given the negative 
repercussions associated with IDA and the potential impacts associated with iron 
deficiency, it is important that awareness amongst medical professionals of the appropriate 
tests and subsequent effective treatment options when an individual presents with HMB 
are established. Further, considering the medical checks undertaken in the present study 
are commonplace and typically conducted on an annual basis, the poor knowledge of iron 
status, and significant prevalence of IDA and iron deficiency also suggests that the 
appropriate screening tests, in a population subset with an increased susceptibility to iron 
deficiency, regardless of HMB presence, may not be being conducted, and that 
interpretation may not be adequate (6). This could in part be due to the historical 
problematic difficulties in the diagnosis of both HMB and iron deficiency. Regardless, these 
findings highlight the need for an improved education for both medical professionals and 
those who exercise (399,400).  
 
The present study found IDA to be associated with participants reporting that their 
menstrual cycle disrupts their everyday lifestyle/exercise performance. Interestingly 
however, this finding was not observed in those with severe or moderate iron deficiency, 
nor was it associated with [Hb] or serum ferritin levels. As previously highlighted, the impact 
of IDA on exercise performance is well known, however the ambiguity surrounding the 
effect of iron deficiency without anaemia demonstrates the need for further research 
(46,51). The lack of a universal agreement on serum ferritin cut-offs for diagnosis of iron 
deficiency particularly amongst the exercising community, in addition to other factors 
confounds this as discussed in chapter 2 and as will be discussed later in this thesis 
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(46,244). The use of serum ferritin as a sole marker of iron status has also been questioned 
(51), and it is possible that optimal levels of serum ferritin are different in those who 
exercise. The present study suggests that the ensuing reported disruption to everyday 
lifestyle/exercise performance caused by the menstrual cycle may be independent from 
the presence of either severe or moderate iron deficiency. While inevitably making an 
assumption, from this it could be inferred that there is no performance detriment of having 
either severe or moderate iron deficiency when defined using the criteria outlined in this 
study. However, considering the lack of association between cited disruption to everyday 
lifestyle/exercise performance caused by the menstrual cycle and [Hb] and serum ferritin, 
it could be suggested that other markers of iron status need consideration. Alternatively,, 
there could be another impact of HMB that is overriding any effect of iron deficiency. Prior 
to forming a definitive conclusion, further investigation as to the diagnosis and impact of 
iron deficiency is required in addition to gaining a better understanding of the aetiology of 
HMB.  
 
HMB was also associated with participants reporting that their menstrual cycle disrupts 
everyday lifestyle/exercise performance. Those identified with HMB were more than four 
times more likely to cite this. This relationship was not however enhanced when combined 
with IDA, and was only minimally attenuated when other potential covariates were 
considered. This indicates that the relationship between HMB and cited menstrual cycle 
related everyday lifestyle/exercise performance disruptions is independent of IDA. Given 
the absence of an association between iron deficiency, serum ferritin or haemoglobin and 
cited menstrual cycle disruptions to everyday lifestyle/exercise performance, the present 
study suggests that when using the outlined identification criteria, the relationship between 
HMB and everyday lifestyle/exercise performance disruptions is independent of iron status. 
Other underlying medical conditions clearly need consideration here and have the potential 
to confound this finding. However, previous research identified no underlying medical 
pathology in 61% of the 34,941 women who had recently received a HMB diagnosis (385). 
Evidently, there is a need to consider the aetiology of HMB, which as an inflammatory 
condition, results in an increase in release of proinflammatory cytokines such as tumour 
necrosis factor alpha (TNF-!) (401). Clearly, increased cytokine levels could be a cause 
for the everyday lifestyle/exercise performance disruption caused by the menstrual cycle.  
 
Given the lack of advice/help sought for heavy periods in those with HMB, and the poor 
awareness of iron status, to prevent either of these from acting as a barrier to exercise 
participation, education surrounding both conditions needs to be improved. If indeed HMB 
alone has a negative effect on exercise regardless of iron status, other reasons for this 
need to be addressed and potential solutions evaluated. Given that a quarter of exercising 
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women here cite that their menstrual cycle disrupts everyday lifestyle/exercise 
performance this research is crucial. With dropout rates from exercise significantly greater 
in girls than boys, research in this area in addition to raising of awareness could go some 
way to addressing this problem. 
 
This study clearly highlights that when identified using the outlined diagnostic series, those 
with HMB should undergo regular screening to check their iron status. Despite the 
relationship between HMB and the reporting that the menstrual cycle disrupts their 
everyday lifestyle/exercise performance being independent from iron status, the impact of 
iron deficiency anaemia alone on both general health and exercise capacity is well 
established.  Future research should focus on best management and treatment strategies 
for HMB, the aetiology of HMB, in addition to assessing the impact of iron deficiency 
without anaemia on exercise performance. 
  
5.5.1 Limitations 
There are several limitations to this study. Firstly, as outlined in chapter 3 and 4, there are 
limitations to the ‘Female Health Questionnaire’ that must be considered, significantly the 
absence of a universally recognised diagnosis for HMB. Secondly, despite school 
education in Singapore being taught in English, results from the 2010 census found that 
only 79.9% of Singaporean residents ≥15 years are literate in English, thus there is 
potential for an element of confusion and misinterpretation in reading the questionnaire 
(402). For increased accuracy in the future the questionnaire should be written in multiple 
languages. Also, participants did not have their blood samples collected when fasted and 
were not given instructions to come in a rested state (i.e. having not exercised that day) 
therefore ferritin, as an acute phase protein, could have been falsely elevated. This group 
were assumed to be a healthy cohort, specific causes of HMB, such as von Willebrand 
disease were not evaluated and other underlying medical conditions were not factored in. 
To ameliorate this, future studies should include measurements for C reactive protein 
(CRP) and interleukin-6, while also capturing other medical conditions and requesting 
participants to be tested in a fasted and rested state. To further reduce likelihood of bias 
when identifying the relationship between iron status and the presence of HMB, the 
questionnaire could include information about dietary iron intake.  
 
As these data were collected at a single time point, other factors could have impacted upon 
these results, such as the day in the menstrual cycle, current health state, or 
haemodilutionary impacts caused by factors such as hydration. Further, SATA 
CommHealth are only one health service offered in Singapore, making assessment of 
whether this data is reflective of only a certain type of patient in Singapore problematic. 
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However, the population of Singapore is fairly homogenous, with a limited range of industry 
and a small area. Additionally, SATA CommHealth is specifically advertised as being 
affordable for the mass market, and they were chosen to conduct health screens as part 
of the National Population Health Survey 2016/17 suggesting that their representation of 
an inhabitant of Singapore is likely to be relatively unbiased. Finally, as explained in the 
methods, the median [Hb] and BMI in this study were comparable to the mean in women 
of a reproductive age in Singapore, as specified by the World Health Organisation and in 
data from the 2007 National Health Surveillance Survey (116,394). Further suggesting that 
this sample is reflective of the general Singaporean population of reproductive women. It 
is acknowledged that the current study is observational, therefore it is not possible to make 
strong causal inferences about the associations we have found. 
 
Ethnicity was also not recorded, and factors such as typical red meat consumption may 
vary amongst different populations (119), thus future research should include this, in 
addition to validating this data in a different cohort.  
 
5.6 Conclusions 
HMB, when identified using the outlined series in chapter 3, is common in exercising 
women and is associated with an increased risk of iron deficiency and IDA. HMB and IDA 
are both independently associated with the perception that the menstrual cycle disrupts 
everyday lifestyle/exercise performance. However, the effect of these was not cumulative, 
suggesting that the mechanism by which HMB may have this effect may be independent 
of iron status. Further, iron deficiency alone did not increase likelihood of individuals 
reporting these disruptions to everyday lifestyle/exercise performance. Future research is 
required to assess the effects of this condition. Given the lack of seeking of advice/help for 
heavy periods and the poor awareness of iron status in this population there is a need for 
an increased vigilance amongst healthcare professionals and education for women, this is 
particularly important given the potential for these to be detrimental to exercise 
performance and possibly quality of life. Medical professionals need to appreciate that 
HMB may occur in those who exercise regularly and will increase risk of iron deficiency. In 
light of its prevalence and its potential to effect exercise capabilities, future research should 
focus on identification of treatment options for HMB.  
 
To conclude, regarding the outlined hypotheses for this chapter, the first hypothesis that 
HMB, when identified using the outlined series, was common and increases risk of iron 
deficiency and IDA in exercising women can be accepted. Since the seeking of advice/help 
for heavy periods in those identified with HMB and awareness of iron status appeared poor 
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the second hypothesis can also be accepted. However, the association between HMB and 
reported disruptions to to everyday lifestyle/exercise performance caused by the menstrual 
cycle was independent of iron status, so the final hypothesis suggesting that iron status 
was the cause must be rejected.  
5.7 Future perspectives 
The aetiology of HMB is thought to result in increased release of pro-inflammatory 
cytokines such as TNF-!. Therefore, it is possible that this could be causing the reported 
disruptions to everyday lifestyle/exercise performance, and this should be investigated 
further.  Evidently there is a need to investigate the impact and diagnosis of iron deficiency 
without anaemia.  
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criteria for definition of an ‘exerciser’, and in accordance with the inclusion criteria extracted 
the relevant data. The author performed all the statistical analysis and conducted all the 
data interpretation.  
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6 The impact of identified heavy menstrual bleeding and iron 
status on fatigue in exercising and menstruating women 
 
6.1 Abstract 
Background: Fatigue is particularly common in women and is frequently unexplained. This 
is often associated with iron deficiency and anaemia. Menstrual blood loss is the most 
common cause of anaemia in the developed world, with anaemia susceptibility increasing 
in those with heavy menstrual bleeding (HMB). The interrelationship between HMB, iron 
deficiency and fatigue is however unknown.   
Methods:  
The healthy, regularly menstruating and exercising women in Singapore attending routine 
clinical screening appointments used in chapter 5 were also used in this study (n = 271, 
median age: 38 years (29 - 43 years), weight: 57.0 kg (50.3 - 63.0 kg), height: 1.60 m (1.55-
1.63 m) and BMI: 22.1 kg·m-2 (20.0 – 24.3 kg·m-2)). Participants completed the 
Multidimensional Fatigue Inventory (MFI-20), alongside the ‘Female Health Questionnaire’, 
and had venous blood samples taken for measurement of iron status.  
Results: Increased fatigue was reported both by those identified with HMB, using the 
outlined criteria in chapter 3 (general fatigue; p=0.04), and by those identified with anaemia 
(mental fatigue; p=0.047). However, the association between HMB and fatigue was not 
mediated by anaemia or IDA. There was no association between iron deficiency alone or 
IDA and fatigue (all p>0.05), nor was there a correlation between [Hb] or serum ferritin and 
fatigue (all p>0.05). Awareness of iron status appeared poor, and those with HMB were 
unlikely to report having sought help/advice for heavy periods. 
Conclusion: Identified HMB and anaemia are both independently associated with 
increased fatigue in menstruating women. However, the relationship between identified 
HMB and fatigue was independent of iron status, as we found no evidence that iron status 
mediates this relationship. Blood tests for iron status should be considered for those 
identified to present with HMB and/or mental fatigue. Existing markers of iron status need 
to be evaluated, in addition to treatment options for those identified with HMB. Awareness 
of HMB and iron status both amongst individuals and in medical professionals needs to be 
improved.  
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6.2 Introduction 
Fatigue is more commonly reported by female patients than by their male counterparts 
(403). It is one of the most common reasons to seek medical advice in primary care, 
reported by 14 - 31% of patients (403,404). Onset of fatigue can be slow and insidious, 
potentially causing it to go unnoticed. Being one of the primary symptoms, fatigue is 
frequently attributed to iron deficiency with or without anaemia (405). In addition to many 
other essential roles, iron is required for neurotransmitter synthesis, activity and 
degradation in both the brain and central nervous system and is therefore fundamental for 
cognitive function (35).  
 
As highlighted throughout this thesis, in states where iron deficiency presents without 
anaemia, and therefore where haemoglobin concentration ([Hb]) is not compromised, 
research is equivocal as to the impact on exercise capacity. Research is also inconclusive 
as to the effects on fatigue. Some have found iron supplementation reduces fatigue and 
improves mental health in iron deficient but not anaemic women (226,247), while others 
have found either no association between serum ferritin and fatigue, or no impact of oral 
or intravenous iron on either fatigue in iron deficient but not anaemic women (38,51,249). 
The potential reasons for this have previously been highlighted in this thesis, and may in 
part be due to a variation in the criteria used to diagnose iron deficiency in research studies 
using serum ferritin, with cut-off values ranging from 12 – 40 µg·L-1 (46), different 
supplementation protocols and routes of administration. Evidently, there is significant 
potential for increased levels of fatigue to impact exercise performance.  
 
In addition to reducing physical, social, emotional and/or material quality of life, HMB is 
also associated with various other co-morbidities (372,406-408). In fact, a number of the 
symptoms of HMB also present in states of iron deficiency and IDA, including fatigue (28). 
A recent study in adolescents found an independent association between HMB and iron 
deficiency and HMB and excessive fatigue (38). However, the potential for an inter-
relationship between all three has not been evaluated, it would be prudent to suggest that 
the fatigue associated with HMB may be due to the increased iron loss, suggesting that 
these are interlinked. Alternatively, as found in chapter 5, the effects of HMB may be 
independent from iron status. 
 
Time for diagnosis of iron deficiency and IDA can be extensive, and an increased need to 
assess iron status when gynaecological conditions present has been highlighted, despite 
the increased susceptibility associated with HMB (409). This is exacerbated by the 
difficulties associated with HMB diagnosis, and the slow and insidious nature of a lack of 
iron.  
  
142 
 
 
6.2.1 Study aims 
To our knowledge, the interaction between HMB, iron status and fatigue has not previously 
been measured in exercising women.  
1. The primary aim was to assess the relationship between HMB, iron status and 
fatigue in exercising women. Identifying whether HMB would be associated with 
IDA, anaemia and iron deficiency and that this association will manifest as fatigue.   
2. The secondary aims were then to assess whether a combination of HMB and 
fatigue will increase the risk of IDA, anaemia and iron deficiency in this population. 
This has high clinical relevance, since predictive measures could be used to 
encourage blood tests for iron status in women presenting with fatigue.  
6.2.2 Study hypotheses 
1. HMB and IDA, anaemia and iron deficiency all increase fatigue. 
2. The relationship between HMB and fatigue is mediated by iron status. 
3. The combination of HMB and fatigue will increase risk of IDA and anaemia.  
 
6.3 Materials and Methods 
6.3.1 Ethics and participant consent 
The ‘Female Health Questionnaire’ was approved by the St Mary’s University Ethics 
Committee. Participants provided written consent at the time of clinic attendance allowing 
for the anonymous use of their data for research.  
 
6.3.2 Inclusion criteria 
The inclusion criteria were: 
• Female; 
• Aged ≥18 years;  
• Pre-menopausal; 
• Undertake regular exercise (≥ 60 minutes/week or indicated taking part in races).  
6.3.3 Exclusion criteria 
The exclusion criteria were: 
• Not menstruated in the previous 12 months; 
• Incompletion of questionnaires. 
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6.3.4 Participants 
The same initial dataset was used as in chapter 5. As previously explained, as a result of 
a collaboration between a research group in Singapore, in addition to limited funds, this 
convenience sample was utilised, and included women attending routine healthcare 
assessments run by The Singapore Anti-Tuberculosis Association (SATA) in Singapore.  
 
6.3.5 Study design  
A retrospective analysis utilising this convenience sample was performed to assess the 
prevalence of HMB, when outlined using a pre-defined diagnostic series, iron deficiency 
and fatigue in all exercising women attending clinics for routine healthcare assessments 
run by The Singapore Anti-Tuberculosis Association (SATA) Healthcare, Singapore 
(insurance screening and drop-in clinics). Alongside a routine blood test, patients were 
invited to fill in a ‘Female Health Questionnaire’ in addition to completing the 
Multidimensional Fatigue Inventory (MFI-20) (410), both in English language only. Those 
who met the outlined inclusion criteria and completed the questionnaires were included in 
the study. As highlighted in chapter 5, most employees in Singapore have yearly health 
checks conducted through organisations such as SATA healthcare, and it is assumed that 
since the population of Singapore is homogenous, with relatively little variety in types of 
industry and a small total area, this sample was largely representative of the average. 
SATA are reported to be frequently used by local companies, providing annual check-ups 
(395). Further, in this study, the median [Hb] of 13.0 g·dL-1, was again comparable to the 
mean [Hb] in women of a reproductive age in Singapore, specified by the World Health 
Organisation (116). The mean BMI of 22.1 kg·m-2 in this study was also in accordance with 
data from the 2007 Singaporean National Health Surveillance Survey which found mean 
BMI in women between the age of 18 and 49 to range from 20.9 – 23.0 kg·m-2 (394).  
 
From July 2015 to November 2015 a total of 777 women attended the healthcare 
assessments, 84 were excluded due to incompletion of the questionnaires, 216 were 
excluded as they did not meet the predefined exercise criteria, and a further 207 were 
excluded as they had not menstruated in the previous year (Figure 6.1). Therefore, data 
from 271 regularly menstruating women were included in the study.  
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Figure 6.1 – Derivation of study sample. 
 
6.3.6 Measurements and definitions  
Female Health Questionnaire 
During clinic attendance, women completed the second version of the ‘Female Health 
Questionnaire’, as  described in chapter 3. This captured; a 4-part diagnostic series for the 
identification of HMB; the seeking of advice/help for heavy periods; awareness of historic 
Excluded (n=84) 
• Incomplete questionnaires 
Women with completed questionnaires 
(n=693) 
 
Menstruating women, with completed 
questionnaires (n=486) 
 
Excluded (n=207) 
• Not menstruated in the last 
year 
Women assessed for eligibility (n=777) 
 
Excluded (n=216) 
• Does ≤ 60 minutes 
exercise/week or does not 
compete in races. 
 
Menstruating women who regularly 
exercise (n=271) 
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and current iron status (iron deficiency or anaemia), and current and historic use of iron 
supplementation (392).  
 
Blood measures 
As part of the ‘well woman’ routine SATA assessment, blood is taken to check the patient’s 
full blood count, urea and electrolytes, and serum ferritin. Following the guidelines from the 
World Health Organisation (WHO), in this study, anaemia was defined as a blood 
concentration of haemoglobin [Hb] < 12.0 g·dL-1 (411). IDA was defined as [Hb] < 12.0 
g·dL-1 with a serum ferritin < 15 µg·L-1 (100). Iron deficiency was defined as serum ferritin 
< 15 µg·L-1 again, the level at which the WHO specifically indicates iron depletion (100). 
As there was no impact of the different levels of severity of iron deficiency in chapter 5, for 
the purpose of this study, only the more severe cut-off was applied (serum ferritin < 15 
µg·L-1). Given the evident ambiguity surround the use of serum ferritin, anaemia alone was 
also considered.  
 
Multi-dimensional Fatigue Inventory (MFI-20) (Appendix 10.15) 
Women were also asked to complete the MFI-20 which is a questionnaire designed to 
evaluate five different sub-categories of fatigue; general fatigue, physical fatigue, mental 
fatigue, reduced activity and reduced motivation (410). It is comprised of 20 questions, 
each with a five-point Likert scale which are broken down on analysis into the five 
subsections. The magnitude of the score is proportional to the extent of fatigue, i.e. a higher 
score means greater fatigue. It has previously been used effectively in both general and 
chronically unwell populations (412-414).       
 
Both the MFI-20 and the ‘Female Health Questionnaire’ were designed to take 4 - 5 
minutes in total for completion.  
 
6.3.7 Data handling and statistical analysis 
As per chapter 5, all data (questionnaire and blood results) were inputted anonymously 
into an excel spreadsheet. Statistical analysis was performed using a statistics computer 
package (IBM SPSS Statistics for Macintosh, Version 21.0, Armonk, New York (NY): IBM 
Corp.). Statistical significance was set at p<0.05.  
 
All data were tested for normality using a Shapiro-Wilk test. Data were analysed 
descriptively to evaluate all questionnaire variables and iron status. Chi-squared tests were 
firstly used to determine an association between iron status, using the criteria outlined 
above and identified HMB, using the criteria outlined in chapter 3. Chi-squared tests were 
also used  to determine whether the seeking of advice/help for heavy periods varied 
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between those with and without anaemia, IDA and iron deficiency. Mann Whitney U tests 
were used to determine whether there were differences in fatigue scores between women 
with and without anaemia, IDA, iron deficiency, and between women who were or were not 
identified to have HMB. Mann Whitney U tests were also used to assess if there was a 
difference in fatigue specific to those identified with HMB who did or did not have IDA, 
anaemia and iron deficiency. Spearman’s correlation coefficient was used to determine 
whether there was an association between [Hb] and serum ferritin with all subscales of 
fatigue. 
 
In order to assess the validity and reliability and to ensure internal consistency of each of 
the five MFI-20 subscales three reliability tests were performed; 1. inter-item correlation, 
2. corrected-to-total correlation, and 3. calculation of the standardised Cronbach’s alpha 
coefficient. Inter-item correlations ranging from 0.30 - 0.70 were kept, while a value for the 
corrected item-total correlation of > 0.20 was deemed adequate (415). A relatively high 
reliability coefficient - Cronbach’s ∝ ranging from 0.70 - 0.95 was considered to be 
sufficient (416). Cronbach’s alpha if item was deleted were also calculated. As the fatigue 
subscales were not normally distributed, correlations between each of the five MFI-20 
subscales and [Hb] and ferritin independently were computed using Spearman’s 
correlation analysis.  
 
A multiple linear regression model was used to investigate the relationship between 
identified HMB and fatigue. To account for potential confounding, this was adjusted for 
age, BMI, number of periods in the last 12 months, and iron supplementation in the 
previous 3 months. Mediation analysis was performed using both the Barron and Kenny 
(417) and Sobel (418) methods to determine if IDA or anaemia were on a causal pathway 
between identified HMB and fatigue.  
 
Cross-sectional predictive factors for IDA and anaemia were determined using binary 
logistic analyses. The independent variables assessed were the identified presence of 
HMB, the MFI-20 subscales, and then other relevant covariates including age, BMI, 
number of periods in the last 12 months, and iron supplementation in the previous 3 
months. The Box-Tidwell (1962) procedure was applied to check for linearity between 
independent and the dependent variables (IDA and anaemia), and a Bonferroni correction 
was applied based on the number of terms (419) A multivariable binomial logistic 
regression was then used to assess the relationship between IDA and anaemia based on 
the identified presence of HMB, the responses to the MFI-20 and the other covariates.  
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6.4 Results 
6.4.1 Participant Characteristics 
As the same population was used in this study as in chapter 5, the median age was 38 
years (29 - 43 years), weight: 57.0 kg (50.3 – 63.0 kg), height: 1.60 m (1.55-1.63 m) and 
BMI: 22.1 kg·m-2 (20.0 – 24.3 kg·m-2) (Table 5.1). Across the population (n=271), 60 
women reported at least 2 of the outlined HMB criteria and were therefore identified to 
have HMB.  
 
Table 6.1 – The difference between the prevalence of IDA, anaemia and iron deficiency in 
those who did or did not meet the outlined HMB criteria.  
 
 BMI – body mass index, IDA – iron deficiency anaemia, ID – iron deficiency, [Hb] – 
haemoglobin concentration, HMB – heavy menstrual bleeding 
Values are median (IQR). Where percentages are given, the number in the brackets is n. 
Significant differences between those with and without HMB are shown as follows: ***p < 
0.005, **p < 0.01, *p < 0.05. 
 
6.4.2 Prevalence and impact of identified HMB on IDA, anaemia and iron 
deficiency 
As in chapter 5, the presence of HMB was reported by 22.1% of the study participants 
(Table 6.1). While 14.8% had IDA, 18.8% had anaemia, and 30.3% were iron deficient. 
Those with HMB were more likely to have IDA (28.3% vs 10.9%; p=0.001; Table 5.1), 
anaemia (28.3% vs 16.1%; p=0.03; Table 5.1), and iron deficiency (48.3% vs 25.1%; 
p=0.001; Table 5.1) compared to those without HMB.  
 
 Total sample HMB No HMB 
Test 
statistic 
p-value 
n 271 60 (22.1%) 211 (77.9%)   
IDA 14.8% (n=40) 
28.3%*** 
(n=17) 
10.9% (n=23) X2 = 11.284 0.001 
Anaemia 18.8% (n=51) 28.3%* (n=17) 16.1% (n=34) X2 = 4.5666 0.033 
ID 30.3% (n=82) 
48.3%*** 
(n=29) 
25.1% (n=53) X2 = 11.931 0.001 
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6.4.3 Impact of HMB and iron status independently on fatigue  
Those identified with HMB were more likely to report increased general fatigue (score: 
11.50 (9.00 – 13.25) vs 11.00 (8.00 – 12.00); p=0.04; Table 6.2), but reported fatigue 
scores were not higher for total, physical or mental fatigue, while neither activity levels or 
motivation were affected (all p>0.05; Table 6.2).  
 
Those with anaemia reported greater levels of mental fatigue than those without across 
the total sample (10.00 (8.00 – 12.00) vs 9.00 (7.00 – 11.00); p=0.047,; Table 6.3). 
However, neither those with IDA nor those with iron deficiency were more likely to report 
any increased degree of fatigue across the measured categories when compared to those 
without (all p>0.05; Table 6.3).  
 
Amongst those identified with HMB, those who also had IDA, anaemia or iron deficiency 
were no more likely to report increased fatigue (all p>0.05; Table 6.4).  
 
Table 6.2 – A comparison in fatigue scores (MFI-20) between those identified with and 
without heavy menstrual bleeding (HMB).  
 
HMB 
n=60 
Not HMB 
n=211 
U p-value 
Total fatigue 
48.00 (43.75 -
57.00) 
47.00 (39.50 -
47.00) 
7183 0.11 
General fatigue 
11.50 (9.00 -
13.25)* 
11.00 (8.00 -
12.00) 
7413.5 0.04 
Physical fatigue 
9.00 (8.00 -
12.00) 
10.00 (7.00 -
12.00) 
6766 0.41 
Reduced activity 
9.50 (7.00 -
11.00) 
9.00 (8.00 -
12.00) 
6056.5 0.61 
Reduced 
motivation 
9.00 (8.00 -
10.00) 
9.00 (7.00 -
11.00) 
7112.5 0.14 
Mental fatigue 
10.00 (8.00 -
11.00) 
9.00 (7.00 -
11.00) 
7012 0.20 
HMB – heavy menstrual bleeding, U – Mann Whitney U test statistic 
Values are median (IQR).  
Significant differences between those with and without HMB are shown as follows: *p < 
0.05. 
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Table 6.3 – A comparison between different fatigue scores (MFI-20) across the total sample between those with and without anaemia, IDA or 
ID. Anaemia ([Hb] < 12.0 g·dL-1), IDA ([Hb] < 12.0 g·dL-1 and serum ferritin < 15 µg·L-1), and iron deficiency (ID; serum ferritin < 15 µg·L-1).  
 
Anaemia 
n=51 
Not 
Anaemia 
n=220 
U 
p-
value 
IDA 
n=40 
Not 
IDA 
n=231 
U p-value 
ID 
n=82 
Not ID 
n=189 
U 
p-
value 
Total fatigue 
50.00 
(42.25-
57.00) 
47.00 
(39.00 -
56.00) 
6066 0.37 
47.00 (40.75 
-57.25) 
47.00 
(40.00 
-57.00) 
4851 0.61 
47.00 
(40.00 -
56.50) 
48.00 
(41.00 - 
57.00) 
7265 0.41 
General 
fatigue 
11.00 
(9.00 -
12.00) 
11.00 (8.00 
-12.00) 
5782.5 0.73 
11.00    (8.75 
-12.00) 
11.00 
(9.00 -
12.00) 
4595.5 0.96 
10.00 
(8.00 -
12.00) 
11.00   
(9.00-
12.00) 
7233 0.38 
Physical 
fatigue 
10.00 
(8.00 -
11.75) 
10.00 (7.00 
-12.00) 
6128.5 0.30 
10.00    (8.00 
-12.00) 
10.00 
(7.00 -
12.00) 
4927 0.50 
9.00 
(7.00 -
11.00) 
10.00    
(7.00 -
12.00) 
7123 0.29 
Reduced 
activity 
9.00 (   
8.00 -
12.00) 
10.00 (7.00 
-12.00) 
5878 0.59 
9.00    (7.00 -
11.25) 
9.00 
(7.50-
11.00 ) 
4719.5 0.83 
9.00 
(7.00 -
11.00) 
10.00   
(8.00 -
12.00) 
7064.5 0.25 
Reduced 
motivation 
9.00    
(8.00 -
11.00) 
9.00    
(7.00 -
11.00) 
5731 0.81 
9.00      (8.00 
-11.00) 
9.00   
(7.00 -
11.00) 
4776.5 0.73 
9.00 
(7.00 -
10.00) 
9.00     
(7.00 -
11.00) 
7345 0.49 
Mental 
fatigue 
10.00 
(8.00 -
12.00)* 
9.00    
(7.00 -
11.00) 
6603 0.047 
10.00   (8.00 
-12.00) 
9.00   
(8.00 -
11.00) 
5417.5 0.08 
10.00 
(8.00 -
11.00) 
10.00    
(8.00 -
11.00) 
7777 0.96 
IDA – iron deficiency anaemia, ID – iron deficiency, U – Mann Whitney U test statistic. Values are median (IQR).  
  
150 
 
Significant differences between those with and without anaemia, IDA or ID are shown as follows: *p < 0.05 
 
Table 6.4 – A comparison between different fatigue scores (MFI-20) in those identified with HMB (n=112) between those with and without 
anaemia, IDA or ID. Anaemia ([Hb < 12.0 g·dL-1), IDA ([Hb] < 12.0 g·dL-1 and serum ferritin < 15 µg·L-1), and iron deficiency (ID; serum ferritin 
< 15 µg·L-1).  
 
Anaemia 
n=17 
Not 
Anaemia 
n=43 
U p-value 
IDA 
n=17 
Not IDA 
n=43 
U p-value 
ID 
n=29 
Not ID 
n=31 
U p-value 
Total fatigue 
47.00   
(40.00 - 
57.00) 
48.00 
(45.00-
57.00) 
350.5 0.81 
47.00 
(40.00 -
57.00) 
48.00 
(45.00 -
57.00) 
350.5 0.81 
47.00 
(40.00 -
57.00) 
49.00 
(45.50 -
57.00) 
355.5 0.16 
General 
fatigue 
11.00    
(9.00 - 
14.00) 
12.00     
(9.50 - 
13.00) 
340 0.67 
11.00 
(9.00 -
14.00) 
12.00 
(9.50 – 
13.00) 
340 0.67 
11.00 
(9.00 – 
13.00) 
12.00 
(10.00-
13.50) 
418.5 0.64 
Physical 
fatigue 
11.00    
(8.00 - 
13.00) 
9.00     
(8.00-  
11.00) 
396 0.61 
11.00 
(8,00 -
13.00) 
9.00    
(8.00 -
11.00) 
396 0.61 
8.00 
(8.00 -
12.00) 
10.00 
(8.00 - 
11.50) 
408.5 0.54 
Reduced 
activity 
10.00    
(7.00 - 
11.00) 
9.00      
(7.00 - 
11.00) 
394.5 0.63 
10.00 
(7.00 -
11.00) 
9.00    
(7.00 -
11.00) 
394.5 0.63 
9.00 
(7.00 -
11.00) 
10.00 
(8.00 - 
11.00) 
398.5 0.45 
Reduced 
motivation 
9.00 (8.00 -
10.00) 
9.00 (8.00 -
10.00) 
332 0.58 
9.00   
(8.00 -
10.00) 
9.00   
(8.00 – 
10.00) 
332 0.58 
8.00 
(8.00 -
10.00) 
10.00 
(8.00 -
11.00) 
378.5 0.29 
  
151 
 
Mental fatigue 
10.00 (8.00 -
11.00) 
10 (8-11) 398 0.59 
10.00 
(8.00 – 
11.00) 
10.00 
(8.00 – 
11.00) 
398 0.59 
10.00 
(8.00 -
11.00) 
10.00 
(8.00 -
12.50) 
371.5 0.24 
IDA – iron deficiency anaemia, ID – iron deficiency, U – Mann Whitney U test statistic. 
Values are median (IQR). 
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6.5 Reliability of the MFI-20 
A summary of the reliability tests for the MFI-20 is given in Table 6.5. It was not necessary 
to remove any items based on the inter-item correlations and the corrected item-total 
correlations as these were all greater than 0.30. While Cronbach’s ∝ showed acceptable 
reliability and good internal consistency, ∝ = 0.87, and when standardised ∝ = 0.92.  
 
Table 6.5 - Mean and standard deviations for each aspect of fatigue, alongside inter-item 
correlations, Cronbach’s alpha if the item is deleted, and the corrected item-total 
correlation.  
 Mean SD GF PF RA RM MF 
Cronbach's 
Alpha if 
item is 
deleted 
Corrected 
Item-Total 
Correlation 
General 
Fatigue 
10.70 2.96 - 0.63 0.44 0.52 0.56 0.86 0.66 
Physical 
fatigue 
9.51 3.07 0.63 - 0.70 0.65 0.56 0.82 0.78 
Reduced 
activity 
9.28 2.65 0.44 0.70 - 0.64 0.49 0.85 0.68 
Reduced 
motivation 
8.96 2.55 0.57 0.65 0.64 - 0.56 0.84 0.74 
Mental 
fatigue 
9.49 2.82 0.56 0.56 0.49 0.56 - 0.86 0.64 
SD – standard deviation, TF – total fatigue, GF – general fatigue, PF – physical fatigue, 
RA – reduced activity, RM – reduced motivation, MF – mental fatigue 
 
6.5.1 Relationship between fatigue and markers of iron status 
There was no strong evidence for a linear relationship between any of the MFI-20 
subscales or total fatigue and either of [Hb] or serum ferritin independently (Table 6.6; all 
p>0.05). 
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Table 6.6 – The association between haemoglobin concentration ([Hb]) and serum ferritin 
and the five subscales of the MFI-20 and total fatigue.  
 
[Hb] Serum ferritin 
Correlation 
coefficient 
p-value 
Correlation 
coefficient 
p-value 
Total Fatigue -0.01 0.83 0.05 0.44 
General Fatigue 0.00 0.99 0.02 0.72 
Physical fatigue -0.05 0.38 0.10 0.12 
Reduced activity -0.01 0.92 0.04 0.49 
Reduced motivation 0.04 0.53 0.02 0.75 
Mental fatigue -0.03 0.66 -0.01 0.84 
 [Hb] – haemoglobin concentration 
 
 
6.5.2 Relationship between identified HMB, anaemia, IDA and fatigue 
First, in an unadjusted logistic regression model, those identified with HMB were twice as 
likely to have anaemia (OR: 2.06, 95% CI: 1.05 – 4.03, p=0.035; Table 6.7) compared to 
those without HMB. Adjusting for mental fatigue slightly decreased the odds ratio between 
HMB and anaemia to 1.96 (95% CI: 1.00 – 3.65). In fact, as shown in Table 6.7, there was 
some evidence to suggest an increase in mental fatigue was associated with a 11% 
increase in likelihood of anaemia (OR 1.11, 95% CI: 1.00 - 1.24; p=0.067). There was no 
evidence for an interaction between identified HMB and mental fatigue (p=0.20) suggesting 
that the effect of HMB, when identified by this means, on anaemia is independent of mental 
fatigue.  
After controlling for other covariates (BMI, age, weekly exercise volume, iron 
supplementation in the last 3 months), the relationship between identified HMB and 
anaemia was not strengthened and became insignificant (OR 1.79, 95% CI: 0.87 – 3.67; 
p=0.11), the relationship between mental fatigue and anaemia was slightly attenuated (OR 
decreased from 1.11 to 1.12, Table 6.7). 
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Table 6.7 – The unadjusted and adjusted results from the logistic regression of anaemia. 
OR – odds ratio, HMB – heavy menstrual bleeding, 95% CI – 95% confidence interval for 
the odds, BMI - body mass index 
Significant interaction of the variable in the model are shown as follows: ***p < 0.005, **p 
< 0.01, *p < 0.05. 
 
In an unadjusted logistic regression model, those identified with HMB were three times 
more likely to have IDA (OR: 3.23, 95% CI: 1.59 – 6.57, p=0.001; Table 6.8) compared to 
those without HMB. Adjusting for mental fatigue slightly decreased this relationship (OR: 
3.10, 95% CI: 1.52 – 6.32, p=0.002; Table 6.8). The lack of evidence for an interaction 
between HMB and mental fatigue (p=0.20) suggests that the effect of HMB on IDA is 
independent of fatigue status.  
After controlling for other covariates (BMI, age, weekly exercise volume, iron 
supplementation in the last 3 months), the relationship between HMB and IDA was only 
minimally attenuated (OR 2.65, 95% CI: 1.25 – 5.62; p=0.01; Table 6.8). 
 
 Unadjusted model 
Adjusted for mental 
fatigue only 
Adjusted for mental 
fatigue and other 
covariates 
 OR 
95% 
CI 
p-value OR 
95% 
CI 
p-value OR 
95% 
CI 
p-value 
HMB 2.06 
1.05 
– 
4.03 
0.035* 1.96 
1.00 
– 
3.85 
0.051 1.79 
0.87 - 
3.67 
0.11 
Mental 
fatigue 
   1.11 
1.00 - 
1.24 
0.067 1.12 
1.00 - 
1.26 
0.06 
BMI       1.02 
0.96 - 
1.02 
0.54 
Age       1.02 
0.99 - 
1.06 
0.18 
Weekly 
exercise 
volume 
      1.00 
1.00 - 
1.00 
0.96 
Iron sup. 
(last 3 
months) 
      2.54 
0.71 
– 
9.05 
0.58 
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Table 6.8 – The unadjusted and adjusted results from the logistic regression of IDA. 
 
OR – odds ratio, HMB – heavy menstrual bleeding, 95% CI – 95% confidence interval for 
the odds, BMI - body mass index 
Significant interaction of the variable in the model are shown as follows: ***p < 0.005, **p 
< 0.01, *p < 0.05. 
 
6.5.3 Relationship between HMB and fatigue 
In an unadjusted model, those identified with HMB scored 0.983 points higher for general 
fatigue than those without HMB (95% CI for difference: 0.14 - 1.83 points; p=0.02; Table 
6.9) on average. When potential confounders were included, this relationship was lost, as 
the coefficient decreased from 0.983 to 0.846 (95% CI: -0.042 – 1.735; p=0.06; Table 6.9). 
BMI was related to fatigue in this mutually adjusted model. For every 1 kg·m-2 increase in 
BMI, mean fatigue score increased by 0.09 points (95% CI: 0.005 - 0.173 points; p=0.04; 
Table 6.9). 
 
 Unadjusted model 
Adjusted for fatigue 
only 
Adjusted for fatigue 
and other covariates 
 OR 
95% 
CI 
p-value OR 
95% 
CI 
p-value OR 
95% 
CI 
p-value 
HMB 3.23 
1.59 
– 
6.57 
0.001* 3.10 
1.52 
– 
6.32 
0.002 2.65 
1.25 
– 
5.62 
0.01 
Mental 
fatigue 
   1.10 
0.97 - 
1.24 
0.138 1.09 
0.95 - 
1.24 
0.21 
BMI       1.04 
0.97 - 
1.12 
0.26 
Age       1.02 
0.98 - 
1.05 
0.45 
Weekly 
exercise 
volume 
      1.00 
1.00 - 
1.00 
0.83 
Iron sup. 
(last 3 
months) 
      1.36 
0.27 
– 
6.76 
0.71 
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Using the Barron and Kenny method, there was no evidence to suggest that anaemia 
mediates the relationship between identified HMB and general fatigue. The pathway 
between anaemia and general fatigue was not significant (p=0.67), and a low proportion 
of the effect was mediated (0.0053). The Sobel test also provided no evidence of mediation 
(z-score 0.42; p>0.05).   
 
Again using the Barron and Kenny method, there was also no evidence to show that IDA 
mediates the relationship between identified HMB and general fatigue. The pathway 
between IDA and general fatigue was not significant (p=0.87), and a low proportion of the 
effect was mediated (0.0030). The Sobel test also provided no evidence of mediation (z-
score 0.17; p>0.05). 
 
Table 6.9 - The unadjusted and adjusted relationship between identified heavy menstrual 
bleeding (HMB) and general fatigue. 
 Unadjusted model Adjusted model 
 B CI p-value B CI p-value 
Constant 10.483 
10.085 – 
10.882 
 9.662 
6.744 – 
12.580 
 
HMB 0.983 
0.136 - 
1.830 
0.02* 0.846 
-0.042 – 
1.735 
0.06 
IDA    -0.357 
-1.417 – 
0.703 
0.51 
Age    -0.032 
-0.070- - 
0.007 
0.11 
BMI    0.089 
0.005 – 
0.173 
0.04* 
Periods in 
last 12 
months 
   0.006 
-0.119 – 
0.132 
0.92 
Iron sup. (last 
3 months) 
   -0.393 
-1.174 - 
0.387 
0.32 
B – coefficient, OR – odds ratio, CI – 95% confidence interval for the odds, HMB – heavy 
menstrual bleeding, IDA - iron deficiency anaemia, BMI - body mass index 
Significant interaction of the variable in the model are shown as follows:, *p < 0.05. 
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6.6 Discussion 
As outlined in Chapter 5, HMB, when identified using the criteria outlined in chapter 3 was 
common in this study population, affecting approximately a quarter of the participants. It 
was associated with an increased prevalence of IDA, anaemia and iron deficiency. 
Identified HMB was found to increase general fatigue, however this pathway was not 
mediated by anaemia or IDA. Anaemia was associated with an increase in mental fatigue, 
but neither IDA nor iron deficiency alone were related to any fatigue subscale, and there 
was no strong correlation between any aspect of fatigue and either [Hb] or serum ferritin. 
The association between IDA or anaemia and fatigue, and HMB and fatigue has previously 
been studied, but to our knowledge this is the first study to address the interrelation 
between all of these in an otherwise healthy, female exercising and menstruating 
population. 
 
In the present study, those identified with HMB were twice as likely to have IDA when 
controlling for potential confounders, demonstrating a strong, if not unsurprising 
association given that HMB is associated with increased blood loss (37). The association 
between both IDA and anaemia with fatigue is well established, and iron therapy has been 
shown to be effective in reducing fatigue. However, research is inconclusive as to the 
association between iron deficiency alone and fatigue (56,226,247-249). Interestingly, in 
the present study while anaemia was associated with increased mental fatigue, neither the 
presence of IDA nor iron deficiency resulted in an increase in measured fatigue across any 
of the subscales. In light of previous uncertainties regarding serum ferritin cut-off values 
for iron deficiency, and the results in chapter 5, the WHO criteria indicating iron ‘depletion’ 
was specifically used here for the diagnosis of iron deficiency (serum ferritin < 15 µg·L-1) 
(40). Further, there was also no relationship between serum ferritin or [Hb] and any of the 
fatigue subscales. Interestingly, a lack of association between fatigue and serum ferritin 
has previously been found in an adolescent population (38). These findings question the 
applicability and power of serum ferritin as a sole means to establish iron status. Due to 
the acute response to inflammation that can ensue with serum ferritin, there is potential for 
an underlying iron deficiency being masked, thus distorting findings (36). This is inevitably 
particularly relevant amongst certain populations, including those with underlying 
inflammatory conditions, and in those who exercise, hence in this study population. This 
can lead to the misdiagnosis of both iron deficiency and IDA. However, providing no prior 
exercise had been done on the day of testing, one would expect inflammation in a healthy 
population, as in the present study, to be limited.  
 
Both the results from the present study, and those in chapter 5 suggest that the use of 
ferritin as a means for diagnosing iron deficiency alone needs further evaluation. 
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Particularly given the apparent lack of increase in fatigue in either those with IDA or iron 
deficiency. It would therefore be advisable to measure other markers of iron status such 
as transferrin saturation, transferrin, serum iron and total iron binding capacity in addition 
to erythrocyte and reticulocyte indices prior to concluding any relationship between iron 
deficiency and fatigue, and future studies should address this. Significantly, in order to 
minimise risk of inaccuracies, testing should occur when participants are in a rested and 
fasted state, markers of inflammation should also be measured, and underlying medical 
conditions recorded and factored into the analysis. 
 
In the present study, when identified using the outlined criteria, HMB was associated with 
increased general fatigue. Previous research has highlighted the impact of HMB on quality 
of life (372,408). Since HMB also increased risk of IDA, anaemia and iron deficiency it 
would seem plausible that the increase in general fatigue associated with HMB could be 
as a result of the increased loss of iron, especially given the association between IDA or 
anaemia and fatigue (405). However, neither IDA nor anaemia were found to mediate the 
relationship between HMB and general fatigue. The lack of association between iron 
deficiency alone and general fatigue also inevitably meant that this was not on the causal 
pathway between HMB and general fatigue. Further, when specifically looking at iron 
status in those with HMB, there was no difference in reported fatigue across any of the 
subscales between those with or without anaemia, IDA or iron deficiency, highlighting the 
independence of the HMB to fatigue pathway. In light of the relatively subjective nature of 
the HMB criteria, and in the absence of a universally validated means for diagnosis, further 
research is required, however it could be suggested that the sheer physical, social and 
mental distress alone caused by the increase in blood loss may be the primary cause of 
the increased fatigue seen here as opposed to the physical increased loss of blood. A 
previous study assessing causes for a reduction in quality of life amongst those with HMB 
supports this, finding no association between volume of blood lost and quality of life score, 
concluding that the physical impact of HMB alone was responsible for the reduction in 
quality of life (372,420). Alternatively, the impact of other underlying aetiologies associated 
with HMB also have the potential to be responsible for its association with increased 
fatigue, and could override any impact of iron status, so this clearly warrants further 
investigation, and this should be addressed in future work. For example, being an 
inflammatory condition, HMB is associated with an increased release of pro-inflammatory 
cytokines, such as tumour necrosis factor alpha (TNF-") (401). There is a strong 
relationship between TNF-" and fatigue (421), therefore it could be hypothesised that the 
increase in pro-inflammatory cytokines in HMB cause the ensuing fatigue. However, it is 
possible that TNF-" would only increase during menses, so if this is driving the fatigue, 
variations may be seen through the menstrual cycle.  
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It must also be considered that current phase of the menstrual cycle was not captured, and 
variation in iron status throughout the menstrual cycle is yet to be conclusively evaluated, 
therefore some individuals may not have been low in iron or feeling the effects of this at 
the time of measurement, skewing results. Further, it is significant to note that not all 
menstrual fluid is blood, the blood content, and therefore amount of iron which is lost can 
vary significantly. While the insidious nature of fatigue may have meant it was not 
appreciated and has become habitual to women with HMB or a compromised iron status, 
altering perception.  
 
To our knowledge this is the first study to address the pathway between HMB and fatigue, 
and given that it appears to be independent of iron status it is important to gain a better 
understanding about the causes of the fatigue, in addition to identifying possible treatment 
options. Future studies should address the above outlined pointed alongside other 
accompanying factors that may be related to HMB. 
 
The results from this study highlight that when an individual presents with either HMB 
and/or signs of mental fatigue it would be prudent to take a blood sample to check iron 
status, while this may not mediate the relationship between HMB and fatigue, and despite 
the impact of IDA and iron deficiency alone being unsure, there is still potential for these 
conditions to impact general health and well-being. Other markers of iron status should 
also be measured alongside these to increase reliability. Further, the independence of the 
association between identified HMB and fatigue in the present study, regardless of IDA or 
anaemia suggests that further research should address other factors associated with HMB 
such as an increased release of pro-inflammatory cytokines that may cause this. 
Additionally, research evaluating the impact of both IDA and iron deficiency is necessary, 
in addition to assessing the use of serum ferritin for diagnosis. This will be addressed in 
the next chapter.  
 
6.6.1 Limitations  
Firstly, the limitations with the ‘Female Healthy Questionnaire’ outlined in chapters 3-5 also 
apply in this chapter. Additionally, the language issues of the questionnaire highlighted in 
chapter 5 also require consideration here, and could have caused confusion or lack of 
understanding of some of the questions. The absence of a measurement for inflammation 
could have also impacted upon study data, considering that ferritin is an acute phase 
reactant. Iron deficiency can take a while to manifest, making the development of 
symptoms slow, so feelings of fatigue may have been adjusted to and missed.  
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Again, as previously highlighted, data collection only occurred on one day, and therefore 
other factors may have affected the results, for example specific day in the menstrual cycle 
or the presence of any illness. Since this population was assumed to be ‘healthy’, the 
potential for underlying medical conditions was not factored into the analysis, but this could 
have had an impact on the results. Finally, the potential bias around only using one 
healthcare body were outlined in chapter 5. In short, given the homogenous nature of 
Singaporean population in addition to the established position that SATA CommHealth 
have in Singapore, and the fact that the haematological data in this study are aligned to 
that outlined by the WHO and in the 2007 National Health Surveillance Survey the risk of 
bias is clearly minimised (116,394). Suggesting therefore that this sample is largely 
reflective of the general Singaporean population of reproductive women.  
 
It is acknowledged that the current study is observational, therefore it is not possible to 
make strong causal inferences about the associations we have found. We have presented 
fully adjusted results, but this cannot account for unmeasured confounding. Finally, while 
the MFI-20 has been validated in multiple populations, it would increase reliability to 
conduct another questionnaire alongside this for purposes of validation.  
 
6.7 Conclusions 
This study showed that HMB and anaemia are both independently associated with an 
increase in fatigue in menstruating women. The general fatigue that ensued with HMB was 
not however mediated by anaemia or IDA. This suggests that the symptoms of HMB 
resulting in fatigue appear to be independent of iron status. HMB increased likelihood of 
IDA, anaemia and iron deficiency, while mental fatigue was independently associated with 
anaemia. Therefore, it would be prudent to measure iron status in women presenting with 
HMB and mental fatigue, however given the lack of association between IDA and iron 
deficiency and fatigue, the current definition of both of these also needs to be evaluated 
alongside any impact they may have.  
 
To conclude, regarding the outlined hypotheses for this chapter, the first hypothesis that 
when identified using the outlined criteria, HMB, IDA, anaemia and iron deficiency increase 
fatigue cannot be accepted, while identified HMB, and anaemia were associated with an 
increase in fatigue, IDA and iron deficiency were not. The second hypothesis that a 
compromised iron status was the cause for the fatigue associated with HMB must be 
rejected since the associated between HMB and fatigue was independent of IDA or 
anaemia. Finally, the third hypothesis that HMB and fatigue together increased IDA or 
anaemia risk must also be rejected as there was no cumulative effect.  
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6.8 Future perspectives 
Being an inflammatory condition, HMB is associated with increased release of pro-
inflammatory cytokines, such as tumour necrosis factor alpha (TNF-") (401). This cytokine 
promotes hypoferremia, and is therefore associated with a systemic iron deficiency, 
resulting in a decrease in soluble transferrin receptor and serum iron. However, as an acute 
phase protein, serum ferritin will be transiently elevated in response to this inflammatory 
mediator (422). However, this would inevitably be dependent on the day of their cycle, 
since during menses, TNF-" would be higher, but this may return to normal during the rest 
of their cycle. The increased blood loss alone associated with HMB clearly increases iron 
deficiency risk, and here there is overt potential for this risk to be exacerbated. To my 
knowledge, research has only looked at these factors independently; the relationship 
between HMB and TNF-", and the relationship between TNF-" and iron status, therefore 
further research is evidently necessary. However, this does again question the suitability 
and use of serum ferritin for iron deficiency diagnosis.  
 
Further, given the association between TNF-" and fatigue, future studies should include 
measurement of pro-inflammatory cytokines alongside fatigue to see if these are in part 
responsible for the increased fatigue seen in those with HMB.  
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applied by the author. The author extracted the relevant data and performed all the 
statistical analysis and interpreted all the data.  
 
  
162 
 
 
7 IRONWOMAN trial: the impact of intravenous iron on 
exercise and aerobic capacity, fatigue and mood 
disturbance in iron deficient, non-elite exercising women  
7.1 Abstract 
Introduction: Those who exercise are at an increased risk of iron deficiency, however 
diagnosis of iron deficiency, particularly amongst the exercising population has historically 
been problematic. With a lack of clarity around diagnosis and efficacy of existing markers, 
particularly in those who exercise, further research is required. Using the principle that a 
positive response to intravenous iron indicates deficiency, the primary aim of this study 
was to evaluate the impact of iron repletion on aerobic and exercise capacity in iron 
deficient, non-elite exercising women.  
Methods: Thirty-two healthy exercising, iron deficient (serum ferritin ≤ 30 µg·L-1) women 
of a reproductive age were recruited to the study (mean age 35.0 ± 8.9 years, weight 61.9 
± 7.8 kg, height 1.65 ± 0.05 m, 22.7 ± 3.0 kg·m-2). Participants completed a maximal 
exercise test, a total haemoglobin mass test, had venous blood samples taken and 
answered questionnaires to assess fatigue and mood disturbance at baseline. They then 
received a single high dose of intravenous iron. Two weeks ± five days later baseline tests 
were repeated. 
Results: Markers of exercise and aerobic capacity increased significantly from baseline to 
post-injection. Relative and absolute V̇O2max increased by 3.30% (49.11 ± 6.41 mL·kg-
1·min-1 to 50.73 ± 7.16 mL·kg-1·min-1; p=0.003) and 2.35% (2974 ± 357 mL·min-1 to 3044 ± 
365 mL·min-1; p=0.03) respectively. Total haemoglobin mass also increased by 3.17% 
(g·kg-1; p=0.005) and 2.44% (g; p=0.03) after the iron injection. However, a significant 
degree of individual response was seen. When broken down into groups based on baseline 
serum ferritin, increase in exercise and aerobic capacity were only seen in those with more 
severe iron deficiency (serum ferritin < 15 µg·L-1). Despite this, there was no association 
between baseline serum ferritin and change in any markers of exercise or aerobic capacity. 
Fatigue and mood disturbance was reduced in all participants. 
Conclusions: While there was an overall increase in markers of exercise and aerobic 
capacity, there was a significant degree of individual response. When results were broken 
down according to baseline serum ferritin, increases were only seen in those with more 
severe iron deficiency. This suggests that serum ferritin cut-offs often applied may be too 
high. However, the lack of association between baseline serum ferritin and exercise and 
aerobic response questions the appropriateness of serum ferritin as a diagnostic marker 
in isolation. Across the board improvements in fatigue may suggest that iron deficiency 
impacts upon cognition prior to aerobic and performance measures. 
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7.2 Introduction 
Iron deficiency anaemia (IDA) and iron deficiency non-anaemia (IDNA) are more common 
in those who exercise than in sedentary controls (206). In agreement with previous 
research, approximately one third of athletes in Chapter 5 were found to be iron deficient 
when using serum ferritin for diagnosis (serum ferritin < 15 g·dL-1) (51,120,121). The 
evident impact of IDA on exercise performance and general health means that intervention 
is necessary. However, the equivocal research surrounding the impact of iron deficiency 
without anaemia, particularly in those who exercise has resulted in inconclusive advice as 
already highlighted in this thesis. This could in part be caused by the use of [Hb] and serum 
ferritin for diagnosis, both of which are susceptible to distinct variation, particularly in those 
who exercise (Section 2.5).  
 
Previous studies evaluating the impact of iron deficiency have applied the principle that 
iron deficiency can be indicated if an individual responds positively to iron therapy (47). 
Since intravenous injections bypass the controlled absorption mechanism, these provide 
the most effective means for evaluation, however, recent research specifically in the 
exercising population using this method has only focused on elite and highly trained 
athletes, who, as a result of the increased physiological stress, may respond differently to 
a more general exercising and healthy population in whom research is sparse (7). Due to 
their substantial training status, potential for improvements in exercise and aerobic 
capacity in elite athletes may be very small, and statistically not significant. This may be a 
cause for the ambiguity in this area. Further, a degree of individual variation in response 
to iron therapy has been found (241), the reasons for this being unknown, but this could 
also be a reflection of the unsuitability of the markers used for diagnosis, or alternatively 
the inconsistencies in the protocol utilised, as previously explained. Utilising the principle 
that a positive response to iron therapy suggests iron deficiency (47), measures of iron 
deficiency could be improved. 
 
No benefit has been demonstrated for supplementing with iron when iron sufficient (39), 
however, it is well known that coaches frequently advise supplementation without prior 
knowledge of iron status. In fact, there is potential for excess supplementation to impact 
iron absorption, causing a transient increase in hepcidin, countering iron absorption (51). 
In fact, recent research has highlighted alternate day oral iron supplementation is more 
effective than consecutive day supplementation (423). Further, unnecessary 
supplementation can have negative health implications, particularly in those who have 
genetic abnormalities that predispose them to iron overload (7). In Chapter 4, nearly 
half of the marathon runners (45.3%) and more than three quarters of the elite athletes 
(78.9%) were found to supplement with iron. While of those who indicated taking 
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supplementation, more than half (50.5%), reported no knowledge of their iron status. Since 
there is currently no evidence-based guidance for treating iron deficiency without anaemia 
in the exercising population, clarity is evidently required, and in accordance with this, 
awareness of best practices when supplementing is essential.  
 
7.2.1 Study aims 
1. The primary aim of this study was to assess the impact of iron repletion on exercise 
and aerobic capacity in iron deficient, but otherwise healthy exercising women 
when using existing criteria for the diagnosis of iron deficiency.  
2. The secondary aims were then to assess the impact of intravenous iron on 
haematological markers and subjective markers of fatigue and mood disturbance 
in iron deficient, but otherwise healthy exercising women when using existing 
criteria for the diagnosis of iron deficiency. 
 
7.2.2 Study hypotheses 
1. Iron repletion improves exercise and aerobic capacity in iron deficient, non-elite 
exercising women. 
2. Iron repletion improves haematological markers and subjective markers of fatigue 
and mood disturbance in iron deficient 
3. Response to iron repletion will be greater in those identified with more severe iron 
deficiency. 
 
7.3 Materials and methods 
7.3.1 Ethics and participant consent 
The IRONWOMAN trial is listed on the ISRCTN registry (ISRCTN14032359) and approved 
by both IRAS NHS Ethics Committee (15/LO/1570), and by the St Mary’s University Ethics 
Committee. At the time of screening, all participants were required to complete and sign a 
consent form.  
 
7.3.2 Inclusion criteria 
• Female; 
• Aged ≥ 18 years; 
• Have a baseline serum ferritin level (≤ 30 µg·L-1); 
• Undertake regular exercise (≥ 60 minutes/week); or 
• Have not made any significant changes to training in the previous 6 months. 
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7.3.3 Exclusion criteria 
• Pregnancy or lactation;  
• A known reason for anaemia; 
• A known history of iron overload or a family history of haemochromatosis, 
thalassemia or a transferrin saturation > 50%;  
• Recent involvement in a study investigating a medical product (previous four 
weeks); 
• Severe asthma or severe allergy requiring hospitalisation in the previous 12 
months;  
• Indication that they will be changing training over the time course of the study.  
 
7.3.4 Participants 
Recruitment of participants took the form of advertisement through various social media 
channels and word of mouth. Eighty-three regularly exercising women who indicated they 
either may be iron deficient or who had a history of iron deficiency had a full screening 
blood test in a fasted state and at rest (no exercise so far that day). A total of 32 women 
(as per the sample size calculation – Section 7.2.19.1) aged between 20 and 55 years met 
the inclusion criteria and were recruited to this study (Table 7.1). Since a lack of iron in 
bone marrow has been observed when serum ferritin is 30 µg·L-1, and using this cut-off 
value, sensitivity and specificity for iron deficiency diagnosis was found to be 92% and 96% 
respectively (42), this cut-off for serum ferritin for iron deficiency diagnosis was applied.  
 
7.3.5 Study design 
The IRONWOMAN trial was an interventional study conducted from March 2016 to October 
2016. After initial screening, iron deficient, exercising women were recruited to this study. 
At baseline, all participants had a %̇&'()* test, the protocol for which is outlined in section 
7.3.7.2, a total haemoglobin mass test, as outlined in section 7.3.8.2 and completed four 
questionnaires to profile fatigue and mood disturbance in addition to haematological 
analysis from a venous blood sample. They were then administered a single dose of 
intravenous iron (iron isomaltoside 1000, Pharmacosmos, UK). Each receiving 20 mg·kg-
1 of bodyweight. Two weeks (±5 days) later, all baseline tests were repeated. An overview 
of the study is described in Figure 7.1. Prior to inclusion, the full screening blood test was 
performed on each participant when fasted and at rest.  
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Figure 7.1 – Study design. 
 
7.3.6 Measurements 
7.3.7 Measurement of Exercise and aerobic capacity: Exercise test 
Maximal aerobic capacity (V̇O2max), which is a component of physical fitness, was 
assessed on a treadmill both at baseline and post-injection. The same warm up protocol 
and set treadmill speed were used in both the baseline and post-injection tests.  
 
Physiology of the measurement  
In a healthy human, at rest, the amount of oxygen consumed (%̇&') is equivalent to that 
required by cells, while the output of carbon dioxide (%̇+&') reflects that produced. This is 
described by the Fick equation, showing that oxygen consumption is the product of cellular 
oxygen delivery and oxygen extraction (424): 
 %̇&' = -̇ 	×	(+1&'	 − 	+3&')	 
 
Where -̇ - cardiac output, +1&'	- arterial oxygen content, +3&' - venous oxygen content. 
 
Therefore, where maximal cardiac output is achieved alongside maximal oxygen 
extraction, a total value for maximal oxygen consumption (%̇&'()*) can be obtained (424). 
This is a measure widely used in exercise physiology to indicate aerobic fitness. 
 %̇&'()* = -̇()* 	×	 (+1&'()*	 − 	+3&'()*) 
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7.3.7.1 Equipment and calibration 
All tests were performed on a Woodway treadmill in the sports performance laboratory at 
St Mary’s University, Twickenham (Figure 7.2). Gas analysis was performed using an 
Jaegar Oxycon Pro (CareFusion, Hoechberg, Germany – running JLab software), which is 
an online breath-by-breath analyser. This measures %̇&', %̇+&', respiratory rate, minute 
ventilation, tidal volume and end-tidal gas tensions. Before each test, participant 
demographics were inputted into the software. 
 
Prior to usage however, a number of calibration procedures took place:  
1. The pressure analyser was calibrated using the in-laboratory barometer (Oregon 
Scientific). 
2. The volume transducer was calibrated.  
3. The oxygen and carbon dioxide analyser was calibrated.  
 
Volume calibration 
The flow sensor was calibrated using a 3-litre syringe according to the manufacturers 
guidelines (Viasys Healthcare, GmbH, Hoechberg, Germany). Smooth strokes were 
required for calibration. Any values outside ± 0.1 litres resulted in calibration failure.  
 
Gas calibration 
After switching on the Oxycon Pro, and allowing time for it to warm up in accordance with 
the instructions from the manufacturer, a two-point gas calibration was conducted. The first 
mixture was ambient air (20.93% oxygen and 0.03% carbon dioxide), the second mixture 
was calibration/reference gas (16% oxygen and 5% carbon dioxide). If gaseous values 
were not within 0.05% (0.02% for carbon dioxide in ambient air) of these values, the 
calibration process failed and would have to be repeated.  
 
A facemask containing an ergospirometric device connecting it to the Oxycon Pro was 
fitted to participants to ensure all inspired and exhaled gas was collected. Potential for 
gaseous leaks was carefully assessed.  
 
7.3.7.2 Test procedure 
Participants performed a 10-minute warm-up at a self-selected speed which was monitored 
and recorded. After a 5-minute break, participants undertook a maximal exercise test. The 
treadmill was set at a continuous pre-determined speed. The gradient of the treadmill 
increased in an incremental manner by 0.5% every 30 seconds until volitional exhaustion 
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was reached. At this point a blood capillary sample was taken immediately from the earlobe 
for blood lactate analysis and measured using an automated analyser (Biosen C-Line, EFK 
Diagnostic, Barleben, Germany). Tests were stopped when participants either hit the ‘stop’ 
button on the treadmill or stepped off the treadmill. Participants were then required to 
undertake active recovery. The same warm up protocol and set treadmill speed were used 
in both the baseline and post-injection tests. Three different fixed treadmill test speeds 
were applied; fast (12 km·h-1), medium (10 km·h-1), and slow (8 km·h-1). These were 
determined based on 5 km best times in the last six months. The groups were as follows: 
 
Fast: those with times < 20 minutes: 15 seconds  
Medium: 20 minutes: 15 seconds – 25 minutes: 15 seconds 
Slow: > 25 minutes: 15 seconds.  
 
Measurement of %̇&'()* 
Rolling 30-second average readings were provided for all gaseous measurements. Those 
sitting four standard deviations from the midpoint of a seven-breath average were 
removed. The highest average %̇&' measure was deemed to be peak %̇&', and therefore 
the %̇&'()*. Similarly, peak %+̇&' and the respiratory exchange ratio were also recorded. 
 
 
 
 
Figure 7.2 - %̇&'()* test in the St Mary’s University performance lab. 
 
7.3.8 Measurement of Exercise and aerobic capacity: Total haemoglobin 
mass test 
The optimised carbon monoxide rebreathing test as described by Schmidt and Prommer 
(4), was used to measure total haemoglobin mass, blood volume and plasma volume at 
baseline and post-injection (Figure 7.3). A bolus of chemically pure carbon monoxide of 
0.9 mL·kg-1 body mass was administered to participants through a closed glass spirometer 
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(Bloodtec, Bayreuth, Germany) and rebreathed for two minutes with 4 L of oxygen. A blood 
gas analyser (ABL80 Flex Radiometer, Denmark) was used to measure 
carboxyhaemoglobin, haematocrit and haemoglobin, from capillary blood samples that 
were taken from the ear lobe in triplicate at baseline and six minutes and eight minutes 
after carbon monoxide administration. A carbon monoxide analyser (Pac700, Drager, 
Lubeck, Germany) was used to measure residual carbon monoxide volume both before 
and four minutes after rebreathing. The remaining carbon monoxide in the spirometer was 
added to the end-tidal carbon monoxide concentration to calculate the total volume that 
had not been taken up by the body. These values were then used to determine total 
haemoglobin mass.  
 
7.3.8.1 Test background 
The optimised carbon monoxide rebreathing test as described by Schmidt and Prommer 
(4), was used to measure total haemoglobin mass, blood volume and plasma volume at 
baseline and post-injection. Unlike a venous blood sample providing a measure of [Hb], 
this test factors in plasma volume to provide an overall value for total haemoglobin mass 
(Section 2.6). Further, since the majority of oxygen travels in the blood bound to 
erythrocytes, total haemoglobin mass can be used to provide a measure of oxygen 
carrying-capacity. Each gram of haemoglobin can bind to 1.39 mL of oxygen. Particularly 
amongst athletes where plasma volume shifts are likely (28,392), haemoglobin mass has 
been suggested to provide a more accurate indication of oxygen transportation ability, in 
fact, Otto et al. (2013) showed total haemoglobin mass to correlate more effectively with %̇&' peak than [Hb] (40), and Wachsmuth et al. (2015) showed a lower coefficient of 
variation in total haemoglobin mass when compared to [Hb] (415).  
 
7.3.8.2 Equipment and test procedure 
After a 15-minute period of seated rest to allow stabilisation of blood volume, residual 
carbon monoxide volume was measured using a carbon monoxide analyser (Pac700, 
Drager, Lubeck, Germany). Capillary blood samples were then taken from the earlobe in 
triplicate (80 µl – Hawksley & Sons), and were analysed immediately using blood gas 
analyser (ABL80 Flex Radiometer, Denmark) to measure for carboxyhaemoglobin, 
haematocrit and haemoglobin.  
 
While still in a seated position, participants rebreathed a bolus of chemically pure carbon 
monoxide of a known volume (0.9 mL·kg-1 body mass) through a closed glass spirometer 
(Bloodtec, Bayreuth, Germany) for two minutes with 100% pure medical grade oxygen. A 
mouthpiece containing approximately 10 g of soda lime (to absorb the carbon dioxide) was 
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fitted to one end of the spirometer. A three litre bag containing the oxygen was fitted to the 
other end of the spirometer. Carbon monoxide was administered through a syringe (Figure 
7.3).  
 
Test procedure 
After placing the nose clip on, participants took a full inhalation, followed by full exhalation 
to residual volume and were connected to the mouthpiece. Participants then inhaled 
deeply and held their breath for ten seconds as the carbon monoxide was administered in 
conjunction with opening the valve to release the oxygen. This was to enable diffusion of 
carbon monoxide into the bloodstream. Since haemoglobin has a much greater affinity for 
carbon monoxide than oxygen it is assumed that this will rapidly enter the bloodstream and 
bind to haemoglobin (425). After this, they then breathed normally within the closed system 
(426) for a further one minute and 50 seconds. The carbon monoxide analyser (Pac700, 
Drager, Lubeck, Germany) was used to check for any gas leaks from the mouth and nose.  
 
Prior to disconnecting from the system, participants exhaled to residual volume, and this 
gas was collected in the three litre bag, allowing determination of the carbon monoxide that 
was not absorbed. Four-minutes after rebreathing the carbon monoxide, the participants 
repeated the assessment for the measurement of residual carbon monoxide volume, using 
the carbon monoxide analyser (Pac700, Drager, Lubeck, Germany). Blood capillary 
samples from the earlobe were then taken in triplicate both at 6-minutes and 8-minutes 
after rebreathing the carbon monoxide and were again measured for carboxyhaemoglobin, 
haematocrit and haemoglobin immediately, using blood gas analyser (ABL80 Flex 
Radiometer, Denmark). 
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Figure 7.3 – Haemoglobin mass test equipment - glass spirometer (A), with bag (B) and 
mouthpiece attached (C), gas syringe (D), oxygen valve (E). Figure adapted from (4). 
 
7.3.8.3 Calculation of total haemoglobin mass 
 
Total haemoglobin mass was calculated using the following formula (as applied by Schmitt 
and Prommer, 2005) (4). This was inserted into an Excel Spreadsheet (Microsoft Excel for 
Apple Macintosh 2011) for automatic calculation.  
 5678199	(:) 	= ;	 × 	<+&	 × 	100	 ×	 (∆67+&%	 ×	1.39)-1 
 ; = current barometric pressure × 760-1 ×	[1 +	(0.003661	 × 	GHIIJK5	5J8LJI15HIJ)] 
 <+& = +&adm – (+&system+lung (after disconnection) + +&exhaled (after disconnection)) 
 
 
Where:  
 +&adm = the volume of CO administered into the system 
 +&system+lung (after disconnection = CO concentration in spirometer x (spirometer volume + lung 
residual volume) 
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+&exhaled (after disconnection) = end-tidal CO concentration x alveolar ventilation x time 
 ∆67+&% = difference between baseline %HbCO and %HbCO in the blood samples after 
rebreathing the carbon monoxide (the average between the samples collected 6-minutes 
and 8-minutes after rebreathing) 
 
1.39 = Hüfners number (ml CO x g·Hb-1) (427) 
 
7.3.8.4 Calculation of blood volume (BV) 
 N%	(8O) 	= PQR()SS	(T)[QR](U·WXYZ) × 	100 
 
7.3.8.5 Calculation of erythrocyte volume (EV) 
 [%	(8O) 	= N%	(8O) 	× 	6G5	(%) 
 
 
7.3.8.6 Calculation of plasma volume 
 \%	(8O) = 	N%(8O) − [%(8O) 
 
Example 
If a participant’s body mass is 54 kg, they will be given 48.6 mL carbon monoxide (given 
that 0.9 mL CO was given per kg of body weight). According to Hüfners number, 35 g of 
haemoglobin will be bound. Then if the change in baseline %HbCO and post rebreathing 
%HbCO is 5.2% (therefore 5.2% of the total Hb is bound to CO) of the total haemoglobin 
mass, their overall total haemoglobin mass will be 673 g (12.5 g·kg-1). 
 
7.3.9 Haematology and biochemistry 
Venepuncture was used to collect venous blood from an antecubital vein in the forearm at 
baseline and post-injection. A 4 mL EDTA vacutainer was filled and inverted ten times, and 
a 10 mL SST gel vacutainer was filled and inverted five times prior to being chilled and 
either taken or sent for lab analysis at the Royal Surrey Hospital, Guildford, Surrey. Full 
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blood count data were provided using an ADVIA 2020i, and serum ferritin was measured 
using the ADVIA Centaur XP immunoassay system. 
 
7.3.10 Fatigue 
To ensure internal validation three fatigue scales were completed by participants at 
baseline and post-injection, including (Appendix 10.15):  
 
Multidimensional Fatigue Inventory (MFI-20) 
The Multidimensional Fatigue Inventory (MFI-20) is a self-reporting tool that includes 20 
statements addressing five aspects of fatigue; general, physical, reduced motivation, 
reduced activity and mental fatigue (410). High scores indicate increased levels of fatigue. 
The MFI-20 has previously been used effectively in exercise and fatigue studies and 
content and construct validity has been shown in a general population and in exercise and 
iron repletion studies (414,428-430).  
 
Piper Fatigue Scale  
The Piper Fatigue Scale is a 22-part self-assessing fatigue scale designed to evaluate 
current fatigue levels (431). High scores indicate a higher degree of fatigue. This has 
previously been used effectively in iron repletion studies with iron deficient patients (226). 
 
European Quality of Life – 5 Dimensions – 5 Levels (EQ-5D-5L) 
The European Quality of Life – 5 Dimensions – 5 Levels (EQ-5D-5L) questionnaire is a 
brief, utility-based means for assessing health related quality of life (368,369). It consists 
of a health descriptive system and a visual analogue scale (EQ-VAS) for respondents to 
self-classify and rate their health on the day of administration of the instrument. It has been 
used widely in a range of different settings to assess quality of life.  
 
7.3.11 Mood disturbance 
Brunel Mood Scale (BRUMS) (Appendix 10.15) 
The Brunel Mood Scale (BRUMS) is a 24-part questionnaire which is an abbreviated 
version of the Profile of Mood States (POMS) questionnaire (370). It addresses six factors 
including confusion, tension, depression, anger, fatigue and vigour (371). Participants 
select a value from 0 to 4 depending on how they feel at the time of asking. This has 
previously been used effectively in the sporting context (58,432).  
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7.3.11.1 Training and menstrual cycle questionnaire 
Participants were asked a series of questions about their exercise participation, menstrual 
cycle and health. These were designed to obtain information about training volume and 
exercise participation level in addition to identifying current menstruation status, including 
the presence of heavy menstrual bleeding, diagnosed using a four-part criteria as used in 
Chapters 4 – 6 and in previous studies (28,392).  
 
7.3.11.2 Physical state and menstrual characteristics 
Participants were requested to complete a questionnaire (appendix 10.14) to establish 
training history and performance, in addition to and menstrual characteristics, in addition 
to enable identification of when in the menstrual cycle tests were conducted. Participants 
were also asked to maintain a similar training schedule and diet between baseline and 
post-injection tests. Therefore every effort was made to ensure the athletes did the post-
injection tests in a similar physiological state and at a comparable time of day to their 
baseline tests. Participants were asked to report any deviations in training or nutrition. Two 
participants suffered ankle injuries between the baseline and post-injection tests, and as a 
result were unable to partake in the post-injection exercise test. No participants reported 
any recent changes in training in the 6 months prior to study involvement.  
 
7.3.12 Iron administration 
All participants were given a single dose of intravenous iron (iron isomaltoside 1000, 
Pharmacosmos, UK). Each receiving 20 mg·kg-1 of bodyweight administered as a single 
infusion over a period of 30 - 90 minutes.  
 
7.3.13 Data analysis 
7.3.13.1 Sample size calculation 
Using external data, we estimated that the standard deviation of the change form baseline 
in V̇O2max will be 2.5 mL·kg-1·min-1. Based on this, we calculated that 32 participants will 
provide 90% power at the 5% significance level to detect a mean change from baseline in V̇O2max of 1.5 mL·kg-1·min-1. This calculation allows for a 5% loss to follow-up. 
7.3.13.2 Statistical analysis 
Statistical analysis was performed using a statistics computer package (IBM SPSS 
Statistics for Macintosh, Version 21.0, Armonk, NK: IBM Corp). Statistical significance was 
set at p<0.05. Graphpad Prism (GraphPad Prism version 7.00b for MacOS X, GraphPad 
Software, La Jolla, California, USA) was also used to visually display the data.  
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All data were tested for normality. Where data was normally distributed, paired t-tests were 
used to identify differences between baseline and post-injection data, and Wilcoxon 
signed-rank tests were used for paired non-normal data. The percentage change in all raw 
values from baseline to post-injection were calculated in an excel spreadsheet (Microsoft 
Excel for Macintosh, 2011).  
 
Participants were divided into groups based on the World Health Organisation’s serum 
ferritin cut-off value for iron deficiency of < 15 µg·L-1 (40). Those with a serum ferritin < 15 
µg·L-1 were included in the ‘severe’ iron deficiency group, and those with a serum ferritin 
> 15 µg·L-1 but ≤ 30 µg·L-1 were placed into the ‘moderate’ iron deficiency group. Paired t-
tests were then performed within each group to assess whether extent of iron deficiency 
affected response. 
 
To assess the relationship between each of baseline [Hb] and baseline serum ferritin and 
both the change in V̇O2max and change in total haemoglobin mass linear regressions were 
performed. To describe the relationship between the combination of baseline [Hb] and 
serum ferritin and change in V̇O2max or change in total haemoglobin mass a multiple linear 
regression model was used. This was then adjusted for potential confounders including 
age, BMI, 5 km personal best time, total exercise volume each week and total running 
volume each week. Linear regressions were used to assess the relationship between 
change in [Hb] and change in serum ferritin and change in markers of exercise and aerobic 
capacity. Pearson’s correlations were used to determine whether there was a relationship 
between baseline and post-injection V̇O2max and total haemoglobin mass, in addition to 
assessing any association between the change in V̇O2max and change in haemoglobin 
mass. While Pearson’s or Spearman’s correlations (depending on the type of data) were 
also used to determine whether there was a relationship between other baseline markers 
and change in the primary outcome variables.  
 
The potential confounding effect of day of the menstrual cycle when looking at the 
association between baseline [Hb] or serum ferritin and functional outcome variables was 
assessed using multiple linear regression.   
 
Wilcoxon signed rank tests were used to identify differences in fatigue (MFI-20 and Piper 
Fatigue Scale) and mood (BRUMS Mood Scale) between baseline and post-injection. To 
assess the validity and reliability and to ensure internal consistency of each of the five MFI-
20 subscales both at baseline and post-injection, three reliability tests were performed; 1. 
inter-item correlation, 2. corrected-to-total correlation, and 3. calculation of the 
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standardised Cronbach’s alpha coefficient. Inter-item correlations ranging from 0.30-0.70 
were kept, while a value for the corrected item-total correlation of > 0.20 was deemed 
adequate (415). A relatively high reliability coefficient - Cronbach’s ∝ ranging from 0.70-
0.95 was considered to be sufficient (416). Cronbach’s alpha if item was deleted were also 
calculated. Linear regressions were also run to assess the relationship between each of 
baseline [Hb] and baseline serum ferritin and change in the MFI subscales.  
 
The EQ-5D-5L data was analysed by determining the percentage of individuals who 
reported no problems, in comparison to those who reported problems. A Wilcoxon signed-
ranks test was then used to determine differences.  
7.4 Results 
7.4.1 Participant characteristics 
Thirty-two participants completed the trial. Participant characteristics are detailed in Table 
7.1.  
 
Table 7.1 – Baseline participant characteristics. 
Characteristic Mean (± SD) Range (min – max) 
Age (years) 35.0 ± 8.9 20 - 55 
Weight (kg) 61.9 ± 7.8 50.1 – 80.8 
Height (m) 1.65 ± 0.05 1.55 – 1.78 
BMI (kg·m-2) 22.7 ± 3.0 18.6 – 31.6 
sFer (µg·L-1) 15.7 ± 7.0 7 – 30 
[Hb] (g·dL-1) 12.4 ± 0.6 11.0 – 14.0 
Average weekly exercise 
volume (h:min:s) 
6:59.50 ± 3:34.16 1:00 – 15:30 
5 km personal best (min:s) 24:02 ± 4:04 18:36 – 36:55 
Heavy menstrual bleeding 64.5% (n=20) - 
Menstrual cycle affected 
training and performance 
54.8% (n=17) - 
BMI – body mass index, sFer – serum ferritin, [Hb] – haemoglobin concentration  
Values are mean ± SD.  
 
7.4.2 Exercise and aerobic capacity 
All markers of exercise and aerobic capacity increased significantly from baseline to post-
injection (Table 7.2; Figure 7.4; p<0.05). Relative and absolute V̇O2max increased by 3.30% 
(49.11 ± 6.41 mL·kg-1·min-1 to 50.73 ± 7.16 mL·kg-1·min-1; p=0.003) and 2.35% (2974 ± 
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357 mL·min-1 to 3044 ± 365 mL·min-1; p=0.03) respectively. Overall, the V̇O2max of 70% of 
the participants increased two weeks after the iron injection, with the mean increase being 
1.62 mL·kg-1·min-1.   
 
Total haemoglobin mass also increased by 3.17% (g·kg-1; Table 7.2; Figure 7.4; p=0.005) 
and 2.44% (g; Table 7.2; Figure 7.4; p=0.03) after the iron injection, and on average 
participants were able to keep running on the treadmill for 56 seconds longer after the 
injection (p<0.0005). 
 
 
Table 7.2 – A comparison between exercise and aerobic capacity, and haematology and 
biochemistry measures at baseline and post intravenous iron injection. 
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 Baseline Post 
Percentage 
change 
p-value  
Exercise and 
aerobic capacity 
     
V̇O2max (mL·kg-
1·min-1)# 
49.11 ± 
6.41 
50.73 ± 
7.16 
+3.30% 0.003**  
V̇O2max (mL·min-1)# 2974 ± 357 3044 ± 
365 
+2.35% 0.026*  
tHbmass (g·kg-1) 9.93 ± 1.10 
10.22 ± 
1.29 
+3.17% 0.007**  
tHbmass (g) 610 ± 65 618 ± 60 +2.44% 0.026*  
Blood Volume 
(g·kg-1) 
87.2 ± 8.47 
86.2 ± 
11.19 
-1.05% 0.53  
TTE (mins)# 
10.13 ± 
2.17 
10.93 ± 
2.29 
+7.90% <0.0005****  
Haematology and 
Biochemistry 
Baseline Post 
Percentage 
change 
p-value 
Clinical 
reference 
range 
sFer (µg·L-1) 15.7 ± 7.0 
367.4 ± 
144.3 
+2242% <0.0005**** 15 – 250 
[Hb] (g·dL-1) 12.4 ± 0.6 
13.1 ± 
0.6 
+5.52% <0.0005**** 
11.5 – 
16.5 
Hct (ratio) 0.37 ± 0.02 
0.40 ± 
0.02 
+6.40% <0.0005**** 
0.37 – 
0.47 
MCH (pg) 29.4 ± 1.8 
29.8 ± 
1.4 
+1.49% 0.011* 26 – 35 
MCV (fL) 88.5 ± 4.2 
90.8 ± 
3.9 
+2.56% <0.0005**** 75 – 105 
CH (pg) 
29.03 ± 
1.75 
29.75 ± 
1.63 
+2.84% <0.0005****  
CHCM (g·L-1) 
329.23 ± 
7.48 
330.37 ± 
10.58 
+0.35% 0.50  
HDW (g·L-1) 
24.96 ± 
1.98 
23.70 ± 
1.73 
-4.86% <0.0005****  
Hyperchromia (%) 0.46 ± 0.24 
0.51 ± 
0.41 
+22.52% 0.97  
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tHbmass – total haemoglobin mass, TTE – time to exhaustion, sFer – serum ferritin, [Hb] 
– haemoglobin concentration, MCH – mean cell haemoglobin, MCV – mean cell volume, 
Hypochromia (%) 2.35 ± 2.61 
1.70 ± 
1.94 
-0.65% 0.022*  
Large platelets 
(109·L-1) 
7.39 ± 2.70 
7.89 ± 
3.64 
+6.32% 0.29  
Lymphocytes 
(109·L-1) 
1.38 ± 0.36 
1.68 ± 
0.51 
+24.21% 0.0003*** 1.0 – 4.0 
Macro (%) 0.54 ± 0.63 
1.36 ± 
1.25 
+260.83% <0.0005****  
MCHC (g·L-1) 
33.20 ± 
0.83 
32.83 ± 
0.83 
-1.05% 0.073 290 – 350 
Micro (%) 1.34 ± 1.69 
0.93 ± 
0.94 
-15.02% 0.0042**  
Monocytes (109·L-
1) 
0.31 ± 0.11 
0.31 ± 
0.10 
+5.34% 0.99 0.2 – 0.8 
MPC (g·dL-1) 
23.73 ± 
1.85 
23.13 ± 
2.01 
-2.18% 0.16  
MPM (pg) 2.19 ± 0.20 
2.16 ± 
0.18 
-1.38% 0.12  
MPV (fL) 9.75 ± 0.78 
9.89 ± 
1.11 
+1.46% 0.36  
Neutrophils (109·L-
1) 
2.97 ± 1.59 
3.12 ± 
1.16 
+41.48% 0.46 2.0 – 7.5 
PCT (%) 0.24 ± 0.06 
0.24 ± 
0.05 
+5.00% 0.41  
PDW (%) 
57.13 ± 
24.56 
52.56 ± 
6.41 
-2.51% 0.71  
Platelets (109·L-1) 
242.94 ± 
61.19 
248.94 ± 
56.03 
+4.49% 0.33 150 – 450 
RBC (1012·L-1) 4.23 ± 0.25 
4.40 ± 
0.27 
+4.06% 0.0029** 3.5 – 5.5 
RDW (%) 
13.72 ± 
1.60 
14.37 ± 
1.73 
+4.92% 0.0016** 
11.0 – 
15.0 
WBC (109·L-1) 5.07 ± 1.83 
5.37 ± 
1.43 
+12.67% 0.21  
  
180 
 
CH – corpuscular haemoglobin content, CHCM – corpuscular haemoglobin concentration 
mean, HDW – haemoglobin distribution width, MCHC – mean cell haemoglobin 
concentration, MPC – mean platelet component, MPM - , MPV – mean platelet volume, 
PCT – platelet haematocrit, PDW – platelet distribution width, RBC – red blood cells, RDW 
– red cell distribution width, WBC – white blood cells  
 
Values are mean ± SD. 
Significant differences between baseline and post injection tests are shown as follows: *p 
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0005. 
# Note that due to sustained injuries n=30 for these data. 
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Figure 7.4 – Effect of intravenous iron on primary and secondary endpoints. Individual 
changes in V̇O2max, time to exhaustion (TTE), total haemoglobin mass (tHbmass), 
haemoglobin concentration ([Hb]), corpuscular haemoglobin content (CH) and ferritin 
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(sFer) from baseline to 2 weeks post intravenous iron. Data are presented as a percent 
change from baseline with individual changes shown in grey, and mean change in black. 
Significant differences between baseline and post injection tests are shown as follows: *p 
< 0.05, **p < 0.01. 
 
7.4.3 Haematology and biochemistry 
Full results are shown in Table 7.2. Both serum ferritin and [Hb] increased significantly 
from baseline to follow up (Table 7.2; Figure 7.4; p<0.0005). Other red cell measures 
including haematocrit (p<0.0005), corpuscular haemoglobin content (p<0.0001), mean cell 
haemoglobin (p=0.01), mean cell volume (p<0.0005) and red cell distribution width 
(p=0.002) also increased (Table 7.2).  
 
7.4.4 The effect of baseline serum ferritin 
Participants were grouped into ‘severe’ and ‘moderate’ iron deficiency using the World 
Health Organisation (WHO) cut-off value of a serum ferritin < 15µg·L-1 (40,41). Those with 
a serum ferritin < 15µg·L-1 were defined as having ‘severe’ iron deficiency, and those with 
a serum ferritin > 15 µg·L-1 but ≤ 30 µg·L-1 were defined as having ‘moderate’ iron 
deficiency. V̇O2max and relative total haemoglobin mass only increased in those in the 
severely iron deficient group (Table 7.3; Figure 7.5; p<0.05). 
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Table 7.3 – Changes in exercise and aerobic capacity when comparing those with severe 
(sFer < 15 µg·L-1) and moderate (sFer > 15 µg·L-1 but ≤ 30 µg·L-1) iron deficiency.  
 sFer < 15µg·L-1 (n=18) p-value 
sFer > 15 µg·L-1 but ≤ 30 
µg·L-1 (n=14) 
p-value 
 Baseline Post  Baseline Post  V̇O2max 
(mL·kg-
1·min-1)# 
50.1 ± 
5.11 
52.5 ± 5.53 0.0009*** 47.82 ± 7.84 
48.43 ± 
8.56 
0.48 
V̇O2max 
(mL·min-1)# 
2922.4 ± 
295.53 
3044.5 ± 
310.08 
0.0029** 3042.85 ± 426.88 
3043.46 
± 440.46 
0.99 
TTE 
(min:sec)# 
10.2 ± 
2.29 
10.83 ± 
2:36 
0.058 10.03 ± 2.09 
11.05 ± 
2.29 
0.0052** 
tHbmass 
(g·kg-1) 
10.1 ± 
0.80 
10.4 ± 0.89 0.039* 9.61 ± 1.39 
9.96 ± 
1.69 
0.066 
tHbmass (g) 
596.30 ± 
57.33 
609.8 ± 
50.77 
0.15 612.36 ± 65.01 
629.46 ± 
70.27 
0.14 
[Hb] (g·dL-1) 12.3 ± 0.7 13.1 ± 0.7 0.0014** 12.5 ± 0.6 
13.0 ± 
0.5 
0.0083** 
 
tHbmass – total haemoglobin mass, TTE – time to exhaustion, sFer – serum ferritin, [Hb] 
– haemoglobin concentration  
Values are mean ± SD. 
Significant differences between baseline and post injection tests within each group are 
shown as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0005. 
# Note that due to sustained injuries n=17 for sFer < 15µg·L-1 and n=13 for sFer > 15 µg·L-
1 but ≤ 30 µg·L-1. 
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Figure 7.5 – Percentage change in V̇O2max from baseline in response to intravenous iron 
when participants were grouped by baseline serum ferritin. Severe iron deficiency – sFer 
< 15 µg·L-1 and moderate iron deficiency - sFer > 15 µg·L-1 but ≤ 30 µg·L-1. 
 
7.4.5 Relationship between baseline iron status and change in end points. 
No relationship was found between either baseline [Hb] or serum ferritin and change in V̇O2max independently (Table 7.4; [Hb] vs change in V̇O2max (mL·kg-1·min-1) – p=0.66 and 
(mL·min-1) p=0.71; serum ferritin vs change in V̇O2max (mL·kg-1·min-1) – p=0.20 and 
(mL·min-1) – p=0.21), or total haemoglobin mass (Table 7.7; [Hb] vs change in total 
haemoglobin mass – (g·kg-1) p=0.42 and (g) p=0.37, serum ferritin vs change in total 
haemoglobin mass – (g·kg-1) p=0.89 and (g) p=0.96).  
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Table 7.4 – The relationship between baseline haemoglobin ([Hb]) and serum ferritin (sFer) 
and the changes in V̇O2max and total haemoglobin mass. 
 [Hb] sFer 
 B CI p-value B CI p-value 
Delta ]̇O2max 
(mL·kg-1·min-1) 
0.36 
-1.27 – 
1.99 
0.66 -0.091 
-0.235 – 
0.052 
0.20 
Delta ]̇O2max 
(mL·min-1) 
-17.78 
-115.59 
– 80.03 
0.71 -5.423 
-13.999 
– 3.154 
0.21 
Delta tHbmass 
(g·kg-1) 
0.133 
-0.199 – 
0.465 
0.42 -0.02 
-0.032 – 
0.028 
0.89 
Delta tHbmass 
(g) 
9.22 
-11.464 
– 29.909 
0.37 -0.047 
-1.898 – 
1.803 
0.96 
 
tHbmass – total haemoglobin mass, [Hb] – haemoglobin concentration, sFer – serum 
ferritin, B – co-efficient 
 
In unadjusted models assessing the relationship between the combination of baseline [Hb] 
and serum ferritin and change in V̇O2max or total haemoglobin mass, no association was 
found (Tables 7.5 – 7.8; all p>0.05). The inclusion of potential confounders did not affect 
any of these relationships (Tables 7.8 – 7.11; all p>0.05).  
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Table 7.5 - The unadjusted and adjusted relationship between the combination of 
haemoglobin ([Hb]) and serum ferritin and change in total haemoglobin mass (g).  
 Unadjusted model Adjusted model 
Variable B CI p-value B CI p-value 
Constant -99.73 
-361.42 
– 161.96 
0.44 175.88 
-143.58 
– 495.33 
0.27 
Baseline [Hb] 9.44 
-11.82 – 
30.71 
0.37 -7.15 
-29.48 – 
15.18 
0.51 
Baseline sFer -0.15 
-2.03 – 
1.72 
0.87 0.80 
-1.16 – 
2.77 
0.41 
Age    0.58 
-0.84 – 
2.01 
0.41 
BMI    -4.82 
-10.23 – 
0.59 
0.08 
5 km PB    -0.02 
-0.10– 
0.06 
0.65 
Total 
exercise/week 
   0.05 
-0.02 – 
0.12 
0.16 
Total 
running/week 
   0.03 
-0.10 – 
0.16 
0.65 
 
[Hb] – haemoglobin concentration, sFer – serum ferritin, BMI – body mass index, 5 km PB 
– 5 km personal best, B – co-efficient, CI – confidence interval 
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Table 7.6 - The unadjusted and adjusted relationship between haemoglobin ([Hb]) and 
serum ferritin and change in total haemoglobin mass (g·kg-1).  
 Unadjusted model Adjusted model 
Variable B CI p-value B CI p-value 
Constant -1.34 
-5.53 – 
2.86 
0.52 3.118 
-2.12 – 
8.36 
0.23 
Baseline [Hb] 0.14 
-0.20 – 
0.48 
0.41 -0.125 
-0.49 – 
0.24 
0.49 
Baseline sFer -0.004 
-0.03 – 
0.03 
0.81 0.011 
-0.02 – 
0.04 
0.49 
Age    0.008 
-0.02 – 
0.03 
0.46 
BMI    -0.084 
-0.17 – 
0.01 
0.06 
5 km PB    -0.000 
-0.001 – 
0.001 
0.76 
Total exercise/week    0.001 
0.000 – 
0.002 
0.17 
Total running/week    0.000 
-0.002 – 
0.003 
0.68 
[Hb] – haemoglobin concentration, sFer – serum ferritin, BMI – body mass index, 5 km PB 
– 5 km personal best, B – co-efficient, CI – confidence interval 
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Table 7.7 - The unadjusted and adjusted relationship between haemoglobin ([Hb]) and 
serum ferritin and change in ]̇O2max (mL·min-1) 
 Unadjusted model Adjusted model 
Variable B CI p-value B CI 
p-
value 
Constant 320.50 
-889.41 
– 
1530.42 
0.59 564.36 
-
1129.04– 
2257.77 
0.50 
Baseline [Hb] -13.40 
-110.67 
– 83.88 
0.78 -14.72 
-129.82 
– 100.38 
0.79 
Baseline sFer -5.33 
-14.09 – 
3.43 
0.22 -7.53 
-18.07 – 
3.01 
0.15 
Age    -5.69 
-13.35 – 
1.98 
0.14 
BMI    -6.96 
-41.66 – 
27.74 
0.68 
5 km PB    0.10 
-0.32 – 
0.51 
0.63 
Total 
exercise/week 
   0.26 
-0.10 – 
0.61 
0.15 
Total 
running/week 
   -0.43 
-1.13 – 
0.27 
0.21 
[Hb] – haemoglobin concentration, sFer – serum ferritin, BMI – body mass index, 5 km PB 
– 5 km personal best, B – co-efficient, CI – confidence interval 
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Table 7.8 - The unadjusted and adjusted relationship between haemoglobin ([Hb]) and 
serum ferritin and change in ]̇O2max (mL·kg-1·min-1). 
 Unadjusted model Adjusted model 
Variable B CI p-value B CI 
p-
value 
Constant -2.32 
-22.43 – 
17.79 
0.82 2.56 
-24.75 – 
29.87 
0.85 
Baseline [Hb] 0.44 
-1.18 – 
2.05 
0.58 0.50 
-1.36 – 
2.36 
0.56 
Baseline sFer -0.09 
-0.24 – 
0.05 
0.20 -0.13 
-0.30 – 
0.04 
-1.57 
Age    -0.10 
-0.22 – 
0.03 
-1.65 
BMI    0.20 
-0.36 – 
0.76 
0.75 
5 km PB    -0.003 
-0.01 – 
0.004 
-0.91 
Total 
exercise/week 
   0.000 
-0.01 – 
0.01 
-0.10 
Total 
running/week 
   -0.01 
-0.02 – 
0.002 
-1.67 
[Hb] – haemoglobin concentration, sFer – serum ferritin, BMI – body mass index, 5 km PB 
– 5 km personal best, B – co-efficient, CI – confidence interval 
 
No relationship was found between change in [Hb] or change in serum ferritin and the 
changes in V̇O2max and total haemoglobin mass. (Table 7.9; Figure 7.9f; all p>0.05).  
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Table 7.9 – The relationship between both change in haemoglobin ([Hb]) and change in 
serum ferritin (sFer) and the changes in V̇O2max and total haemoglobin mass. 
 Delta [Hb] Delta sFer 
 B CI p-value B CI p-value 
Delta ]̇O2max 
(mL·kg-1·min-1) 
0.41 
-1.15 – 
1.96 
0.60 -0.004 
-0.01 – 
0.003 
0.28 
Delta ]̇O2max 
(mL·min-1) 
14.70 
-78.49 – 
107.89 
0.75 -0.16 
-0.58 – 
0.27 
0.46 
Delta tHbmass 
(g·kg-1) 
-0.09 
-0.35 – 
0.18 
0.51 0.00 
-0.002 – 
0.001 
0.73 
Delta tHbmass 
(g) 
-7.90 
-24.28 – 
8.49 
0.33 -0.02 
-0.11 – 
0.07 
0.68 
tHbmass – total haemoglobin mass, B – co-efficient, CI – confidence interval, [Hb] – 
haemoglobin concentration, sFer – serum ferritin 
 
7.4.6 Relationship between ]̇O2max and total haemoglobin mass 
There was a significant relationship between V̇O2max and total haemoglobin mass both at 
baseline (p<0.0005; Figure 7.6) and post injection (p<0.0005; Figure 7.6). However, there 
was no relationship between the magnitude of the change in V̇O2max and the magnitude of 
the change in total haemoglobin mass (r=-0.05; p=0.81; Figure 7.7). 
 
 
Figure 7.6 – The relationship between total haemoglobin mass and V̇O2max at a. baseline 
and b. post injection. 
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Figure 7.7 – The relationship between change in total haemoglobin mass and change in 
total V̇O2max in response to the intravenous iron injection. 
 
7.4.7 Other markers that are potentially related to change in endpoints.  
There was a significant relationship between each of baseline V̇O2max (p=0.003; Figure 7.8 
c), reported 5 km personal best time (p=0.02; Figure 7.8 a), the total amount of exercise 
reported over a typical week (p=0.009; Figure 7.8 b), haematocrit (p=0.02; Figure 7.8e), 
and corpuscular haemoglobin concentration mean (p=0.01; Figure 7.8 d), and the change 
in haemoglobin mass after the iron treatment. Therefore, those who had a higher baseline V̇O2max, or who reported a faster 5 km personal best time were more likely to show a greater 
increase in total haemoglobin mass, and those who did more exercise each week were 
more likely to have a greater increase in total haemoglobin mass (Figure 7.8). A lower 
baseline CHCM, and a higher baseline haematocrit were associated with a larger change 
in haemoglobin mass (Figure 7.8 d and e). Change in haemoglobin mass was also related 
to both mean platelet component (p=0.019; Figure 7.9 a) and platelet distribution width 
(p=0.032; Figure 7.9 b). 
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Figure 7.8 - Relationship between change in total haemoglobin mass and a. 5 km personal 
best time, b. weekly exercise volume, c. baseline V̇O2max, d. CHCM, and haematocrit in 
response to intravenous iron, f. Relationship between change in haemoglobin 
concentration ([Hb]) and change in V̇O2max in response to intravenous iron. tHbmass – total 
haemoglobin mass, PB – personal best, CHCM - corpuscular haemoglobin concentration 
mean, [Hb] – haemoglobin concentration.  
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Figure 7.9 – Relationship between change in total haemoglobin mass (tHbmass) and 
baseline platelet biomarkers. a. association between change in haemoglobin mass and 
baseline mean platelet component, b. association between change in haemoglobin mass 
and platelet distribution width. 
 
7.4.8 Training and menstrual cycle questionnaire 
Controlling for day of the menstrual cycle had no impact on the association between 
baseline [Hb] or serum ferritin and any of the primary outcome measures (Table 7.10; all 
p>0.05). Nearly two thirds of the participants met the criteria for having a history of heavy 
menstrual bleeding (64.5%; Table 7.1). 
 
Table 7.10 – The impact of day of the menstrual cycle on the relationship between baseline 
haemoglobin ([Hb]) and serum ferritin (sFer) and changes in V̇O2max and total haemoglobin 
mass. 
 Baseline Post-injection 
 [Hb] sFer [Hb] sFer 
 B 
p-
value 
B 
p-
value 
B 
p-
value 
B 
p-
value 
Delta ]̇O2max 
(mL·kg-1·min-1) 
-0.89 0.40 -0.08 0.31 -0.69 0.50 -0.082 0.29 
Delta ]̇O2max 
(mL·min-1) 
-19.69 0.77 -4.64 0.36 -8.90 0.89 -4.26 0.38 
Delta tHbmass 
(g·kg-1) 
-0.077 0.70 -0.006 0.66 -0.04 0.86 -0.004 0.77 
Delta tHbmass 
(g) 
-2.26 0.86 -0.36 0.71 -0.13 0.99 -0.17 0.86 
 
tHbmass – total haemoglobin mass, [Hb] – haemoglobin concentration, sFer – serum 
ferritin, B – co-efficient 
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7.4.9 Fatigue 
7.4.9.1 Multidimensional Fatigue Inventory 
A decrease in fatigue was seen after iron treatment when assessed using the multi-
dimensional fatigue inventory (MFI), with a reduction observed across all subscales (all 
p<0.01; Figure 7.10). 
 
 
 
 
Figure 7.10 – Effects of intravenous iron on fatigue (MFI). A comparison between subscale 
Multidimensional Fatigue Inventory scores (MFI);  
Values are median ± IQR at baseline and post-injection.  
Significant differences between baseline and post injection tests are shown as follows: *p 
< 0.01, **p < 0.001. 
 
A summary of the reliability tests for the MFI-20 both at baseline and post-injection is given 
in Tables 7.11 and 7.12. It was not necessary to remove any items in Table 7.11 based on 
the inter-item and corrected inter-item correlations as they were all greater than 0.30. While 
Cronbach’s ∝ showed acceptable reliability and good internal consistency, ∝ = 0.81, and 
when standardised ∝ = 0.91. However as shown in Table 7.12, there were three 
correlations < 0.30 between general fatigue and each of reduced activity, reduced 
motivation and mental fatigue. Despite this, Cronbach’s ∝ showed acceptable reliability 
and good internal consistency, ∝ = 0.79, and when standardised ∝ = 0.88. 
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Table 7.11 – Mean and standard deviations for each aspect of fatigue, alongside inter-item 
correlations, Cronbach’s ∝	if the item is deleted and the corrected item-total correlation for 
tests at baseline. 
 
Mean (± 
SD) 
TF GF PF RA RM MF 
Cronbach's ∝	if item is 
deleted 
Corrected 
Item-Total 
Correlation 
Total 
Fatigue 
52.72 ± 
13.88 
- 0.69 0.85 0.81 0.87 0.77 0.86 1.00 
General 
Fatigue 
11.13 ± 
2.54 
0.69 - 0.78 0.35 0.41 0.36 0.80 0.64 
Physical 
fatigue 
9.86 ± 
3.67 
0.85 0.78 - 0.59 0.63 0.46 0.76 0.81 
Reduced 
activity 
9.25 ± 
3.45 
0.81 0.35 0.59 - 0.76 0.51 0.77 0.76 
Reduced 
motivation 
9.72 ± 
3.66 
0.87 0.41 0.63 0.76 - 0.64 0.76 0.84 
Mental 
fatigue 
12.77 ± 
3.92 
0.77 0.36 0.46 0.51 0.64 - 0.77 0.70 
TF – total fatigue, GF – general fatigue, PF – physical fatigue, RA – reduced activity, RM 
– reduced motivation, MF – mental fatgue 
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Table 7.12 – Mean and standard deviations for each aspect of fatigue, alongside inter-item 
correlations, Cronbach’s alpha if the item is deleted and the corrected item-total correlation 
for the post-injection tests. 
 
Mean ± 
SD 
TF GF PF RA RM MF 
Cronbach's ∝	if item is 
deleted 
Corrected 
Item-Total 
Correlation 
Total 
Fatigue 
41.91 ± 
11.46 
- 0.40 0.84 0.84 0.90 0.71 0.81 1.00 
General 
Fatigue 
9.75 ± 
1.87 
0.40 - 0.54 0.10 0.28 0.01 0.81 0.33 
Physical 
fatigue 
7.44 ± 
2.61 
0.84 0.54 - 0.55 0.67 0.50 0.76 0.80 
Reduced 
activity 
7.34 ± 
3.53 
0.84 0.10 0.55 - 0.83 0.47 0.74 0.79 
Reduced 
motivation 
7.47 ± 
3.46 
0.90 0.28 0.67 0.83 - 0.49 0.72 0.87 
Mental 
fatigue 
9.91 ± 
3.44 
0.71 0.01 0.50 0.47 0.49 - 0.76 0.62 
TF – total fatigue, GF – general fatigue, PF – physical fatigue, RA – reduced activity, RM 
– reduced motivation, MF – mental fatgue 
 
 
In an unadjusted model, neither baseline [Hb] nor baseline serum ferritin were associated 
with change in any of total, general, physical or mental fatigue or reduced activity (Table 
7.13; all p>0.05). Baseline [Hb] was also not related to reduced motivation (Table 7.13; 
p=0.99), however this was related to baseline serum ferritin (Table 7.13; p=0.02).
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Table 7.13 – The unadjusted relationship between MFI subscales at baseline and baseline haemoglobin concentration and level of serum ferritin. 
B – coefficient, CI – confidence interval, [Hb] – haemoglobin concentration 
Significant relationships are shown as follows: *p < 0.05.  
 
Total fatigue General fatigue Physical fatigue Reduce activity 
Reduced 
motivation 
Mental fatigue 
 
B CI 
p-
value 
B CI 
p-
value 
B CI 
p-
value 
B CI 
p-
value 
B CI 
p-
value 
B CI 
p-
value 
Baseline 
[Hb] 
1.32 
-6.01 
– 8.64 
0.72 -0.28 
-1.48 
– 0.92 
0.64 0.64 
-1.23 
– 2.51 
0.49 -0.32 
-2.37 
– 1.72 
0.75 0.01 
-2.13 
– 2.15 
0.99 1.27 
-0.58 
– 3.11 
0.17 
Serum 
ferritin 
0.60 
-0.04 
– 1.24 
0.07 0.08 
-0.02 - 
0.19 
0.12 0.08 
-0.09 
– 0.25 
0.34 0.12 
-0.07 
– 0.30 
0.21 0.22 
0.04 – 
0.40 
0.02* 0.10 
-0.07 
– 0.27 
0.25 
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7.4.9.2 Piper Fatigue Scale 
When assessed using the Piper Fatigue scale, all dimensions of fatigue decreased (all 
p<0.01; Figure 7.11). All reported values reduced by more than one-point. Previous studies 
suggest a minimum of a one-point reduction for clinical significance (431). 
 
 
 
 
 
Figure 7.11 – Effects of intravenous iron on fatigue (Piper fatigue score). A comparison 
between subscale Piper fatigue scores (PFS; median ± IQR) at baseline and post-injection.  
Significant differences between baseline and post injection tests are shown as follows: *p 
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0005. 
7.4.9.3 EQ-5D-5L 
When assessed using the EQ-5D-5L scale, impacts on usual activity (p=0.008), 
pain/discomfort (p=0.05) and anxiety/depression (p=0.03) all reduced (Table 7.14), while 
using the EQ-VAS, health overview increased from a median of 78.5 (70 – 85) to 85.0 (75 
– 90) (z = 60.0; p=0.001). No problems in ‘Self-care’ were reported at baseline or post 
injection.  
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Table 7.14 – Effects of intravenous iron on feelings of health on the day of testing using 
the EQ-5D-5L questionnaire. The percentage of participants who reported no problem 
compared to those who reported any problem (from slight to extreme).  
EQ-5D Dimension Baseline Post p-value 
Mobility No problems 
96.88% 100.00% 
>0.9999 
Problems 
3.13% 0.00% 
Self-care No problems 
100.00% 100.00% 
- 
Problems 
0.00% 0.00% 
Usual activity No problems 
75.00% 96.88% 
0.0078** 
Problems 
25.00% 3.13% 
Pain/discomfort No problems 
50.00% 50.00% 
0.046* 
Problems 
50.00% 50.00% 
Anxiety/depression No problems 
46.88% 59.38% 
0.027* 
Problems 
53.13% 40.63% 
Significant differences between baseline and post injection tests are shown as follows:  
***p < 0.005, **p < 0.01, *p < 0.05  
 
7.4.10 Mood disturbance 
7.4.10.1 BRUMS 
Iron supplementation had a significant impact on mood disturbance when using the 
BRUMS mood score. Perceived vigour increased (p<0.0005), while tension (p<0.0005), 
depression (p=0.002), fatigue (p=0.001), and confusion (p=0.002) all decreased in 
response to intravenous iron (Figure 7.12).  
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Figure 7.12 - Effect of intravenous iron on mood disturbance using the BRUMS mood 
scale. A comparison between mood disturbance at baseline and post-injection.  
Significant differences between baseline and post injection tests are shown as follows:  
****p < 0.0001, ***p < 0.005, **p < 0.01, *p < 0.05.  
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7.5 Discussion 
Previous research evaluating the effect of iron repletion on markers of exercise 
performance in iron deficient but not anaemic athletes has been inconclusive, resulting in 
a lack of clarity regarding both the impact and diagnosis of this condition. Studies are 
confounded by several inconsistencies which are likely to have exacerbated the variability 
in outcomes. The key finding in the IRONWOMAN trial was that a single high dose of 
intravenous iron was associated with an increased exercise and aerobic capacity in healthy 
iron-deficient, non-elite, regularly exercising women when measured two weeks after iron 
administration. Haematological markers of iron status improved, while fatigue and mood 
disturbance decreased. Since iron deficiency can be indicated by a positive response to 
iron therapy (47), it would seem prudent to suggest that the iron deficiency criteria (serum 
ferritin ≤ 30 µg·L-1) used in this study is appropriate for diagnosis. However, there was a 
distinct degree of individual variation in response, and when participants were divided into 
groups according to their baseline serum ferritin measurement, improvements in exercise 
and aerobic capacity were only seen in those with ‘severe’ iron deficiency (serum ferritin < 
15µg·L-1). Yet, the magnitude of the change in exercise and aerobic capacity was not 
directly associated with baseline serum ferritin or baseline [Hb], questioning the suitability 
of these markers, which are typically the clinical markers used for the diagnosis of iron 
deficiency and IDA. To my knowledge this is the first study to measure all of these outcome 
variables at any one time in otherwise healthy, non-elite exercising women in response to 
an intravenous iron injection, and to evaluate the suitability of [Hb] and serum ferritin for 
diagnosis when assessing this using evaluation of key outcome variables.  
 
As discussed throughout this thesis, and evaluated in Section 2.13.3, studies in sports 
science and sports medicine have typically defined iron deficiency using serum ferritin 
values ranging from 12 - 40 µg·L-1, and have used different protocols incorporating different 
supplementation routes (oral, intravenous or intramuscular) and dosing strategies, with 
equivocal results. These studies frequently have small sample sizes, and haven’t 
conducted sample size calculations, and often differ through the involvement of athletes of 
varying degrees of training status (48-54). Injection studies where the controlled absorption 
process in enterocytes is bypassed are sparse, and have focused on elite athletes (51,52). 
The participants in this study were specifically non-elite, therefore representing a large 
proportion of the exercising population. Despite this, the overall magnitude of the 
improvements in V̇O2max and total haemoglobin mass found here were similar to those seen 
in the intravenous iron group in the well trained runners in the study by Garvican et al. 
(2014) (52).  
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It has previously been suggested that the evident discrepancies in research may be due 
to some participants being slightly anaemic at baseline, therefore improvements in aerobic 
performance could be attributed to increases in [Hb] (52). Given the impact of IDA on 
aerobic performance, this seems plausible, and a number of studies support this 
hypothesis, showing increases in [Hb] alongside improvements in aerobic performance 
(236,243,433). The wide [Hb] reference range, typically 12.0 g·dL-1 – 16.0 g·dL-1 in women, 
means that there is also potential for significant decreases in [Hb] to occur before IDA is 
diagnosed as previously highlighted in Section 2.5, so a relative state of anaemia may be 
present, yet unknown and not diagnosed. However, the recent study by Garvican et al. 
(2014) found improvements in exercise measures without concomitant increases in [Hb] in 
response to intravenous iron in iron deficient endurance runners (52). In the present study, 
a mean increase in [Hb] was observed, however [Hb] did not increase in all participants. 
Further, increases in V̇O2max and/or total haemoglobin mass were not always accompanied 
by increases in [Hb]. Where there was a change in both [Hb], and V̇O2max or total 
haemoglobin mass, there was no association between the magnitude of these changes. In 
light of these results, this suggests that non-haematological effects of iron deficiency could 
be hypothesised.  
 
According to the Fick equation, maximal oxygen consumption (V̇O2max) depends on cardiac 
output and oxygen extraction (section 7.3.7.1) (1). Since the transport of oxygen is 
dependent on [Hb], increases in [Hb] will clearly be a cause for increases in V̇O2max. 
However, there are a number of possible causes for increases in V̇O2max without 
concomitant increases in [Hb], as seen here. Firstly, there could have been an increase in 
cardiac output, through a proportional increase in total haemoglobin mass and blood 
volume, or alternatively, oxygen extraction and utilisation may have improved through iron-
dependent mechanisms (1). In instances where haemoglobin mass increased without an 
associated increase in [Hb], it is likely that blood volume increased proportionally with total 
erythrocyte mass.  
 
As previously highlighted and shown in earlier studies, the suitability of [Hb] as a tool for 
the identification of red cell volume, and therefore the diagnosis of IDA is questionable 
(section 2.5). The use of total haemoglobin mass provides a more accurate means for 
identifying when oxygen transport capacity is limited, particularly amongst those who 
exercise, as this group are particularly susceptible to plasma volume shifts and changes 
in blood volume (108). Previous research has found total haemoglobin mass to correlate 
more effectively with V̇O2max peak, with a lower coefficient of variation when compared to 
[Hb] (section 2.6) (241,434). Accordingly, total haemoglobin mass has been suggested to 
aid the accuracy of IDA diagnosis. A close correlation was also found in this study (Figure 
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7.6) in support of this, therefore providing further evidence for the use of haemoglobin 
mass, particularly amongst the exercising population. Future clinical practice could 
consider longitudinal monitoring of haemoglobin mass, where significant decrements may 
indicate a state of IDA.  
 
Significantly, while there was a strong correlation between total haemoglobin mass and V̇O2max both at baseline and post-injection, there was no relationship between the 
magnitude of the change in these markers in response to iron repletion. Again, this 
suggests that in some participants, the improvement in exercise capacity (V̇O2max) could 
have been caused by non-haematological factors, such as an improvement in iron 
dependent oxygen extraction and utilisation mechanisms, for example increased function 
of the iron-containing haem enzymes and iron-sulphur clusters. Therefore suggesting, in 
this non-elite, iron deficient population, that factors other than those associated with 
erythropoiesis may be limiting V̇O2max. While previously discussed in the literature, this has 
not been demonstrated before. To my knowledge, to date, one other study has evaluated 
the association between changes in V̇O2max and total haemoglobin mass in response to 
iron therapy. Wachsmuth et al. (2015) assessed response to oral iron therapy over a 12-
week supplementation period, and, unlike in this study, a direct relationship was found 
between the magnitude of changes in V̇O2max and total haemoglobin mass (241). The 
reason for this discrepancy is unsure, however it is significant to note that in the present 
study. intravenous iron therapy was used as opposed to oral therapy, bypassing the 
controlled uptake mechanism in enterocytes. It is also possible that there was insufficient 
time for the full response to iron treatment to manifest here. The restoration of non-
haematological impacts of iron deficiency could occur prior to those related to 
erythropoietic demands. Future studies should address this, considering other time points. 
However, in the study by Garvican et al. (2014), in those receiving four iron injections, the 
final tests were performed two weeks after the final injection (52), however Burden et al. 
(2015) had follow up tests after four weeks (51).   
 
Evidently, the results in the present study beg the question of the impact of iron deficiency 
without anaemia. In addition to being a key component of haemoglobin, and being vital for 
oxygen delivery, iron is essential for numerous other functions as highlighted previously in 
this thesis. For example, its role in the electron transport chain, culminating in ATP 
production within mitochondria, utilising its ability to freely exchange electrons suggests 
that there are likely to be other non-haematological impacts of iron deficiency with the 
potential to affect exercise capacity. As previously highlighted, research in animals, in 
particular in rodent models, is far advanced of that in humans, where the non-
haematological functions of iron have been studied, and the impact of iron deficiency in 
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the absence of anaemia is better understood (227). The sparsity of research in humans 
makes conclusions problematic, but it is possible that where increases in exercise capacity 
occurred in isolation of changes in red cell mass, and therefore oxygen transport capacity, 
these may be in part caused by improvements in mitochondrial or enzymatic functioning 
involving iron-dependent pathways for example, enhancing the production of ATP. This 
would be in accordance with the findings by Finch et al. in 1976, as iron deficiency without 
anaemia was found to impact mitochondrial activity in rats (227). Thereby iron repletion 
would cause functional improvements without an associated change in [Hb] or total 
haemoglobin mass. It is possible that this response may be more likely in non-elite 
exercisers where non-oxidative mechanisms may not be so well developed.   
 
Significantly, in less well trained individuals, limitations in V̇O2max have been attributed to 
oxygen consumption as opposed to oxygen supply (i.e. erythrocyte mass) (1). Therefore, 
in elite athletes with true IDNA, where oxygen supply is not limited, as [Hb] is not 
compromised, improvements in V̇O2max may be less likely to be significant when compared 
to non-elite athletes since oxygen consumption mechanisms are already well-developed. 
This provides another potential cause for discrepancies in research.     
 
It is also significant that an increase in total haemoglobin mass was seen in some 
participants without an increase in V̇O2max. This is likely to be due to limitations to oxygen 
extraction and utilisation.  
 
Despite the overall increase in exercise and aerobic capacity seen in this trial, when 
separating participants into groups according to baseline serum ferritin, increases were 
only seen in those with ‘severe’ iron deficiency (serum ferritin < 15 µg·L-1). This finding is 
similar to results from both Krayenbuehl et al. (2011) (56), when assessing fatigue in iron 
deficient non-athletes and Garvican et al. (2014) (52) evaluating exercise performance in 
iron deficient well-trained distance runners, both concluding that response to iron therapy 
was more significant in those who were more iron deficient. This suggests that, contrary to 
the belief of many, the criteria for iron deficiency diagnosis (serum ferritin ≤ 30 µg·L-1) in 
this study may be too high, and that lower serum ferritin cut-off values may be required. 
This could in part explain some of the ambiguity in previous studies, since many applied 
significantly higher serum ferritin cut-off values. Despite the WHO suggesting that serum 
ferritin < 15 µg·L-1 signifies iron depletion (100), a lack of iron in bone marrow has been 
observed when serum ferritin is 30 µg·L-1 (42). Accordingly, particularly amongst the 
athlete population, performance is considered to be affected much earlier than when serum 
ferritin < 15 µg·L-1, and as a result, clinically, treatment is typically initiated well before 
serum ferritin levels have dropped to this point (46,173). Appreciably though, despite the 
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improvements in aerobic and exercise performance seen in those with ‘severe’ iron 
deficiency, there was still a wide range of individual variation in response seen across all 
endpoints. 
 
In addition to mean [Hb], mean serum ferritin and red cell indices (MCH, MCV, CH, RBC, 
RDW) all significantly increased in response to the intravenous iron in this study. An 
increase in serum ferritin in response to iron therapy has been widely shown and would be 
expected after administration of a high dose of intravenous iron directly into the circulation, 
bypassing the mechanism for controlled absorption in enterocytes (46,244). Despite a 
previous study showing a correlation between baseline serum ferritin and the magnitude 
of increase in total haemoglobin mass in response to oral iron therapy (241), when 
specifically looking at the individual results in this study, no relationship was observed 
between baseline serum ferritin and the magnitude of the change in either total 
haemoglobin mass or V̇O2max. Given the direct administration route, bypassing the gut, 
there was no confounding issue of absorption. Evidently, and in accordance with previous 
research, this study highlights that the suitability of serum ferritin for the diagnosis of iron 
deficiency in the exercising population needs to be questioned. A conclusion that was also 
drawn in Chapters 5 and 6, where a lack of association between serum ferritin and fatigue 
was observed. The use of other markers should be explored for diagnosis, particularly in 
those who exercise. However, in light of the individual responses seen here, particularly 
amongst those with a serum ferritin < 15 µg·L-1, one could also postulate that optimal levels 
of serum ferritin may be specific to an individual, and that for best practice, athletes should 
be monitored longitudinally over time, with intervention only when significant decreases 
from their normal occur. While it is significant that two weeks may not have been suffice to 
enable a full response to be established, some participants had not shown any indication 
of response by this point. Previous research has demonstrated that two weeks is suffice 
for a significant response to be evident (52,53,435). 
 
If indeed optimal ferritin values are specific to an individual and longitudinal monitoring was 
possible, given the limitations associated with both serum ferritin and [Hb], as previously 
suggested, total haemoglobin mass measurements could be used alongside these to 
provide a better indication of the onset of iron deficiency. This has been used effectively in 
a previous study to monitor recovery from iron deficiency (241).  
 
As [Hb] and serum ferritin are the primary indicators for the diagnosis of IDA, in the present 
study the combination of these was also considered, assessing whether, in conjunction, 
they were associated with changes in exercise and aerobic capacity, therefore establishing 
whether, despite no individual relationship between [Hb] and serum ferritin and response, 
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when combined they had a cumulative effect. However, no association was found, even 
after factoring in potential confounders, again supporting the questions surrounding their 
suitability. Given the possible implications associated with iron deficiency, in addition to the 
known negatives of iron treatment when not necessary, the lack of power that [Hb] and 
serum ferritin have in this study to determine response to intravenous iron, and therefore 
to indicate the presence of iron deficiency needs to be addressed. The power of other 
markers of iron status such as transferrin saturation, soluble transferrin receptor, hepcidin, 
and total iron binding capacity, at identifying response to iron therapy should be evaluated, 
possibly in conjunction with [Hb] and serum ferritin to provide a more robust analysis of 
iron status. In isolation, these markers (e.g. transferrin saturation) may not have the power 
to accurately identify iron deficiency, but power could be significantly increased when 
combined with other markers (436). Again, this need is likely to be particularly relevant in 
those who exercise who are subject to exercise related variation in haematological indices. 
The soluble transferrin receptor/log ferritin index has shown significant potential for 
example and should be investigated further (115). 
 
Despite the lack of association between baseline serum ferritin and [Hb] and exercise and 
aerobic capacity, baseline V̇O2max, total weekly exercise volume and 5 km personal best 
time were all independently found to be associated with the change in circulating mass of 
haemoglobin. This suggests that these could in part be determinants of change in aerobic 
capacity. Hence, individuals who were fitter and who trained more responded better to iron 
treatment. While it should be highlighted that these relationships are only moderate to 
weak, it is interesting that three different indicators of fitness and exercise status point to a 
relationship. One could infer that since the follow-up testing was only conducted two weeks 
after the injection, the relationship could be as a result of an increased erythropoietic 
stimulus, triggered by the increased exercise volume and potentially increased intensity of 
exercise in those who train more and are fitter. Alternatively, these fitter individuals could 
have an accelerated and more efficient erythropoietic response. From a non-
haematological perspective, it could be hypothesised that fitter individuals have a more 
efficient mechanism for iron utilisation and incorporation into enzymes, again meaning that 
they respond more quickly than those deemed less fit. Previous research has 
demonstrated changes in total haemoglobin mass (52,435), and V̇O2max (53) in response 
to iron treatment across participants of all training levels within a comparable, and in some 
cases a shorter timescale, countering this. However, this is not to say that the time course 
for reaching the peak response is not dictated by fitness, so the full extent of response may 
not have been reached after two weeks. It is however significant that previous repletion 
studies using intravenous iron have only been conducted in elite and well-trained athletes, 
therefore this option needs further consideration in a more general exercising female 
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population. Again, as previously highlighted, there is a lack of studies in non-elite athletes, 
and future studies are required to evaluate difference in response time between elite and 
non-elite athletes.  
 
A number of studies have also suggested that fitness may be a determinant in response. 
A recent meta-analysis found increases in V̇O2max to occur only in trained women when 
compared to those untrained in response to iron treatment (232), and another study 
assessing response to oral iron therapy also demonstrated an increased response in those 
with a higher baseline V̇O2max (241). Conversely, in a different meta-analysis, significant 
increases in V̇O2max in response to iron repletion were only seen in those with a baseline V̇O2max < 40 mL·kg-1·min-1, with no effect being concluded in those with a V̇O2max > 45 
mL·kg-1·min-1(46). This was thought due to a reduced potential for improvement (46). In 
the present study this was not the case, however owing to the specific lack of intravenous 
iron repletion studies in non-elite athletes, only studies involving oral and intramuscular 
administration routes were included in the meta-analysis (46). Further research is evidently 
required to evaluate the determinant of fitness on response. Markers of erythropoiesis such 
as reticulocytes, GDF-15, and erythropoietin, should also be included to provide a better 
mechanistic understanding of iron deficiency, while there is an evident need to assess the 
effect of low iron on mitochondrial function. It could be hypothesised that optimal serum 
ferritin levels are associated with fitness, suggesting that when using this for diagnosis, 
less fit individuals may not experience impairments in physical function as readily as those 
who are fitter, likely because there is more potential for underlying inflammation or a 
haemoconcentration to reduce accuracy of measurement in those who train more and at 
an increased intensity. However, when controlling for 5 km personal best time and total 
exercise and running time each week, there was still an absence of any relationship 
between serum ferritin and the magnitude of markers of exercise and aerobic capacity.  
 
Baseline corpuscular haemoglobin concentration mean (CHCM) and haematocrit were 
also found to be associated with change in haemoglobin mass in response to iron repletion. 
These relationships are not surprising given they are associated with erythrocyte 
production, size and content. However, it could be suggested that future research could 
consider the use of these as part of a diagnostic panel for the diagnosis of iron deficiency, 
particularly given the ease of a blood test when compared to the measurement of total 
haemoglobin mass using the carbon monoxide rebreathing test.  
 
Previous research has shown an association between markers of thrombocytosis and IDA 
(437). While specific markers of platelet function and therefore thrombocytosis were not 
measured in the present study, a relationship between both baseline mean platelet 
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component and baseline platelet distribution width and change in haemoglobin mass was 
observed. It is thought that there are some iron-containing enzymes in platelets that aid 
the haemostasis process, so when iron levels are insufficient, platelet function is 
compromised (438). Again, this is an area that should be addressed in future work. 
 
As highlighted in Chapter 6, fatigue is a significant health issue which is particularly 
common in women (403,404). IDA is a leading cause of fatigue, but research evaluating 
the association between iron deficiency alone and fatigue is unsure. Most research in non-
athletic iron deficient but not anaemic individuals suggests a reduction in fatigue and 
improvements in quality of life in response to iron therapy without a concomitant increase 
in [Hb] (56,226,247,248,439). However, some contradict this, finding no impact of iron 
repletion in the reduction of fatigue (249), again likely in part caused by the ambiguity 
surrounding the serum ferritin cut-off values used for the diagnosis of iron deficiency in 
addition to varying study protocols amongst the aforementioned other inconsistent factors 
(226,247). In Chapter 6, despite using the WHO’s serum ferritin cut-off to indicate iron 
depletion, neither iron deficiency, nor IDA were associated with increased fatigue, however 
anaemia alone was ([Hb] < 12.0 g·dL-1). Due to the insidious nature of fatigue it must be 
appreciated that individuals may have adjusted to the fatigue and established a new sense 
of ‘normal’, which isn’t realised until iron stores are repleted, hence repletion studies are 
required for a more accurate evaluation.  
 
It has been suggested that for peak cognitive performance serum ferritin levels should in 
fact be higher than those viewed as optimal for physical performance, with some 
suggesting a serum ferritin cut-off of < 50 µg·L-1 (247). Accordingly, impacts of iron 
deficiency on exercise and aerobic capacity are hypothesised to be secondary to cognitive 
performance (58). There is however an absence of previous research assessing the impact 
of iron deficiency on fatigue and mood disturbance alongside exercise capacity and 
haematology in individuals who exercise. This has been highlighted in the literature, with 
only speculative prior hypotheses, thus making conclusions to this avail difficult (51,52). 
To my knowledge, the IRONWOMAN trial is the first study to capture all these factors in 
iron-deficient, but otherwise healthy regularly exercising women. In support of the 
hypothesis that cognitive performance is impaired prior to physical performance, there was 
a universal improvement in factors associated with cognition, i.e. a reduction in fatigue and 
mood disturbance, without a universal increase in exercise and aerobic capacity. It must 
however be appreciated that the reduction in fatigue and mood disturbance could be 
attributable to a placebo effect, particularly because this was an observational non-blinded 
study. In fact, a placebo effect has been found in previous studies regardless of blinding 
(56,226). In an attempt to ameliorate this impact in the present study, construct validity was 
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obtained by conducting three separate fatigue questionnaires, alongside a mood 
questionnaire. Reliability tests were also specifically performed on the MFI-20, and I 
believe that the sheer number of questions in addition to the time lag between 
questionnaire completion would also have helped to minimise the impact. 
 
When specifically evaluating the responses from the MFI-20 questionnaire, the magnitude 
of the change in the fatigue subscales was not related to baseline [Hb], suggesting that 
fatigue reductions were not due to underlying IDA. Bar the association between serum 
ferritin and change in motivation, no other changes in fatigue subscales were related to 
baseline serum ferritin. Given that there was a decrease in fatigue and mood disturbance 
in some participants without a concomitant increase in total haemoglobin mass or [Hb], 
again, non-haematological effects of iron deficiency could be implicated, suggesting that 
an increase in oxygen transport was not responsible for the improvements seen. Iron is 
thought to have a number of roles in neurotransmitter biochemistry in the brain, including 
dopamine and serotonin signalling, the development of the neural network, energy 
metabolism and myelination (440). Therefore, it is possible that these could be 
compromised in states of iron deficiency, prior to functions associated with physical 
performance and oxygen carriage. This could potentially provide an explanation as to why 
cognitive performance could be impacted prior to physical function in iron deficient states.  
 
With likelihood of iron deficiency being significantly greater in those identified with heavy 
menstrual bleeding (HMB) when utilising the criteria applied throughout this thesis as 
previously shown in Chapters 5 and 6 in this thesis, it was interesting to see that in the 
present study prevalence of this condition was nearly double that of the general exercising 
population discussed in Chapter 4 (35.5%) (28,392). This is in accordance with earlier 
findings that HMB increases risk of IDA and iron deficiency. A relatively recent study found 
an association between platelet dysfunction, IDA and HMB, suggesting that IDA causes 
the platelet dysfunction which is the reason for the increased menstrual blood loss (441). 
It could therefore be suggested, that the lack of iron could be responsible for HMB. Specific 
markers of platelet aggregation and secretion were not included in the present study, but 
should be considered in future work. Given that previous studies found iron therapy to 
reverse the presence of HMB (408), this could have significant future potential given the 
prevalence and impact of both HMB and IDA as shown in this thesis. There is a lack of 
previous studies addressing platelet aggregation and secretion in those with HMB and iron 
deficiency without anaemia, however, considering the results in the present study, further 
investigation is clearly warranted.  
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In this study, barring the two participants whose exercise results were excluded due to 
injury, no differences were reported in training pre- and post- supplementation, and no 
dietary alterations were highlighted. Further, controlling for day of the menstrual cycle had 
no significant impact on the results.  
 
It is common for athletes to supplement with iron, often prior to knowledge of iron status. 
This was demonstrated in Chapter 4 where 78.9% reported supplementing with oral iron, 
despite more than half being unaware of iron status. Previous studies have demonstrated 
no benefit of iron supplementation in iron sufficient athletes, and given that not all 
participants showed an improvement in exercise and aerobic capacity despite evident 
increases in serum ferritin, this study is in agreement (51). In light of the placebo effect, it 
is difficult to gage the true source of the reduction in fatigue and mood disturbance. Further, 
as already highlighted in this thesis, given the side effects associated with oral 
supplementation, including gastrointestinal distress, nausea (257), increases in oxidative 
stress and inflammation (61), in addition to the upregulation of hepcidin expression, 
decreasing iron absorption and potentially worsening iron status (261), supplementation 
should only be used when necessary. Further, excess iron supplementation is a risk factor 
in those genetic abnormalities that predispose them to iron overload, for example in 
those with haemochromatosis (7). Elite endurance athletes may be at particular risk 
where mutations to the HFE haemochromatosis gene are more common than in the 
general population (259). Dependant on the circumstances, if iron deficiency is evident or 
thought possible, dietary modifications should be the initial treatment option.  
 
While demonstrating that cut-off values for serum ferritin for the diagnosis of iron deficiency 
may be too lenient, the present study also highlights the potential unsuitability of both 
serum ferritin and [Hb] for the diagnosis of both iron deficiency and IDA. Other markers 
need to be assessed to determine whether they could provide a more accurate analysis, 
while longitudinal monitoring of iron status should be considered as it is possible that 
optimal values for markers of iron status are specific to an individual. Given the impacts 
that iron deficiency can have, as demonstrated here, in addition to the potential side effects 
of unnecessary supplementation, future research needs to focus on improving iron 
deficiency diagnosis. While the mechanism for iron deficiency should also be established.  
 
7.5.1 Limitations 
With no randomisation, this research is subject to bias caused by a placebo effect. 
However, while time to exhaustion, fatigue and mood are subject to variation to this avail, 
total haemoglobin mass and haematological indices cannot be altered, and providing V̇O2 
peak is attained, this is also not subject to a placebo effect. The multiple different measures 
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collected here will reduce the impact of the placebo effect somewhat, however it cannot 
be ignored, and future studies should take the form of a randomised, double-blinded 
controlled trial.   
 
The follow-up tests were only conducted two weeks after intravenous iron administration, 
therefore it is unlikely that the full response was captured. Additionally, the initial response 
(i.e. after 48 hours) as shown in previous research was not measured (51). However many 
studies have shown significant outcomes in a comparable time frame (52,53,435). Further, 
while participants were asked to maintain a normal diet through the duration of the study 
food diaries were not kept, so specific dietary intake was not monitored. Training diaries 
were kept; however, it was difficult to determine effort and physiological impact of different 
training sessions. In an attempt to reduce these effects, participants were requested to 
have post-injection tests in the same physiological state as those conducted at baseline, 
therefore they were asked to keep training and lifestyle as similar as possible in the couple 
of days prior to each test. This was very difficult to control as physiological state and 
wellness can be influenced by many external factors, and particularly since these athletes 
were not elite, other lifestyle impacts are likely to play a part such as diet and sleep. 
However, these factors should not impact total haemoglobin mass measurements, which 
have been found to be relatively stable in trained athletes (1), or haematological measures. 
The addition of reticulocyte measures, GDF-15 and erythropoietin would have enabled 
assessment of whether the improvements in aerobic and exercise capacity were due to a 
haematological response and future studies should include these. While measures of 
hepcidin and other iron status parameters would enable increased mechanistic 
understanding as to the factors driving the results seen, while also offering future possible 
diagnostic means. 
 
While all participants had run on a treadmill before, they had not all previously undertaken 
a V̇O2max test. Therefore, in the follow-up test they may have been more comfortable with 
the equipment. They were however blinded to total time on the treadmill.  
 
7.6 Conclusions 
A single high dose intravenous iron injection was associated with an increase in exercise 
and aerobic capacity in otherwise healthy non-elite, iron-deficient exercising women. 
However, there was a significant degree of individual variation despite increases in serum 
ferritin in all participants. When participants were divided into groups based on baseline 
serum ferritin, increases in V̇O2max and total haemoglobin mass were only observed in 
those with severe iron deficiency (serum ferritin < 15 µg·L-1). Despite this, the magnitude 
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of improvements in exercise and aerobic capacity were not associated with either baseline 
serum ferritin or [Hb], suggesting response could be driven by a different mechanism, or 
questioning the suitability of existing markers used for iron deficiency diagnosis. Following 
iron repletion there was a universal decrease in fatigue and mood disturbance, while this 
may in part be due to a placebo effect, it could also be that iron deficiency affects cognitive 
performance prior to exercise and aerobic capacity.  
 
To conclude, regarding the outlined hypotheses for this chapter, the first hypothesis that 
iron repletion improves exercise and aerobic capacity in iron deficient (serum ferritin < 30 
µg·L-1), non-elite exercising women can be accepted. The second hypothesis that iron 
repletion reduces fatigue and mood disturbance in iron deficient (serum ferritin < 30 µg·L-
1), non-elite exercising women can also be accepted. Despite, there being a significant 
degree of individual variation in response, and no direct correlation, the third hypothesis 
that those with a lower baseline serum ferritin saw greater increases in exercise and 
aerobic capacity and reductions in fatigue and mood disturbance can also be accepted.  
 
7.7 Future perspectives 
The IRONWOMAN trial clearly demonstrates the limitations of using serum ferritin as a 
sole marker of iron status in those who exercise. While serum ferritin may be able to 
establish an ‘at risk’ population, future studies should consider using other biomarkers in 
addition to, or as an alternative to this to improve diagnosis. Future studies should also 
include a blinded placebo group, to further ascertain whether iron deficiency first impacts 
cognitive performance prior to factors associated with physical performance. In an attempt 
to gain a better mechanistic understanding, muscle oxidative capacity should be 
measured. 
 
The relationship between IDA and HMB should be further established, if indeed IDA can 
cause HMB, intravenous iron therapy could have fundamental use in treatment of this 
condition, which was shown in previous research to have a substantial impact. 
 
7.7.1 Future studies 
The present study clearly highlights the need for further research in this field. The following 
factors need consideration: 
 
When using the same diagnostic criteria, the impact of iron repletion on markers of 
erythropoiesis and mitochondrial oxidative function. This will enable a better understanding 
as to whether the presence of non-haematological impacts of iron deficiency. 
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A randomised control trial needs to be conducted to minimise the impact of bias. This 
should involve both elite and non-elite athletes to enable determination as to whether 
baseline fitness dictates response. Based on previous research, more follow-up time points 
are warranted, for example at 48 hours post injection and four weeks post injection. Platelet 
measures should be investigated alongside HMB presence to identify any presence of a 
causal relationship.  
 
7.8 Author Contributions 
The author recruited all the potential participants, and conducted all screening blood tests 
and either organised for a courier to collect these for delivery to the laboratory or delivered 
them personally, following advice regarding the required environmental conditions. The 
author provided feedback to participants regarding whether they met the inclusion criteria 
and where this was met, scheduled the subsequent appointments (baseline test, iron 
injection and follow up tests). The author conducted all baseline and follow up tests 
(exercise and total haemoglobin tests and oversaw the completion of the questionnaires). 
A trained medical professional at the Iron Therapy Clinic administered the intravenous iron. 
 
The author inputted all data onto a secured database and conducted the statistical analysis 
and the interpretation of the results. 
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8 General Discussion, overall conclusions and future 
research 
 
In this section, the key findings in this thesis will be outlined, providing overall conclusions 
while also describing future perspectives, studies and recommendations.  
 
Firstly, this thesis examined whether HMB, when identified using the outlined criteria for 
diagnosis, is a dysfunction that is common in exercising women. In the absence of a 
validated and universally accepted means for the diagnosis of HMB, a four-part series, 
similar to that which has been used previously was applied as explained in chapter 3. This 
relied on individuals to self-report symptoms experienced. After establishing, when using 
this diagnostic means that HMB was common, there was a need to evaluate unbiased 
prevalence. This was done using London Marathon runners. The presence of identified 
HMB and its association with individuals perceiving that their menstrual cycle disrupts their 
exercise training/performance was then evaluated. The prevalence of iron deficiency, iron 
deficiency anaemia (IDA) and anaemia in a different exercising cohort was then 
established. The association between these and HMB (when identified using the same 
means) both independently and together with the perceived menstrual cycle disruption to 
exercise training/performance or everyday lifestyle/exercise performance and fatigue was 
then evaluated. Finally, the impact of iron repletion in iron deficient non-elite exercising 
women was assessed when diagnosing iron deficiency using serum ferritin, which is the 
primary diagnostic marker used clinically. In so doing, the efficacy of serum ferritin for iron 
deficiency diagnosis was evaluated. Significantly, despite non-elite exercising women 
encompassing a very large and growing population, research as to the impact of iron 
deficiency both on physiological and psychological elements within this group is lacking.  
 
8.1 Prevalence and impact of HMB in the exercising population 
Despite the lack of a universal consensus on a means for HMB diagnosis, research has 
shown HMB to be common in the general population, previously found to affect 27.2% of 
a European population (28), and 10 - 35% of reproductive aged women in the United States 
(442). This condition has not however been researched in those who exercise, and this 
thesis provides new insights into the potential occurrence of HMB in this group. With the 
assumption that the primary menstrual cycle dysfunctions in those who exercise are 
amenorrhea and oligomenorrhea, little research has addressed other menstrual 
dysfunctions, yet both chapters 4 and 5 highlight that using a diagnostic series, 
incorporating aspects of other diagnostic means, (28) (218), HMB is a significant issue in 
this population. Appreciably, and contrary to many beliefs, HMB was also identified in elite 
athletes, affecting 36.7%. Despite prevalence in the Singaporean population in chapter 5 
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being lower (22.1%), evidently, HMB is still a significant issue amongst this exercising 
group. The differences in prevalence between the likely primarily British and Singaporean 
groups could be due to ethnicity, since, while not recorded, it can be assumed that the 
majority of participants in chapter 4 were Caucasian, and that the majority of participants 
in chapter 5 were Asian. While difficult to decisively conclude, since there is a lack of 
research comparing these two populations when using the same means for diagnosis.  
 
The NICE define HMB as “excessive menstrual blood loss which interferes with a woman’s 
physical, social, emotional and/or material quality of life” (26). However, this definition is 
purely subjective, relying on the perception of an individual, and suggests that it is the 
sheer physical impact of the blood loss that causes identification of HMB, not the actual 
volume of blood lost. The historical definition established by Hallberg et al. utilised an 
objective measure of 80 mL of blood loss (217), but one has to question the applicability 
of this discreet value. They used an alkaline haematin method to estimate haemoglobin 
loss. However, blood volume can vary significantly between women, therefore it would be 
more appropriate to identify HMB as a percentage of total blood volume, if indeed it is the 
blood loss that deems an individual to be a heavy bleeder. Further, the physical 
identification of blood loss is difficult, not only due to hygiene concerns, which are likely to 
lead to the lack of desire to measure, but blood is also lost when passing urine, defecating, 
or through flooding into clothing or bedding. Additionally, given that not all menstrual fluid 
is blood, this causes further problems in quantification.  
 
The criteria utilised in this thesis, while not validated, provides a more objective, realistic 
and hygienic indication of blood loss, which could easily be used by practitioners. Despite 
still having a subjective, perceptual element, the questions have increased clarity when 
compared to the NICE definition, aiding individuals and practitioners with an indication of 
what may be abnormal. Significantly, the key consideration is the impact that HMB may 
have, if this is purely psychological then the need to intervene is different to if there is either 
an underlying aetiology, an associated impact on iron status or other resulting factors that 
could negatively impact health and well-being. A simple tool for quick evaluation of risk is 
warranted, and further evaluation can follow to better understand need for treatment. This 
thesis highlights that when applying the outlined criteria, there is potential for this tool to 
identify those who are at increased risk of a compromised iron status and those who may 
suffer disruption to lifestyle/exercise training/performance. For the purposes of this 
research it was important to establish whether HMB should be considered in those who 
exercise and whether there are negative repercussions associated with it, and these were 
clearly demonstrated. Further, as previously explained, iron deficiency can take a while to 
manifest, therefore it is very possible for the impact of HMB on iron status can take a while 
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to manifest. It is also significant to note that the aetiology of HMB is often unknown. A 2014 
study in university students, which diagnosed HMB using the pictorial blood assessment 
chart, found only 20.7% of the participants with HMB (n=82) to have underlying bleeding 
disorders or menstrual cycle related pathologies (i.e. endometriosis or polycystic ovary 
syndrome) (Gursel et al. 2014). This is significant, suggesting the presence of HMB as a 
condition in its own entirety that needs to be appreciated.  
 
Chapters 4 and 5 clearly demonstrate the potential for HMB, when using the outlined 
diagnostic series, to be a cause for disruption to exercise training/performance or to 
everyday lifestyle/exercise performance. The marathon runners with HMB in chapter 4 
were more than three times more likely to report that their menstrual cycle disrupts their 
exercise training/performance than those without HMB, while those with HMB in chapter 5 
were more than four times more likely to cite this when compared to those without HMB. 
Previous research in the general population has focused on the effects of HMB on quality 
of life, but as already outlined there is a dearth of research assessing prevalence and 
effects of HMB in those who exercise. In light of this, the mechanism for this association is 
unsure. Given the known association between HMB and iron deficiency, which was 
demonstrated in chapters 5 and 6, it would seem prudent to suggest that a lack of iron may 
be the cause for any detriment in performance. In fact, HMB is considered to be the primary 
cause of IDA and iron deficiency in the general population (443). Chapter 4 supported this 
hypothesis, finding a reported history of anaemia to be greater in those identified with HMB 
than in those without. However, despite confirming haematologically that identified HMB 
presence increased the risk of a compromised iron status in chapter 5, when factored into 
a model, the relationship between HMB and the perception that the menstrual cycle 
disrupts everyday lifestyle/exercise performance was found to be independent of either 
IDA or iron deficiency. This suggests that the mechanism by which HMB may cause this is 
independent of iron status. future research must address this, and there is a clear need for 
treatment options. Being an inflammatory condition, it is possible that the increased levels 
of inflammation may be a cause for performance detriment, however prior to establishing 
this further research is needed to objectively measure performance.  
 
Interestingly, the identified prevalence of HMB in chapter 7 was significantly higher than 
that in the chapters 4 - 6 and in that found previously in the general population. It has been 
suggested that IDA can cause a platelet dysfunction which results in increased menstrual 
blood loss (441). As a result, it could be hypothesised that a lack of iron is causing HMB 
as opposed to the converse. In fact iron repletion has been found to be an effective 
treatment for HMB in these instances (408). Further research should address this 
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association, in particular in those without anaemia. Iron repletion could be considered as 
a potential treatment option.  
 
The subjective nature of the question surrounding the perception that the menstrual cycle 
disrupts exercise training/performance makes the drawing of conclusions problematic, 
however, while not addressing physical performance and still including a subjective 
element, chapter 6 provided a different means for evaluating the potential impact of HMB. 
The presence of HMB was clearly associated with increased general fatigue.  
 
While this thesis used one tool to establish prevalence of HMB, there is a clear need to 
create one universally agreed diagnosis means. As already highlighted in this thesis 
existing tools have elements which will affect accuracy. It would however be advisable to 
identify the significance and implication of identification of HMB when identifying the best 
tool to use. For example, this thesis has demonstrated the increased risk of a compromised 
iron status and an association with the perception that the menstrual cycle disrupts 
exercise training/performance in those identified with HMB. While this firstly suggests that 
this tool could be used by practitioners to identify when a blood test should be taken for 
iron status, the results from this thesis also highlight that associated effects of HMB need 
consideration, such as an increased production of inflammatory markers.  
 
8.2 HMB, iron status and fatigue 
The symptoms of HMB and IDA are similar, both impacting on quality of life and altering 
ability to execute everyday social, mental and physical activities (28). In light of this, it could 
be suggested that a poor iron status could be on the causal pathway between HMB and 
fatigue. However, to date, the interrelationship between HMB, a suboptimal iron status and 
fatigue has not been assessed. A recent study in adolescents evaluated the association 
between HMB and serum ferritin and the effect of HMB on fatigue independently, but did 
not evaluate whether iron status was responsible for the increased fatigue seen in those 
with HMB (38). This hypothesis was tested in chapter 6, where interestingly, the 
association between identified HMB and an increase in general fatigue was not found to 
be mediated by IDA or anaemia. This suggests that the fatigue associated with HMB is 
caused by a different mechanism, independent of iron status.  
 
The results from chapters 5 and 6 demonstrate that HMB, when identified using the 
outlined criteria throughout this thesis, is a condition in its own entity, and that the 
repercussions that ensue with this are not simply those associated with IDA or iron 
deficiency. The increased release of pro-inflammatory cytokines such as TNF-$ could be 
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the cause for this, and (401) the relationship between TNF-$ and fatigue is well established 
(421).  Impairments in exercise are also inevitable in response to increased levels of 
underlying inflammation, therefore future research should investigate this, as a better 
understanding of this could guide potential treatment mechanisms. This association has 
not previously been highlighted and given the demonstrated potential for exercise 
impairment and high prevalence in those who exercise, this is of particular significance. 
This could even provide another potential means for diagnosis. 
 
8.3 Prevalence of iron deficiency 
The prevalence of IDA in the exercising population in chapters 5 and 6 was 14.8%, this is 
comparable to previous studies reporting a prevalence of 8 – 14% (119-121), and likely 
slightly higher due to this being an exercising population. As highlighted already, the 
diagnosis of iron deficiency has historically been problematic, particularly in those who 
exercise, with prevalence ranging from 24 – 47% (59). In chapter 5, applying the WHO 
criteria for iron depletion (serum ferritin < 15 µg·L-1), 29.9% were iron deficient. When 
applying a more lenient criteria, in accordance with other studies in athletes, and in line 
with findings from Wish et al. (2006) (436), where bone marrow iron stores were found to 
be compromised when serum ferritin < 30 µg·L-1, prevalence was 48.0%. Unsurprisingly, 
and as previously shown, the identified presence of HMB, using the diagnostic series 
outlined, increased the likelihood of a compromised iron status.  
 
With the potential for nearly one in two exercising women to be iron deficient, there is an 
evident need to evaluate the diagnosis and resulting need for treatment, optimal treatment 
options and the mechanism by which iron deficiency has an effect. As outlined in chapter 
2, there are a number of reasons for the existing lack of clarity. Chapter 7 aimed to address 
this and to advance understanding, as will be discussed subsequently.  
 
8.4 Impact of iron deficiency 
8.4.1 Effect on exercise and aerobic capacity 
Results from previous studies regarding the effect of iron deficiency on exercise and 
aerobic capacity are equivocal, in part due to inconsistencies in study protocol (e.g. study 
duration, supplementation route and outcome measurements), iron deficiency diagnosis, 
participant performance level and sample sizes (46). In chapter 7, while an overall increase 
in exercise and aerobic capacity was seen, when broken down into groups based on 
baseline serum ferritin, increases were only evident in those more severely iron deficient 
(serum ferritin < 15 µg·L-1). No association was found between serum ferritin and the 
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magnitude of change in outcome markers, and primary endpoints did not increase in all 
participants in the severely iron deficient group. This suggests that while a serum ferritin < 
15 µg·L-1 could be used to identify increased risk, these results clearly question the 
suitability of the use of serum ferritin alone for iron deficiency diagnosis in those who 
exercise.  
 
8.4.2 Effect on fatigue and mood disturbance 
Iron deficiency is associated with fatigue, and previous studies have found a reduction in 
fatigue in response to iron repletion in iron deficient but not anaemic individuals 
(56,226,247,248,439), however this has not been found by all (249). While chapter 6 found 
anaemia to be associated with increased fatigue, these findings were not mirrored in those 
with IDA or iron deficiency. However, in response to iron therapy in chapter 7 there was a 
universal decrease in fatigue and mood disturbance. The potential for a placebo effect 
cannot be ignored here, however construct validity was obtained by conducting three 
separate fatigue questionnaires. It is important to consider that due to the insidious nature 
of fatigue, it can be missed, and may not be appreciated until iron stores are repleted. A 
lack of association was found between serum ferritin and fatigue in either chapter 6 or 7, 
and to date, only one other study has addressed this, also concluding no relationship, again 
highlighting the need to re-evaluate markers used for iron deficiency diagnosis (38), while 
a future double-blinded study is necessary. 
 
8.4.3 Diagnosis  
The majority of previous research has focused on assessing the efficacy of iron repletion, 
and has not specifically evaluated the suitability of markers to diagnose iron deficiency. 
Further, most recent studies in the sporting context have been conducted in elite or well-
trained athletes, and there is a particular absence of studies using intravenous iron in non-
elite exercisers. To my knowledge, the IRONWOMAN trial is the first study to assess iron 
repletion in non-elite exercising women when repleting iron stores using intravenous iron. 
This is significant because not only may elite athletes respond differently to non-elite 
exercisers (1), but this has the potential to influence a very large number of people.  
 
Clinically being the primary marker used for the diagnosis of iron deficiency (40,100,444), 
serum ferritin was used for diagnosis throughout this thesis. However, the findings from 
chapters 5, 6 and 7 all clearly question its suitability in those who exercise. There is much 
ambiguity surrounding the appropriate serum ferritin cut-off in the literature and amongst 
medical professionals (46). In chapter 5, in an attempt to address this, when evaluating the 
association between identified HMB, iron status and reported menstrual cycle effects on 
performance, both a ‘severe’ and ‘moderate’ serum ferritin iron deficiency cut-off was 
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applied. The WHO’s criteria for depleted iron stores (serum ferritin < 15 µg·L-1) was used 
to define ‘severe’ iron deficiency. Then a more lenient diagnosis (serum ferritin < 30 µg·L-
1), reflecting that postulated by Wish et al. (2006) (436), and in line with that commonly 
used clinically and in sports science research, was used and termed ‘moderate’ iron 
deficiency. However, as neither ‘severe’ nor ‘moderate’ iron deficiency were associated 
with the perception that the menstrual cycle disrupts everyday lifestyle/exercise 
performance, this study did not help to address the ambiguity surrounding iron deficiency 
diagnosis. In light of this, chapter 6 only applied the serum ferritin cut-off for ‘severe’ iron 
deficiency. While HMB and anaemia were found to be associated with an increase in 
fatigue, there was no relationship between IDA or iron deficiency and fatigue, and 
significantly there was also no relationship between either [Hb] or serum ferritin and fatigue.  
 
In chapter 7, increases in aerobic and endurance capacity were only seen in the group 
with severe iron deficiency (serum ferritin < 15 µg·L-1), yet response was not associated 
with or dictated by baseline serum ferritin levels. Factoring in [Hb] did not aid in the 
prediction of response, suggesting that an underlying state of IDA was not confounding 
results. It could be hypothesised that optimal levels of serum ferritin are specific to an 
individual, therefore for best practice, serum ferritin could be monitored regularly over time, 
ensuring that athletes are in a comparable state when tested (rested and fasted), with any 
significant declines in serum ferritin indicating need for intervention. Despite being subject 
to a placebo effect, the universal reduction in mood disturbance and fatigue is significant 
and needs further assessment, but again serum ferritin was not associated with this. 
 
Evidently, the results from chapters 5, 6 and 7 highlight a need to reassess the use of 
serum ferritin alone as a primary means for indicating iron deficiency. There is a clear need 
to investigate the use of other markers. Given that nearly one in two were found to be iron 
deficient in chapters 5 and 6, and that the exercise industry is rapidly expanding, this has 
fundamental clinical significance. This need is exacerbated by the large number of 
individuals supplementing with iron. Clear guidelines are necessary.  
 
8.4.4 Mechanism of iron deficiency 
The findings in chapter 7 suggest that there are non-haematological effects of iron 
deficiency, which may occur prior to haematological effects. In some participants, V̇O2max 
increased without concomitant increases in total haemoglobin mass or [Hb]. Non-
haematological effects of iron deficiency on exercise capacity have not been shown before 
in humans. Research in iron deficient rodent models has shown mitochondrial function and 
composition to be affected in iron deficient states (227). However, as described in chapter 
2, research in humans as to the impact and mechanism of iron deficiency is equivocal. 
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The increase in V̇O2max without an increase in markers of erythropoiesis seen in chapter 7 
suggests that the improvements could be due to enhanced cellular oxygen uptake or 
utilisation, both involving iron dependent pathways, for example enhanced iron containing 
haem enzyme activity in the electron transport chain in mitochondria. Indeed, in non-elite 
athletes there is increased potential for factors other than haemoglobin mass to impact 
upon V̇O2max, and research suggests that the V̇O2max of non-elite athletes is more likely to 
be limited by cellular uptake kinetics than by oxygen supply when compared to elite 
athletes (1). The training status and performance level of athletes may therefore affect their 
response, and given the historical lack of research in non-elite athletes, particularly when 
using intravenous iron, this could be the reason for the novel non-haematological effects 
of iron deficiency found here. The use of intravenous iron in chapter 7 as opposed to oral 
iron meant that the controlled absorption route through enterocytes was bypassed. This 
provides a more reliable assessment of the effect of iron repletion and the resulting efficacy 
of markers of iron deficiency.  
 
While inevitably subject to a placebo effect, the universal reduction in fatigue and mood 
disturbance seen in chapter 7 supports previous hypotheses that optimal serum ferritin 
levels for the prevention of impacts on cognitive performance may in fact be higher than 
often thought. It has been hypothesised that cognitive performance will be affected when 
serum ferritin < 50 µg·L-1 (247). This suggests that iron deficiency impairs cognitive 
performance prior to functional repercussions. However, to my knowledge no previous 
studies have evaluated both markers relating to fatigue and physical function in iron 
deficient women to further establish this, therefore to my knowledge this is the first study 
to assess this. Given the additional non-haematological roles of iron this is plausible, 
however as previously highlighted, studies looking at the mechanism for this in humans 
are lacking. The outcomes of this research could have significant implications, particularly 
given the sheer number of women with relatively low ferritin levels, in fact, a study in a 
general adolescent European population found mean serum ferritin in women to be 29.9 
µg·L-1 (445). The addition of a blinded placebo group in a future study would be very 
insightful to aid further evaluation.  
 
8.4.5 Awareness and supplementation 
The findings of this thesis are in agreement with previous work highlighting a poor 
awareness of iron status, and the potential for a lack of awareness of HMB. Fraser et al. 
(2015) found that 46% of those with HMB have not sought medical help, suggesting no 
prior knowledge (28). In the marathon population in chapter 4, 55.6% had not sought 
advice/help for heavy periods, while 66.6% and 68.9% in chapters 5 and 6 had not sought 
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this. Worryingly however, in chapter 6, the prevalence of IDA, anaemia and iron deficiency 
did not differ in those with HMB who had or had not sought advice/help. While making an 
assumption, this could suggest that appropriate medical tests are not being conducted in 
response to HMB. A lack of awareness amongst medical professionals has previously 
been shown (384), and the ambiguity of the diagnosis of HMB is a likely confounder. In 
light of the significant impact of HMB shown here; being associated with perceived 
menstrual cycle driven disruptions to exercise training/performance , increasing fatigue 
and worsening iron status, there is an evident need to raise awareness of this condition. 
Further, when using this means for diagnosis, as it is clearly a prevalent condition amongst 
athletes and exercising women, sports medics should specifically be alerted to it. Given 
the ease of the applied diagnostic series, use of this or an abbreviation should be 
considered amongst medical professionals. However, the need for treatment options is 
imperative, and priority needs to be placed on research to this avail. For example, given 
the likely increase in inflammation, nutritional interventions with anti-inflammatory benefit 
could be prioritised during or prior to menstruation.  
 
With less than half of those with IDA (41.2%) in chapter 5 reporting prior knowledge, and 
only 8.8% suggesting prior knowledge in the previous three months, awareness of iron 
status was poor. Given the known impact of IDA, this is concerning and more needs to be 
done to highlight the symptoms of this condition. Notably, many were found to supplement 
with iron despite a lack of prior knowledge of iron status, with nearly 80% of elite athletes 
in chapter 4 reporting supplementation. While of those in this study who indicated a lack of 
awareness of prior anaemia, more than half reported having taken iron supplementation. 
It is known that coaches encourage athletes to supplement with iron, however both chapter 
7 and previous research (39) have demonstrated no benefit of unnecessary 
supplementation, and given the possible side effects associated with unnecessary 
supplementation, including an increase in oxidative stress and inflammation (61), and the 
consequences that this may have on iron absorption, it is important to improve education 
and clarify when supplementation should be used. Further, there are added risks 
associated with unnecessary supplementation, particularly in those with mutations to the 
haemochromatosis, HFE gene. Individuals with this genotype have an increased likelihood 
of iron overload. Significantly, this condition is particularly common in elite athletes (259), 
highlighting that supplementation must only be administered when iron status is known. 
 
Throughout this thesis, it is evident that the use and suitability of serum ferritin for the 
determination of iron status particularly in those who exercise regularly is questionable. It 
is the most common and cost effective test used clinically, however its ability to diagnose 
iron deficiency appears limited, and has been found to exhibit significant disparity 
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throughout the day in athletes, with variation ranging from 13 – 75% (45). Chapters 5 - 7 
show no evidence to specifically demonstrate that serum ferritin alone can be used to 
elucidate who will respond to iron therapy, and therefore to diagnose iron deficiency. While 
it is evident that those with serum ferritin < 15 µg·L-1 are at an increased risk of detriments 
to aerobic and exercise capacity, this was not universal. Further, while all participants in 
the IRONWOMAN study saw a reduction in fatigue and mood disturbance this was 
independent of baseline serum ferritin. With this in mind it would be prudent to investigate 
the use of other markers, possibly in conjunction with serum ferritin to determine iron 
status, while also considering whether optimal serum ferritin levels are specific to an 
individual. From the perspective of applying these findings clinically, it would be advisable 
to monitor athletes longitudinally, always testing them in a rested and fasted state, with 
intervention only when a significant decline is observed.  
 
8.5 Limitations 
Throughout this thesis a number of limitations have been outlined in each chapter. To 
summarise, it must be acknowledged that in the absence of any universally approved 
validated tool, the diagnostic series applied for the identification of HMB throughout this 
thesis was self-derived. This could obviously lean to significant inaccuracies, while also 
appreciating that the underlying goal of HMB identification still needs to be established. 
There were also a number of limitations associated with the female health questionnaires 
utilised, including inconsistency of time frames for reporting of factors such as performance 
times and training volumes, adding to risk of bias in the development of conclusions. It also 
must be appreciated that these questions were subjective. 
 
The use of the convenience sample in chapters 5 and 6 also needs to be highlighted, this 
is a different population which may have encountered language barriers regarding 
questionnaire completion.  
 
The lack of a control group or randomisation in the IRONWOMAN study meant that this is 
subject to a placebo effect, and this needs to be addressed in future studies. This study 
was also limited by only measuring one time point in follow-up and the lack of measurement 
of additional iron parameters and erythropoietic biomarkers.    
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8.6 Future studies and directions 
There are a number of future directions that could be taken based on the findings 
throughout this thesis. Firstly, the limitations highlighted involving the female health 
questionnaires used in this thesis warrant the need for the development of a new version.  
 
8.6.1 Future derivation of a Female Health Questionnaire 
In order to develop this research further, and given the highlighted limitations with the 
female health questionnaires applied in this thesis, it would be advisable to develop a new 
questionnaire that can be used widely. In order to do this, it is vital for a universally 
recognised and approved diagnosis for HMB to be established. Essentially, as already 
highlighted consideration of the desired impact of HMB firstly needs to be identified; is it 
the physical or psychological impact that is the key factor. Once this is known, a realistic 
means for diagnosis needs to be used. There are a number of benefits to the application 
of the criteria used throughout this thesis as previously highlighted, including those related 
to hygiene, the increased element of objectivity and the ease of application, so a similar 
series could be applied. Even if this is used to highlight risk, it would really advance practice 
in this field, and evidently as identified here, the enhanced risk of a compromised iron 
status alone warrants its application.  
 
Addressing the other issues with the Female Health Questionnaire, in order to gain 
association with awareness, individuals should specifically be asked whether they have 
sought medical advice about heavy menstrual bleeding and whether they deem 
themselves to have this condition. Timescales throughout the questionnaire also need to 
be consistent, however arguably, given that the repercussions of HMB can be slow to 
manifest the proposed time scale may be long in duration. Perhaps this could in part be 
overcome by simply asking whether heavy periods have disrupted exercise 
training/performance. Further, identification of performance level may, as opposed to 
performance times or training volume may be more appropriate.  
 
Regarding use of hormonal contraception, a future questionnaire should establish whether 
any form of hormonal contraception is used, and could also consider asking whether this 
was initiated as a means to treat HMB. The presence of underlying pathologies should also 
be recorded, as it could help develop understanding as to the aetiology of the condition. 
 
8.6.2 Other future directions 
Despite the ambiguity surrounding HMB diagnosis, it is evident throughout this thesis that 
utilising the applied criteria, risk of a compromised iron status, fatigue and citation that the 
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menstrual cycle disrupts exercise training/performance. These areas all need to be 
considered in further details and future studies should be conducted to better understand 
these relationships. Primarily, due to the lack of involvement of iron status in either of the 
associations between identified HMB and fatigue or reported menstrual cycle-driven 
disruptions to exercise training/performance, other haematological markers should be 
measured. For example TNF-$, or oxidative stress, to determine whether these could 
indicate the primary biomarkers involved in these relationships. It would also be beneficial 
to more objectively measure performance and fatigue.  
 
A randomised and blinded study needs to be conducted to minimise any element of bias 
in the IRONWOMAN trial – this is particularly significant from the perspective of impact on 
fatigue and mood disturbance. Future studies should also address other time points, and 
given the questionable ability of serum ferritin at identifying a compromised iron status 
throughout this thesis, future studies should include additional markers of iron status.    
 
8.7 Conclusions 
In conclusion, this thesis firstly addressed the prevalence of HMB when evaluated using a 
diagnostic series outlined in chapter 3, and then the association between this and the 
perception that the menstrual cycle disrupts exercise training/performance and fatigue. It 
then assessed the potential involvement of iron in these relationships, and finally evaluated 
the effect of iron repletion on markers of exercise and aerobic capacity and cognitive 
performance. In so doing, the efficacy of existing markers used for the diagnosis of iron 
deficiency was evaluated, while also highlighting the potential impact that both HMB and 
iron deficiency may have.  
 
This thesis highlights the presence of some common issues experienced by women in 
sport that have the ability to significantly affect their exercise performance and general 
health. Given the increasing acknowledgement that the menstrual cycle can have an 
impact on exercise performance there is much scope for future research to evaluate further 
means in which the menstrual cycle can affect performance, while also identifying 
appropriate strategies to mitigate this. This is a particularly exciting time for research in 
female athletes.  
  
Overall conclusions can be summarised as follows and are outlined in Figure 8.1:  
 
i. When utilising the outlined criteria to identify presence, HMB is common in both 
exercising women and elite athletes. In light of the overt lack of investigation 
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surrounding HMB, this finding is of great significance, particularly given its 
association with: the perception that the menstrual cycle disrupts exercise 
training/performance; increases in fatigue; and an enhanced risk of iron 
deficiency, as evidenced in this thesis.  
ii. The association between HMB (when identified using the outlined criteria) and 
the perception that the menstrual cycle disrupts  exercise training/performance 
is independent of iron status. Other associated outcomes of HMB, e.g. release 
of pro-inflammatory cytokines, need to be assessed to determine whether this 
is overriding any impact of a compromised iron status. However, given the 
potential limitations associated with serum ferritin for iron deficiency diagnosis, 
this relationship should be further evaluated using additional iron status 
markers. 
iii. The association between HMB (when identified using the outlined criteria) and 
fatigue is not mediated by IDA or iron deficiency when using serum ferritin and 
haemoglobin concentration for diagnosis. Again, factors associated with HMB 
need to be considered as these may be the primary in driving the increase in 
fatigue.  
iv. An increase in endurance and aerobic capacity and a reduction in fatigue and 
mood disturbance was seen in non-elite, exercising, iron deficient women when 
repleted with intravenous iron. However, when individuals were separated into 
two groups based on severity of iron deficiency, endurance and aerobic 
capacity only increased in those with more severe iron deficiency as defined 
using serum ferritin. Despite this, there was a range of individual variation in 
response, and serum ferritin was not able to predict this. Those with an 
increased susceptibility to iron deficiency can be identified, but future work 
must address other markers of iron status alongside serum ferritin or as an 
alternative to this measure to enhance reliability of diagnosis. Considering the 
significant reported use of supplementation, this work is essential. Further, the 
impacts of iron deficiency on cognitive performance need further consideration, 
particularly since there is potential for these to be affected prior to impacts on 
exercise and aerobic capacity. 
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Figure 8.1 - An overview of the conclusions. i. There is an association between identified 
HMB and IDA and ID; ii. The association between HMB and the perception that the 
menstrual cycle disrupts exercise training/performance is independent of IDA and ID; iii. 
The relationship between identified HMB and fatigue is not mediated by IDA and ID; and 
iv. There was an overall increase in exercise and aerobic capacity in response to 
intravenous iron in iron deficient (serum ferritin < 15 µg·L-1), non-elite exercising women, 
but this response was not universal and independent of serum ferritin. However, a 
reduction in fatigue was observed in all. There is potential for IDA and possibly ID to 
actually be a causative factor for the development of HMB. 
  
8.8 Key recommendations 
• Diagnosis of HMB – a universal tool needs to be created for HMB diagnosis. This 
needs to factor in the subjective nature of this condition, but also the repercussions 
and implications that may ensue. Further agreement as to the desired outcome of 
HMB needs to be evaluated, be is psychological or physical. 
• Awareness of HMB – with the majority of individuals who met the outlined HMB not 
reporting to have sought help/advice for heavy periods, it could be suggested that 
awareness that blood loss is potential abnormal and excessive is poor. In light of 
the negative implications that were found to be associated with HMB here an 
improved education is necessary. Firstly, appreciation amongst sports medical 
professionals that HMB is a common condition in athletes of all levels is necessary. 
Secondly, appropriate tests, e.g. measurements of iron status, need to be 
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performed where HMB is diagnosed. Finally, a greater understanding of HMB is 
needed amongst individuals, so that they know when to visit a medical 
professional. Excessive bleeding is evidently not a topic frequently discussed, 
however increased discussion and knowledge around this should reduce the 
potential reluctance of women to discuss this personal issue. 
• Given the implications, priority should also be placed on finding appropriate 
treatment options for HMB alongside evaluating the aetiology of this condition – 
which could also aid in future physical diagnosis.  
• The use of serum ferritin alone for iron deficiency diagnosis is evidently 
questionable. While it could be used to assess risk, measurement of other markers 
alongside serum ferritin is advisable, e.g. transferrin saturation. For best practice, 
iron status should be monitored longitudinally, alongside total haemoglobin mass, 
with intervention only when a significant decline is seen.  
• Future research needs to address the potential for other more suitable markers for 
the diagnosis of iron deficiency.  
• This thesis highlights that unnecessary iron supplementation is rife and does not 
benefit aerobic or exercise capacity. Many athletes, those who are elite in 
particular, supplement without knowledge of iron status. Given the potential 
adverse side effects of unnecessary supplementation it is important that individuals 
and their support personal appreciate that supplementation must only be taken 
when necessary. A food first approach at correcting iron status should be taken 
where possible.  
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LETTER
The prevalence and impact of
heavy menstrual bleeding
among athletes and mass
start runners of the 2015
London Marathon
The single most common cause of iron
deﬁciency anaemia in the developed
world in premenopausal females is the
menstrual cycle.1 It is well recognised and
reported that amenorrhoea and oligome-
norrhoea are common in elite athletes
typically as a result of relative energy deﬁ-
ciency;2 however, little is known about
the prevalence of other menstrual abnor-
malities. Heavy menstrual bleeding (HMB
or menorrhagia) affects a quarter of the
general population,3 yet no data exist
for athletes or exercising women. It is
possible that HMB might impact signiﬁ-
cantly on women’s participation in sport.
HMB can lead to fatigue, anxiety, reduced
mood and energy levels with a negative
impact on quality of life and productivity.4
Furthermore, iron turnover in exercising
females is likely to be increased further
due to factors such as haemolysis putting
them at a high risk of iron deﬁciency
anaemia.5 Iron is an essential micronu-
trient required for numerous biological
functions, and deﬁciency can result in
adaptive changes limiting haemoglobin
production and a state of iron deﬁciency
anaemia. We sought to identify the preva-
lence and impact of HMB in exercising
females where anaemia may have a signiﬁ-
cant effect on training and performance.
We recently conducted a ‘Female
Health Questionnaire’, which incorpo-
rated a validated diagnostic HMB series,
demographics, athlete ability data, training
status, known anaemia, iron supplementa-
tion and questions concerning the effect
of the menstrual cycle on training and
performance. The survey was initially
conducted online (n=789 women),
advertised via social media. Subsequently,
to obtain non-biased data, the same
survey was then conducted via face-to-face
interviews with runners during registra-
tion for the 2015 London Marathon
Exhibition (n=1073 women). Among the
group a total of 90 participants were clas-
siﬁed as ‘elite’. The key ﬁndings from this
survey were that HMB was common in
both groups; reported by over half of
those online (54%), and by more than a
third of the marathon runners (36%). In
total, 55% (online) and 32% (marathon
runners) stated that their menstrual cycle
impacted on training and performance,
this being more common in those with
HMB (χ2=183.4, p<0.01). Surprisingly,
HMB was also prevalent among elite ath-
letes (37%). Overall, 32% of all partici-
pants reported a history of anaemia, with
this also being more common in those
who have experienced HMB (41% vs
26%; χ2=70.765, p<0.01), while 50%
had previously supplemented with iron.
Only a minority (22%) had sought
medical advice. No signiﬁcant association
was found between average weekly exer-
cise volume and HMB presence.
In summary, we found HMB to be
highly prevalent in female athletes, asso-
ciated with anaemia, an increased use of
iron supplementation and reported nega-
tive impacts on performance. Somewhat
unexpectedly, our results suggest that
HMB is more common in the exercising
population than in the general population.
Although there are a number of limita-
tions to this questionnaire-based study, we
highlight that HMB may be under-
recognised. Further research is needed to
describe this issue and to understand its
implications. Interventions to support
female athletes such as iron therapy,6 and
an increased awareness of HMB among
sports medicine professionals could have
far reaching beneﬁts for the female
athlete.
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Abstract
To identify the prevalence and impact of heavy menstrual bleeding (HMB) in exercising
females where anemia may have a significant effect on training and performance a ‘Female
Health Questionnaire’ was designed incorporating a validated diagnostic HMB series,
demographics, exercise ability data, training status, anemia, iron supplementation and
whether the menstrual cycle had affected training and performance. The survey was con-
ducted in two stages; initially online, advertised via social media, and then repeated via
face-to-face interviews with runners registered for the 2015 London Marathon. 789 partici-
pants responded to the online survey, and 1073 completed the survey at the marathon.
HMB was reported by half of those online (54%), and by more than a third of the marathon
runners (36%). Surprisingly, HMB was also prevalent amongst elite athletes (37%). Overall,
32% of exercising females reported a history of anemia, and 50% had previously supple-
mented with iron. Only a minority (22%) had sought medical advice. HMB is highly prevalent
in exercising females, associated with self-reported anemia, increased use of iron supple-
mentation and a perceived negative impact on performance. Further research is needed to
investigate the impact of HMB, iron deficiency and anemia in exercising females.
Introduction
Heavy menstrual bleeding (HMB) is common, affecting a quarter of the female population.[1]
HMB can negatively impact on physical, emotional and social quality of life and reduce work
capacity.[2,3]
Diagnosing HMB can be subjective and definitions include; blood loss of more than 80ml
per menstrual cycle or “excessive menstrual blood loss which interferes with a woman’s physi-
cal, social, emotional and/or material quality of life”.[3,4] In a recent Europe-wide study a diag-
nosis of HMB was given if two or more of the following criteria were met; 1. passing of large
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blood clots, 2. need for double sanitary protection (both towels and tampons), 3. need for fre-
quent changes of tampons and towels (meaning changes every 2 hours or less, or 12 sanitary
items per period) and 4. flooding through to clothes or bedding.[1]
The greater blood loss in HMB increases susceptibility to iron deficiency, which if left
untreated may progress to iron deficiency anemia (IDA). Iron is an essential micronutrient
required for numerous biological functions, including oxygen transport, cellular and mito-
chondrial respiration, electron transfer reactions, gene regulation, cell growth and differentia-
tion.[5] Compromised iron stores cause adaptive changes, eventually resulting in limitations to
the production of hemoglobin and a state of IDA. Menstruation is the most common single
cause of IDA in females of a childbearing age,[6] with HMB specifically identified as the princi-
pal cause of iron deficiency and IDA in clinical practice in this population.[7] In a recent study
of women with HMB, 63% of respondents reported being deficient in iron at some point.[1]
However, despite the high prevalence of HMB, awareness is poor, with only a small minority
(6%) of women seeking medical help annually.[8]
The impact of compromised iron stores on oxidative metabolism in endurance athletes can
be significant, potentially reducing total hemoglobin mass, oxygen carrying capacity and per-
formance.[9,10] Furthermore, those who exercise are at higher risk of iron deficiency as a
result of increased iron loss through hematuria (blood in urine), gastrointestinal bleeding,
sweating and hemolysis (particularly exacerbated in impact sports involving foot strike).[11–
14] Research into the impact of iron deficiency without anemia is inconclusive, with an identi-
fied need for further research.[15]
While HMB has been shown to affect more than a quarter of women in the general popula-
tion, the prevalence of HMB and the impact upon training and performance in exercising
females has been unknown. We have recently published this headline data in a brief letter,[16]
and in this paper we aim to 1. provide the full methods and results from this study, identifying
the prevalence of HMB in exercising females; 2. determine any differential effect on exercisers
of varying abilities; and 3. outline the perceived reported impact of HMB on training and per-
formance which we were able to do through this research.
Materials and Methods
This research has been approved by the St Mary's University Ethics Committee. A 12-item
‘Female Health Questionnaire’ including free-text and yes-no polar questions was developed
and designed to take 2–3 minutes to complete. The four-symptom definition of HMB [1] was
used to identify HMB sufferers and information was collected on age, ‘personal best’ sports
performance times, current training volume, previous history of anemia and iron supplementa-
tion (including as part of a multivitamin), the menstrual cycle and difficulties caused by it, and
oral contraceptive pill (OCP) usage (S1 Appendix). The participants were informed that by
indicating that they agree to the terms and completing the survey they have provided written
informed consent for their information to be used in this study. The inclusion criteria were:
female, aged!18 years, pre-menopausal and regularly exercising (!90 minutes/week).
Stage 1—online questionnaire
The questionnaire was administered online and advertised through social media including
Twitter, Facebook, online blogs and forums, university newsletters, websites and by word of
mouth between 22 January 2015 and 19 May 2015. A link was provided to the internet-based
survey in addition to some brief information about the research.
Heavy Menstrual Bleeding in Exercising Females
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Stage 2—marathon exhibition questionnaire
Females registering for the 2015 London Marathon at the pre-event exhibition were surveyed
using the same questionnaire. No bias was applied when selecting females to question and to
avoid a response bias a scripted standardized introduction was made providing no specific
information about the context of the survey. To ensure maximum response yield, surveys were
completed at the time of asking. The questions and format of the paper copies used at the Exhi-
bition were identical to the online survey to maintain equivalency and reliability of this mixed
mode strategy.[17]
Data Analysis
Data were analyzed descriptively to summarize the prevalence of HMB, known anemia, iron
supplementation, the seeking of medical help and impact of HMB on training and performance
in both stages 1 and 2. The statistical analysis was completed using a predictive analytic soft-
ware statistics computer package (IBM SPSS Statistics for Macintosh, Version 21.0, Armonk,
NY: IBM Corp.). Statistical significance was set at P<0.05. Chi-squared tests were used to
determine whether there was an association between HMB and presence of anemia and HMB
and self-reported impacts on training and performance. Mann-Whitney U and Kruskal Wallis
H tests were used to determine whether age and average weekly training volume were related
to HMB. A Kruskal-Wallis H test with post hoc analysis and correction was used to determine
whether 5km personal best time was linked to the number of HMB symptoms experienced,
and Mann-Whitney U tests and Chi-squared tests were used to determine whether participant
performance level (based on 5km personal best) was related to HMB incidence.
After combining both groups, a sub-analysis was conducted to separate out elite athletes
using the following criteria: 5km!18 minutes, 10km!36 minutes, half marathon!80 min-
utes, 2km row!7 minutes:45 seconds (elite running criteria defined using the 2015 ‘Great
Run’ series definitions of ‘elite’, rowing criteria defined by English Institute of Sport physiolo-
gist). Participants were split into the following groups based on typical total minutes exercised
per week<90, 90–180, 180–360, 360–540, 540–720, and>720 minutes.
Results
Stage 1
A total of 789 surveys were completed online. More than half (54.1%) of the participants had
experienced HMB at some point (Table 1).[16] 55.4% stated that their menstrual cycle impacts
upon their training and performance (Table 1), with those meeting the HMB criteria (n = 427)
being more likely to state this (69.3% vs. 39.0%; χ2 = 867.593, p<0.01) (Table 2).[16] Those
with a history of HMB were found to be older (31 years ±9.32 vs. 29 years ±7.49; H(2) = 10.392,
p<0.01).
Of the 427 participants who met the HMB criteria, 37.2% had sought medical help for
heavy periods (Table 2).
Stage 2
1091 face-to-face surveys were collected and inputted into the Bristol Online Survey platform
manually by the lead investigator and an assistant. Those with missing data or those completed
by females who did not meet the inclusion criteria were excluded, resulting in a final sample
size of 1073 for further analysis. Eight individuals declined to complete the survey once they
had read the study information, and 61 declined answering the survey prior to being informed
Heavy Menstrual Bleeding in Exercising Females
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about the content typically citing a lack of time. Therefore, in stage 2, the survey was fully com-
pleted by 94% of randomly approached female marathon runners.
The prevalence of HMB in females undertaking the 2015 London Marathon was 35.5%
(Table 1).[16] Overall nearly one third (31.7%) said that their menstrual cycle impacts upon
their training and performance (Table 1).[16] This was more than twice as likely to be a prob-
lem in those with HMB (48.3% vs. 22.5%; χ2 = 1151.481, p<0.01; Table 2). Those who have
experienced HMB were older than those who have not (35 years ±7.95 vs. 32 years ±7.83; H(2)
= 18.936, p<0.01). Of the 381 participants who met the criteria for HMB, 44.6% had sought
medical help (Table 2).
Across both groups, known anemia was reported by 603 (32.4%) participants, while 1049
(56.3%) specified that they were unsure whether they have had anemia.[16] Reported anemia
was more common in those with HMB (40.7% vs. 26.0%; χ2 = 70.765, p<0.01).[16] Use of
iron supplementation was also more common in those reporting HMB (58.4% vs. 50.3%;
χ2 = 39.199, p<0.01).[16] Less than a quarter of all surveyed reported having sought help for
heavy periods (22.3%), with this increasing in those who met the HMB criteria (40.7%).[16]
When a sub-analysis was conducted and elite athletes were separated out from both groups,
36.7% met the HMB criteria, with 51.1% indicating that their menstrual cycle has impacted
upon their training and performance, with these being significantly related (χ2 = 5.046,
p<0.05). A history of anemia was reported by 52.2%, with 78.9% having supplemented with
iron (Table 1).
When participants who specified a 5km personal best time (n = 1166) were divided into
groups based on the number of HMB symptoms they have experienced, a significant difference
was found between groups (H(4) = 11.464, p<0.05), despite distributions looking similar. How-
ever, a post hoc analysis using pairwise statistics revealed no statistically significant pairwise
comparisons. When simply comparing those with and without HMB, median 5km times were
Table 1. Self reported prevalence of heavymenstrual bleeding (HMB), the effects on training and performance, seeking of help, history of anemia
and iron supplementation. [16]
Stage 1 (n = 789) Stage 2 (n = 1073) Elite athletes (n = 90)
HMB 427 (54.1%) 381 (35.5%) 33 (36.7%)
Affects training and performance 437 (55.4%) 340 (31.7%) 46 (51.1%)
Sought help 190 (24.1%) 226 (21.1%) 21 (23.3%)
History of anemia 303 (38.4%) 300 (28.0%) 47 (52.2%)
History of iron supplementation 451 (57.2%) 486 (45.3%) 71 (78.9%)
doi:10.1371/journal.pone.0149881.t001
Table 2. Self reported prevalence of heavymenstrual bleeding (HMB), its effects on training and performance, seeking of help, history of anemia
and iron supplementation in those who havemet the HMB criteria.
Stage 1 (n = 427) Stage 2 (n = 381) Elite athletes (n = 33)
Affects training and performance 296 (69.3%)* 184 (48.3%)* 22 (66.7%)***
Sought help 159 (37.2%)* 170 (44.6%)* 14 (42.4%)**
History of anemia 184 (43.1%)* 145 (38.1%)* 19 (57.6%)
History of iron supplementation 262 (61.4%)*** 210 (55.1%)* 27 (81.8%)
Signiﬁcant differences between the values here from those meeting the HMB criteria and those who haven’t are shown as follows:
*p < 0.001,
**p < 0.01,
***p < 0.05.
doi:10.1371/journal.pone.0149881.t002
Heavy Menstrual Bleeding in Exercising Females
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significantly different (25 minutes:0 seconds vs. 24 minutes:24 seconds; z = 3 .099, p<0.05).
When 5km personal best times were divided into quartiles (Q1 being the fastest athletes), a sig-
nificant difference was seen in HMB prevalence between groups (χ2 = 14 .890, p<0.01), the
faster runners in Q1 being less likely to have HMB (39.1%) than the slower runners in Q4
(53.1%) (Fig 1).
No statistically significant association was found between average weekly exercise volume
and HMB presence (z = -0.811, p>0.05). Those exercising for>720 minutes each week
appeared as likely to suffer from HMB as those exercising for<90 minutes each week (χ2 =
6.765, p>0.05).
Discussion
This is the first study to identify that HMB is a common problem amongst exercising females.
Stage 1 of this research was used to ascertain whether HMB was prevalent amongst exercising
females. It is acknowledged that this online survey was likely to be biased because females with
menstrual cycle issues were more likely to complete the questionnaire, however with 54.1%
meeting the HMB criteria this demonstrated that this is a significant problem within this popu-
lace. To obtain unbiased prevalence data a large study (stage 2) incorporating a number of con-
trols to prevent bias was conducted at the 2015 London Marathon Exhibition. This found that
35.5% marathon runners met the HMB criteria therefore confirming the outcome in stage 1
that this is a common problem amongst exercising females. HMB has previously been shown
to affect more than a quarter of the general female population,[1] but this is the first study to
investigate prevalence amongst exercising females.
Only 43.1% and 38.1% of those females from stages 1 and 2 with HMB had sought medical
help. This highlights the need for increased HMB awareness. However, previous research has
demonstrated that almost half of females meeting the criteria for HMB who sought help did
not have HMB confirmed,[1] and the results of an audit conducted by the Royal College of
Obstetricians showed that once diagnosed one third were not given treatment in primary care.
[18] This suggests that from both a diagnostic and treatment perspective an increased
Fig 1. Prevalence of reported heavymenstrual bleeding (HMB) across participant performance level.
5km personal best times (minutes:seconds) are divided into quartiles, Q1 representing those with the fastest
times, Q4 the slowest. A significant difference was found between groups (p < 0.01).
doi:10.1371/journal.pone.0149881.g001
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awareness of HMB prevalence and treatment options is required. However, a review of treat-
ment methods has shown there to be considerable variation in the treatment procedures and
medications used, highlighting the need for further research.[19]
Due to the increased blood loss, those with HMB are more likely to suffer from iron defi-
ciency and anemia, and this is consistent with our finding that those meeting the HMB criteria
were more likely to report previous diagnosis of anemia than those who do not (40.7% com-
pared to 26.0%). This may be higher as more than half of all respondents said that they were
unaware whether or not they have been anemic. In the general population IDA has been
shown to affect two thirds of women with HMB.[3] Regardless of menstruation, those partici-
pating in endurance exercise are susceptible to iron deficiency due to increased iron losses as a
result of foot strike hemolysis, sweating, and gastrointestinal bleeding.[11–14] Dietary intake
of iron has also been found to be suboptimal in those who exercise, and particularly in females.
[20] This iron deficiency and IDA risk is further exacerbated in those with HMB. Many elite
athletes routinely supplement with iron—as shown here with 78.9% reporting supplementa-
tion. Coaches often encourage supplementation without knowledge of iron status due to the
unfounded but common belief that iron deficiency is rife and supplementation may benefit
performance. Less than half of those with HMB have sought medical help, therefore it is neces-
sary to raise awareness as clinical iron deficiency and IDA can result in fatigue, weakness,
impaired cognition and psychological morbidity, negatively impacting upon quality of life.[21]
Similar to the findings fromMarret et al,[22] this study demonstrated that HMB was mar-
ginally more likely in those who were older. Unsurprisingly those with HMB were more likely
to report that their menstrual cycle impacts upon their training and performance.
The sub-analysis from the elite athlete sample showed that more than one third met the
HMB criteria. This is somewhat surprising because it is well documented that elite female ath-
letes, particularly endurance athletes are susceptible to amenorrhea and oligomenorrhea often
as a result of a relative energy deficiency associated with a high training volume.[23,24] This
suggests that elite athletes may also be susceptible to other menstrual disturbances. Further-
more, it could be hypothesized that increases in training volume would equate to increased risk
of amenorrhea or oligomenorrhea, potentially decreasing HMB incidence, but this was not the
case here with no identified relationship between total number of minutes exercised per week
and HMB presence. However, those with faster 5km personal best times were less likely to
report HMB, with the median 5km time in the HMB group being slower. The slower times
seen in Q3 and Q4 where HMB prevalence is higher when compared to Q1 could be caused by
an increased incidence of IDA, which is impacting upon performance, alternatively increased
rates of amenorrhea in Q1 could reflect the lower HMB incidence seen here. However these dif-
ferences were only marginal, and further research is required before forming a definitive con-
clusion. Historically, much research has focused on the female athlete triad and the new term
‘Relative Energy Deficiency in Sport’–RED-S, particularly in elite athletes.[25,26] These syn-
dromes are characterized by amenorrhea or oligomenorrhea, however this study suggests that
other menstrual cycle issues are also commonplace, highlighting the need for further more gen-
eral research across other menstrual cycle irregularities in exercising women.
There are a number of limitations of this study. Firstly, the self-reported nature of this ques-
tionnaire could have resulted in inaccurate data, however the HMB diagnostic criteria does not
lean itself to comparison bias. Secondly, stage 2 data was only collected in marathon runners,
which may not be representative of other running events and sports. It has been shown that
exercise increases susceptibility to iron deficiency,[27] however blood parameters including
markers of iron status have not been measured therefore we are making an assumption. Addi-
tionally, the presence of illnesses (i.e. endometriosis) or the use of medication was not recorded,
these could increase the likelihood of participants meeting the HMB criteria. To obtain
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standardized performance comparisons a means for knowing finishing time in the marathon
would strengthen ability to determine any relationships between participant performance level
and HMB presence. Relationship between anthropometrical parameters and and HMB pres-
ence could also be explored. Further studies are required to address these limitations.
Conclusions
This study has demonstrated that HMB is common in the exercising population. HMB was
associated with anemia, iron supplementation and slower performance times. Further research
is however needed to explore the impact of HMB and iron deficiency on performance. The lack
of medical help sought by the participants in this study suggests that either females don’t feel
or realize this is a problem, or have learnt to cope with it, highlighting that more research and
awareness is needed. HMB is also surprisingly common amongst elite athletes, ostensibly
impacting upon their training and performance, and potentially causing iron deficiency,
although further research is needed to confirm this association.
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Sport, exercise and the menstrual
cycle: where is the research?
G Bruinvels,1,2,3 R J Burden,2,3,4 A J McGregor,5 K E Ackerman,6
M Dooley,7 T Richards,1 C Pedlar2,6
Despite a decreasing gender gap in exer-
cise participation, there still remains a sig-
niﬁcant under-representation of women
included in sport and exercise medicine
research studies.1 A review of 1382 sport
and exercise research studies involving
over 6 million participants, from 2011 to
2013, found the representation of women
to be 39%.1 The complexities of the men-
strual cycle are considered major barriers
to the inclusion of women in clinical
trials.
Historically, partially due to concerns
of potentially damaging unborn fetuses,
medical trials—including drug trials—
were conducted solely in men. Further,
women were perceived as more physiolo-
gically variable, therefore utilising only
male participants would allow meaningful
results with fewer participants and less
funding. Since men were viewed as ade-
quate proxies for women, the years of
exclusion of female participants from
research were considered inconsequential.
However, it is now known that women
can respond very differently to drug
treatments than men. Evidence suggests
that women are almost twice more likely
to have an adverse reaction to a drug
than their male counterparts, and 80% of
drugs withdrawn from the market are
due to unacceptable side effects in
women.2
When research involving exercise meta-
bolism includes women, participants are
often tested in the early follicular phase of
their menstrual cycle, when hormone
levels are at their lowest, in order to mini-
mise the possible impacts oestradiol and
progesterone may have on the study out-
comes.3 This type of research practice
leaves much ambiguity around how such
hormones may inﬂuence the unique phy-
siological processes in women, from
blood pressure to substrate metabolism,
thus perpetuating the signiﬁcant gap in
understanding how the menstrual cycle
impacts exercise performance. Sheel4
recently described a number of sex differ-
ences in the physiological response to
exercise, likely caused in part by ovarian
hormones, highlighting a lack of under-
standing and a need for further research.
We recently reported that 41.7% of
exercising women believe their menstrual
cycle has a negative impact on exercise
training and performance.5 However,
largely due to the dearth of sports and
exercise research in women, explanations
for this are lacking. Heavy menstrual
bleeding with unknown or undiagnosed
iron deﬁciency could be a cause but this is
speculative.
There is a clear need to gain better
understanding of female physiology and
to deﬁne the effects of the cyclical varia-
tions in hormones, both positive and
negative, on athletic performance. Also, a
greater understanding of the menstrual
cycle is needed to address the reported
negative impacts on exercise training
in order to encourage participation and
avoid further disparity in gender
representation.
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therapy for iron deficient non-anaemic adults. Started June 2015, work still on going 
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10.10 IRONWOMAN Trial: Participant Information Sheet  
 
 
 
 
 
 
 
 
            
                                                                                                       
 
 
                                  
PARTICIPANT INFORMATION SHEET 
Version 3 – 8 October 2015 
 
Study Title: IRON WOMAN – Iron therapy for female athletes 
 
Chief Investigator: Professor Toby Richards 
Student Researcher: Miss Georgie Bruinvels 
Principal Investigators: Dr Charles Pedlar and Dr Richard Burden 
 
You are being invited to take part in this pilot research study as a result of your recent expression of 
interest in our work. Before you decide whether to participate, it is important for you to understand why 
the research is being done and what it will involve. Please take time to read the following information 
carefully. Please do us if there is anything that is not clear or if you would like more information.  
 
Study Purpose and Research Overview 
This study is being conducted to fulfil the requirements of a Graduate Research Degree (PhD) being 
undertaken by Miss Georgie Bruinvels, Division of Surgery and Interventional Science at University 
College London (UCL). 
 
Our research group aims to optimise the health and well being of athletes. The research group at St 
Mary’s University, Twickenham in collaboration with UCL is specifically looking at the effects of low iron 
(i.e. iron deficiency anaemia and iron deficiency non-anaemia) and it’s impact on performance.  
Endurance exercise can cause small iron loss through haematuria (blood in urine), gastrointestinal 
bleeding, sweating and haemolysis (destruction of red blood cells, particularly exacerbated in impact 
sports involving foot strike). Females who participate regularly in endurance training therefore have an 
increased susceptibility to iron deficiency, and this is likely to be exacerbated in menstruating females. 
Iron is essential for the healthy functioning of the body and deficiency will eventually result in a 
reduction in energy levels, weakness, impaired cognition and motivation amongst other long-term 
detrimental affects to the human body.  
 
The purpose of this study is therefore to see whether intravenous iron supplementation improves 
exercise performance and quality of life in iron deficient exercising women.  
 
 
Why have I been invited to take part in this study? 
We are contacting you because you have indicated that you may be low in iron and exercise on a 
regular basis.  
 
Do I have to take part in this study? 
You are under no obligation to take part in this research, participation is voluntary, but if you do decide 
to partake please read and keep this information sheet, and sign the consent form at the end. If you 
decide that you no longer want to be a part of this research then you will be able to withdraw safely, at 
any time with no notice or reasoning. Declining to take part or withdrawing from this study will have no 
impact on future care or involvement in other research. 
 
 
What will happen to me if I take part in this study? 
You are being contacted because you think you may meet our predefined criteria for being iron 
deficient. If you decide that you would like to continue involvement in this study you will undergo some 
tests and answer some questionnaires, then be given a single injection of iron. The initial tests and 
completion of questionnaires will then be repeated on one or two occasions. The aim of giving you iron 
is to return your iron levels to a ‘clinically normal’ level. You will need to visit St Mary’s University, 
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Twickenham on four occasions for a number of tests, and 112 Harley Street, London as explained 
below; 
 
1. Screening test – this will involve having a blood test to check your iron status to see if you are 
eligible for this research. During the visit to the lab you will be given an overview of the study 
and will be able to ask questions. This will take place at St Mary’s University, Twickenham. 
 
2. Baseline testing – you will be required to have an exercise test (the test is called a VO2max test, 
and it measures the maximum amount of oxygen that you can take in and use while exercising. 
It is the main test used in exercise physiology to assess physical fitness, and a higher value 
indicates a higher level of fitness), a blood test, a total haemoglobin mass test (explained 
below), provide a urine sample and answer 5 questionnaires (approx. 2 hours for all tests). This 
will take place at St Mary’s University, Twickenham. 
 
3. Iron injection - after the baseline tests you will be required to go to the iron therapy clinic located 
at 112 Harley Street, London to receive an iron injection. This will be given by a trained medical 
professional. Iron will be infused over a minimum period of 15 minutes and you will be observed 
for 30 minutes after this. (approx. an hour in total) 
 
4. Follow up testing – 2 weeks after you have had the iron injection you will be required to come 
back to St Mary’s University, Twickenham and repeat the tests that were performed at baseline, 
including – an exercise test, a blood test, a total haemoglobin mass test, provision of a urine 
sample and to complete the 5 questionnaires. 3 months (12 weeks) after the iron injection you 
will be required to come back to St Mary’s again for a blood test and to answer the 5 
questionnaires.  
 
How long am I likely to be in this study? 
After you have come into the lab for your familiarisation trial you will complete your baseline tests, you 
will receive your iron injection within the next 2 weeks, follow up testing will take place 2 weeks and 3 
months (12 weeks) after this. Therefore from the baseline testing you will be in the study for 
approximately 16 weeks.  
 
 
What are the possible benefits of taking part in this study? 
You will receive information about your current level of physical fitness, and will be given key target 
training and heart rate zones that you can use for your training. You will also gain information about 
your general health and well-being. If your iron deficiency is having an impact on your quality of life and 
exercise performance you will also benefit from the restoration of your iron levels.  
 
 
What are the possible side effects, disadvantages and risks of taking part in this study? 
The risks associated with a VO2max test are minimal but include the following: fatigue, muscle soreness, 
irregular heartbeat and chest pain. We will conduct testing in the standardised procedure under the 
guidance of an experienced exercise physiologist; heart rate and rate of perceived exhaustion will be 
continuously monitored throughout the test in a controlled environment.  
 
We will also require you to complete a total haemoglobin mass test. This test is routinely used in sport 
and exercise science and provides another way of measuring fitness, showing how much oxygen your 
body can transfer. The test involves breathing a very small amount of carbon monoxide, less than you 
would breathe in when sitting in a queue of traffic. This will be performed by a trained physiologist, and 
is very unlikely to have any effects on your health and wellbeing.  
 
The most common reported side effects of intravenous iron are dizziness, high blood pressure and/or 
injection site reactions.  
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Other uncommon side effects (occur in less than 1 in 100 (1%) and more than 1 in 1,000 (0.1%) 
patients receiving iron) are allergic reaction (hypersensitivity), sensation of pain (paraesthesia), a 
change in your taste sensation (dysgeusia), high heart rate (tachycardia), low blood pressure 
(hypotension), redness in the face (flushing), difficulty breathing (dyspnoea), vomiting, upset stomach 
(dyspepsia), flatulence, abdominal pain, constipation, diarrhoea, itching (pruritus), hives (urticaria),  
redness of the skin (erythema), rash, muscle, joint and/or back pain (myalgia and arthralgia), muscle 
spasm, fever (pyrexia), tiredness (fatigue), chest pain, swelling of the hands and/or the feet (oedema 
peripheral), pain and/or chills. 
 
In all the clinical trials reported to date (including over 6000 patients) there has been no report of 
increased side effects in patients receiving the intravenous iron compared to those patients who 
received the placebo. 
 
If you encounter any problems following the IV iron treatment you should contact Professor Toby 
Richards immediately (Tel: 0207 679 6454). 
 
Is it compulsory for me to take part? 
No, it is not compulsory; participation is voluntary and specific to this study. If you do agree to be 
involved in this study it does not mean that you agree to being involved in other studies.  
 
What are the alternatives for treatment of iron deficiency? 
In the UK, typically iron is given in tablet form, however this is typically poorly absorbed and there are 
some side effects including abdominal pain, constipation and heartburn. Also, restoration of iron stores 
typically takes 3-6 months. Additionally, those who exercise may have increased levels of inflammation, 
which will hinder absorption. Conversely, intravenous iron which can be administered as a single 
treatment in a relatively short length of time (minimum of 15 minuets) enables rapid restoration of iron 
status. Intravenous iron is widely and effectively used in countries such as Switzerland and Australia. 
 
Why will iron be delivered intravenously and not orally? 
As restoration of iron stores is slow and poorly absorbed through oral iron treatment intravenous iron 
therapy is being used. This has been shown to be much more effective. 
 
 
What will happen if I do not want to carry on with the study? 
If you decide during the study that you no longer want to participate you can withdraw yourself at any 
time and do not need to give a reason. After study completion, any stored blood or tissue samples that 
can still be identified as yours will be destroyed if you would like. 
 
If there is anything you do not understand or wish to ask questions about, please feel free to ask.  
 
In the unlikely event of a loss of capacity to consent, the research team will retain tissue and personal 
data collected during this study and continue to use it confidentially for research purposes.  This could 
include further research after the current project has ended.  
 
What if something goes wrong?  
In the unlikely event that you are harmed while taking part in this research project, there are no special 
compensation arrangements. But, if you are harmed due to someone's carelessness, then you may 
have grounds for legal action but you may have to pay for it. 
 
Will my taking part in this study be kept confidential?  
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All information that is collected about you during the course of the research will be kept strictly 
confidential. You will be referred to by a unique code, and any information about you will have your 
name and address removed so that you cannot be recognised. 
 
Will my General Practitioner be notified? 
On agreement, your general practitioner will be informed of your inclusion and will be provided with your 
results from this research. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available about the 
subject being studied. Should this happen a member of the research team will tell you about it and 
discuss with you whether you want to continue in the study.  
 
What will happen to the results of the research study?  
Results will be published in a peer-reviewed scientific journal once the study is completed. You will be 
given with a lay summary of the research results. You will not be identified in any publication. 
 
Who has reviewed the study?  
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests.  This study has been reviewed and given favourable opinion by 
the London-Westminster Research Ethics Committee.   
The St Mary’s University Ethics Committee has also reviewed and approved this research. 
 
 
What will happen to any samples I give? 
Any blood samples that are taken as part of the research study will be transferred to a central 
laboratory for analysis. The blood will only be identified by using your unique study number. The blood 
will be frozen at -80°C. The samples will be transported to a laboratory in central London called The 
Doctors Laboratory (TDL). The bloods will be analysed. Any serum excess (blood product) will be 
stored for future research.  All results will be sent to the statistician who is based at the London School 
of Hygiene and Tropical Medicine (LSHTM). This is where the staff organising this study are based.  
Unless you withdraw your consent, we will ask you to gift your blood to the people running the study 
and in so doing give up all future claims to its use that may include further research. 
 
 
 
If you wish to find out more about this research study, you can contact: 
 
Georgie Bruinvels – georgie.bruinvels@stmarys.ac.uk; georgie.bruinvels.14@ucl.ac.uk 
 
 
Thank you for taking time to read this information.  
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10.11 IRONWOMAN Trial: NHS Ethics Approval letter  
 
 
 
London - Westminster Research Ethics Committee 
4 Minshull Street 
Manchester 
M1 3DZ 
 
Telephone: 0207 104 8012 
 
16 November 2015 
 
Mr Toby Richards 
University College London 
Division of Surgery & Interventional Science 
74 Huntley Street 
London 
WC1E 6AA 
 
 
Dear Mr Richards  
 
Study title: The role and effect of intravenous iron isomaltoside at 
improving functional performance outcome measures 
and quality of life in iron deficient exercising females 
REC reference: 15/LO/1570 
IRAS project ID: 180318 
 
Thank you for your submission of 03 November 2015, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair and Mr 
Robert Goldstein.  
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this opinion letter.  Should you wish to provide a substitute contact point, require further 
information, or wish to make a request to postpone publication, please contact the REC 
Manager, Ms Rachel Katzenellenbogen, nrescommittee.london-westminster@nhs.net. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
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study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations involved 
in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on 
a publically accessible database within 6 weeks of recruitment of the first participant (for medical 
device studies, within the timeline determined by the current registration and publication trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but for 
non clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Non-NHS sites 
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The Committee has not yet completed any site-specific assessment (SSA) for the non-NHS 
research site(s) taking part in this study.  The favourable opinion does not therefore apply to any 
non-NHS site at present. We will write to you again as soon as an SSA application(s) has been 
reviewed. In the meantime no study procedures should be initiated at non-NHS sites. 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document   Version   Date   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only)  
  20 July 2015  
GP/consultant information sheets or letters [IRON WOMAN Trial - 
Letter to GP]  
1  20 August 2015  
IRAS Checklist XML [Checklist_24082015]    24 August 2015  
Other [Response to validation query]    26 August 2015  
Participant consent form [IRONWOMAN - Consent Form v2]  V2  03 November 2015  
Participant information sheet (PIS) [IRON WOMAN Trial - Participant 
information sheet v3]  
V3  03 November 2015  
REC Application Form [REC_Form_24082015]    24 August 2015  
Referee's report or other scientific critique report    31 October 2014  
Research protocol or project proposal [IRON WOMAN Trial - 
Protocol]  
1  20 August 2015  
Summary CV for Chief Investigator (CI) [Toby Richards - 2 page CV]  1  18 August 2015  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed guidance 
on reporting requirements for studies with a favourable opinion, including: 
 
x Notifying substantial amendments 
x Adding new sites and investigators 
x Notification of serious breaches of the protocol 
x Progress and safety reports 
x Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of changes 
in reporting requirements or procedures. 
 
 
User Feedback 
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The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/    
 
HRA Training 
 
We are pleased to welcome researchers and R&D staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/   
 
15/LO/1570                          Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
Dr Alan Ruben 
Chair 
 
Email:nrescommittee.london-westminster@nhs.net 
 
Enclosures:  “After ethical review – guidance for researchers” 
 
Copy to: Mr Toby Richards, University College London 
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10.12 IRONWOMAN Trial: St Mary’s Ethics Approval  
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
Georgie Bruinvels (SHAS): ‘Ironwoman – iron therapy for female athletes’. 
 
 
29 February 2016 
 
 
Dear Georgie 
University Ethics Sub-Committee  
Thank you for submitting your ethics application for the above research.  
I can confirm that your application has been considered by the Ethics Sub-Committee and 
that ethical approval is granted. 
 
Yours sincerely 
Dr Conor Gissane 
Chair of the Ethics Sub-Committee 
 
 
Cc   Charlie Pedlar 
 Richard Burden 
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10.13 IRONWOMAN Trial: Informed consent  
 
 
 
 
 
 
 
 
                                                                                                                   
 
INFORMED CONSENT 
Version 2 – 28 October 2015 
 
Study Title: IRONWOMAN – Iron therapy for female athletes 
 
Participant Identification Number for this trial: _____ 
Chief Investigator: Professor Toby Richards 
Student Researcher: Miss Georgie Bruinvels 
Principal Researchers: Dr Charles Pedlar and Dr Richard Burden 
 
Please initial boxes to indicate agreement with each specific point below. 
 
•  I confirm that I have read and understand the information sheet dated ____________ 
(version ____) for the above study. I have had the opportunity to ask questions and 
have had these satisfactorily answered. 
 
• I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason without my legal rights being affected. 
 
• I am satisfied that the researchers have explained the purpose, principles and 
procedures of the study, outlining any possible risks. 
 
• I understand how my data will be collected and used and that confidential information 
will only be seen by researchers. 
 
• I understand that I will have three venous blood samples and a urine sample 
collected, and I give permission for these to be stored in accordance with the Human 
Tissue Act for current and future research.  
 
• I understand that I will be required to perform two maximal exercise tests (and have a 
familiarisation trial). 
 
• I understand that I will have my haemoglobin mass measured on two occasions. 
 
• I understand that I am gifting my samples to the investigators and in so doing give up 
all future claims to its use that may include further research with the appropriate 
ethical approval. 
 
• I agree to my General Practitioner being informed of my participation in this study. 
 
• I agree to take part in the above study. 
 
 
  
           
Name of participant            Date       Signature 
      
           
Name of person taking consent          Date       Signature 
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10.14 IRONWOMAN Trial: Female athlete monitoring questionnaire 
 
 
Ironwoman Trial Female Health
Questionnaire
0% complete
Page 1
There is much ambiguity about the possible impacts of the menstrual cycle on exercise
performance. Research in the female athlete at all menstrual cycle phases is
lacking, however we are really keen to start addressing this and help understand why
many females feel that their menstrual cycle holds them back. 
In order to participate in this study you must be:
Female
18 years or older
Pre-menopausal
By completing this survey you are giving consent for the information you provide to be
included in this study. Your participation is voluntary and is specific to this study, and
shall not be taken to imply consent to participate in any subsequent experiment or
deviation from that detailed. All information will remain confidential as to your identity,
and you may withdraw from the study at anytime without reason. If there is anything
you do not understand or wish to ask questions about, please feel free to ask.
Thank you for participating
 
 
 Yes
 No
Do you agree to these terms? 
Skip: 1 / 3∠  Return  PREVIEW  Ironwoman Trial Female Health
Questionnaire
Next  ∠ #
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This part of the survey uses a table of questions, view as separate questions instead?
Time (minutes:seconds)
5km run (inc Parkrun)
10km run
Half marathon
10M TT cycle
25M TT cycle
100km cycle
2km row
Please specify your personal best times for all/any of the below in the last year 
Yes  No
Do you use the oral contraceptive pill? * Required
If you use any other contraceptive device that will stop regular bleeding please specify 
Approximately how many periods have you had in the last year? 
How long does your average menstrual cycle last (days)? - from the start of one bleed
to the next 
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How long does each bleed normally last? (days) 
Yes  No
Have you ever sought advice/help for heavy periods? 
Yes  No  Don't know
To your knowledge have you ever had anaemia? 
Yes  No  Don't know
Have you ever supplemented with iron? 
 Flooding through to clothes or bedding
 Need of frequent changes of sanitary towels or tampons (meaning changes
every 2 hours or less or 12 sanitary items per period)
 Need of double sanitary protection (tampons and towels)
 Pass large blood clots
Have you ever experienced any of the below during your period? (please select all that
apply) 
Yes  No
Do you feel that your menstrual cycle disrupts your training/performance? 
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This part of the survey uses a table of questions, view as separate questions instead?
Day after started previous menstrual cycle (first day of
bleeding)
Screening blood
test
Baseline tests
Iron injection
Follow up tests
How many days after you started your previous menstrual cycle were you at the
following times: 
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10.15 Questionnaires 
10.15.1.1 The MFI-20 
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10.15.1.2 The EQ-5D-5L Questionnaire 
EQ-5D-5L Questionnaire 
Under each heading, please tick the ONE box that best describes your health TODAY  
 
MOBILITY 
I have no problems in walking about     q 
I have slight problems in walking about    q 
I have moderate problems in walking about    q 
I have severe problems in walking about    q 
I am unable to walk about      q 
 
SELF-CARE 
I have no problems washing or dressing myself   q 
I have slight problems washing or dressing myself   q 
I have moderate problems washing or dressing myself  q 
I have severe problems washing or dressing myself   q 
I am unable to wash or dress myself     q 
 
USUAL ACTIVITIES (e.g. work, study, housework,  
family or leisure activities) 
I have no problems doing my usual activities    q 
I have slight problems doing my usual activities   q 
I have moderate problems doing my usual activities   q 
I have severe problems doing my usual activities   q 
I am unable to do my usual activities     q 
 
PAIN / DISCOMFORT 
I have no pain or discomfort      q 
I have slight pain or discomfort     q 
I have moderate pain or discomfort     q 
I have severe pain or discomfort     q 
I have extreme pain or discomfort     q 
 
ANXIETY / DEPRESSION 
I am not anxious or depressed     q 
I am slightly anxious or depressed     q 
I am moderately anxious or depressed    q 
I am severely anxious or depressed     q 
I am extremely anxious or depressed     q 
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• We would like to know how good or bad your health is  
TODAY. 
• This scale is numbered from 0 to 100. 
• 100 means the best health you can imagine. 
0 means the worst health you can imagine. 
• Mark an X on the scale to indicate how your health is 
TODAY.  
• Now, please write the number you marked on the 
scale in the box below.  
                     
 
 
 
YOUR HEALTH TODAY  = 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
10 
0 
20 
30 
40 
50 
60 
80 
70 
90 
100 
5 
15 
25 
35 
45 
55 
75 
65 
85 
95 
The best health        
 you can imagine 
 
The worst health        
 you can imagine 
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10.15.1.3 Piper Fatigue Scale 
 
1. To what degree is the fatigue you are feeling now causing you distress? 
No Distress        A Great Deal 
1 2 3 4 5 6 7 8 9 10  
 
2. To what degree is the fatigue you are feeling now interfering with your ability to 
complete your work or school activities? 
None         A Great Deal 
1 2 3 4 5 6 7 8 9 10  
 
3. To what degree is the fatigue you are feeling now interfering with your ability to 
socialize 
with your friends? 
None         A Great Deal 
1 2 3 4 5 6 7 8 9 10  
 
4. To what degree is the fatigue you are feeling now interfering with your ability to 
engage in sexual activity? 
None         A Great Deal 
1 2 3 4 5 6 7 8 9 10  
 
5. Overall, how much is the fatigue which you are now experiencing interfering with your 
ability to engage in the kind of activities you enjoy doing? 
None         A Great Deal 
1 2 3 4 5 6 7 8 9 10  
 
6. How would you describe the degree of intensity or severity of the fatigue which you are 
experiencing now? 
None         Severe 
1 2 3 4 5 6 7 8 9 10  
 
7. To what degree would you describe the fatigue which you are experiencing now as 
being? 
Pleasant        Unpleasant 
1 2 3 4 5 6 7 8 9 10  
 
8. To what degree would you describe the fatigue which you are experiencing now as 
being? 
Agreeable        Disagreeable 
1 2 3 4 5 6 7 8 9 10  
 
9. To what degree would you describe the fatigue which you are experiencing now as 
being? 
Protective        Destructive 
1 2 3 4 5 6 7 8 9 10  
 
10. To what degree would you describe the fatigue which you are experiencing now as 
being? 
Positive        Negative 
1 2 3 4 5 6 7 8 9 10  
 
11. To what degree would you describe the fatigue which you are experiencing now as 
being: 
Normal        Abnormal 
1 2 3 4 5 6 7 8 9 10  
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12. To what degree are you now feeling: 
Strong         Weak 
1 2 3 4 5 6 7 8 9 10  
 
13. To what degree are you now feeling: 
Awake         Sleepy 
1 2 3 4 5 6 7 8 9 10  
 
14. To what degree are you now feeling: 
Lively         Listless 
1 2 3 4 5 6 7 8 9 10  
 
15. To what degree are you now feeling: 
Refreshed        Tired 
1 2 3 4 5 6 7 8 9 10  
 
16. To what degree are you now feeling: 
Energetic        Unenergetic 
1 2 3 4 5 6 7 8 9 10  
 
17. To what degree are you now feeling: 
Patient        Impatient 
1 2 3 4 5 6 7 8 9 10  
 
18. To what degree are you now feeling: 
Relaxed        Tense 
1 2 3 4 5 6 7 8 9 10  
 
19. To what degree are you now feeling: 
Exhilarated        Depressed 
1 2 3 4 5 6 7 8 9 10  
 
20. To what degree are you now feeling: 
Able to concentrate      Unable to concentrate 
1 2 3 4 5 6 7 8 9 10  
 
21. To what degree are you now feeling: 
Able to remember       Unable to remember 
1 2 3 4 5 6 7 8 9 10  
 
22. To what degree are you now feeling: 
Able to think clearly      Unable to think clearly 
1 2 3 4 5 6 7 8 9 10  
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10.15.1.4 BRUMS Mood Scale 
 
 Not at 
all 
A little Moderately Quite 
a bit 
Extremely 
Panicky 0 1 2 3 4 
Lively 0 1 2 3 4 
Confused 0 1 2 3 4 
Worn out 0 1 2 3 4 
Depressed 0 1 2 3 4 
Downhearted 0 1 2 3 4 
Annoyed 0 1 2 3 4 
Exhausted 0 1 2 3 4 
Mixed-up 0 1 2 3 4 
Sleepy 0 1 2 3 4 
Bitter 0 1 2 3 4 
Unhappy 0 1 2 3 4 
Anxious 0 1 2 3 4 
Worried 0 1 2 3 4 
Energetic 0 1 2 3 4 
Miserable 0 1 2 3 4 
Muddled 0 1 2 3 4 
Nervous 0 1 2 3 4 
Angry 0 1 2 3 4 
Active 0 1 2 3 4 
Tired 0 1 2 3 4 
Bad 
Tempered 
0 1 2 3 4 
Alert  0 1 2 3 4 
Uncertain 0 1 2 3 4 
 
 
 
